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Abstract	  Sporadic	   inclusion	  body	  myositis	   (IBM)	   is	   the	   commonest	  myopathy	   acquired	  after	   50	   years	   of	   age	   and	   causes	   significant	   disability.	   No	   effective	   treatment	  exists	  despite	  several	  clinical	   trials	  of	   immunotherapies.	  This	  reflects	  a	   lack	  of	  pre-­‐clinical	   disease	   models.	   The	   work	   described	   in	   this	   thesis	   began	   with	  development	  of	  such	  a	  system,	  in	  which	  disease	  relevant	  pathological	  outcome	  measures	   were	   characterised	   in	   vitro	   using	   primary	   satellite	   cell	   cultures.	  Through	   over-­‐expression	   of	   β-­‐Amyloid	   Precursor	   Protein	   or	   exposure	   to	  inflammatory	   mediators	   IL1β	   and	   TNFα,	   IBM-­‐like	   pathology	   was	   induced.	  Myotubes	   demonstrated	   ubiquinated	   intracellular	   aggregates,	   increased	  expression	   of	   MHC	   Class	   I,	   cytoplasmic	   translocation	   of	   TDP-­‐43,	   ER	   stress,	  calcium	  dyshomeostasis	  and	  activation	  of	  NFκB.	  As	  some	  of	  these	  are	  proposed	  to	  be	   central	  pathogenic	  mechanisms	   in	   IBM,	   they	  provide	  a	  panel	  of	   tools	  on	  which	  to	  assess	  new	  IBM	  treatment	  strategies.	  	  The	   effects	   of	   heat	   shock	   response	   augmentation	   were	   examined	   using	  Arimoclomol,	   a	   co-­‐inducer	   of	   the	   transcription	   factor	   HSF-­‐1	   that	   drives	  expression	   of	   key	   endogenous	   Heat	   Shock	   Proteins.	   Arimoclomol	   treatment	  ameliorated	   several	   IBM-­‐relevant	   features,	   represented	   by	   improved	   cell	  viability,	   reduced	   ER	   stress,	   inhibition	   of	   NFκB	   and	   reduced	   cytoplasmic	  translocation	  of	  TDP-­‐43.	  These	   data	   supported	   further	   evaluation	   of	   HSR	   manipulation	   as	   a	   potential	  therapy	   for	   IBM.	   Therefore,	   Arimoclomol	   was	   advanced	   into	   a	   randomised,	  placebo-­‐controlled	   clinical	   trial	   involving	  24	  patients	  with	   IBM	  over	  one	   year.	  The	  primary	  outcome	  measure	  was	   safety	  and	   tolerability.	  Muscle	  biopsy	  was	  performed	  before	  and	  after	  the	  treatment	  phase	  to	  evaluate	  HSP	  expression	  and	  histopathological	  changes.	  Together,	   this	   in	   vitro	   model	   and	   clinical	   trial	   represent	   a	   novel	   translational	  research	  pathway	   in	   IBM,	  the	   lack	  of	  which	  has	  hampered	  the	  development	  of	  effective	  treatments	  for	  this	  disease.	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Chapter	  1:	  General	  Introduction	  
	  
1.1	  Preface	  Sporadic	   Inclusion	   Body	   Myositis	   (IBM)	   represents	   a	   host	   of	   clinical	   and	  scientific	   challenges	   in	   the	   field	   of	   neuromuscular	   diseases.	   Despite	   being	   the	  commonest	   myopathy	   acquired	   after	   the	   age	   of	   fifty	   years,	   the	   condition	  remains	   without	   effective	   management.	   As	   a	   result,	   most	   patients	   suffer	  progressive	   limb	   weakness	   and	   significant	   disability	   (Dalakas	   2006).	  Traditionally	   classified	   with	   the	   primary	   myositides,	   Polymyositis	   (PM)	   and	  Dermatomyositis	   (DM),	   yet	   appearing	   clinically	   more	   similar	   to	   degenerative	  conditions	  such	  as	  Motor	  Neuron	  Disease	  (MND),	  IBM’s	  mystery	  is	  represented	  by	  a	  divided	  literature.	  The	  lack	  of	  treatment	  for	  IBM	  reflects	  several	  deficiencies	  in	  our	  understanding	  of	  and	  approach	  to	  the	  disease.	  Most	  fundamentally,	  the	  pathogenesis	  of	  IBM	  is	  enigmatic,	   comprising	   a	   plethora	   of	   interlinking	   processes	   and	   cascades,	   the	  initial	   trigger	   of	   which	   remains	   elusive.	   Even	   the	   significance	   of	   individual	  downstream	  pathological	  elements	  is	  debated	  and	  it	  follows	  that	  no	  coordinated	  translational	   research	   programme	   in	   IBM	   has	   yet	   been	   established.	   Rather,	   a	  series	   of	   small,	   typically	   underpowered,	   clinical	   trials	   represents	   the	  unsuccessful	  effort	  to	  develop	  a	  therapeutic	  strategy.	  A	  more	  robust	  foundation	  requires	   a	   panel	   of	   preclinical	   models	   in	   which	   a	   selection	   of	   relevant	  pathological	   outcome	   measures	   are	   characterised,	   on	   which	   potential	  treatments	  can	  be	  evaluated.	  To	  advance	  promising	  agents	  towards	  the	  clinic,	  a	  large	  and	  well	  characterised	  patient	  population,	  diagnosed	  according	  to	  widely	  accepted	   criteria,	   is	   essential.	   Validated	   clinical	   outcome	   measures	   are	   then	  required	   to	   determine	   the	   number	   of	   participants	   and	   duration	   required	   of	  future	  clinical	  trials.	  This	  thesis	  represents	  one	  theme	  in	  such	  a	  proposed	  framework	  of	  translational	  research	   in	   IBM.	   It	   is	   introduced	  by	  a	  consideration	  of	  existing	   IBM	   literature,	  through	  which	  various	  pathogenic	  and	  clinical	  priorities	  were	  determined	  and	  applied	  to	  the	  subsequent	  experiments.	  Throughout	  the	  process,	  the	  overriding	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focus	  was	  to	  achieve	  the	  most	  efficient	  and	  effective	  programme	  for	  translation	  of	  the	  basic	  science	  towards	  meaningful	  clinical	  differences	  for	  patients.	  	  
1.2	  Clinical	  description	  of	  IBM	  
1.2.1	  Epidemiology	  In	   clinical	   practice,	   IBM	   remains	   an	   undefined	   entity	   since	   the	   two	   generally	  accepted	  diagnostic	   criteria	   are	  not	   consistently	   applied	   and	  do	  not	   reflect	   all	  advances	   in	  histopathological	   findings	  during	   the	  past	   ten	  years.	  For	  example,	  the	  most	   commonly	  used	  Griggs’	   criteria	   frequently	   require	   the	   application	  of	  electron	  microscopy,	  which	  is	  not	  routinely	  performed	  in	  even	  specialist	  clinical	  neuropathology	   departments	   in	   Europe,	   or	   electromyography,	   which	   is	   not	  routinely	  performed	  on	  suspected	  IBM	  cases	  in	  most	  countries.	  Therefore,	  it	  can	  be	   difficult	   to	   distinguish	   IBM	   from	   other	   myopathies	   that	   display	   an	  inflammatory	   infiltrate,	   notably	   PM.	   This	   may	   prevent	   refinement	   of	   a	  descriptive	  diagnosis	  of	   ‘myositis’,	  particularly	  in	  cases	  without	  a	  stereotypical	  clinical	  presentation.	  Furthermore,	  the	  reasonable	  histological	  characterisation	  of	   IBM	   as	   a	   ‘Polymyositis-­‐plus’	   condition	   means	   that	   misdiagnosis	   of	   PM	   is	  extremely	  common	  where	  insufficiently	  detailed	  analysis	  of	  the	  biopsy	  has	  been	  performed.	  Indeed,	  it	  has	  been	  estimated	  that	  IBM	  is	  the	  initial	  diagnosis	  in	  only	  16%	   of	   subsequently	   confirmed	   IBM	   cases,	   with	   the	   most	   frequent	   first	  diagnosis	   being	   PM	   in	   18%	   (Badrising	   et	   al.	   2000).	   The	   outdated	   Bohan	   and	  Peter	   criteria,	   which	   do	   not	   exclude	   IBM,	   are	   still	   employed	   to	   diagnose	   PM	  (Bohan	  et	  al.	  1975).	  This	   contributes	   to	   the	   likely	  underestimation	  of	   the	   true	  prevalence	  of	   IBM.	  There	   is	   further	   ascertainment	  bias	   from	   the	  unstructured	  distribution	   of	   patients	   with	   myositis	   among	   primary	   care	   physicians,	  rheumatologists	   and	   neurologists,	   the	   delay	   between	   presentation	   and	  diagnosis	  and	  the	  potential	  overlap	  of	  the	  mild	  end	  of	  the	  IBM	  disease	  spectrum	  with	  weakness	  attributed	   to	   the	   sarcopenia	  of	   ageing.	  Conversely,	   factors	   that	  may	   contribute	   towards	   overestimation	   of	   the	   prevalence	   of	   IBM	   include	   the	  lack	  of	  routine	  screening	  for	  myofibrillar	  myopathies	  (MFMs)	  and	  other	  genetic	  causes,	  in	  addition	  to	  the	  lack	  of	  routine	  neurophysiology,	  precluding	  detection	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of	  slowly	  progressive	  motor	  neuron	  disease	  (MND).	  Overall,	  however,	  it	  appears	  most	  likely	  that	  IBM	  remains	  under	  diagnosed.	  There	   have	   been	   relatively	   few	   large	   epidemiological	   studies	   of	   IBM.	  Nevertheless,	   these	   suggest	   IBM	   is	   the	   commonest	   muscle	   disease	   acquired	  after	   the	   age	   of	   50	   years	   and	   represents	   at	   least	   28%	   of	   all	   inflammatory	  myopathies	   (Lotz	   et	   al.	   1989).	  One	  national	   study	  of	   IBM	  epidemiology	   in	   the	  Netherlands	  estimated	  a	  prevalence	  of	  16	  x	  10-­‐6	  among	   inhabitants	  aged	  over	  50	  years,	  and	  4.9	  x	  10-­‐6	  among	   the	  general	  population	  (Badrising	  et	  al.	  2000).	  However,	   this	   estimation	  was	  based	  on	  a	   sample	  of	  only	  76	   living	  patients,	   of	  which	   a	   small	   alteration	  would	   have	   produced	   a	   substantial	   difference	   in	   the	  final	   estimate.	   Indeed,	   the	   variation	   between	   0	   and	   9.3	   per	   million	   of	   the	  population	  in	  the	  twelve	  provinces	  of	  the	  Netherlands	  reveals	  the	  magnitude	  of	  the	  potential	  sampling	  error.	  Wilson	  and	  colleagues	  estimate	  the	  prevalence	  of	  IBM	  in	  Olmsted	  County,	  Minnesota	  at	  71	  x	  10-­‐6	  and	  PM	  at	  34.5	  x	  10-­‐6	  (Wilson	  et	  al.	  2008).	  This	  reflects	  an	  IBM	  sample	  of	  only	  9	  patients,	  using	  the	  stricter	  Griggs’	  diagnostic	  criteria.	  	  A	  further	  regional	  study	  in	  Western	  Australia	  also	  included	  patients	   meeting	   Griggs’	   criteria	   and	   identified	   17	   patients,	   giving	   an	   overall	  prevalence	  of	  9.3	  x	  10-­‐6,	  adjusted	  to	  35.3	  x	  10-­‐6	  among	  those	  aged	  over	  50	  years	  (Phillips	  et	  al.	  2000).	  In	  summary,	  previous	  epidemiological	  studies	  of	  IBM	  have	  been	   small	   and	   yielded	   substantially	   different	   estimations	   of	   the	   true	   disease	  prevalence.	   In	   a	   large	   part,	   this	   reflects	   the	   use	   of	   diagnostic	   criteria	   that	   are	  likely	  to	  exclude	  a	  significant	  number	  of	  patients	  whose	  biopsy	  did	  not	  fulfill	  a	  considerable	  set	  of	  histological	  features.	  This	  may	  have	  excluded	  patients	  in	  the	  early	  stages	  of	  the	  disease,	  where	  such	  features	  have	  not	  yet	  developed.	  A	  consistent	  finding	  in	  epidemiological	  studies	  of	  IBM	  is	  a	  male	  preponderance,	  the	   magnitude	   of	   which	   may	   be	   between	   two	   and	   four	   male	   cases	   for	   each	  female	  case	  (Cox	  et	  al.	  2011).	  The	  increased	  prevalence	  of	  IBM	  with	  greater	  age,	  particularly	   over	   50	   years,	   is	   also	   consistent	   (Dalakas	   2006).	   Together,	   the	  apparent	  susceptibility	  of	  elderly	  males	  to	  IBM	  is	  notably	  inconsistent	  with	  the	  young	  female	  population	  typical	  affected	  by	  autoimmune	  conditions,	  and	  more	  in	  keeping	  with	  a	  degenerative	  disease.	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Finally,	  considerable	  time	  typically	  separates	  symptoms	  at	  onset	  and	  a	  biopsy-­‐confirmed	   diagnosis.	   Engel’s	   study	   of	   64	   patients	   reported	   this	   delay	   as	   5.9	  years	  (SD	  ±4.4)	  (Chahin	  et	  al.	  2008).	  This	  is	  likely	  to	  reflect	  a	  combination	  of	  the	  slow	  progression	  of	  the	  disease,	  initial	  misdiagnosis	  and	  limitations	  of	  ability	  to	  apply	  diagnostic	  criteria.	  	  	  
1.2.2	  Clinical	  features	  The	   hallmark	   of	   IBM	   is	   slowly	   progressive	   weakness	   of	   forearm	   flexor	   and	  quadriceps	   muscles.	   This	   clinical	   pattern,	   reflecting	   involvement	   of	   the	   distal	  upper	   limbs	   and	   proximal	   lower	   limbs,	   is	   a	   relatively	   unusual	   one	   for	   other	  neuromuscular	   conditions	   and	   represents	   an	   important	   early	   indicator	   to	   the	  diagnosis	   (Hilton-­‐Jones	   et	   al.	   2010).	   Specifically,	   this	   contrasts	   with	   PM,	   in	  which	   patients	   typically	   demonstrate	   predominantly	   proximal	   weakness	  (Chahin	  et	  al.	  2008).	  The	  deep	  tendon	  reflexes	  are	  frequently	  reduced	  or	  absent,	  which	  is	  consistent	  with	  a	  chronic	  myopathy.	  There	   have	   been	   relatively	   few	   phenotypic	   studies	   of	   IBM	   and	   these	   are	  discrepant,	   reflecting	   the	   use	   of	   different	   diagnostic	   inclusion	   criteria	   and	   the	  inter-­‐	   or	   intra-­‐investigator	   variability	   of	   the	  Medical	   Research	   Council	   (MRC)	  score	  of	  limb	  power.	  	  Until	   2008,	   the	   largest	   single	   centre	  natural	   history	   study	  of	   IBM	  was	   that	   by	  Lotz,	   in	   1989,	   of	   forty	   consecutive	   patients	   with	   electromicroscopically	  confirmed	  diagnosis	  (Lotz	  et	  al.	  1989).	  All	  patients	  described	  weakness	  at	  onset	  and	   at	   diagnosis.	   The	   second	   commonest	   symptom	   was	   dysphagia,	   affecting	  four	  patients	  at	  onset	  and	  sixteen	  by	  the	  point	  of	  diagnosis.	  Fatigue,	  muscle	  pain	  and	   paraesthesia	   were	   less	   common.	   Interestingly,	   contrasting	   with	   the	  phenotypic	   stereotype,	   this	   study	   describes	   biceps	   and	   triceps	   as	   the	  predominantly	   affected	   muscles,	   in	   which	   weakness	   was	   detected	   in	  approximately	  half	  of	  all	  patients.	  In	   2008,	   Chahin	   and	   Engel	   described	   a	   cohort	   of	   64	   patients	   with	   IBM,	   27	  patients	   with	   PM	   and	   16	   patients	   in	   whom	   either	   diagnosis	   remained	   a	  possibility.	   55	   of	   the	   64	   IBM	   patients	   displayed	   selective	   weakness	   of	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quadriceps	   and	   finger	   flexors.	   Of	   the	   remaining	   9	   patients,	   8	   had	   selective	  quadriceps	  weakness	  and	  one	  had	  selective	  finger	  flexor	  weakness.	  Tellingly,	  14	  of	   the	   16	   indeterminate	   cases	   resembled	   IBM	   clinically	   from	   the	   beginning	   of	  their	   illness	   and	   the	   remaining	   two	   developed	   an	   IBM	   phenotype	  within	   two	  years	   of	   onset	   (Chahin	   et	   al.	   2008).	   This	   concept	   of	   a	   clinically	   defined	  population,	   who	   may	   not	   yet	   demonstrate	   sufficient	   pathological	   features	   to	  achieve	  a	  pathologically	  defined	  diagnosis,	  has	  been	  highlighted	  as	  potentially	  important	  subgroup	  with	  respect	  to	  understanding	  IBM	  and	  planning	  of	  clinical	  trials	   since	   these	   patients	   may	   be	   the	   most	   likely	   to	   respond	   to	   treatment	  (Hilton-­‐Jones	  et	  al.	  2010).	  	  35	  patients	  were	  described	  in	  a	  study	  by	  Felice	  (Felice	  et	  al.	  2001),	  which	  also	  confirmed	   weakness	   as	   the	   commonest	   symptom,	   with	   54%	   also	   suffering	  dysphagia.	   Interestingly,	   43%	   of	   patients	   were	   felt	   to	   have	   facial	   weakness,	  which	   is	   considered	   an	   atypical	   feature.	   All	   patients	   demonstrated	   atrophy	   of	  the	   anterior	   thigh	   and	   91%	   of	   the	   forearm	   flexor	   compartment.	   This	  corresponded	   with	   the	   characteristic	   features	   of	   this	   population	   being	  weakness	  of	  quadriceps,	  long	  finger	  flexors	  and	  ankle	  extensors.	  	  Badrising	   and	   colleagues	   reported	   a	   national	   population	   of	   64	   IBM	   patients	  from	  the	  Netherlands	  (Badrising	  et	  al.	  2000).	  This	  largely	  supports	  the	  findings	  of	  the	  others	  studies,	  with	  63%	  of	  patients	  describing	  quadriceps	  weakness	  as	  their	   first	  symptom,	   followed	  by	  14%	  who	  first	  noted	  finger	   flexion	  weakness.	  The	   authors	   provided	   a	   detailed	   and	   interesting	   breakdown	   of	  MRC	   strength	  scores	  on	  examination	  of	  all	  muscle	  groups	  (Fig	  1.1).	  This	  confirmed	  that	  knee	  extension	  was	  the	  commonest	  region	  of	  weakness	  and,	  importantly,	  was	  normal	  in	  only	  a	  fraction	  of	  patients.	  Elbow	  flexors	  and	  the	  deep	  finger	  flexors	  were	  the	  next	  commonest	  affected	  respectively.	  Examination	  of	   these	  data	  supports	   the	  notion	   that	   the	   combination	   of	   weak	   knee	   extension	   (quadriceps),	   which	  exceeds	  weakness	  of	  hip	  flexion	  (iliopsoas),	  and	  weak	  grip	  is	  highly	  consistent	  with	   a	   diagnosis	   of	   IBM.	   Similar	   to	   the	   study	   by	   Felice,	   41%	   of	   patients	  demonstrated	   mild	   symmetrical	   facial	   weakness.	   Outside	   these	   muscles,	   it	   is	  evident	  that	  weakness	  does	  extend	  considerably;	   IBM	  is	  not	  specific	  to	  certain	  muscles,	  rather	  some	  muscles	  appear	  to	  be	  more	  severely	  affected	  than	  others.	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Primary	  muscle	  disorders	  are	  often	  characterised	  by	  a	  symmetrical	  severity	  and	  IBM	  is	  again	  atypical	  in	  this	  respect,	  with	  the	  majority	  of	  patients	  demonstrating	  asymmetrical	  weakness	  (Felice	  et	  al.	  2001).	  	  
	  
Figure	  1.1	  Distribution	  of	  weakness	  in	  IBM	  by	  MRC	  score	  From	  (Badrising	  et	  al.	  2005).	  Examination	  of	  the	  distribution	  of	  weakness	  in	  this	  cohort	   of	   64	   patients	   supports	   the	   stereotypical	   description	   of	   IBM’s	  predilection	   for	   knee	   extensors	   and	   deep	   finger	   flexors,	   although	   a	   small	  number	   of	   patients	   demonstrate	   normal	   power	   in	   these	   groups.	   The	   data	  highlight	   that	   the	   differential	   involvement	   of	   muscles	   occurs	   along	   a	   fairly	  smooth	   spectrum	   rather	   than	   a	   binary	   fashion.	   In	   notable	   contrast	   to	   the	  clinically	   similar	   condition,	   Amyotrophic	   Lateral	   Sclerosis,	   the	   neck	   extensors	  were	  not	  weak	   in	   any	  patient.	  Black	  =	  MRC	  grade	  5	   (full	  power),	  Grey	  =	  MRC	  grade	  4	  (weakness	  when	  resistance	  is	  applied),	  White	  =	  MRC	  grades	  ≤3	  (marked	  weakness,	  evident	  without	  resistance).	  
	  	  	  The	  steadily	  progressive	  nature	  of	  symptoms	  is	  a	  consistent	  feature	  of	  IBM	  and	  this	   typically	   leads	   to	   the	   accumulation	   of	   disability.	   In	   one	   representative	  natural	  history	  study,	  63%	  could	  not	  ambulate	  independently	  after	  7	  years	  and	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mean	   duration	   until	   wheelchair	   dependency	   was	   approximately	   15	   years	  (Cortese	   et	   al.	   2013).	   This	   reflects	   an	   annual	   decline	   of	   muscle	   strength,	   as	  estimated	   over	   a	   period	   of	   12	   years	   in	   the	   longest	   examined	   single	   cohort,	   of	  3.5%	  by	  manual	  muscle	  testing	  or	  5.4%	  by	  quantitative	  muscle	  testing	  (Cox	  et	  al.	  2011).	  Neuromuscular	   respiratory	   insufficiency	   is	   not	   a	   typical	   feature	   of	   IBM,	  differentiating	  it	  from	  MND	  (Hardiman	  et	  al.	  2011).	  Respiratory	  symptoms	  are	  more	   likely	   to	   represent	   aspiration	   consequent	   to	   dysphagia	   which	   explains	  why	  pneumonia	  is	  the	  commonest	  cause	  of	  death	  in	  IBM	  (Felice	  et	  al.	  2001).	  Life	  expectancy	  per	  se	  does	  not	  appear	  to	  be	  significantly	  reduced	  (Cox	  et	  al.	  2011).	  	  	  
1.2.3	  Associated	  conditions	  In	   keeping	   with	   the	   aetiological	   hypothesis	   that	   IBM	   is	   an	   autoimmune	  condition,	   considerable	   attention	   has	   focused	   on	   its	   associations	   with	   other	  autoimmune	   disorders.	   The	   epidemiological	   study	   by	   Lotz	   observed	  autoimmune	   diseases	   in	   6	   of	   the	   40,	   or	   15%	   of	   patients	   (Lotz	   et	   al.	   1989).	  However,	   one	   of	   these	   conditions	   was	   Dermatomyositis,	   implying	   lack	   of	  diagnostic	  clarity,	  and	  two	  were	  idiopathic	  interstitial	  pneumonitis,	  of	  which	  the	  possible	  primary	  causes	  include	  many	  non-­‐immune	  conditions.	  Of	  note	  were	  the	  11	  patients	  who	  demonstrated	  evidence	  of	  peripheral	  neuropathy.	  In	  3	  patients,	  this	   was	   attributed	   to	   diabetes	   mellitus.	   The	   study	   by	   Felice	   did	   not	   suggest	  strong	   associations	   between	   IBM	   and	   other	   conditions.	   The	   commonest	  concurrent	   medical	   problem	   was	   hypertension,	   affecting	   37%	   of	   patients,	  consistent	   with	   the	   expected	   prevalence	   in	   this	   age	   group.	   Autoimmune	  conditions	  were	  rare,	  affecting	  only	  4	  patients	  (Felice	  et	  al.	  2001).	  Chahin	  and	  Engel’s	  cohort	  detected	  coexistent	  autoimmune	  disease	  in	  8	  of	  64	  IBM	  patients,	  or	   12.5%,	   compared	   with	   4	   of	   27	   PM	   patients,	   or	   14.8%.	   These	   included	  Hashimoto	  thyroiditis,	  coeliac	  disease,	  Sjögren’s	  syndrome,	  rheumatoid	  arthritis	  and	  ocular	  myasthenia	  gravis	  (Chahin	  et	  al.	  2008).	  Contrasting	  with	  adult	  onset	  DM,	  in	  which	  associated	  malignancy	  must	  be	  assumed	  until	  disproven,	  no	  clear	  association	  exists	  between	  malignancy	  and	  IBM	  (Lotz	  et	  al.	  1989).	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There	  are	  also	  reported	  cases	  in	  which	  IBM	  has	  been	  proposed	  to	  arise	  from	  the	  presence	  of	  another	   immune	  condition.	  A	  potential	  viral	   trigger	  has	   long	  been	  considered,	   with	   one	   case	   adenovirus	   type	   2	   being	   detected	   in	   the	   muscle	   a	  patient	  with	   IBM	  and	   further	   case	  of	  mumps	  virus	   antigen	   (Mikol	   et	   al.	   1982;	  Chou	   1986).	   Indeed,	   Chou	   suggested	   that	   the	   cytoplasmic	   and	   intranuclear	  inclusion	   bodies	   of	   IBM	   represent	   nucleocapsids	   of	   mumps	   viral	   infection.	  Interestingly,	   he	   also	   noted	   the	   similarity	   of	   these	   intranuclear	   bodies	   with	  those	  observed	  in	  osteoclasts	  affected	  by	  Paget’s	  disease	  of	  bone.	  This	  condition	  can	   be	   caused	   by	   mutations	   of	   Valosin-­‐containing-­‐protein	   (VCP)	   in	   which	   it	  coexists	   with	   Frontotemporal	   dementia	   and	   an	   inclusion	   body	   myopathy.	   	   A	  viral	  hypothesis	  for	  sporadic	  IBM	  is	  also	  supported	  by	  Dalakas,	  who	  described	  four	   cases	   of	   IBM	   that	   appeared	   to	   follow	   infection	   with	   human	  immunodeficiency	   virus	   in	   which	   there	   viral	   specific	   clonal	   expansion	   of	  cytotoxic	   CD8+	   T-­‐cells	   (Dalakas	   et	   al.	   2007).	   	   However,	   the	   potential	  contribution	   of	   antiretroviral	   mediated	   mitochondrial	   toxicity	   should	   also	   be	  borne	   in	  mind.	   Similar	   rare	   observations	   of	   an	   IBM-­‐like	  myopathy	   have	   been	  made	  in	  cases	  of	  human	  T-­‐lymphocytic	  virus	  type	  1	  (HTLV-­‐1)	  infection	  (Ozden	  et	  al.	  2001).	  
	  
1.2.4	  Genetic	  predisposition	  To	  date,	   no	   large	   exome	   sequencing	  or	   genome	  wide	  association	   studies	  have	  been	   undertaken	   in	   sporadic	   IBM.	   Smaller	   studies	   have	   revealed	   genetic	  associations	   with	   inflammatory	   and	   degenerative	   connotations.	   HLA	   genes	  represent	   the	   most	   widely	   studied	   area,	   revealing	   association	   with	   the	  DRβ1*0301	   and	  DQβ1*0201	   alleles	   (Koffman	   et	   al.	   1998).	   The	  B8-­‐DR3-­‐DR52-­‐DQ2	  haplotype	  is	  detected	  in	  a	  similar	  proportion	  of	  patients	  with	  IBM	  and	  the	  autoimmune	   condition	   myasthenia	   gravis	   and	   correlates	   with	   earlier	   disease	  onset	   (Badrising	   et	   al.	   2004).	   Apolipoprotein	   E4,	  which	   has	   strong	   links	  with	  susceptibility	   to	   Alzheimer’s	   disease,	   also	   appears	   to	   associate	   with	   IBM	  (Garlepp	  et	  al.	  1995).	  A	   distinct	   group	   of	   conditions	   termed	   hereditary	   IBMs	   (hIBMs),	   demonstrate	  considerable	  phenotypic	  or	  histological	  distinction	  from	  sporadic	  IBM.	  Nonaka	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or	   ‘GNE’	  myopathy	  (hIBM2)	   follows	  mutations	  of	  UDP-­‐N-­‐Acetylglucosamine	  2-­‐Epimerase/N-­‐Acetylmannosamine	   kinase	   (GNE)	   on	   chromosome	   9.	   Patients	  tend	  not	   to	  display	  quadriceps	  weakness,	  which	   is	  almost	  uniform	   in	  sporadic	  IBM.	   The	   condition	   originally	   referred	   to	   as	   hIBM1,	   which	   is	   a	   vacuolar	  myopathy	   that	   does	   manifest	   with	   quadriceps	   weakness	   has	   since	   been	  reclassified	  as	  a	  myofibrillar	  myopathy	  (MFM)	  due	  to	  mutations	  of	  desmin.	  Autosomal	   dominant	   mutations	   of	   VCP/p97	   on	   chromosome	   9	   produce	   IBM	  with	   Paget’s	   disease	   of	   bone	   and	   Frontotemporal	   dementia	   (IBMPFD).	   This	  disorder	   demonstrates	   some	   similar	   pathological	   characteristics	   to	   sporadic	  IBM,	   including	   formation	   of	   cytoplasmic	   proteinaceous	   aggregates	   and	  upregulation	  of	  NFκB.	  However,	  it	  lacks	  a	  pronounced	  endomysial	  inflammatory	  infiltrate.	   Furthermore,	   the	   clinical	   phenotype,	   in	   addition	   to	   its	   earlier	   age	  of	  onset,	   is	   typically	   different	   to	   sporadic	   IBM;	   that	   cranial	   nerve	   territories	   are	  often	  significantly	  affected,	   individual	   limb	  weakness	   is	   typically	  proximal	  and	  distal,	  and	  mortality	  is	  far	  higher	  (Watts	  et	  al.	  2007).	  The	  myofibrillar	  myopathies	  (MFMs)	  are,	  anecdotally,	  the	  commonest	  group	  of	  genetic	  myopathies	  that	  mimic	  IBM.	  This	  highlights	  the	  importance	  of	  including	  a	  minimum	  age	  of	  onset	  within	  diagnostic	  criteria,	  until	  the	  spectrum	  of	  genes	  causing	   MFM	   is	   fully	   determined.	   The	   MFMs	   are	   currently	   known	   to	   reflect	  mutations	  of	  desmin,	  αB-­‐cystallin,	  myotillin,	  ZASP,	   filamin	  C	  and	  BAG-­‐3	  genes,	  referred	   to	   as	   MFM	   1-­‐6	   respectively.	   None	   has	   been	   routinely	   detected	   in	   a	  cohort	  of	  sporadic	  IBM	  patients.	  
1.2.5	  Laboratory	  abnormalities	  Any	  rise	  in	  creatine	  kinase	  is	  conspicuously	  moderate	  in	  IBM	  cases,	  contrasting	  with	  several	  other	  myopathies,	  notably	  PM	  (Machado	  et	  al.	  2009).	  Indeed,	  even	  a	   normal	   CK	   value	   is	   consistent	   with	   a	   diagnosis	   of	   IBM.	   Interpretation	   of	  particular	   values	   is	   limited	   due	   to	   variability	   in	   normal	   ranges	   between	  laboratories	  and	  ethnic	  groups.	  One	  study	  of	  40	  cases	  of	  IBM	  described	  a	  range	  between	   23	   and	   605	   IU/ml,	  with	   a	  mean	   value	   of	   199.7	   IU/ml	   for	  males	   and	  189.6	  IU/ml	  for	  females	  (Lotz	  et	  al.	  1989).	  In	  a	  further	  cohort,	  17	  of	  63	  patients	  with	   IBM	  were	   found	   to	  have	  a	  normal	  CK	  and	   the	  mean	  CK	  at	  diagnosis	  was	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three	   to	   four	   times	   greater	   among	   patients	   with	   PM	   than	   those	   with	   IBM	  (Chahin	  et	  al.	  2008).	  
1.2.6	  Neurophysiology	  There	   is	   anecdotal	   evidence	   in	   the	   field	   that	   IBM	   patients	   display	   abnormal	  neurophysiological	   readings	   in	   addition	   to	   the	   short	   duration	   motor	   unit	  potentials	   and	   polyphasic	   potentials	   that	   are	   demonstrated	   in	   various	  inflammatory	  myopathies.	  One	  study	  of	  35	  patients	  described	  abnormal	  nerve	  conduction	   studies	   in	   43%,	   reflecting	   23%	   with	   sensorimotor	   axonal	  polyneuropathy	   and	   20%	   with	   absent	   lower	   extremity	   SNAPs	   (Felice	   et	   al.	  2001).	  Although	  some	  of	  this	  may	  reflect	  age	  related	  changes,	  the	  consistency	  of	  abnormal	  neurophysiology	   in	   IBM	   is	  notable	  and	  could	   indicate	  a	  neuropathic	  element	  that	  has	  not	  yet	  been	  fully	  characterised.	  
1.2.7	  Imaging	  Relative	   to	   diseases	   of	   the	   central	   nervous	   system,	   the	   role	   of	   imaging	   in	   neuromuscular	  conditions	  is	  limited.	  Indeed,	  radiological	  investigations	  are	  not	  yet	  routinely	  performed	  in	  the	  diagnosis	  or	  evaluation	  of	  IBM.	  The	  basis	  of	  the	  particular	   distribution	   of	   IBM,	   and	   indeed	   other	   myopathies,	   remains	   unclear.	   The	  detailed	  anatomical	  description	  afforded	  by	  MRI	  can	  directly	  indicate	  which	  muscles	   appear	   more	   susceptible	   to	   the	   pathological	   processes	   involved.	   Studies	  of	  magnetic	   resonance	   imaging	   (MRI)	   in	   IBM	  have	  yielded	   interesting	   results	   and	   largely	   support	   the	   phenotypic	   distribution	   suggested	  clinically,	  including	  asymmetrical	  muscle	  involvement.	  	  Muscles	   affected	   by	   IBM	   demonstrate	   signal	   hyperintensity	   on	   T1-­‐weighted	  sequences	  and	  T2-­‐weighted	  sequences	  with	   fat	   suppression,	   such	  as	  short	   tau	  inversion	   recovery	   (STIR).	   This	   is	   thought	   to	   represent	   intramuscular	   fat	  accumulation	  and	   the	  presence	  of	   fluid,	   as	   inflammatory	  oedema,	   respectively	  (Machado	   et	   al.	   2014).	   In	   contrast,	   cases	   of	   PM	   tend	   to	   demonstrate	   purely	  muscle	  oedema,	  which	  is	  typically	  restricted	  to	  more	  proximal	  groups	  (Dion	  et	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al.	  2002;	  Cantwell	  et	  al.	  2005).	  In	  DM,	  unlike	  either	  PM	  or	  IBM,	  inflammation	  is	  apparent	  in	  fascia	  and	  subcutaneous	  fat	  (Garcia	  2000).	  	  Phillips	   reported	   a	   study	   of	   9	   patients	   with	   IBM,	   in	   whom	   there	   appeared	   a	  strong	   correlation	   between	   clinical	   weakness	   and	   changes	   of	   proton-­‐density	  images	   or	  mean	   T2	   relaxation	   time	   of	   the	   quadriceps	   and	   hamstring	  muscles	  (Phillips	   et	   al.	   2001).	   Radiologically,	   quadriceps	   was	   the	   most	   commonly	  severely	  affected	  muscle	  group,	  often	  asymmetrically,	  and	  was	  abnormal	  in	  7	  of	  9	   patients.	   Further,	   in	   keeping	   with	   the	   clinical	   findings,	   flexor	   digitorum	  profundus	  (FDP)	  was	  radiologically	  abnormal	   in	   the	  same	  number	  of	  patients,	  three	   of	   whom	   showed	   no	   coexistent	   involvement	   of	   adjacent	   muscle	   flexor	  digitorum	  sublimis	   (FDS).	  This	  pattern	   is	  consistent	  with	   the	   findings	  of	  Sekul	  and	  colleagues	  who	   found	  MRI	  of	   the	   forearm	  to	  reveal	  marbled	  brightness	  of	  FDP	   in	   20	   of	   21	   subjects,	   again	   with	   sparing	   of	   FDS	   even	   late	   in	   the	   disease	  course	  (Sekul	  et	  al.	  1997).	  The	   largest	   single	   study	   of	   MRI	   in	   IBM	   to	   date	   was	   reported	   by	   Cox	   and	  colleagues.	   Here,	   32	   patients	   with	   IBM	  were	   evaluated,	   all	   of	   whose	   imaging	  demonstrated	   abnormalities,	   the	   commonest	   of	  which	  was	   fatty	   infiltration	  of	  muscle.	   This	   number	   of	   muscles	   displaying	   this	   feature	   correlated	   with	   the	  clinical	  duration	  of	  the	  disease.	  In	  the	  forearm,	  FDP	  was	  preferentially	  affected,	  sometimes	   in	   isolation,	  and	  was	  abnormal	   in	   three	  quarters	  of	  patients.	   In	   the	  lower	   limb,	  and	  overall,	  vastus	   lateralis	  and	  the	  medial	  head	  of	  gastrocnemius	  were	   the	   most	   consistently	   abnormal	   muscles.	   There	   was	   relative	   sparing	   of	  rectus	  femoris,	  hamstrings	  and	  adductor	  muscles	  (Cox	  et	  al.	  2011).	  Interestingly,	   the	  majority	  of	  previous	  MRI	  studies	   in	   IBM	  also	  detected	  signal	  abnormalities	   of	   the	   medial	   head	   of	   gastrocnemius.	   This	   does	   not	   typically	  manifest	  clinically,	  presumably	  due	  to	  the	  lack	  of	  involvement	  of	  other	  muscles	  responsible	   for	   ankle	   plantarflexion	   such	   as	   soleus	   and	   the	   lateral	   head	   of	  gastrocnemius.	   However,	   this	  muscle	   can	   appear	   radiologically	   abnormal	   in	   a	  range	  of	  neuropathic	  and	  myopathic	  conditions	  (Wattjes	  et	  al.	  2010;	  Sinclair	  et	  al.	  2012).	  Two	  studies	  demonstrated	  relative	  sparing	  of	  the	  quadriceps	  muscle	  rectus	  femoris	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MRI	  offers	  considerable	  practical	  advantages	  over	  muscle	  strength	  testing	  and	  tissue	   biopsy	   as	   a	   potential	   outcome	   measure	   in	   clinical	   trials.	   Quantitative	  methods	  of	  muscle	  MRI	  are,	  accordingly,	  being	  explored	  in	  this	  context	  and	  have	  been	   validated	   in	   populations	   of	   healthy	   volunteers	   (Morrow	   et	   al.	   2014).	  Intramuscular	  fat	  accumulation,	  for	  example,	  can	  be	  quantified	  using	  the	  three-­‐point	   Dixon	   sequence	   (Glover	   et	   al.	   1991)	   and	   appears	   to	   correlate	   inversely	  with	  strength	  of	  knee	  extension	  in	  IBM	  patients	  (Morrow	  2011).	  	  
1.3	  Pathological	  abnormalities	  The	  formal	  diagnosis	  of	  IBM	  continues	  to	  rest	  upon	  on	  histological	  evidence	  and,	  indeed,	   it	   is	   histology	   that	   provided	   the	   first	   insight	   into	   the	   range	   of	  pathological	   processes	   IBM	   represents	   (Fig	   1.2).	   Biopsy	   remains	   particularly	  useful	   in	   distinguishing	   IBM	   from	   PM.	   The	   histopathological	   changes	   may	   be	  broadly	  divided	  into	  those	  with	  represent	  either	  inflammatory	  or	  degenerative	  processes,	  a	  divide	  which	  reflects	  the	  debate	  on	  the	  underlying	  aetiology	  of	  IBM.	  
	  
1.3.1	  Inflammation	  IBM’s	   traditional	   classification	   alongside	   PM	   and	   DM	   as	   an	   inflammatory	  myositis	   rests	   upon	   the	   frequent	   demonstration	   of	   endomysial	   infiltration	   by	  immune	  cells.	  This	  pattern	  largely	  mimics	  that	  observed	  in	  PM	  rather	  than	  DM,	  in	  which	  the	  inflammation	  is	  predominantly	  perivascular.	  There	  is	  widespread	  upregulation	  of	  MHC	  Class	  I,	  which	  is	  not	  normally	  expressed	  by	  skeletal	  muscle,	  along	  with	   infiltration	  of	  non-­‐necrotic	   fibres	  by	  predominantly	  CD8+	   cytotoxic	  T-­‐cells,	  which	  are	  clonally	  expanded.	  This	  contrasts	  with	  the	  chiefly	  CD4+	  T-­‐cell	  infiltrate	   that	   characterise	   DM	   (Dalakas	   2006).	   It	   is	   proposed	   that	   myofibres	  may	  act	  as	  antigen	  presenting	  cells.	  Costimulatory	  molecules	  BB1	  and	  inducible	  costimulator	  ligand	  are	  upregulated	  and	  there	  is	  colocalisation	  of	  such	  molecule	  with	  cytotoxic	  T-­‐cells	  (Murata	  et	  al.	  1999;	  Schmidt	  et	  al.	  2004).	  The	  secretion	  by	  myofibres	  of	  proinflammatory	  cytokines,	  such	  as	  IL1β,	  and	  chemokines,	  such	  as	  CXCL-­‐9,	   likely	   attract	   and	   perpetuate	   the	   T-­‐cell	   response	   (De	   Bleecker	   et	   al.	  2002).	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The	  upregulation	  of	  MHCI	  in	  IBM,	  detectable	  by	  immunohistochemistry,	  extends	  to	  fibres	  that	  appear	  otherwise	  normal	  and	  the	  absence	  of	  this	  feature	  raises	  	  
	  
Figure	  1.2	  Histopathological	  features	  of	  IBM	  	  In	   haematoxylin	   and	   eosin	   stained	   sections	   there	   may	   be	   variation	   in	   fibre	  diameter	   (A)	   and	   fibre	   necrosis	   (arrow	   in	   A).	   Vacuoles	   rimmed	   by	   basophilic	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granular	  material	   are	   seen	   (arrows	   in	   B)	   and	   are	   sometimes	   associated	   with	  hyalinised	  eosinophilic	  inclusions	  (arrow	  in	  C).	  Fibre	  necrosis	  can	  be	  confirmed	  using	   the	   acid	   phosphatase	   histochemical	   preparation	   (D).	   Fibres	   lacking	  cytochrome	  oxidase	  activity	  may	  be	  present	  (arrow	  in	  E).	  There	  is	  widespread	  expression	   of	  MHC	   Class	   I	   at	   the	   sarcolemma	   (F).	   Lymphocytic	   infiltrates	   are	  largely	   endomysial	   and	   are	   composed	   predominantly	   of	   CD8	   expressing	   cells	  (G)	  which	   infiltrate	   into	   intact	  myofibres	   (arrow	   in	  H).	  A-­‐C:	  haematoxylin	  and	  eosin;	   D:	   acid	   phosphatase	   histochemistry;	   E:	   cytochrome	   oxidase	  histochemistry;	   F:	   MHC	   class	   I	   immunohistochemistry;	   G-­‐H	   CD8	  immunohistochemistry.	  Bar	  in	  A	  represents	  25μm	  in	  A-­‐D	  &	  H,	  and	  50μm	  in	  E-­‐G.	  From	  (Machado	  et	  al.	  2009)	  	  diagnostic	  doubt,	  since	  it	  is	  observed	  in	  96%	  of	  cases.	  Its	  upregulation	  does	  not	  appear	  to	  be	  affected	  by	  short-­‐term	  use	  of	  immunosuppressive	  agents	  (van	  der	  Pas	  et	  al.	  2004).	  Whilst	  the	  sensitivity	  of	  MHCI	  expression	  appears	  high,	  it	  is	  not	  specific	   to	   IBM	   or	   the	   established	   primary	   inflammatory	   myositides	   and	   has	  been	   demonstrated	   in	   cases	   of	   Duchenne	   muscular	   dystrophy	   and	  dysferlinopathy.	   Endomysial	   inflammation	   is	   additionally	   seen	   in	   FSHD,	   statin	  myopathy,	  caveolinopathy,	  calpainopathy	  and	  merosinopathy.	  In	  each	  of	  these,	  MHCI	   expression	   is	   presumed	   to	   be	   a	   secondary	   response	   to	   the	   underling	  primary	   genetic	   or	   toxic	   insult	   (van	   der	   Pas	   et	   al.	   2004).	   Indeed,	   both	   MHCI	  expression	   and	   lymphocytic	   infiltration	   of	   muscle	   can	   be	   observed	   in	  neurogenic	  atrophy	  (Troost	  et	  al.	  1992).	  The	  evidence	  of	  humoral	  immunity	  in	  IBM	  is	  less	  well	  defined.	  Those	  antibodies	  associated	  with	  autoimmune	  myositides,	  such	  as	  anti-­‐signal	  recognition	  peptide	  (SRP),	   Jo-­‐1	   or	   Mi-­‐2,	   are	   absent	   in	   IBM.	   Microarray	   studies	   suggest	  immunoglobulin	   genes	   are	   among	   the	   most	   abundantly	   differentially	  transcribed	  genes	   in	   IBM	  muscle,	  accounting	   for	  a	  greater	  proportion	  of	   those	  upregulated	   more	   than	   20-­‐fold	   than	   in	   PM	   muscle	   (Greenberg	   et	   al.	   2005).	  There	   is	   immunohistochemical	   evidence	   of	   CD19	   and	   CD20	   B-­‐cells,	  outnumbered	  by	  CD138	  differentiated	  plasma	  cells.	  Myeloid	  dendritic	  cells,	  with	  the	   potential	   for	   antigen	   presentation	   and	   production	   of	   interferons,	   are	   also	  detected	  in	  IBM	  muscle	  (Greenberg	  et	  al.	  2007).	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The	  identification	  of	  antibodies	  to	  a	  43kDa	  antigen,	  subsequently	  determined	  as	  cytosolic	   5’-­‐nucleotidase	   1A	   (C5N1A),	   provides	   the	   best	   evidence	   of	   humoral	  immunity	  in	  IBM.	  Although	  it	  is	  not	  clear	  that	  these	  antibodies	  are	  pathogenic,	  a	  dot	  blot	  assay	  has	  demonstrated	  up	  to	  70%	  sensitivity	  and	  92%	  specificity	  for	  IBM	  in	  one	  group	  of	  165	  patients	  with	  neuromuscular	  disease.	  In	  keeping	  with	  the	   known	   location	   of	   the	   target	   antigen,	   C5N1A	   immunohistochemistry	  localises	   to	   the	   perinuclear	   region	   and	   to	   rimmed	   vacuoles,	   supporting	   the	  hypothesis	  that	  these	  represent	  myonuclear	  degeneration	  in	  IBM	  (Larman	  et	  al.	  2013).	  	  	  
1.3.2	  Degenerative	  features	  
1.3.2.1	  Rimmed	  vacuoles	  Sarcoplasmic	  vacuoles	  are	  a	   feature	  of	   several	  myopathies	   in	  addition	   to	   IBM,	  including	   hereditary	   Inclusion	   Body	   Myopathies,	   oculopharyngeal	   muscular	  dystrophy,	   Emery-­‐Dreifuss	   muscular	   dystrophy,	   Becker’s	   muscular	   dystrophy	  and	   also	   chronic	   neuropathies	   including	   poliomyelitis	   and	   spinal	   muscular	  atrophy	   (Villanova	   et	   al.	   1993;	   Semino-­‐Mora	   et	   al.	   1998;	   Paradas	   et	   al.	   2005;	  Malicdan	  et	  al.	  2007;	  Momma	  et	  al.	  2012).	   In	  IBM,	  these	  vacuoles	  are	  typically	  detected	   in	   those	   fibres	   not	   invaded	   by	   lymphocytes	   and	   the	   overwhelming	  majority	   are	   ‘rimmed’	   by	   basophilic	   granular	   deposits	   at	   their	   peripheries	  (Greenberg	   et	   al.	   2006).	   A	   relatively	   small	   proportion	   of	   fibres	   demonstrate	  rimmed	  vacuoles,	  with	  estimates	  ranging	  between	  less	  than	  1	  and	  6%	  (Mhiri	  et	  al.	  1990;	  Mendell	  et	  al.	  1991).	  The	  origin	  of	  rimmed	  vacuoles	  is	  unclear	  but	  autophagic	  lysosomal	  degradation	  or	   myonuclear	   breakdown	   have	   been	   proposed	   (Villanova	   et	   al.	   1993).	   The	  latter	   hypothesis	   is	   supported	   by	   detection	   of	   nuclear	   membrane	   proteins	  emerin	   and	   lamin	   A/C	   by	   immunohistochemistry	   in	   the	   vacuolar	   lining	   along	  with	   electron	   microscopic	   evidence	   of	   nuclear	   membrane	   rupture.	   An	  association	   of	   vacuoles,	   15-­‐21nm	   tubulofilaments	   and	   nuclear	   abnormalities	  has	   been	   proposed	   since	   these	   features	   are	   shared	   by	   Paget’s	   disease,	  IBMPDFTD,	  hIBM	  due	  to	  GNE	  mutations	  and	  OPMD	  (Greenberg	  et	  al.	  2006).	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1.3.2.2	  Intracellular	  protein	  deposition	  IBM	   tissue	   is	   further	   characterised,	   and	   distinguished	   from	   PM,	   by	  proteinaceous	   nuclear	   and	   cytoplasmic	   aggregates.	   These	   contain	   a	   variety	   of	  proteins	   commonly	   associated	   with	   neurodegenerative	   diseases,	   including	  
βamyloid	  species,	  phosphorylated	  tau,	  presenelin,	  α-­‐synuclein,	  TDP-­‐43	  and	  p62	  (Nogalska	   et	   al.	   2009;	   Salajegheh	   et	   al.	   2009;	   Askanas	   et	   al.	   2012).	   These	   are	  typically	   detected	   on	   histological	   examination	   by	   immunohistochemistry.	  Electron	  microscopy	  demonstrates	  15-­‐21nm	   tubulofilamentous	   inclusions	  and	  cytoplasmic	   collections	   of	   6-­‐10nm	   amyloid-­‐like	   filaments.	   Some	   myonuclei	  contain	  7nm	  filaments	  (Fig	  1.3).	  The	  particular	  pathogenic	  relevance	  of	  protein	  aggregation	   in	   IBM	   is	   discussed	   further	   below	   (see	   Chapter	   4	   Introduction,	  Sections	  4.2	  and	  4.3).	  	  
1.3.2.3	  Mitochondrial	  abnormalities	  Mitochondrial	   dysfunction	   is	   evidenced	   by	   ragged	   red	   fibres	   on	   Gomori	  trichrome	  staining	  and	  by	  an	  excessive	  number	  of	  cytochrome-­‐oxidase	  negative	  fibres	   adjusted	   for	   patient	   age	   (Fig	   1.2,	   Image	   E).	   The	   latter	   feature	   is	  particularly	   common,	   affecting	   63	   of	   64	   biopsies	   in	   one	   study	   (Chahin	   et	   al.	  2008).	   Mitochondria	   also	   display	   structural	   abnormalities	   in	   IBM,	   including	  paracrystalline	  inclusions	  (Oldfors	  et	  al.	  2006).	  	  The	  accumulation	  of	  COX	  negative	  fibres	  with	  ‘normal’	  ageing	  appears	  to	  reflect	  focal	  deficits	  of	  oxidative	  phosphorylation,	  reflecting	  clonal	  expansion	  of	  mtDNA	  mutations.	   This	   can	   be	   quite	   marked,	   affecting	   up	   to	   15%	   of	   fibres	   and	   has,	  accordingly,	   been	   hypothesised	   as	   contributory	   in	   the	   sarcopenia	   of	   ageing	  (Wallace	   1992).	   Quantification	   of	   COX	  negativity	   is	   further	   complicated	   by	   its	  tendency	   to	   affect	   fibres	   segmentally,	   meaning	   there	   is	   a	   tendency	   towards	  underestimation	  of	  the	  number	  of	  COX	  negative	  fibres	  through	  use	  of	  standard	  cross-­‐sectional	   histological	   analysis.	   Nevertheless,	   mtDNA	   mutations,	  predominantly	  large-­‐scale	  deletions,	  have	  similarly	  been	  demonstrated	  in	  COX-­‐deficient	  fibres	  of	  IBM	  patients	  (Oldfors	  et	  al.	  1993).	  Southern	  blot	  has	  implied	  that	  the	  overall	  amount	  of	  mutated	  mtDNA	  is	  low	  in	  IBM,	  consistent	  with	  the	  	  






Figure	  1.3	  Electron	  microscopic	  features	  of	  IBM	  Ultrastructural	   examination	   of	   muscle	   fibres	   demonstrates	   whorled	  membranous	  debris	  (arrow	  in	  A)	  and	  associated	  randomly	  orientated	  filaments	  (B).	   Bar	   in	   A	   represents	   700nm	   in	   A	   and	   200nm	   in	   B.	   From	   (Machado	   et	   al.	  2009)	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lack	  of	  impaired	  oxidative	  metabolism	  in	  31P	  MR	  spectroscopy	  (Santorelli	  et	  al.	  1996;	  Lodi	  et	  al.	  1998).	  Mutations	  have	  not	  been	  detected	  in	  the	  nuclear	  genes,	  that	  encode	  for	  mitochondrial	  proteins,	  such	  as	  POLG,	  in	  patients	  with	  IBM.	  A	   distinct	   disease	   entity	   of	   ‘Polymyositis	   with	   mitochondrial	   pathology	   in	  muscle’	   (PM-­‐Mito)	   has	   been	   proposed	   (Temiz	   et	   al.	   2009).	   This	   term	   was	  applied	   to	   patients	   with	   a	   stereotypical	   IBM	   phenotype	   and	   whose	   muscle	  biopsies	   lack	   vacuoles	   but,	   nevertheless,	   display	   similar	   inflammatory	  characteristics	  to	  those	  observed	  in	  IBM	  or	  PM.	  There	  appears	  little	  evidence	  to	  support	  PM-­‐Mito	  being	  anything	  other	  than	  part	  of	  the	  sporadic	  IBM	  spectrum.	  First,	   the	   use	   of	   the	   Polymyositis	   stem	   is	   inconsistent	   with	   the	   clinical	  phenotype	   being	   highly	   distinctive	   of	   IBM	   rather	   than	   PM.	   Secondly,	   the	  presence	  in	  ‘PM-­‐Mito’	  biopsies	  of	  congo-­‐red	  fluorescent	  aggregates	  of	  βamyloid,	  phosphorylated	   tau	   and	   TDP-­‐43	   is	   entirely	   consistent	   with	   IBM.	   Thirdly,	   the	  absence	  of	  vacuoles	  is	  arbitrary	  since	  it	  these	  represent	  just	  one	  established	  feature	  of	  IBM	  muscle	  biopsies	  and,	  conversely,	  the	  rare	  occurrence	  of	  vacuoles	  in	  DM	  has	  not	  led	  to	  creation	  of	  a	  distinct	  diagnostic	  entity	  (Layzer	  et	  al.	  2009).	  Therefore,	   the	   term	   IBM-­‐Mito	  may	   be	  more	   appropriate.	   To	   support	   this,	   one	  study	  has	  determined	  significantly	  greater	  proportions	  of	  COX	  negative	  fibres	  in	  ‘PM-­‐mito’	   than	   IBM,	   along	   with	   significantly	   fewer	   fibres	   affected	   by	   tau	   and	  TDP-­‐43	   pathology	   (Temiz	   et	   al.	   2009).	   It	   is	   equally	   likely	   that	   these	   patients	  represent	   one	   element	   of	   the	   extensive	   IBM	   histological	   spectrum.	  Pragmatically,	   a	   significant	   proportion	   of	   this	   group	   may	   represent	   the	  ‘clinically	  defined’	  population	  who	  have	  a	  milder	  form	  of	  the	  disease	  or	  who	  less	  pathologically	   advanced	   at	   the	   point	   of	   biopsy.	   Definition	   of	   this	   population	  could	   prove	   useful	   for	   identification	   of	   patients	   more	   likely	   to	   respond	   to	  treatments	  targeted	  at	  degenerative	  aspects	  of	  IBM.	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1.3.3	  Summary	  of	  features	  of	  IBM	  and	  primary	  myositides	  After	   considering	   the	   various	   clinical	   and	   pathological	   features	   of	   IBM,	   it	   is	  useful	   to	  compare	  these	  with	  the	  primary	  myositides,	  PM	  and	  DM,	  with	  which	  IBM	   is	   traditionally	   classified	   (Table	   1.1).	   This	   highlights	   that,	   although	   some	  similarities	   do	   exist,	   there	   are	   numerous	   significant	   differences	   in	   both	   the	  clinical	  and	  pathological	  domains.	  Perhaps	  most	  notable	   is	   the	  distinct	  patient	  population	  affected	  by	  each	  disorder.	  	  	  	  




• CD8+	  T-­‐Cells	  
• MHC	  Class	  I	  expression	  
• Intracellular	  inclusions	  
• TDP-­‐43	  translocation	  
• Mitochondrial	  
impairment	  
• Rimmed	  vacuoles	  
• Endomysial	  
inflammation	  
• CD8+	  T-­‐Cells	  
• MHC	  Class	  I	  expression	  
• Perivascular	  
inflammation	  
• CD4+	  T-­‐Cells	  
• MAC	  expression	  
Clinical	  
• >50	  year-­‐old	  Men	  
• Forearm	  flexors	  and	  
quadriceps	  
• Some	  association	  with	  
autoimmunity	  
• Mild	  Increase	  in	  CK	  
• Denervation	  on	  
neurophysiology	  
• >18	  year-­‐old	  Men	  and	  
Women	  
• Proximal	  limb	  muscles	  
• Strong	  association	  with	  
autoimmunity	  
• Large	  Increase	  in	  CK	  
• Paediatric	  /	  
strong	  
association	  with	  
cancer	  in	  adults	  
• Rash	  
• Large	  increase	  
CK	  
Table	  1.1	  Basic	  comparison	  of	  IBM	  and	  primary	  myositides	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1.4	  Diagnostic	  criteria	  After	   consideration	   of	   its	   clinical	   and	   histological	   phenotype,	   a	   number	   of	  diagnostic	   criteria	   for	   IBM	   have	   emerged.	   These	   are	   of	   significance	   in	  considering	   the	   validity	   of	   the	   boundaries	   such	   criteria	   impose	   between	   IBM	  and	   its	   differential	   diagnoses.	   Indeed,	   in	   seeking	   to	   formulate	   a	   translational	  research	  project,	  it	  is	  essential	  that	  a	  defined	  group	  of	  applicable	  patients	  can	  be	  readily	   identified.	   In	   a	   sporadic	   condition,	   particularly	   one	   of	   uncertain	  aetiology,	   the	   establishment	   of	   validated	   diagnostic	   criteria	   is	   challenging.	   A	  review	  of	   these	   criteria	  was	   of	   particular	   importance	   in	   designing	   the	   clinical	  study	  described	  in	  this	  thesis	  (described	  in	  Chapter	  5).	  	  
1.4.1	  Griggs’	  criteria	  The	  most	   commonly	   applied	   criteria	   are	   those	   described	   by	  Tawil	   and	  Griggs	  (Tawil	  et	  al.	  2002)	  which	  allow	  diagnosis	  of	  definite	  or	  probable	   IBM.	  Patients	  meeting	  either	  definition	  are	  routinely	  included	  in	  clinical	  studies,	  reflecting	  the	  high	  threshold	  for	  diagnosis	  set	  by	  these	  criteria.	   	  Definite	  IBM	  is	  a	  histological	  diagnosis	   in	   which	   invasion	   of	   non-­‐necrotic	   fibres	   by	   mononuclear	   cells,	  vacuolation	   and	   either	   amyloid	   deposits	   or	   15-­‐18nm	   tubulofilaments	   are	  required.	   In	   this	   case,	   the	   clinical	   features	   are	   not	   considered.	   Probable	   IBM	  refers	  to	  the	  combination	  of	  invasion	  of	  intact	  fibres	  by	  mononuclear	  cells	  and	  vacuoles	   but	  without	   the	   other	   pathological	   features.	   In	   this	   case,	   the	   clinical	  presentation	  must	  be	  stereotypical,	  in	  that	  there	  must	  be	  at	  weakness	  of	  at	  least	  one	  of	  finger	  flexion,	  wrist	  flexion	  or	  the	  quadriceps.	  Furthermore,	  the	  serum	  CK	  must	   be	   <12	   times	   the	   upper	   limit	   of	   normal	   and	   electromyography	  must	   be	  ‘consistent	   with	   an	   inflammatory	  myopathy’.	   Evidently,	   even	   the	   diagnosis	   of	  
probable	   IBM	   requires	   meeting	   the	   majority	   of	   the	   clinical	   and	   histological	  features	  discussed	  above.	  Criticisms	  of	  these	  criteria	  have	  included	  that	  patients	  who	   are	   clinically	   stereotypical	   of	   IBM	   but	   are	   relatively	   early	   in	   the	   disease	  course	  at	  the	  time	  of	  muscle	  biopsy	  may	  lack	  the	  particular	  histological	  features	  described.	   Furthermore,	   the	   use	   of	   ‘invasion	   of	   intact	   fibres	   by	   mononuclear	  cells’	   as	   a	   surrogate	  marker	   of	   inflammation	  may	   not	   be	   demonstrated	   by	   all	  biopsies	   which	   nevertheless	   contain	   CD8+	   lymphocytes	   and	   up-­‐regulation	   of	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MHC	  Class	  I.	  Indeed,	  the	  widespread	  expression	  of	  MHC	  Class	  I	  appears	  to	  be	  a	  more	  reliable	  segregator	  of	  myositis	   from	  the	  secondary	   inflammation	  seen	   in	  dystrophies	   (van	   der	   Pas	   et	   al.	   2004).	   Neither	   the	   application	   of	   electron	  microscopy	  to	  biopsies	  nor	  the	  use	  of	  neurophysiology	  are	  routine	  practices	  in	  evaluation	   of	   suspected	   IBM	   cases,	   limiting	   their	   practical	   use	   outside	  specialised	  centres.	  Most	  importantly,	  several	  histological	  features,	  such	  as	  the	  presence	   of	   p62	   and	   TDP-­‐43	   on	   immunohistochemistry,	   have	   emerged	   in	   the	  years	   succeeding	   the	   publication	   of	   Griggs’	   criteria	   in	   2002	   (Nogalska	   et	   al.	  2009;	  Salajegheh	  et	  al.	  2009).	  	  It	   appears	   likely	   that	   these	   criteria	   are	   highly	   specific	   for	   IBM	   but	   are	   of	   low	  sensitivity.	   Some	   have	   proposed	   that	   those	   patients,	   who	   lack	   the	   features	  required	  to	  meet	  Griggs’	  criteria,	  may	  have	  the	  greatest	  potential	  benefit	   from	  treatment	  and	  should	  be	   the	  primary	   target	   for	   recruitment	   into	  clinical	   trials	  (Hilton-­‐Jones	  et	  al.	  2010).	  	  
1.4.2	  European	  Neuromuscular	  Centre	  criteria	  The	  ENMC	  diagnostic	  criteria	  were	  described	  in	  1997	  (Table	  1.2).	  In	  the	  single	  direct	  comparison	  with	  Griggs’	  criteria,	  these	  appear	  to	  set	  a	  lower	  threshold	  for	  
definite	   IBM	  but	  do	  not	   represent	  a	  different	   level	  of	   sensitivity	  once	  probable	  cases	  are	  included.	  In	  this	  study,	  103	  patients	  were	  identified,	  of	  whom	  72	  were	  
definite	  and	  31	  probable	  according	  to	  ENMC	  criteria.	  Applying	  Griggs’	  criteria	  to	  the	   same	   population,	   16	   cases	   would	   have	   been	   considered	   definite	   and	   87	  
probable	   (Badrising	  et	   al.	   2000).	   The	  ENMC	  criteria	  place	  greater	  onus	  on	   the	  clinical	  description	  of	  the	  disease.	  	  
1.4.3	  MRC	  Centre	  for	  Neuromuscular	  Diseases	  criteria	  Following	   an	   international	   workshop	   in	   2008,	   a	   further	   set	   of	   criteria	   was	  proposed	   that	   contains	   a	   ‘pathologically	   defined’	   group,	   characterised	   as	   per	  Griggs’	   criteria,	   and	   also	   a	   ‘clinically	   defined’	   group	   (Table	   1.3).	   Such	  patients	  demonstrate	   disproportionate	   weakness	   of	   finger	   flexion	   relative	   to	   shoulder	  abduction	  and	  of	  knee	  extension	  relative	  to	  hip	  flexion,	  reflecting	  the	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European	  Neuromuscular	  Centre	  (ENMC)	  Criteria	  for	  Diagnosis	  of	  IBM	  
A.	  Clinical	  
1.	  Presence	  of	  muscle	  weakness	  	  
2.	   Weakness	   of	   forearm	   muscles,	   particularly	   finger	   flexors,	   or	   wrist	   flexors	  
more	  than	  wrist	  extensors	  	  
3.	  Slowly	  progressive	  course	  	  
4.	  Sporadic	  disease	  
B.	  Histopathology	  	  
5.	  Mononuclear	   inflammatory	   infiltrates	  with	   invasion	   of	   non-­‐necrotic	  muscle	  
fibres	  
6.	  Rimmed	  vacuoles	  
7.	  Ultrastructure:	  tubulofilaments	  of	  16	  to	  21	  nm	  
	  
Definite	  inclusion	  body	  myositis:	   1,	  2,	  3,	  4,	  5,	  6	   or	  	  	  	   1,	  3,	  4,	  5,	  6,	  7	  
Probable	  inclusion	  body	  myositis:	   1,	  2,	  3,	  4,	  5	   or	   1,	  3,	  4,	  5,	  6	  
Table	  1.2	  ENMC	  diagnostic	  criteria	  for	  IBM	  	   	  









• Invasion	  of	  non-­‐necrotic	  fibres	  
my	  mononuclear	  cells,	  rimmed	  
vacuoles	  and	  either	  
intracellular	  amyloid	  deposits	  
or	  15-­‐18nm	  filaments	  
Clinically	  Defined	  
Clinical	  Features	  
• Duration	  >	  12	  months	  
• Age	  >	  35	  years	  
• Weakness	  of	  finger	  flexion	  >	  
shoulder	  abduction	  AND	  of	  
knee	  extension	  >	  hip	  flexion	  
Pathological	  
Features	  
• Invasion	  of	  non-­‐necrotic	  fibres	  
by	  mononuclear	  cells	  or	  
rimmed	  vacuoles	  or	  increased	  
MHC-­‐I	  but	  no	  intracellular	  




• Duration	  >	  12	  months	  
• Age	  >	  35	  years	  
• Weakness	  of	  finger	  flexion	  >	  
shoulder	  abduction	  OR	  of	  knee	  
extension	  >	  hip	  flexion	  
Pathological	  
Features	  
• Invasion	  of	  non-­‐necrotic	  fibres	  
by	  mononuclear	  cells	  or	  
rimmed	  vacuoles	  or	  increased	  
MHC-­‐I	  but	  no	  intracellular	  
amyloid	  deposits	  or	  15-­‐18nm	  
filaments	  
Table	  1.3	  MRC	  Centre	  criteria	  for	  diagnosis	  of	  IBM	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stereotypical	   IBM	  phenotype	  but	  biopsy	  may	  display	  only	  one	  of	  mononuclear	  cell	  invasion,	  increased	  MHCI	  or	  rimmed	  vacuoles	  (Hilton-­‐Jones	  et	  al.	  2010).	  The	  additional	  criterion	  of	  age	  being	  over	  than	  35	  years	  represented	  the	  minimum	  age	  at	  which	  any	  of	  an	  invited	  panel	  of	  experts	  had	  observed	  sporadic	  IBM.	  It	  is	  hypothesised	   that	   these	   patients	   may	   represent	   the	   earlier	   portion	   of	   the	  disease	  spectrum.	  
1.4.4	  Overall	  discussion	  of	  diagnostic	  criteria	  The	  principal	  aim	  of	  diagnostic	  criteria	  is	  to	  distinguish	  IBM	  from	  its	  differential	  diagnoses,	   which	   incorporate	   both	   the	   primary	   inflammatory	   myositides	   PM	  and	   DM,	   a	   range	   of	   genetic	   muscular	   dystrophies	   and	   amyotrophic	   lateral	  sclerosis	  (ALS).	  	  Until	   the	   aetiological	   differences	   between	   IBM	   these	   conditions	   are	   fully	  understood,	   diagnostic	   criteria	   will	   be	   of	   limited	   accuracy.	   The	   pathological	  differences	   appear	   to	   be	   of	   a	   subtlety	   not	   currently	   incorporated	   by	   standard	  clinical	   practice,	   such	   as	   the	   use	   of	   detailed	   immunohistochemical	   analysis.	  Therefore,	   current	   criteria	   must	   maintain	   a	   high	   threshold	   for	   diagnosis	   and	  hence	   a	   high	   degree	   of	   specificity	   rather	   than	   risk	   the	   inclusion	   of	   non-­‐IBM	  cases	   in	   clinical	   studies	  of	   IBM.	  The	   stereotypical	   clinical	  phenotype	   is	   readily	  recognised	  by	  neuromuscular	   specialists	   and	   the	   study	  of	   a	   ‘clinically	  defined’	  population	   may	   prove	   important	   in	   identifying	   subgroups	   with	   particular	  potential	  for	  benefit	  from	  new	  treatments.	  The	  exclusion	  of	  MFM	  in	  such	  cases	  is	  particularly	  important.	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1.5	  Treatment	  of	  IBM	  There	   is	   no	   effective	   pharmacological	   treatment	   for	   IBM.	   Standard	   clinical	  management	   is	   to	   offer	   only	   supportive	   therapies	   such	   as	   physiotherapy,	  occupational	  therapy	  and	  psychological	  support.	  Anecdotally,	  empirical	  courses	  of	   corticosteroids	   are	   common	   despite	   lack	   of	   supporting	   trial	   evidence.	   A	  number	   of	   small	   trials,	   all	   of	  which	   have	   included	   immune	   based	   drugs,	   have	  been	  undertaken	  without	  significant	  evidence	  of	  efficacy.	  These	  are	  considered	  in	  detail	  in	  Chapter	  5	  (see	  Chapter	  5	  Introduction,	  Section	  5.1.2).	  Although	  one	  inference	  of	  the	  failure	  of	  these	  trials	  could	  be	  that	  the	  inflammatory	  component	  in	  IBM	  is	  not	  clinically	  significant,	  it	  is	  unlikely	  that	  these	  trials	  were	  powered	  to	  detect	  realistic	  clinical	  changes;	  therefore	  this	  must	  be	  done	  with	  caution.	  	  
1.6	  Hypotheses	  of	  IBM	  pathogenesis	  Two	   dominant	   views	   have	   emerged	   on	   the	   pathogenesis	   of	   IBM;	   these	   are	  distinguished	  by	  the	  relative	  importance	  each	  attaches	  to	  pathological	  features	  that	   can	   broadly	   be	   described	   as	   either	   inflammatory	   or	   degenerative.	   The	  potential	   contribution	   towards	  overall	   pathogenesis	   by	   individual	   elements	  of	  either	  of	   these	  processes	   is	  considered	  elsewhere	   in	  this	   thesis	  (see	  Chapter	  3	  and	  4,	  Introductions).	  The	  general	  basis	  of	  the	  ‘inflammatory’	  and	  ‘degenerative’	  hypotheses	  is	  described	  below.	  
1.6.1	  IBM	  as	  a	  primary	  immune	  disease	  The	   argument	   for	   a	   primarily	   inflammatory	   or	   autoimmune	   mechanism,	   as	  proposed	  by	  Dalakas	  and	  colleagues	   is	  based	  upon	  evidence	  that	  degenerative	  features	   in	   IBM	  are	  secondary	   to	  such	   inflammation,	  and	  has	  supported	   IBM’s	  traditional	   classification	   as	   a	   primary	   myositis	   alongside	   PM	   and	   DM.	  Autoimmunity	  is	  implied	  by	  an	  immunogenetic	  association	  with	  HLA	  haplotypes,	  the	   presence	   of	   autoantibodies	   at	   levels	   comparable	   to	   other	   autoimmune	  disorders	  (Badrising	  et	  al.	  2004),	  the	  expression	  of	  paraproteins	  and	  the	  clonal	  expansion	   of	   autoinvasive	   CD8+	   T-­‐cells	   (Muntzing	   et	   al.	   2003).	   If	   IBM	   is	  autoimmune	  the	  trigger	  for	  breakdown	  in	   immune	  tolerance	   is	  not	  clear.	  Viral	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infection	  has	  been	  postulated	  due	  to	  rare	  descriptions	  of	  an	  IBM-­‐like	  myopathy	  following	  retroviral	  infection	  by	  HTLV	  (Ozden	  et	  al.	  2001)	  and	  HIV	  (Cupler	  et	  al.	  1996)	   but	   viral	   RNA	   or	   DNA	   has	   not	   been	   consistently	   detected	   in	   cases	   of	  sporadic	  IBM.	  More	  direct	  evidence	  has	  gradually	  emerged	  on	  the	  mechanisms	  through	  which	  inflammation	   leads	   to	   protein	  mishandling.	   Inflammation,	   induced	   in	   skeletal	  muscle	   via	   lipopolysaccharide,	   has	   been	   shown	   to	   increase	   βamyloid	  concentration	   and	   enhance	   phosphorylation	   of	   tau	   (Kitazawa	   et	   al.	   2005).	  Furthermore,	  exposure	  of	  myogenic	  cells	  in	  vitro	  to	  the	  inflammatory	  mediators	  IL1β	   and	   IFNγ	   increases	   amyloid	   load,	   as	   assessed	   by	   immunostaining	   and	  western	   blotting.	   A	   linear	   relationship	   has	   been	   observed	   between	   the	  concentration	   of	   cytokine	   and	   chemokine	  mRNA	   and	   the	   expression	   of	   βAPP,	  tau,	   and	   ubiquitin	   in	   IBM	   in	   vivo	   (Schmidt	   et	   al.	   2008).	   Therefore,	   the	   local	  expression	  of	   proinflammatory	   chemokines	   	   (including	  CC-­‐	   or	  CXC-­‐chemokine	  ligands	   and	   cytokines	   such	   as	   interleukin-­‐1β	   (IL1β),	   tumour	   necrosis	   factor	  alpha	   (TNFα),	   interferon	   gamma	   (IFNγ)	   and	   transforming	   growth	   factor-­‐β	  (TGFβ)	   could	   represent	   an	   early	   pathogenic	   occurrence	   (Tews	   et	   al.	   1996;	  Lundberg	  et	  al.	  1997;	  De	  Bleecker	  et	  al.	  1999;	  Confalonieri	  et	  al.	  2000;	  Civatte	  et	  al.	   2005;	   Raju	   et	   al.	   2005;	   De	   Paepe	   et	   al.	   2007;	   Tournadre	   et	   al.	   2007).	   The	  consequent	   chronic	   upregulation	   of	   MHC	   Class	   I	   (MHCI)	   may	   contribute	   to	  endoplasmic	  reticulum	  stress	  and,	  consequent	  perpetuation	  of	  NFκB	  activation	  that	   would	   generate	   further	   pro-­‐inflammatory	   signalling	   and	   create	   a	   self-­‐sustaining	  cycle.	  However,	  MHCI	  upregulation	   is	  a	   feature	  of	  other	  myositides,	  as	  well	  as	  a	  non-­‐specific	  finding	  in	  some	  primary	  genetic	  myopathies.	  Therefore,	  either	  the	  chronicity	  or	  magnitude	  of	  over-­‐expression	  would	  need	  to	  be	  greater	  in	   IBM,	  which	  has	  not	  been	  established,	  or	  additional	   factors	  contribute	  to	  the	  downstream	  effects.	  Nevertheless,	  the	  effect	  of	  cytokines	  (Goldgaber	  et	  al.	  1989)	  and	   NFκB	   (Grilli	   et	   al.	   1996)	   to	   increase	   βAPP	   transcription,	   and	   βamyloid	  translation,	   may	   exacerbate	   endoplasmic	   reticulum	   (ER)	   stress	   and	   thereby	  contribute	  to	  proteasome	  dysfunction	  and	  misfolded	  protein	  accumulation,	  in	  a	  second	  self-­‐perpetuating	  cycle.	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1.6.2	  IBM	  as	  a	  degenerative	  disease	  Despite	   the	   evidence	   for	   an	   inflammatory	  mechanism,	   there	   are	   fundamental	  clinical	  and	  pathological	  differences	  observed	  between	  IBM	  and	  the	  established	  inflammatory	  myopathies,	   Polymyositis	   (PM)	   and	  Dermatomyositis	   (DM).	   The	  elderly,	   predominantly	  male,	   population	  who	   suffer	   from	   IBM,	   contrasts	  with	  the	   young,	   female	   cohort	   typically	   affected	   by	   autoimmune	   diseases.	  Degenerative	   features,	   such	   as	   intracellular	   protein	   aggregates	   and	   rimmed	  vacuoles,	  are	  conspicuously	  absent	  from	  PM	  or	  DM	  despite	  also	  demonstrating	  upregulation	  of	  MHCI.	  Moreover,	  the	  ER	  stress	  induced	  in	  transgenic	  mice	  over-­‐expressing	   MHCI,	   does	   not	   translate	   to	   intracellular	   protein	   aggregation	   or	  vacuolation	  (Nagaraju	  et	  al.	  2000;	  Nagaraju	  et	  al.	  2005).	  	  Furthermore,	  while	  DM	  and	   PM	   conditions	   respond	   clinically	   to	   immunotherapy,	   IBM	   does	   not,	   even	  when	  histological	  inflammation	  is	  reduced	  (Barohn	  et	  al.	  1995).	  	  In	  keeping	  with	  these	  criticisms	  against	  a	  purely	  inflammatory	  basis	  for	  IBM,	  an	  alternative	   hypothesis	   exists	   that	   IBM	   is	   primarily	   degenerative.	   This	   was	  proposed	   by	   the	   work	   of	   Askanas	   and	   Engel,	   which	   also	   places	   β-­‐amyloid	  accumulation	  as	  an	  early	  upstream	  event	  (Askanas	  et	  al.	  2006).	  For	  this	  reason,	  IBM	  has	  been	  referred	  to	  as	  ‘The	  Alzheimer’s	  of	  Muscle’.	  In	  this	  theory,	  following	  protein	  misfolding	  and	  accumulation,	  ER	  stress	  and	  oxidative	  stress	  combine	  to	  trigger	   a	   T-­‐cell	   response	   to	   antigens	   derived	   from	   the	   accumulating	   proteins.	  Amyloid	   accumulation	   does	   induce	   muscle	   inflammation	   in	   vivo;	   transgenic	  mice	  that	  overexpress	  βAPP	  in	  skeletal	  muscle	  develop	  myositis	  (Sugarman	  et	  al.	  2002).	   Furthermore,	   when	   the	   Aβ42	   oligomer	   is	   selectively	   augmented,	   this	  inflammation	   is	   characterised	   by	   CD8+	   T-­‐cells,	   reflecting	   IBM	   patient	   tissue	  (Kitazawa	  et	   al.	   2006).	  This	   is	   associated	  with	   calcium	  dyshomeostasis,	  which	  reflects	   the	   potential	   for	   functional	   impairment	   of	   skeletal	   muscle	   excitation-­‐contraction	  coupling	  by	  β-­‐amyloid	  (Moussa	  et	  al.	  2006).	  In	  addition	  to	  a	  potential	  role	  in	  triggering	  inflammation,	  protein	  accumulation,	  particularly	   amyloid	   oligomers,	   can	   induce	   other	   key	   components	   of	   IBM	  pathology	   in	  vitro.	  βAPP	  over-­‐expression,	  with	  consequent	  Aβ42	  accumulation	  in	   intracellular	   aggregates,	   results	   in	   a	   dose-­‐dependent	   cytopathic	   effect,	  impaired	   innervation	   by	   co-­‐cultured	   neurons	   and	   mitochondrial	   dysfunction	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(Askanas	   et	   al.	   1996;	   Askanas	   et	   al.	   1997).	   It	   also	   produces	   proteasomal	  dysfunction,	   a	   feature	   of	   human	   IBM	   tissue	   that	   appears	   both	   to	   induce	   and	  arise	   from	   intracellular	   protein	   accumulation	   and	   is	   compounded	   by	  mutated	  ubiquitin	  UBB+1	  (Bence	  et	  al.	  2001;	  Fratta	  et	  al.	  2005).	  As	  is	  postulated	  in	  other	  conditions,	  β-­‐amyloid	   toxicity	  may	  not	  be	  directly	   related	   to	   that	   contained	   in	  the	   insoluble	   aggregates,	   but	   rather	   to	   its	   soluble	   oligomers	   and	   protofibrils	  (Martins	   et	   al.	   2006).	   However,	   among	   the	  many	   neurodegenerative	   proteins	  detected	  in	  IBM,	  the	  particular	  role	  of	  β-­‐amyloid	  is	  debated	  due	  to	  the	  disparity	  in	   its	   rate	   of	   detection	   by	   different	   groups	   and	   contrasting	   interpretations	   of	  existing	   evidence	   (Greenberg	   2009;	   Schmidt	   et	   al.	   2013).	   Nevertheless,	   the	  majority	  of	  the	  other	  aggregated	  proteins	  demonstrated	  by	  IBM-­‐affected	  tissue,	  notably	   TDP-­‐43,	   have	   similar	   associations	   with	   ER	   stress,	   proteasomal	  dysfunction	   and	   mitochondrial	   impairment	   in	   models	   of	   other	   diseases,	   as	  discussed	  below	  (see	  Chapter	  4	  discussion	  on	  ER	  stress,	  NFκB	  and	  TDP43).	  An	   alternative	   source	   of	   evidence	   for	   potential	   degenerative	   drivers	   of	  secondary	  inflammation	  in	  IBM	  emerges	  through	  comparison	  with	  the	  relatively	  common	   neurodegenerative	   condition	   amyotrophic	   lateral	   sclerosis	   (ALS),	  whose	   lower	  motor	  neuron	  variant	   is	  phenotypically	  more	  reminiscent	  of	   IBM	  than	  PM	  or	  DM.	  It	  shares	  a	  predilection	  for	  aged	  male	  subjects	  and	  tendency	  for	  distal	  upper	  limb	  muscle	  wasting,	  which	  is	  rare	  among	  all	  myopathies.	  Further	  clinical	   similarity	   is	   found	   in	   the	   frequent,	   albeit	   non-­‐specific,	   neurogenic	  abnormalities	   demonstrated	   on	   neurophysiology	   of	   IBM	   patients	   (Askanas	  1998).	   Several	   myopathological	   similarities	   between	   IBM	   and	   ALS	   have	   been	  observed	   despite	   a	   relatively	   small	   number	   of	   studies	   of	   skeletal	   muscle	   in	  patients	   with	   ALS.	   Both	   conditions	   demonstrate	   preferential	   involvement	   of	  fast-­‐fatiguable	   (Type	   IIb)	  muscle	   fibres	   that	  constitute	  high	  proportions	  of	   the	  muscle	   groups	   typically	   involved	   (Atkin	   et	   al.	   2005)	   (Parker	   et	   al.	   2009).	  Interestingly,	   the	   denervated	   muscle	   of	   ALS	   patients	   also	   commonly	  demonstrates	   upregulation	   of	   MHC	   Class	   I	   (Troost	   et	   al.	   1992).	   Indeed,	   the	  addition	   of	   denervation	   augments	   the	   inflammatory	   myopathy	   of	   SJL	   mice,	  which	   develop	   a	   spontaneous	   myositis,	   through	   upregulation	   of	   MHCI	   and	  significantly	  increased	  lymphocytic	  infiltration	  by	  CD8+	  T-­‐cells	  (Kampman	  et	  al.	  1999).	  Even	   the	   transient	  MHCI	  expression	   that	   results	   from	  peripheral	  nerve	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injury,	   thought	   to	   represent	   an	   additional	   regenerative	   function,	   might	   be	  sufficient	   in	   a	   given	   context,	   to	   establish	   a	   self-­‐perpetuating	   pathogenic	   cycle	  (Maehlen	  et	  al.	  1989).	  Additionally,	   several	   degenerative	   histological	   features	   of	   IBM	   including	  rimmed	  vacuolation,	  β-­‐amyloid	  deposits	  and	  ubiquinated	  inclusions	  can	  be	  seen	  in	  muscle	   from	   patients	  with	   chronic	   denervation	   (Semino-­‐Mora	   et	   al.	   1998).	  Recently,	  skeletal	  muscle	  of	  a	  patient	  with	  the	  genetic	  C9orf72	  form	  of	  ALS	  was	  found	   to	   demonstrate	   p62	   and	   ubiquitin	   aggregation	   (Turk	   et	   al.	   2014).	  Upregulation	  of	  βAPP	  in	  skeletal	  muscle	  of	  patients	  with	  ALS	  and	  the	  SOD1G93A	  mouse	   model	   of	   ALS	   is	   evident	   at	   phenotypic	   presentation	   (Koistinen	   et	   al.	  2006)	   and,	   indeed,	   genetic	   ablation	   of	   βAPP	   in	   the	   SOD1G93A	   mouse	   model	  attenuates	  disease	  progression	  significantly	  (Bryson	  et	  al.	  2012).	  	  
1.6.3	  Unifying	  mechanisms;	  contribution	  of	  the	  aged	  cell	  environment	  It	   is	  unclear	  whether	   IBM	  displays	  a	  predominantly	   inflammatory	  phase	   in	   its	  early	  stage,	  before	  a	  degenerative	  ‘end	  stage’	  emerges.	  This	  would	  be	  analogous	  to	  typical	  thinking	  about	  other	  conditions	  that	  combine	  these	  processes,	  such	  as	  multiple	   sclerosis.	   It	   is	   curious	   that	   the	   chronic	   inflammation	   of	   Polymyositis	  does	   not	   appear	   to	   result	   in	   those	   additional	   features	   demonstrated	   by	   IBM	  tissue,	   suggesting	   that	   factors	   additional	   to	   MHCI	   upregulation	   and	  inflammatory	  cell	  infiltration	  may	  be	  fundamental	  to	  IBM	  pathogenesis.	  Notably,	  there	   have	   been	   reports	   of	   chronic	   Dermatomyositis	   assuming	   some	  pathological	  features	  of	  IBM,	  including	  rimmed	  vacuoles	  (Layzer	  et	  al.	  2009).	  If	  inflammatory	   factors	  are	   indeed	   the	   triggers	  of	   IBM,	   it	   is	   tempting	   to	  propose	  the	   vulnerability	   of	   the	   underlying	   cellular	   environment	   as	   a	   candidate,	   on	  which	   inflammation	   is	   superimposed,	   for	   differences	   observed	   between	   IBM	  and	  the	  purely	  inflammatory	  myositides.	  For	  example,	  the	  sarcopenia	  of	  normal	  ageing	  combines	  muscle	  atrophy	  and	  reduced	  contractile	  force,	  which	  reflects	  a	  number	  of	  degenerative	  susceptibilities.	  These	  would	  render	  an	  elderly	  patient	  cohort	  with	  significantly	  impaired	  ability	  to	  counter	  some	  of	  the	  consequences	  of	   chronic	   inflammation.	   These	   susceptibilities	   are	   discussed	   in	   more	   detail	  elsewhere	   (see	   Chapter	   4,	   Introduction)	   but,	   briefly,	   include	   ER	   ‘handicap’,	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elevated	   basal	   calcium	   concentration,	   proteasomal	   dysfunction,	   deficient	  protein	  handling,	   attenuated	   cell	   chaperone	   responses,	   elevated	  production	  of	  reactive	   oxygen	   species	   (ROS)	   and	   accumulation	   of	   mitochondrial	   DNA	  mutations.	  	  	  
1.6.4	  Overall	  consideration	  of	  pathogenesis	  In	  a	  condition	  where	  the	  fundamental	  pathological	  trigger	  is	  unknown,	  there	  are	  two	  principal	  strategies	  with	  which	  to	  prioritise	  targets	  for	  potential	  treatments.	  First,	  is	  to	  consider	  those	  elements	  that	  appear	  to	  be	  particularly	  characteristic	  of	   the	   disease	   and	   differentiate	   it	   from	   other	   similar	   conditions.	   In	   IBM	   this	  would	   represent	   inference	   from	   its	   differences	   with	   Polymyositis	   that,	   in	  contrast,	   does	   respond	   to	   immunotherapy.	  One	  would	   focus,	   therefore,	   on	   the	  degenerative	   aspects	   of	   the	   condition.	   Alternatively,	   is	   to	   prioritise	   those	  elements	   that	   appear	   to	   link	   other	   components	   of	   the	   pathology,	   thereby	  appearing	   to	   act	   as	   central	   pathogenic	   mechanisms.	   The	   advantage	   of	   this	  approach	  in	  IBM	  is	  that	  it	  does	  not	  rely	  on	  a	  polarised	  view	  about	  whether	  the	  upstream	  events	  are	  predominantly	  inflammatory	  or	  degenerative.	  For	  example,	  if	   one	  accepts	   the	  historical	  view	   that	   IBM	   is	  a	   form	  of	   	   ‘Polymyositis-­‐plus’,	   in	  which	   an	   initial	   inflammatory	   phase	   evolves	   into	   a	   degenerative	   and	  inflammatory	   one,	   these	   potentially	   important	   points	   of	   interaction	   emerge.	  Equally,	   they	   remain	   relevant	   if	   viewing	   the	   disease	   in	   reverse,	   where	  degenerative	   mechanisms	   drive	   secondary	   inflammation	   (Fig	   1.4).	   Therefore,	  regardless	   of	   its	   initial	   trigger,	   IBM	   could	   best	   be	   viewed	   as	   an	   interactive	  network	  of	   self-­‐perpetuating	  pathological	   cycles.	  This	   view	  was	  maintained	   in	  the	  consideration	  of	  the	  specific	  aims	  of	  this	  thesis,	  detailed	  below,	  which	  unite	  towards	   the	   overriding	   hypothesis	   that	   through	   characterisation	   of	   certain	  aspects	  of	  IBM	  pathology,	  novel	  potential	  therapeutic	  avenues	  can	  be	  explored.	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Figure	  1.4	  Potential	  mechanism	  of	  IBM	  pathogenesis.	  Elements	   of	   inflammatory	   (blue)	   and	  degenerative	   (red)	   pathology	  may	  drive	  one	  another,	  regardless	  of	  which	  occurs	  first.	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1.7	  Specific	  aims	  of	  this	  Thesis:	  1. To	  establish	  a	  pre-­‐clinical	  disease	  model	  of	  salient	  pathological	  features	  of	  IBM	  2. To	   characterise	   these	   features	   in	   order	   to	   establish	   a	   panel	   of	  quantifiable	  IBM-­‐relevant	  pathological	  outcome	  measures	  3. To	   test	   the	   effectiveness	   of	   novel	   treatment	   strategies	   in	   this	   system,	  determined	  by	  consideration	  of	  the	  literature	  4. To	  determine	  how	  those	  treatments	  could	  be	  advanced	  towards	  clinical	  effectiveness	  in	  IBM	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Chapter	  2:	  General	  Methods	  This	   Chapter	   describes	   the	   general	   methods	   underlying	   the	   in	   vitro	  experiments.	  Refinement	  of	   relevant	  components	  of	   individual	   techniques	  and	  determination	  of	  cell-­‐based	  assays	  is	  described	  in	  the	  corresponding	  sections	  of	  the	   results	   (throughout	   Chapters	   3	   and	   4).	   Composition	   of	   solutions	   and	  antibody	  dilutions	  are	  provided	  in	  the	  general	  appendix.	  Methods	  specific	  to	  the	  clinical	  trial	  are	  described	  separately	  in	  Chapter	  5.	  	  
2.1	  Myogenic	  satellite	  cell	  culture	  The	  results	  described	  in	  Chapter	  3	  detail	  refinement	  of	  the	  cell	  culture	  protocol.	  The	   basic	   standard	   protocol,	   which	   represented	   the	   starting	   point	   for	   these	  experiments,	  is	  described	  below.	  	  
2.1.1	  Standard	  culture	  protocol	  Wild-­‐type	  Sprague	  Dawley	  rats	  or	  C57-­‐B6/SJLF1	  mice	  aged	  postnatal	  day	  0,	  1	  or	  2	  were	  culled	  by	  Schedule	  1	  methods	  in	  accordance	  with	  the	  Animals	  (Scientific	  Procedures)	   Act	   1986.	   Hind	   limb	  muscles	   were	   retrieved	   by	   blunt	   dissection	  and	  washed	  in	  Phosphate	  Buffered	  Saline	  (PBS)	  with	  4%	  Penicillin	  100	  units/ml	  and	   Streptomycin	   100µg/ml	   (PenStrep),	   at	   4°C.	   All	   subsequent	   steps	   were	  performed	  under	  sterile	  conditions.	  Muscle	  tissue	  was	  cut	  into	  smaller	  sections	  then	  placed	  in	  a	  shaker	  within	  an	  incubator	  at	  37°C	  with	  3ml	  0.1%	  collagenase	  II	   per	  0.05g	  of	  muscle	   for	  45	  minutes,	   triturating	  every	  15	  minutes	   through	  a	  1ml	  pipette	  tip.	  The	  resulting	  solution	  was	  filtered	  through	  100µm	  nylon	  mesh	  to	  remove	  remaining	  undigested	  fragments	  of	   tissue	  and	  then	  twice	  through	  a	  40µm	   mesh	   (BD	   Biosciences™).	   5ml	   of	   PBS	   per	   5ml	   of	   cell	   suspension	   was	  added	  and	  the	  suspension	  centrifuged	  at	  480g	  for	  10	  minutes.	  Supernatant	  was	  removed	  and	  the	  pellet	  was	  re-­‐suspended	  in	  1ml	  of	  muscle	  medium:	  20%	  Fetal	  Calf	   Serum,	   2%	   PenStrep	   and	   0.5%	   Chick	   Embryo	   Extract	   in	   Dulbecco’s	  Modified	  Eagle	  Medium	  (DMEM)	  GlutaMAX-­‐1	  (Invitrogen™).	  This	  solution	  was	  stored	   for	   20	   minutes	   ‘pre-­‐plating’	   within	   a	   plastic	   container	   in	   attempt	   to	  remove	   fibroblasts	   by	  means	   of	   their	   greater	   propensity	   to	   adhere	   to	   plastic	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surfaces.	   Satellite	   cells	  were	   identified	   by	   light	  microscopy	   of	   a	   10µL	   sample,	  mixed	   with	   10µL	   Tryphan	   blue	   (Sigma	   Aldrich™)	   to	   identify	   dead	   cells.	   The	  concentration	   of	   viable	   satellite	   cells	  was	  determined	  with	   a	   haemocytometer	  and	   the	   cells	  were	   then	   seeded	  onto	   gelatinised	   cover-­‐slips	   in	   a	   24-­‐well	   plate	  with	   500µl	   of	  muscle	  media.	   Plates	  were	   incubated	   in	   5%	   CO2	   at	   37°C.	   Upon	  reaching	   confluency,	   typically	   after	   24	   hours,	   myotube	   differentiation	   was	  encouraged	   by	   substitution	   of	   the	   initial	   medium	   by	   differentiating	   muscle	  medium	   (10%	  Horse	   Serum,	   2%	  PenStrep	   and	   0.5%	  Chick	   Embryo	  Extract	   in	  DMEM	  GlutaMAX-­‐1).	  Muscle	  medium	  was	   subsequently	   changed	   at	   48	   hourly	  intervals	   unless	   otherwise	   stated.	   After	   fixation,	  myogenicity	  was	   determined	  through	   demonstration	   of	   positive	   immunocytochemical	   staining	   for	   muscle	  specific	   proteins,	   such	   as	   myosin	   heavy	   chain	   or	   desmin.	   The	   absolute	   then	  percentage	  myogenicity	  was	  determined	  through	  counting	  the	  number	  of	  nuclei	  (identified	   with	   DAPI	   staining)	   present	   within	   myogenic	   cells.	   As	   cultures	  progressed,	  typically	  beyond	  two	  to	  three	  days,	  myocytes	  began	  to	  fuse	  to	  form	  myotubes,	   were	   readily	   identified	   by	   their	   characteristic	   long,	   thin	  multinucleated	   morphology.	   The	   ‘fusion	   index’	   was	   determined	   by	   the	  proportion	   of	   nuclei	   contained	   within	   multinucleated	   myotubes	   versus	  myocytes.	  
	  All	   culture	  protocols,	   and	  subsequent	  experimental	   cultures,	  were	   repeated	   in	  full	   at	   least	   3	   times,	   with	   each	   experiment	   including	   at	   least	   6	   wells	   for	   any	  given	  culture	  condition.	  	  
2.1.2	  Differential	  centrifugation	  A	  mixed	  cellular	  population	  can	  be	  separated	  into	  cells	  of	  similar	  type	  by	  means	  of	   centrifugation	   through	   a	   density	   gradient	   medium.	   This	   technique,	   for	  isolation	   of	   the	   myogenic	   fraction	   from	   a	   muscle	   tissue	   homogenate,	   was	  previously	   described	   by	   Mau	   and	   colleagues	   (Mau	   2008).	   Percoll®	   (GE	  Healthcare	   Lifesciences™)	   is	   a	   sterile	   colloidal	   suspension	   comprised	   of	   silica	  particles,	  15–30	  nm	  in	  diameter,	  coated	  with	  polyvinylpyrrolidone	  (PVP),	  which	  spontaneously	  forms	  a	  density	  gradient	  when	  centrifuged.	  A	  variety	  of	  density	  gradients	  were	   investigated	   to	  refine	   this	  procedure	   in	  our	  rat	  cell	  cultures	  as	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described	  in	  Chapter	  3.	  In	  brief,	  the	  cellular	  suspension	  produced	  by	  the	  above	  protocol	  was	  carefully	  pipetted	  on	  top	  of	  three	  layered	  Percoll®	  suspensions	  of	  differing	   percentages	   then	   centrifuged	   at	   1250g	   for	   20	   minutes.	   Resulting	  cellular	   fractions	   were	   collected	   at	   the	   junctions	   between	   each	   Percoll®	  suspension	   layer	   and	   cultured	   separately	   to	   determine	   the	   characteristics	   of	  each	  fraction.	  	  
2.1.3	  Fluorescence	  activated	  cell	  sorting	  Cellular	   suspensions	   were	   obtained	   according	   to	   the	   above	   culture	   protocol.	  Then	  cells	  were	  incubated	  for	  30	  minutes	  at	  room	  temperature	  with	  antibody,	  either	   NCAM/CD56	   conjugated	   to	   Phycoerythrin	   (PE)	   (BD	   Biosciences	  Pharmingen™,	   10µl/million	   cells)	   or	   anti-­‐mouse	   CD34	   conjugated	   to	  Fluorescein	   (FITC)	   (Santa	   Cruz	   Biotech™,	   5µl/million	   cells).	   An	   unexposed	  aliquot	   was	   kept	   as	   a	   negative	   control.	   Surplus	   antibody	   was	   washed	   off	   by	  adding	  5ml	   of	   PBS	   and	   centrifuging	   at	   480g	   for	   5	  minutes.	   The	   cellular	   pellet	  was	   resuspended	   in	   0.5ml	   2%	   fetal	   calf	   serum	   in	   PBS	   and	   transferred	   to	   5ml	  polystyrene	   round	   bottom	   tubes	   (BD	   Falcon™).	   To	   indicate	   cell	   viability,	   1	  µg/ml	   propidium	   iodide	   (Invitrogen™)	  was	   added.	   A	  MoFLo-­‐XPD™	   cell	   sorter	  (Beckman	   Coulter™)	   was	   calibrated	   for	   the	   fluorescence	   and	   light	   scatter	  channels	   following	   manufacturers	   guidance.	   Analyses	   by	   light	   scattering	  properties	   and	   fluorescence	  were	   performed,	   prior	   to	   cell	   sorting	   into	   sterile	  1ml	   tubes	  according	  to	   the	  relevant	  antibody	  positivity.	  As	  a	  control,	  antibody	  negative	  cells	  were	  sorted	  by	  the	  same	  criteria.	  	  	  
2.1.4	  Fixation	  of	  cultured	  cells	  Muscle	  media	  was	  removed	  from	  cultured	  cells	  and	  each	  well	  washed	  once	  with	  PBS.	   Either	   ice-­‐cold	   1:1	   acetone-­‐methanol	   solution	   or	   paraformaldehyde	   was	  added	   to	   each	  well	   for	   10	  minutes,	   at	   4°C	   or	   room	   temperature	   respectively.	  Fixative	  was	  then	  replaced	  with	  PBS,	  and	  the	  samples	  stored	  at	  4°C.	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2.1.5	  Homogenisation	  of	  cultured	  cells	  When	  cultured	  cells	  were	  intended	  for	  subsequent	  Western	  blot	  analysis,	  750	  μl	  of	  homogenization	  buffer	  were	  added	   to	  each	  well	  at	   room	  temperature.	  Cells	  were	  placed	  in	  a	  shaker	  at	  100rpm	  for	  approximately	  30	  minutes	  at	  37°C.	  The	  resulting	   homogenate	   was	   then	   transferred	   to	   a	   1.5	   ml	   Eppendorf	   tube	   and	  stored	  at	  -­‐20°C.	  	  
2.2	  Induction	  of	  IBM-­‐like	  pathology	  in	  vitro	  
2.2.1	  βAPP	  overexpression	  For	  transfection	  of	  βAPP,	  a	  DNA	  construct	  containing	  full-­‐length	  human	  β-­‐APP	  gene	   of	   2312bp	   was	   cloned	   into	   the	   plasmid	   pcDNA3.1+.	   The	   plasmid	  pcDNA3.1+	  without	   the	   βAPP	   gene	  was	   used	   as	   an	   Empty	   Vector	   control	   for	  transfections.	   Transfection	   of	   the	   plasmid	   was	   achieved	   using	   standard	  Lipofectamine™	  2000	  protocol	  as	  per	  manufacturer’s	  instructions	  (Invitrogen).	  Differentiating	  muscle	  medium	  was	   removed	   and	   replaced	  with	  Optimem™.	  A	  transfection	   solution	   was	   prepared	   in	   Optimem™,	   comprising	   DNA	   and	  Lipofectamine™	  with	  the	  desired	  ratio	  of	  µg	  DNA	  to	  µl	  Lipofectamine™	  (typically	  1:3,	  as	  detailed	  in	  Chapter	  3	  Results)	  then	  incubated	  at	  room	  temperature	  for	  20	  minutes.	  50μl	  transfection	  solution	  was	  prepared	  for	  each	  well	  and	  mixed	  with	  200μl	  of	  Optimem™	  before	  substituting	  the	  Optimem™	  previously	  added	  to	  each	  well.	  	  Cultures	  were	  incubated	  at	  37°C	  for	  5	  hours	  with	  the	  transfection	  solution	  before	   this	   was	   replaced	   with	   standard	   muscle	   medium.	   The	   cells	   were	  maintained	  in	  culture	  for	  the	  required	  length	  of	  time	  before	  being	  fixed	  or	  other	  analysis	   conducted.	   The	   timing	   of	   transfection	   and	   the	   ratio	   of	   DNA	   to	  Lipofectamine	  were	  optimised	   to	  maximise	  expression	  of	  βAPP	  within	  cells	  of	  myogenic	  lineage	  (as	  described	  in	  Chapter	  3	  Results).	  	  
2.2.2	  Transfection	  efficiency	  When	  employing	  transfection	  as	  a	  means	  specifically	  to	  examine	  the	  function	  of	  an	  exogenous	  protein,	  commonly	  a	  mutated	  protein,	  it	  is	  necessary	  to	  quantify	  the	   efficiency	   of	   transfection.	   This	   either	   requires	   the	   demonstration	   of	   the	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expressed	  protein	  through	  a	  specific	  probe	  or,	  more	  commonly,	  tagging	  with	  an	  easily	  visualized	  marker	  such	  as	  green	  fluorescent	  protein	  (GFP).	  The	  purpose	  of	   overexpression	   in	   this	   context	   was,	   rather,	   to	   induce	   a	   suitably	   consistent	  degree	   of	   IBM-­‐representative	   pathological	   sequelae,	   such	   as	   the	   cytoplasmic	  translocation	  of	  TDP-­‐43	  or	  ER	  stress.	  Put	  the	  other	  way,	  the	  expression	  of	  βAPP	  
per	   se	  was	   not	   considered	   to	   indicate	   IBM-­‐like	   pathology.	   Therefore,	   since	   no	  particular	   magnitude	   of	   effect	   was	   sought,	   the	   determination	   of	   transfection	  ‘efficiency’	   in	   this	   way	  was	   unnecessary.	   Furthermore,	   it	   was	   noted	   that	   GFP	  tagging	  can	  alter	  the	  function	  of	  the	  introduced	  protein	  (Stevens	  et	  al.	  2010)	  so	  to	   introduce	   this	   step	   was	   not	   justified	   in	   this	   context.	   To	   demonstrate	   that	  transfection	  had	  occurred,	  the	  relative	  expression	  of	  βAPP	  by	  immunoblot	  was	  compared	   in	   cultures	   transfected	   with	   the	   βAPP	   versus	   empty	   vector.	   In	  addition,	   immunocytochemistry	   was	   performed	   to	   examine	   inclusions	  containing	  βAPP	  products.	  	  	  
2.2.3	  Exposure	  to	  other	  conditions	  As	  indicated,	  cells	  in	  culture	  were	  exposed	  to	  inflammatory	  mediators	  including	  IL1β	   (1-­‐20ng/ml),	   TNFα	   (1-­‐25ng/ml),	   IFNγ	   (1-­‐1000U/ml)	   and/or	   to	   the	   drug	  Arimoclomol	   (1-­‐100μM),	   all	   of	   which	   were	   added	   to	   the	   culture	   medium	   to	  achieve	  the	  corresponding	  desired	  concentration.	  Where	  comparison	  with	  βAPP	  over-­‐expressing	  cultures	  was	  made,	  inflammatory	  mediators	  were	  incorporated	  in	   the	   culture	   medium	   from	   the	   equivalent	   time	   point	   at	   which	   βAPP	   was	  transfected.	  
 
2.3	  Examination	  of	  cells	  
2.3.1	  Immunocytochemistry	  Following	  fixation,	  coverslips	  were	  washed	  three	  times	  in	  PBS	  (Oxoid	  Ltd™)	  for	  5	   minutes	   before	   incubation	   at	   room	   temperature	   for	   one	   hour	   in	   blocking	  solution,	  which	  consisted	  either	  of	  5%	  milk	  and	  3%	  serum	  in	  PBS-­‐0.1%	  Triton	  X-­‐100	  (Sigma-­‐Aldrich™)	  or	  10%	  serum	   in	  PBS-­‐0.1%	  Triton	  X-­‐100.	  Serum	  type	  was	   selected	   according	   to	   the	   secondary	   antibody	  host.	   The	   blocking	   solution	  was	   aspirated	   and	   the	   coverslips	  were	  washed	   three	   times	  with	   PBS	   prior	   to	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incubation,	  either	   for	  one	  hour	  at	   room	  temperature	  or	  overnight	  at	  4°C,	  with	  primary	  antibody	  	  (listed	  in	  Table	  2.1)	  diluted	  in	  blocking	  solution.	  The	  primary	  antibody	   solution	   was	   then	   removed	   and	   the	   coverslips	   were	   washed	   three	  times,	   for	  10	  minutes,	   in	  PBS.	  The	  secondary	  antibody	  was	   then	  applied	  at	   its	  corresponding	   concentration	   prior	   to	   covering	   in	   foil	   and	   incubation	   at	   room	  temperature	   for	   2	   hours.	   All	   antibodies	   were	   subject	   to	   a	   negative	   control,	  where	   either	   the	   primary	   or	   secondary	   antibodies	   were	   omitted	   to	   ensure	  appropriate	   specificity.	   Following	   a	   further	   3	  washes	   in	   PBS,	   some	   coverslips	  were	   then	   incubated	   with	   DAPI	   (Sigma-­‐Aldrich™,	   1:2000	   in	   PBS)	   at	   room	  temperature	  for	  10	  minutes.	  The	  slides	  were	  then	  washed	  in	  PBS	  before	  being	  mounted	  on	  glass	   slides	  with	   fluorescent	  mounting	  medium	  (DakoCytomation	  Fluorescent	   mounting	   medium	   S3023).	   Cells	   were	   visualised	   with	   a	   Leica	  Fluorescent	   Microscope	   (DFC420C)	   at	   magnifications	   between	   20	   and	   100x.	  After	  determination	  of	  the	  appropriate	  magnification	  for	  the	  given	  experiment	  3	  fields	  per	  cover-­‐slip	  were	  examined	  and	  the	  cells	  within	  those	  images	  counted.	  Unless	   otherwise	   stated,	   each	   condition	  was	   represented	   by	   a	  minimum	   of	   3	  cover-­‐slips	   (i.e.	   cells	   from	  3	  culture	  wells	  within	  a	  plate)	  and	  at	   least	  3	  plates,	  representing	   3	   cultures,	   were	   populated	   for	   each	   experimental	   condition.	  Throughout	   this	   thesis,	   in	   reference	   to	   immunocytochemical	   experiments,	   ‘n’	  refers	  to	  the	  number	  of	  cultures.	  	  
2.3.2	  Western	  blots	  Prior	   to	   Western	   Blotting,	   the	   protein	   concentration	   in	   the	   cellular	   pellet	  harvested	   from	   cultures	   was	   determined	   by	   Bio-­‐Rad	   Protein	   assay.	   100μl	  homogenising	  buffer	  (2%	  SDS,	  2mM	  EDTA,	  2mM	  EGTA	  dissolved	  in	  500ml	  5mM	  Tris	  (5mM	  TRIS	  HCL,	  5mM	  Trizma	  base	  in	  dH2O)	  pH6.8)	  was	  added	  to	  each	  well	  and	   cell	   pellet	   was	   triturated	   three	   times.	   BSA	   standards	   (Bovine	   Serum	  Albumin,	  Sigma™)	  were	  diluted	  to	  make	  a	  protein	  concentration	  gradient	  (Zero,	  0.05,	   0.1,	   0.25,	   0.5,	   1,	   and	   2	  mg/ml)	   and	   10μl	   of	   BSA	   standards	   and	   samples	  were	  added	  to	  a	  96-­‐well	  plate.	  The	  Bio-­‐Rad	  DC	  (detergent	  compatible)	  Protein	  Assay	   contained	   3	   reagents,	   A,	   B	   and	   S	   (Bio-­‐Rad™)	  which	  were	  mixed	   as	   per	  manufacturer’s	  instructions	  to	  give	  225μl	  per	  sample	  well	  (200μl	  reagent	  B	  and	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   Primary	  Antibodies	  








Mouse	   DSHB-­‐Iowa	   1:20	   -­‐	  
βAPP	   Rabbit	   Invitrogen	   1:250	   1:500	  
Aβ40	   Rabbit	   Biosource	   1:200	   1:500	  
Aβ42	   Rabbit	   Biosource	   1:100	   1:500	  
TDP-­‐43	   Rabbit	   Proteintech	   1:200	   1:1000	  
HSP70	   Mouse	   Santa	  Cruz	  Biotech	   1:200	   1:500	  
MHC	  Class	  I	   Rabbit	   Abcam	   1:200	   1:5000	  
NFκB	   Rabbit	   Abcam	   1:200	   -­‐	  
Phospho-­‐
Tau	   Mouse	   Pierce	  Endogen	   1:500	   -­‐	  
Ubiquitin	   Mouse	   Genetex	   1:500	   -­‐	  
BiP	   Rabbit	   Abcam	   -­‐	   1:1000	  
ATF	   Mouse	   Abcam	   -­‐	   1:1500	  
CHOP	   Mouse	   Abcam	   -­‐	   1:500	  
βActin	   Mouse	   Abcam	   -­‐	   1:5000	  
GAPDH	   Mouse	   Abcam	   -­‐	   1:1000	  	  
Table	  2.1	  Primary	  antibodies	  used	  Table	   details	   the	   primary	   antibodies,	   and	   their	   corresponding	   concentrations,	  used	  in	  immunocytochemistry	  or	  western	  blots.	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25μl	   reagent	   A	   and	   S).	   Plates	   were	   incubated	   at	   room	   temperature	   for	   15	  minutes	  and	  absorbance	  measured	  at	  750nm	  on	  a	  spectrophotometer.	  	  	   	   	  	  Two	   chambers	   for	   Western	   Blotting	   were	   assembled	   for	   according	   to	  manufacturer’s	   instructions	   (Bio-­‐Rad™).	   Resolving	   gel	   was	   prepared	   with	  acrylamide	   concentration	   between	   5%	   and	   15%	   according	   to	   the	   molecular	  weight	   of	   protein	   being	   investigated	   (Protogel	   4X	   resolving	   buffer,	   distilled	  water,	   40%	   acrylamide,	   10%	   ammonium	   persulphate,	  tetramethylethylenediamine	   (TEMED)).	   Resolving	   gel	   was	   poured	   into	  chambers	  and	  covered	  with	  a	  thin	  layer	  of	  water-­‐saturated	  butanol	  before	  being	  left	  at	  room	  temperature	  for	  one	  hour	  to	  polymerise.	  Stacking	  gel	  was	  prepared	  as	  manufacturer’s	  instructions	  (Protogel	  stacking	  buffer,	  40%	  acrylamide,	  10%	  ammonium	   persulphate,	   TEMED)	   and	   poured	   over	   the	   polymerised	   resolving	  gel.	  Combs	  were	  inserted	  with	  care	  to	  ensure	  absence	  of	  no	  air	  bubbles	  and	  the	  stacking	   gel	   left	   to	   polymerise	   for	   30	   minutes	   at	   room	   temperature.	   Protein	  samples	   were	   combined	   in	   1:1	   ratio	   with	   sample	   buffer,	   ensuring	   uniform	  protein	  content	  across	  all	  samples,	  then	  boiled	  and	  loaded	  into	  the	  wells	  created	  by	  combs.	  One	  well	  in	  each	  gel	  was	  loaded	  with	  a	  protein	  marker	  (5	  µl,	  Bio-­‐Rad)	  to	  allow	  subsequent	  determination	  of	  molecular	  weight.	  Gels	  were	  transferred	  into	  a	  frame	  according	  to	  manufacturer’s	  instructions	  and	  placed	  within	  a	  tank	  filled	  with	  electrode	  buffer	  (TRIS	  base,	  glycine,	  SDS	  in	  distilled	  water).	  Gels	  were	  run	  at	  160V	  for	  approximately	  1	  hour	  to	  achieve	  adequate	  separation	  of	  protein	  bands.	  Gels	  were	  then	  removed	  from	  their	  frames	  and	  placed	  on	  a	  nitrocellose	  membrane	  (Amersham™)	  within	  a	  frame,	  bracketed	  by	  filter	  paper	  and	  sponges	  within	   transfer	   frames,	   immersed	   in	   transfer	   buffer	   (Tris-­‐Glycine	   transfer	  buffer,	  National	  Diagnostics™)	  at	  2°C.	  13.	  Transfer	  of	  proteins	  to	  the	  membrane	  was	  achieved	  by	  running	  at	  100V	  for	  60	  minutes	  and	  confirmed	  with	  a	  Ponceau	  stain.	  Blots	  were	  blocked	  for	  1	  hour	  in	  PBS+0.1%	  Tween	  20+5%	  milk	  fat	  protein	  before	   incubation	   with	   primary	   antibody	   at	   4°C	   overnight.	   Following	   three	  washes	   in	   PBS-­‐Tween,	   blots	  were	   incubated	   in	   an	  HRP	   conjugated	   secondary	  antibody	  (Dako,	  1:1000)	  for	  2	  hours,	  while	  shaking.	  Blots	  were	  visualised	  with	  Amersham	  ECL	  reagent	  (GE	  Lifesciences™)	  or	  Supersignal	  (Thermoscientific™)	  according	  to	  manufacturer’s	   instructions	  and	  then	  developed	  on	  Kodak	  film	  or	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visualised	  under	  a	  fluorescent	  camera	  with	  FluorChem.	  Band	  densitometry	  was	  performed	  by	  ImageJ	  (open	  software).	  For	   this,	  rectangular	  regions	  of	   interest	  of	   equal	   size	   were	   superimposed	   over	   each	   band	   and	   the	   background	   signal	  subtracted	   before	   the	   density	   was	   determined.	   The	   density	   corresponding	   to	  each	  band	  of	  interest	  was	  then	  expressed	  relative	  to	  that	  corresponding	  to	  the	  control	   protein	   (e.g.	   GAPDH).	   This	   was	   then	   compared	   across	   a	   minimum	   of	  three	  blots	  per	  condition	  under	  experimentation.	  This	  mean	  optical	  density	  then	  calculated	  relative	  to	  that	  of	  same	  protein	  by	  the	  relevant	  control	  population.	  	  	  
2.3.3	  MTT	  assay	  The	   MTT	   3-­‐(4,5-­‐Dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐diphenyltetrazolium	   bromide	   assay	  was	  employed	  as	  a	   standard	  measure	  of	   cell	   viability.	  Broadly,	   the	  MTT	  assay	  provides	  an	  estimate	  of	  mitochondrial	  activity,	  which	  is	  linearly	  proportional	  to	  the	   number	   of	   viable	   cells.	   It	   is	   a	   colorimetric	   assay	   which	   depends	   on	   the	  reduction	  of	  yellow	  tetrazolium	  dye	  to	  water-­‐insoluble	  purple	  formazan	  crystals	  by	  mitochondrial	  dehydrogenase	  enzymes.	  This	  colour	  change	  can	  be	  quantified	  spectrophotometrically.	   As	   discussed	   above	   (see	   Chapter	   1,	   Section	   1.3.2.3),	  mitochondrial	   impairment	   is	   an	   important	   characteristic	   of	   IBM	   tissue.	  Therefore,	   in	  comparison	  to	  other	  viability	  assays,	   for	  example	   the	  LDH	  based	  assay,	   the	   MTT	   appears	   more	   directly	   relevant	   in	   this	   context.	   Finally,	   it	   is	  widely	  used	  in	  early	  stage	  evaluation	  of	  drugs,	  lending	  itself	  to	  the	  desired	  high-­‐throughput	  of	  a	  pre-­‐clinical	  evaluation	  system	  that	  is	  the	  underlying	  purpose	  of	  these	  experiments	  (Kaspers	  et	  al.	  2005).	  	  	  An	  MTT	  working	   solution	  was	   prepared	   from	   12mM	   Thiazolyl	   blue	   solution-­‐PBS	   (Sigma™)	   diluted	   1:10	   with	   incubating	   medium.	   50μl	   of	   this	   working	  solution	   substituted	   existing	   cell	   culture	   medium	   in	   each	   well	   for	   4	   hours	   at	  37°C.	   The	   resulting	   precipitate	   was	   dissolved	   in	   100μl	   of	   0.4M	   HCl	   and	   the	  absorbance	   measured	   at	   570nm	   by	   spectrophotometry.	   Each	   sample,	  representing	   an	   individual	   well,	   was	   run	   in	   triplicate	   and	   the	   mean	   then	  calculated.	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2.3.4	  Live	  cell	  Calcium	  imaging	  The	  refinement	  of	  the	  technique	  used	  for	  determination	  of	  cytosolic	  calcium	  is	  described	  in	  Chapter	  4	  Results.	  The	  basis	  of	  the	  method	  is	  described	  below.	  	  
2.3.4.1	  Selection	  of	  Ca2+	  fluorescent	  dye	  	  A	  variety	  of	  Ca2+	  indicators	  are	  available,	  each	  of	  which	  has	  its	  own	  advantages	  and	  disadvantages.	  Broadly,	  indicators	  can	  be	  described	  as	  either	  ratiometric	  or	  non-­‐ratiometric.	   The	   former	   employ	   methods	   based	   on	   a	   ratio	   between	   two	  fluorescence	  intensities.	  These	  indicators,	  such	  as	  Fura-­‐2	  demonstrate	  a	  shift	  in	  emission	  or	   excitation	   spectra	  upon	   calcium	  binding;	   therefore	   two	   excitation	  lasers	  or	   two	  detection	   ranges	  are	   required.	  An	   intensity	   ratio	   is	   calculated	  at	  the	  wavelength	   at	  which	   there	   is	  maximal	   difference	   between	   fluorescence	   in	  the	   bound	   and	   free	   indicator.	   The	   advantage	   of	   this	   technique	   relates	   to	  correction	  of	  artefact	  consequent	  to	  dye	  bleaching	  or	  changes	  in	  laser	  intensity.	  However,	   they	   frequently	   require	   ultraviolet	   activation,	   which	   is	   associated	  with	  direct	  phototoxic	  effects	  on	  the	  cell	  being	  tested	  and	  also	  overlaps	  with	  the	  excitation	   and	   emission	   peaks	   of	   other	   intracellular	   chemicals	   such	   as	  NADH,	  thereby	   confounding	   the	   overall	   fluorescent	   signal	   through	   ‘autofluorescence’	  (Takahashi	   et	   al.	   1999).	   Non-­‐ratiometric	   or	   ‘single	   wave’	   dyes	   such	   as	   Fluo4,	  typically	  have	  a	  low	  basal	  fluorescence	  intensity	  which	  itself	  shifts	  upon	  binding	  to	  Ca2+.	  This	  means	  that	  increase	  in	  intensity	  directly	  reflects	  a	  change	  in	  [Ca2+]	  and	   calculation	   of	   [Ca2+]	   is	   more	   straightforward.	   Further	   considerations	  include	   the	   approximate	   concentration	   of	   Ca2+	   being	   measured,	   whether	  organelle	   loading	   is	   desired	   (which	   it	   is	   typically	   not)	   and	   propensity	   for	  technical	   issues	   related	   to	   most	   dyes,	   such	   as	   uneven	   loading,	   bleaching	   and	  quenching.	  The	  dye	  Fluo-­‐4	  AM	  (Fig	  2.1)	  is	  the	  most	  widely	  applied	  dye	  for	  cell	  calcium	  imaging,	  likely	  because	  of	  its	  dissociation	  constant	  (Kd)	  approximating	  cytosolic	   [Ca2+],	  which	  corresponds	  to	   the	  range	   in	  which	   fluorescent	  dyes	  are	  most	   accurate	   (Takahashi	   et	   al.	   1999).	   It	   is	   an	   analogue	   of	   Fluo-­‐3,	   originally	  described	  by	  Tsien	   and	   colleagues	   (Minta	   et	   al.	   1989)	   but	   is	   preferred	  due	   to	  increased	   fluorescence	   excitation	   at	   488nm.	   Fluo-­‐4	   is	   synthesised	   as	   an	  acetoxymethyl	   (AM)	   ester	   derivative	   that	   is	   membrane	   permeant.	  Within	   the	  cell,	   the	  ester	  group	   is	  cleaved	  by	  esterases,	   leaving	   the	  now	  impermeant	  Ca2+	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sensitive	  dye	  trapped	  inside	  it.	  It	  is	  most	  suitable	  for	  the	  experimental	  protocol	  detailed	  here,	  which	  relies	  on	  depletion	  of	  ER	  calcium,	  as	  it	  has	  low	  tendency	  to	  organelle	  loading.	  	  	  	  	  
	  	  
Figure	  2.1	  Chemical	  structure	  of	  Fluo	  dyes	  From	  Lifetechnologies	  The	  Molecular	  Probes®	  Handbook	  	  	  
2.3.4.2	  ER	  calcium	  depletion	  with	  Thapsigargin	  	  Thapsigargin	   (TG)	   non-­‐competitively	   and	   specifically	   inhibits	   the	  sarco/endoplasmic	   reticulum	   ATPase	   (SERCA)	   pump,	   located	   on	   the	   ER	  membrane,	  without	  directly	  affecting	  plasma	  membrane	  Ca2+	  ATPases	  (Treiman	  et	   al.	   1998).	   This	   rapidly	  depletes	  ER	  Ca2+	  since	  uptake	  of	   cytosolic	   calcium	   is	  precluded,	  whilst	  calcium	  release	  via	  ER	  ryanodine	  and	  IP3	  receptors	  persists.	  The	  Ca2+	  release	  from	  the	  ER	  leads	  to	  elevation	  of	  the	  cytosolic	  [Ca2+],	  which	  is	  reflected	  in	  increased	  fluorescence	  intensity	  of	  the	  calcium	  dye	  (in	  this	  case	  Fluo	  4-­‐AM).	  Therefore,	   the	  magnitude	  of	   this	   change	   indicates	   the	   initial	  ER	   [Ca2+].	  Previous	  work	  suggests	  the	  ER	  is	  unlikely	  to	  be	  entirely	  depleted	  of	  Ca2+,	  rather	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by	  approximately	  85%	  (Verma	  et	  al.	  1990).	  However,	  to	  determine	  absolute	  ER	  [Ca2+]	   accurately	   requires	   direct	   measurement,	   which	   is	   experimentally	  challenging	   (it	   is	   relatively	   precluded	   through	   the	  use	   of	   chemical	   fluorescent	  dyes	  due	  to	  the	  high	  [Ca2+]	  significantly	  exceeding	  their	  Kd)	  and	  not	  the	  purpose	  of	   these	  experiments.	  Here,	   the	  purpose	   is	   to	  examine	   is	   the	  effect	  of	   IBM-­‐like	  conditions	   on	   cytosolic	   and	   ER	   [Ca2+],	   which	   is	   achieved	   through	   comparison	  with	  control	  cultures.	  	  
2.3.4.3	  Determination	  of	  cytosolic	  and	  ER	  Ca2+	  Confocal	  images	  were	  obtained	  on	  a	  Leica	  SPE	  inverted	  confocal	  laser	  scanning	  microscope.	  Cells	  were	  kept	  at	  37°C	  and	  5%	  CO2	  within	  a	  specialised	   imaging	  incubator.	   Coverslips	   were	   loaded	   with	   500	   ml	   of	   5	   mM	   Fluo	   4-­‐AM	  (Invitrogen™)	  and	  0.005%	  pluronic	  acid	  (a	  dispersing	  agent	  that	  facilitates	  cell	  loading)	  diluted	  in	  confocal	  recording	  medium.	  Coverslips	  were	  incubated	  in	  the	  dark	   for	  approximately	  30	  minutes	  at	  37°C.	  Fluo	  4-­‐AM	  was	  excited	  at	  488	  nm	  and	  the	  emission	  fluorescence	  was	  measured	  at	  518	  nm.	  A	  z	  stack	  of	  images	  was	  taken	   approximately	   every	   one	   second	   within	   a	   field	   of	   interest	   that	   was	  maintained	  for	  the	  duration	  of	  the	  protocol.	  Thapsigargin	  was	  applied	  and,	  after	  diminishment	   of	   the	   subsequent	   elevation	   of	   fluorescence,	   the	   ionophore	  ionomycin	  was	  applied,	  which	  releases	  calcium	  from	  all	  intracellular	  organelles,	  providing	  a	  maximum	  calibration	  point	  (Figure	  2.2).	  	  Images	  were	  collected	  until	  the	  peak	  response	  to	  ionomycin	  had	  been	  reached.	  Myotubes	  were	  randomly	  selected	  for	  or	  specifically	  excluded	  from	  analysis	  as	  described	  in	  Chapter	  4.	  Background	  fluorescence	  was	  subtracted.	  Fluorescence	  values	  were	   then	  converted	   to	  a	   [Ca2+]	   concentration	   in	  nM	  using	   the	   formula	  below.	  	  	  	  
	  For	   Fluo	   4-­‐AM:	   Kd	   =	   350nM,	   Fmax	   =	   maximum	   fluorescence	   which	   is	  determined	  by	  application	  of	  Ionomycin,	  Rf	  =	  100	  (Maravall	  et	  al.	  2000).	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Figure	  2.2	  Live	  cell	  Ca2+	  imaging	  protocol	  Example	   trace	   of	   Ca2+	   fluorescence	   from	   one	   cell	   during	   the	   protocol	   used	   to	  determine	  cytosolic	  and	  ER	  [Ca2+]	  	  
2.4	  Statistical	  analysis	  Analysis	   of	   normally	   distributed	   results	   was	   performed	   using	   a	   t-­‐test	   or,	   for	  comparison	   of	   greater	   than	   two	   groups,	   a	   one-­‐way	  ANOVA.	   For	   non-­‐Gaussian	  distributed	   results,	   the	   non-­‐parametric	   Mann–Whitney	   U-­‐test	   was	   used.	   As	  standard,	   p<0.05	   was	   considered	   to	   reject	   the	   null	   hypothesis	   and	   indicate	  statistical	  significance	  in	  this	  thesis	  unless	  otherwise	  stated.	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Chapter	  3:	  Development	  of	  an	  in	  vitro	  model	  of	  IBM	  
pathology	  	  This	  Chapter	  describes	  experiments	  related	  to	  the	  first	  specific	  aim	  of	  this	  thesis,	  the	   development	   of	   a	   preclinical	  model	   of	   IBM	   pathology.	   First,	   the	   relative	  merits	  of	  various	  types	  of	  disease	  model	  were	  considered.	  After	  selecting	  an	  in	  
vitro	   technique,	  a	  variety	  of	   cultures	  conditions	  were	  evaluated	  using	  primary	  myogenic	  satellite	  cell	  cultures,	  before	  IBM-­‐like	  conditions	  were	  induced.	  	  
3.1	  Introduction:	  justification	  for	  an	  IBM	  model	  The	  lack	  of	  treatment	  for	  IBM	  reflects	  the	  absence	  of	  a	  coordinated	  programme	  of	  translational	  research.	  Historically,	  investigation	  into	  potential	  treatments	  for	  IBM	   has	   taken	   the	   form	   of	   small	   clinical	   trials	   (Schmidt	   et	   al.	   2013)	   and	   no	  meaningful	   preclinical	   drug	   studies	  have	  been	  undertaken.	  This	   demonstrates	  the	  lack	  of	  widely	  accepted	  pre-­‐clinical	  disease	  models.	  The	  method	  of	  repeated	  empirical	   clinical	   trials	   is	   expensive,	   complicated,	   lengthy	   and	   limited	   by	   its	  restriction	   to	   agents	   that	   are	   already	   licensed	   for	  other	   indications.	  There	   are	  additional	   concerns	   about	   the	   previous	   human	   treatment	   trials	   in	   IBM	  stemming	   from	   the	   lack	   of	   standardised	   diagnostic	   criteria,	   limited	  understanding	   of	   the	   disease’s	   natural	   history	   and	   absence	   of	   validated	  biomarkers	   (Hilton-­‐Jones	   et	   al.	   2010).	   The	   relative	   rarity	   of	   the	   condition	  significantly	  limits	  the	  feasibility	  and	  size	  of	  early	  phase	  trials.	  A	  more	  sustainable	  pathway	  to	  the	  development	  of	  IBM	  treatment	  must	  include	  preclinical	  screening	  of	  larger	  panels	  of	  drugs,	  allowing	  more	  promising	  agents	  to	   be	   advanced	   towards	   clinical	   testing.	   This	   also	   affords	   the	   advantage	   of	  selecting	  particular	  disease	  components	  for	  investigation.	  In	  turn,	  this	  advances	  understanding	  of	  IBM	  pathogenesis	  and	  allows	  targeting	  of	  treatments	  to	  those	  mechanisms	  deemed	  most	  active	  in	  propagating	  the	  disease.	  IBM	   is	  a	   sporadic	  disease,	  which	  presents	   inherent	  challenges	   in	  creating	  pre-­‐clinical	  disease	  models.	   	  Whereas	  monogenetic	  disorders	  have	  a	  clear	  primary	  
	   64	  
cause	   that	   can	  be	   correspondingly	   expressed	   in	   a	   cellular	  or	   animal	   system,	   a	  sporadic	  disorder	  represents	  a	  particular	  combination	  of	  genetic	  susceptibility	  and	   environment.	   Therefore,	   a	   model	   of	   sporadic	   disease	   must	   be	   tailored	  according	  to	  the	  specific	  requirement	  that	  model	  seeks	  to	  explore.	  For	  example,	  to	   investigate	   the	   role	   of	   immunological	  mechanisms	   in	   IBM	  would	   require	   a	  wholly	   different	   approach	   to	   determining	   its	   genetic	   risk	   factors.	   The	   lack	   of	  consensus	   on	   which	   of	   IBM’s	   numerous	   pathological	   processes	   lies	   furthest	  upstream	   complicates	   matters	   further.	   Here,	   the	   decision	   process	   on	   how	   to	  approach	   the	   problem	   of	   disease	   modeling	   was	   approached	   with	   these	  arguments	   in	   mind,	   relating	   to	   the	   primary	   aim	   of	   this	   work;	   to	   develop	   a	  system	  in	  which	  the	  initial	  efficacy	  of	  potential	  treatments	  could	  be	  tested	  in	  a	  disease	  relevant	  way.	  Additionally,	  the	  fact	  this	  would	  represent	  an	  early	  stage	  in	  the	  translational	  research	  pathway	  meant	  that	  the	  ability	  to	  gain	  preliminary	  results	  quickly,	  allowing	  adjustment	  or	  redesign,	  was	  a	  further	  priority.	  The	  following	  criteria	  were	  required	  of	  the	  disease	  model:	   	  i. To	   reflect	   elements	   of	   IBM	   pathology	   which	   are	   relevant,	   preferably	  unique	  ii. To	   incorporate	   the	  potentially	  different	  primary	  pathologies	  present	   in	  IBM	  iii. To	  allow	  the	  determination	  of	  quantifiable	  outcome	  measures	  iv. To	  allow	  high	  throughput	  of	  compounds	  for	  testing	  v. To	  be	  reproducible	  within	  efficient	  time	  and	  financial	  constraints	  The	   traditional	   pathway	   of	   preclinical	   drug	   assessment	   begins	   in	   vitro	   and	  promising	  agents	  are	  advanced	  to	  in	  vivo	  animal	  studies.	  There	  are	  advantages	  of	   either,	   most	   basically	   summarized	   as	   there	   being	   a	   greater	   propensity	   for	  detecting	  treatment	  effects	  in	  vitro	  but	  a	  greater	  likelihood	  of	  effects	  detected	  in	  
vivo	  translating	  to	  clinical	  effect.	  Therefore,	  both	  options	  were	  considered.	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3.1.1	  Animal	  versus	  cellular	  models	  	  There	  are	  general	  comparisons	  to	  be	  made	  between	  animal	  and	  cellular	  models	  of	  disease,	  and	  further	  comparisons	  specific	  to	  IBM.	  	  
Characteristic	   Animal	  Model	   Cellular	  Model	  
Time	  for	  development	  and	  
characterisation	  
Longer	   Shorter	  
Time	  for	  evaluation	  of	  drugs	   Longer	   Shorter	  
Number	  of	  testable	  drugs	  in	  given	  time	   Fewer	   More	  
Ease	  of	  changes	  during	  course	  of	  
experimental	  programme	  
Harder	   Easier	  
Likelihood	  of	  detecting	  a	  treatment	  
effect	  (whether	  genuine	  or	  false	  
positive)	  
Lower	   Higher	  
Likely	  accuracy	  of	  representation	  of	  the	  
corresponding	  human	  disease	  
Higher	   Lower	  
Likelihood	  of	  translation	  to	  clinically	  
meaningful	  results	  
Higher	   Lower	  
Cost	   Higher	   Lower	  
Table	  3.1:	  Relative	  merits	  of	  animal	  and	  cellular	  models	  of	  disease	  Advantages	  are	  highlighted	  in	  bold	  	  The	   weighting	   of	   the	   general	   comparators	   listed	   above	   is	   not	   equal,	   and	  depends	  on	  the	  priority	  of	  the	  particular	  experiment	  or	  programme	  concerned.	  The	   greater	   likelihood	   of	   animal	   models	   to	   represent	   the	   relevant	   disease	   is	  particularly	   dependent	   upon	   the	   contemporaneous	   status	   of	   overall	  understanding	  on	   that	  disease	  and	   the	  animal	  being	  well	   characterised.	  There	  are	  additional	  constraints	  of	  finance,	  labour	  and	  time.	  This	  limits	  their	  use	  to	  a	  few	  candidate	  drugs.	  
	  
3.1.2	  Lack	  of	  an	  established	  animal	  model	  of	  IBM	  Since	   the	   pathogenesis	   of	   IBM	   in	   human	   patients	   remains	   unexplained,	   it	  follows	   that	   an	  animal	  model	   that	   recapitulates	  all	   features	  of	   the	  disease	  has	  not	  been	  established.	  There	  are,	  however,	  several	  animal	  models	  that	  do	  share	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several	   important	   characteristics	   with	   human	   IBM	   and	   these	   have	   some	  capacity	  as	  preclinical	  models	  for	  investigation	  of	  potential	  therapeutic	  agents.	  Moreover,	   the	   descriptions	   of	   these	   animals	   offer	   a	   degree	   of	   insight	   into	  potential	  mechanisms	  of	  sporadic	  IBM,	  particularly	  those	  that	  link	  inflammatory	  and	  degenerative	  processes.	  
3.1.2.1	  Mice	  over-­‐expressing	  MHCI	  The	   upregulation	   of	   Major	   Histocompatibility	   Complex	   Class	   I	   (MHCI)	   is	   a	  characteristic	  histopathological	  feature	  of	  muscle	  tissue	  affected	  by	  IBM.	  It	  has	  been	  proposed	  as	   a	   central	   feature	   in	  driving	  both	  downstream	   inflammatory	  processes	   and	   degenerative	   mechanisms	   such	   as	   ER	   stress	   (Dalakas	   2006).	  Nagaraju	   and	   colleagues	   described	   a	   transgenic	   mouse	   that	   over-­‐expresses	  MHCI	   specifically	   in	   skeletal	   muscle,	   resulting	   in	   severe	   and	   self-­‐sustaining	  myositis,	   associated	   with	   myositis-­‐specific	   antibodies	   (Nagaraju	   et	   al.	   2000).	  Despite	   significant	   inflammation,	   and	   development	   of	   non-­‐specific	   features	   of	  muscle	  damage	  such	  as	  centralised	  nuclei	  and	  variation	  in	  fibre	  size,	  there	  was	  conspicuous	   absence	   of	   degenerative	   features	   such	   as	   rimmed	   vacuoles,	  intracellular	   inclusions	   or	   mitochondrial	   abnormalities.	   Indeed,	   the	  inflammation	   per	   se	   was	   predominantly	   by	   mononuclear	   cells,	   with	   only	  occasional	  T-­‐cells,	  which	  were	  CD3+	  rather	  than	  the	  CD8+	  form	  that	  characterise	  IBM.	   This	   implies	   that	   aspects	   of	   both	   the	   inflammatory	   and	   degenerative	  components	  of	  IBM	  require	  additional	  triggers	  beyond	  the	  upregulation	  of	  MHCI,	  thereby	  limiting	  the	  scope	  of	  these	  mice	  to	  model	  this	  disease.	  
3.1.2.2	  Mice	  over-­‐expressing	  β-­‐Amyloid	  in	  skeletal	  muscle	  La	   Ferla	   and	   colleagues	   described	   two	   transgenic	  mouse	   lines	   in	  which	   βAPP	  was	  selectively	  overexpressed	  in	  skeletal	  muscle	  by	  means	  of	  a	  muscle	  creatine	  kinase	   promoter	   (Kitazawa	   2006).	   In	   one	   double	   transgenic	   line,	   the	   Aβ42	  oligomer	   was	   selectively	   augmented	   by	   crossing	   the	   original	   βAPP-­‐over-­‐expressing	   mice	   with	   others	   harbouring	   a	   presenelin-­‐1	   mutation.	   The	   Aβ42	  form	   is	   considered	   more	   pathogenic	   than	   its	   Aβ40	   relative	   and	   is	   more	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amyloidogenic	   (Ferreira	   2007).	   These	   mice	   displayed	   IBM-­‐like	   muscle	  pathology,	   including	   infiltration	   by	   CD8+	   T-­‐lymphocytes,	   intracellular	  accumulation	  of	  Aβ42	  and	  elevation	  of	  phosphorylated	  tau.	  This	  pathology	  was	  associated	   with	   a	   decline	   in	   motor	   performance.	   Further	   characterisation	   of	  βAPP	   transgenic	   mice	   has	   revealed	   impairment	   of	   muscle	   force,	   SR	   calcium	  release	  and	  calcium	  uptake	  via	  the	  SERCA,	  implying	  a	  direct	  pathological	  effect	  of	   amyloid	   species	   on	  muscle	   function	   (Shtifman	  2008).	   It	   is	   unclear	  whether	  the	  resulting	  inflammation	  stems	  from	  a	  direct	  pro-­‐inflammatory	  effect	  of	  βAPP	  or	   is	   a	   secondary	   response	   to	   the	   expression	   of	   a	   human	   protein	   within	   the	  mouse.	   	   Importantly,	   in	   practical	   terms,	   it	   was	   24	   months	   before	   the	   mice	  demonstrated	  the	  full	  plethora	  of	  phenotypic	  and	  histological	  effects	  compared	  to	  controls.	  
	  
3.1.2.3	  VCP	  transgenic	  mice	  	  Inclusion	  Body	  Myopathy,	  Frontotemporal	  dementia	  and	  Paget’s	  disease	  of	  bone	  are	   combined	   in	   the	   rare	   autosomal	   dominantly	   inherited	   condition	   IBMPFD.	  This	   is	  caused	  by	  mutant	  valosin-­‐containing	  protein	  (VCP),	   the	  normal	  protein	  being	  a	  type	  2	  AAA+	  protein	  (ATPase	  Associated	  with	  diverse	  cellular	  Activities)	  associated	  with	  a	  wide	  range	  of	   functions.	   Interestingly,	   it	  appears	   that	  VCP	   is	  involved	  in	  the	  extraction	  and	  degradation	  of	  abnormally	  folded	  proteins	  from	  the	   ER.	   Pestronk	   and	   colleagues	   describe	   a	   transgenic	  mouse	   line	   expressing	  mutant	   VCP,	   which	   is	   associated	   with	   motor	   impairment	   preceded	   by	  ubiquinated	   intracellular	   inclusions	   and	   formation	   of	   autophagosomes	   (Weihl	  2007).	  This	  model,	  whilst	   it	  shares	  some	  aspects	  of	  IBMPFD,	  is	  unsuitable	  as	  a	  model	   of	   sporadic	   IBM.	   There	   are	   fundamental	   clinical	   and	   pathological	  differences	   between	   the	   clinical	   myopathy	   displayed	   by	   each	   condition	  (Kimonis	  et	  al.	  2000;	  Kovach	  et	  al.	  2001).	  Further,	  and	  notably,	  this	  model	  does	  not	  demonstrate	  endomysial	  inflammation,	  a	  defining	  characteristic	  of	  sporadic	  IBM.	  Taylor	  and	  colleagues	  more	  recently	  characterised	  a	   further	   transgenic	  mouse	  model	   of	   IBMPFD,	   harbouring	   either	   expressing	   the	   R155H	   or	   A232E	  mutant	  forms	  of	  VCP,	  which	  are	  associated	  with	  the	  human	  form	  of	  the	  disease	  (Custer	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2010).	   These	   mice	   demonstrate	   numerous	   characteristics	   of	   IBMPFD,	   both	  phenotypically	   and	   in	   tissue	   from	   muscle,	   bone	   and	   brain.	   Muscle	   pathology	  includes	   rimmed	   vacuolation,	   activation	   of	   the	  NFκB	   cascade	   and	   cytoplasmic	  dispersion	  of	  TDP-­‐43	  where	  ubiquinated	  inclusions	  are	  formed.	  These	  changes	  account	  for	  progressive	  muscle	  weakness	  and	  reduced	  body	  mass.	  These	  mice,	  therefore,	   appear	   to	   represent	   a	   robust	  model	   of	   IBMPFD	   and,	   due	   to	   several	  myopathological	  similarities,	  may	  offer	  insight	  into	  some	  pathogenic	  aspects	  of	  sporadic	   IBM.	   	   Again,	   however,	   the	   notable	   clinical	   disparity	   between	   this	  distinct	  genetic	  disease	  and	  sporadic	  IBM	  represents	  a	  significant	  limitation.	  
3.1.3	  Previous	  cellular	  models	  of	  IBM	  and	  consideration	  of	  IBM-­‐relevant	  stimuli	  in	  
vitro	  In	   reflection	  of	   the	   contrasting	  wider	  views	  on	   the	   fundamental	   cause	  of	   IBM,	  previous	  efforts	   to	  study	   IBM	   in	  vitro	  have	   typically	  explored	  either	  a	  primary	  degenerative	  or	  inflammatory	  stimulus.	  
3.1.3.1	  Overexpression	  of	  βAPP	  Having	  detected	  βAPP	  immunoreactivity	  within	  intracellular	  aggregates	  of	  IBM	  tissue,	   the	   work	   of	   Askanas	   and	   colleagues	   has	   established	   that	   the	   over-­‐expression	   of	   βAPP	   in	   cultured	   human	   myocytes	   reproduces	   several	   of	   the	  fundamental	  pathological	   features	  demonstrated	   in	  IBM	  muscle.	  These	   include	  the	   formation	   of	   intracellular	   proteinaceous	   aggregates	   (Askanas	   et	   al.	   1997),	  the	  inhibition	  of	  proteasomal	  function	  (Fratta	  et	  al.	  2005),	  increased	  production	  of	   myostatin	   precursor	   protein	   (Wojcik	   et	   al.	   2007)	   and	   impairment	   of	  mitochondrial	  function	  (Askanas	  et	  al.	  1997).	  This	  supports	  other	  cellular	  work	  describing	  amyloid	  toxicity	  in	  myoblasts	  (Jayaraman	  2008)	  as	  well	  as	  the	  in	  vivo	  studies	  of	  APP	  over-­‐expression	  described	  above	  (see	  Section	  3.1.2.2).	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3.1.3.2	  Exposure	  to	  inflammatory	  cytokines	  Schmidt	   and	   colleagues	   established	   that	   the	   exposure	   of	   cultured	   human	  myocytes	  to	  a	  variety	  of	  inflammatory	  cytokines,	  including	  IL1β,	  IFNγ	  and	  TNFα,	  appeared	  to	  elevate	  the	  intracellular	  concentration	  of	  βAPP,	  broadly	  suggesting	  that	   the	   inflammatory	   mechanisms	   in	   IBM	   could,	   via	   βAPP,	   drive	   the	  degenerative	  process	  (Schmidt	  et	  al.	  2008).	  It	  is	  also	  known	  that	  such	  mediators	  upregulate	  MHC	  Class	  I	  	  in	  cultured	  myotubes	  (Michaelis	  et	  al.	  1993).	  Cytokines	   are	   low	   molecular	   weight	   proteins	   that	   function	   as	   chemical	  messengers	  between	  tissues	  and	  the	  innate	  and	  adaptive	  immune	  systems,	  and	  are	  therefore	  important	  drivers	  of	  a	  tissue	  specific	  inflammatory	  response	  such	  as	  that	  seen	  in	  IBM.	  	  The	  interleukin	  (IL),	  interferon	  (IFN)	  and	  tumour	  necrosis	  factor	   (TNF)	   subgroups	   are	   those	   most	   associated	   with	   myositis.	   Indeed,	  expression	   of	   mRNA	   of	   IL1β,	   IFNγ	   and	   TNFα	   are	   all	   elevated	   in	   IBM	   versus	  normal	  controls.	  Moreover,	  IFNγ	  mRNA	  is	  significantly	  higher	  in	  IBM	  that	  PM	  or	  DM,	  and	  TNFα	  mRNA	  significantly	  higher	  than	  in	  DM	  (Schmidt	  et	  al.	  2008).	  IFNs	  have	   broad	   immune	   functions,	   including	   maturation	   of	   B-­‐calls,	   activation	   of	  dendritic	  cells	  and	  lymphocytes	  and	  antiviral	   immunity,	  all	  of	  which	  are	  either	  demonstrated	   by	   or	   have	   been	   postulated	   in	   IBM	   (Greenberg	   et	   al.	   2007;	   De	  Paepe	  et	  al.	  2009).	  Interleukin-­‐1	  cytokines	  augment	  the	  expression	  of	  adhesion	  molecules	   by	   endothelium,	   permitting	   leukocyte	   transmigration	   and	   also	  promote	   antibody	   production.	   IL1β	   has	   been	   demonstrated	   to	   colocalise	  with	  MHC	  I	   in	  myofibres	  affected	  by	  IBM.	  This	  distinguishes	  IBM	  from	  Polymyositis	  and	   Dermatomyositis,	   where	   IL1β	   is	   only	   detected	   at	   sites	   of	   marked	  inflammation	  or	  in	  leukocytes	  (De	  Paepe	  et	  al.	  2009).	  All	  these	  cytokine	  families	  are	   linked	   by	   their	   potentially	   central	   pathogenic	   contribution	   to	   IBM,	   and	  indeed	  to	  the	  established	  primary	  myositides,	  through	  the	  upregulation	  of	  MHC	  I,	  which	  is	  reproduced	  by	  myotubes	  in	  vitro	  (Bao	  et	  al.	  1990).	  Chemokines	   are	   a	   subset	   of	   cytokines	   that	   influence	   the	   migration	   of	  lymphocytes	  through	  a	  concentration	  gradient	  in	  a	  process	  termed	  chemotaxis.	  	  These	   small	   molecules	   are	   further	   categorized	   by	   amino	   acid	   positions	   that	  influence	   the	   position	   of	   their	   first	   two	   cysteine	   residues,	   with	   the	   majority	  falling	   into	   α/‘CXCL’	   or	   β/‘CCL’	   classes.	   The	  Mig	   (CXCL9)	   and	   IP-­‐10	   (CXCL10)	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mRNA	  chemokines,	  which	   are	   induced	  by	   IFNγ,	   have	  been	   found	   in	   increased	  quantity	  in	  IBM	  muscle	  in	  vivo	  (Raju	  et	  al.	  2003),	  implying	  that	  IFNγ	  contributes	  to	   recruitment	   of	   the	   T-­‐cells	   which	   represent	   the	   predominant	   inflammatory	  cell	  demonstrated	  in	  the	  condition.	  MCP-­‐1	  (CCL3),	  upregulated	  by	  TNFα,	  is	  also	  known	   to	  be	  expressed	  at	   sites	  of	   inflammation	   in	   IBM	   in	  vivo,	  as	   is	  CCL4	   (De	  Bleecker	   et	   al.	   2002).	   Cultured	   human	   myotubes	   also	   upregulate	   a	   similar	  chemokine	   profile	   in	   response	   to	   cytokine	   exposure	   in	   vitro	   (Schmidt	   et	   al.	  2008).	   	   In	   addition,	   they	   also	   increase	   expression	   of	   intercellular	   adhesion	  molecules	  such	  as	  CD54	  under	  such	  stimuli	  (Michaelis	  et	  al.	  1993).	  	  
3.1.3.3	  Satellite	  cells	  of	  patients	  with	  IBM	  Satellite	  cells	  harvested	  from	  IBM	  patients	  appear	  to	  differ	  from	  those	  of	  normal	  subjects.	  They	  demonstrated	  impaired	  proliferation	  rates,	  telomeric	  shortening	  and	  a	  propensity	  to	  accumulate	  amyloid	  (Morosetti	  et	  al.	  2010).	  However,	  since	  IBM	  is	  not	  proposed	  to	  be	  a	  primary	  disease	  of	  satellite	  cell	  dysfunction,	  these	  findings	  suggest	  the	  unsuitability	  of	  patient	  satellite	  cells	  for	  disease	  modeling.	  	  
3.1.4	  Overall	  comparison	  between	  in	  vitro	  and	  in	  vivo	  models	  of	  IBM	  Basic	   comparison	   between	   the	   relative	   merits	   of	   animal	   and	   cellular	   studies	  highlights	   the	   several	   practical	   advantages	   of	   in	   vitro	   systems.	   	   For	   a	   disease	  with	  an	  established	  and	  reproducible	  primary	  cause,	  along	  with	  a	  theoretically	  sound	  treatment	  target,	  in	  vivo	  studies	  appear	  appropriate.	  In	  the	  context	  of	  IBM,	  the	  doubt	   that	   surrounds	   the	  pathogenesis	  obliges	   investigation	  of	  potentially	  downstream	   or	   secondary	   disease	  markers.	   The	   evaluation	   of	   drug	   action	   on	  animal	  models	  of	  limited	  accuracy	  is	  a	  potentially	  costly	  and	  inefficient	  process.	  Any	   results	   would	   be	   open	   to	   criticism	   regards	   their	   advancement	   toward	  human	  studies.	  The	  relative	  malleability	  of	  cellular	  studies	   in	  response	  to	  new	  developments	  in	  the	  field	  is	  a	  significant	  advantage	  in	  this	  context.	  Therefore,	  in	  combination	  with	  the	  existing	  data	  to	  support	  their	  use,	  a	  cell	  based	  system	  was	  preferred	  for	  the	  experiments	  undertaken	  in	  this	  thesis.	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3.1.5	  Muscle	  cell	  culture:	  history	  and	  development	  
3.1.5.1	  Selection	  of	  primary	  cultures	  The	  first	  step	  in	  the	  development	  of	  a	  cellular	  model	  was	  to	  decide	  whether	  to	  use	  primary	  cells	  or	  an	  immortalised	  cell	  line.	  The	  existing	  literature	  supported	  the	  possibility	  that	  primary	  muscle	  cell	  cultures	  could	  be	  manipulated	  to	  show	  certain	  characteristics	  of	  IBM	  (Askanas	  et	  al.	  1997;	  Schmidt	  et	  al.	  2008).	  Given	  that	   primary	   cells	   are	   generally	   felt	   to	   represent	   the	   activities	   of	   cells	   in	   vivo	  more	  closely,	  and	   the	   inherent	  conflict	  presented	  by	   investigating	  a	  disease	  of	  aged	  tissue	  in	  an	  immortalised	  line,	  primary	  cells	  were	  preferred.	  Furthermore,	  the	   study	   of	  muscle	   lends	   itself	   to	   primary	   cell	   culture	   given	   that	   all	  muscles	  contain	   a	   population	   of	   precursor	   cells	   that	   can	   be	   readily	   extracted	   and	  cultured,	   thereby	   preventing	   the	   need	   for	   multiple	   passages	   of	   subclones.	  Therefore,	  a	  review	  of	  this	  technique	  was	  performed.	  
	  
3.1.5.2	  Satellite	  cells	  As	   post-­‐mitotic	   tissue,	   skeletal	   muscle	   can	   only	   replace	   lost	   constituent	   cells	  rather	   than	   reproduce	   them	   through	   cell	   division	   as	   occurs	   in	   skin.	   Initially	  described	   in	   1961,	   satellite	   cells	   are	   responsible	   for	   much	   of	   adult	   skeletal	  muscle’s	   considerable	   properties	   of	   recovery	   and	   regeneration	   after	   insult	   or	  injury	  (Mauro	  1961).	  Under	  basal	  conditions,	   these	  precursor	  cells	  are	   located	  between	  the	  sarcolemma	  and	  basal	  lamina	  where	  they	  reside	  in	  a	  quiescent	  and	  non-­‐proliferative	  state	  (Muir	  et	  al.	  1965).	  Indeed,	  there	  is	  no	  apparent	  turnover	  in	   normal	   adult	   skeletal	  muscle	   (Decary	   et	   al.	   1997).	   Satellite	   cells	   appear	   to	  represent	   a	   heterogeneous	   population	   comprising	   true	   stem	   cells	   and	  committed	   progenitors	   (Kuang	   et	   al.	   2007).	   Their	   origins	   are	   in	   embryonic	  somites	   as	   Pax3/Pax7-­‐expressing	   cells,	   the	   dorsal	   embryonic	   aorta	   and	   also	  adult	   stem	   cells	   during	   regeneration	   (Polesskaya	   et	   al.	   2003;	   Ben-­‐Yair	   et	   al.	  2005).	  Activation	  triggers	  a	  cascade	  of	  pro-­‐myogenic	  differentiation	  that	  is	  reminiscent	  of	   skeletal	   muscle	   development.	   Satellite	   cells	   evolve	   to	   myoblasts,	   primitive	  myogenic	   cells,	   which	   readily	   fuse	   to	   form	   elongated	   and	   multinucleated	  myotubes,	   the	   terminally	   differentiated	   basic	   building	   block	   of	   the	   myofibre.	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Stimulation	   of	   the	   satellite	   cell,	   therefore,	   restores	   mature	   muscle	   either	   by	  replacement	  with	  new	  fibres	  or	  by	  the	  incorporation	  of	  myocytes	  into	  existing	  fibres	  (Moss	  et	  al.	  1971).	  This	  process	  is	  accompanied	  by	  generation	  of	  progeny	  that	  restore	  the	  original	  quiescent	  satellite	  cell	  pool	  (Fig	  3.1).	  	  
	  
Figure	  3.1	  Regenerating	  muscle	  fibre	  Regenerating	   muscle	   fibre.	   (A)	   Normal	   muscle	   fibre	   with	   myonuclei	   and	   a	  satellite	  cell.	  (B)	  Damaged	  muscle	  fibre.	  The	  satellite	  cell	  has	  become	  activated	  and	  proliferated	   in	   response	   to	   the	   damaged	   fibre.	   (C)	  Muscle	   precursor	   cells	  derived	  from	  the	  satellite	  cell	  have	  fused	  together	  to	  repair	  the	  damaged	  muscle	  fibre.	   (D)	   Regenerated	   muscle	   fibre,	   with	   a	   new	   satellite	   cell	   and	   centrally-­‐placed,	  newly-­‐regenerated	  myonuclei.	  Reproduced	  from	  (Morgan	  et	  al.	  2003).	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The	   genetic	   expression	   status	   of	   satellite	   cells	   alters	   markedly	   during	   this	  process	  of	  differentiation	  (Fig	  3.2).	  Whereas	  the	  quiescent	  status	  is	  marked	  by	  Pax7	  (Seale	  et	  al.	  2000),	  M-­‐cadherin	  (Cornelison	  et	  al.	  1997),	  NCAM	  and	  VCAM	  (Covault	  et	  al.	  1986),	  activated	  cells	  express	  desmin	  and	  MyoD	  (Cornelison	  et	  al.	  1997).	  Indeed,	  the	  expression	  of	  MyoD	  appears	  fundamental	  and	  can	  cells	  other	  than	   satellite	   cells,	   such	   as	   fibroblasts	   and	   chondroblasts	   into	  myogenic	   cells	  (Choi	  et	  al.	  1990).	  	  	  
	  	  
Figure	  3.2	  Schematic	  representation	  of	  adult	  myogenesis	  Quiescent	   skeletal	  muscle	   satellite	   cell	   can	   are	   activated	  by	   stimuli	   from	   their	  associated	   fibre	   or	   microenvironment.	   Their	   progeny,	   skeletal	   myoblasts,	  express	   the	   paired-­‐box	   transcriptions	   factors	   Pax7	   and	   Pax3,	   as	   well	   as	   the	  myogenic	  regulatory	  factors	  Myf5	  and	  MyoD.	  Once	  committed	  to	  differentiation,	  myoblasts	   stop	   proliferating	   and	   reduce	   expression	   of	   Pax7,	   Pax3	   and	   Myf5.	  Differentiating	   myogenin	   positive	   myocytes	   then	   align	   and	   fuse	   to	   form	  multinucleated	  myofibres.	  MRF4	  is	  required	  for	  hypertrophy	  of	  these	  new	  fibers.	  Reproduced	  from	  (Le	  Grand	  et	  al.	  2007).	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3.1.5.3	  Satellite	  cell	  culture	  It	  has	  been	  established	  for	  some	  time	  that	  muscle	  can	  be	  dissociated	  to	  release	  intact	   satellite	   cells	   and	   these	   can,	   in	   turn,	   be	   cultured	   in	   vitro	   (Cossu	   et	   al.	  1980),	   (Hantai,	   Tassin	   et	   al.	   1985).	  Here	   they	   replicate	   at	   a	   decelerating	   rate,	  initially	   doubling	   in	   number	   over	   approximately	   twenty-­‐four	   hours	   before	  differentiating	   and	   fusing	   to	   form	  multinucleated	  myotubes	   (Le	  Moigne	   et	   al.	  1990).	   This	   technique	   has	   been	   widely	   exploited	   to	   investigate	   normal	  mechanisms	   of	   muscle	   development	   and	   regeneration	   and	   the	   pathogenic	  processes	  of	  muscle	  disease.	  	  	  
3.1.6	  Limitations	  and	  considerations	  of	  cell	  culture	  In	  the	  knowledge	  that	  elements	  of	  IBM-­‐relevant	  pathology	  had	  previously	  been	  induced	  in	  cultured	  muscle	  in	  vitro	  (Askanas	  et	  al.	  1997;	  Schmidt	  et	  al.	  2008),	  a	  number	   of	   initial	   considerations	  were	  made	   to	   evaluate	   the	   suitability	   of	   this	  technique	  in	  the	  context	  of	  the	  specific	  aims	  of	  this	  work.	  	  	  
3.1.6.1	  Purity	  Myogenic	  progenitor	  cells	  that	  can	  be	  harvested	  from	  skeletal	  muscle	  appear	  to	  represent	  two	  groups,	  satellite	  cells	  and	  a	  ‘side	  population’	  (Hawke	  et	  al.	  2001)	  that	  do	  not	  express	  those	  cellular	  markers	  typical	  of	  a	  satellite	  cell,	  such	  as	  Pax7.	  Whilst	  the	  cells	  constituting	  the	  side	  population	  do	  not	  typically	  enter	  myogenic	  differentiation,	   when	   cultured	   in	   isolation,	   subjected	   intramuscular	  transplantation,	   co-­‐cultured	  with	  myoblasts	  or	   induced	   to	  express	  MyoD,	   they	  do	  form	  myocytes	  (Asakura	  et	  al.	  2002).	  Interestingly,	  satellite	  cells	  also	  appear	  to	   be	   pluripotent	   and	   can	   differentiate	   to	   osteocytes	   or	   adipocytes	   following	  exposure	  to	  bone	  morphogenic	  proteins	  or	  adipogenic	  factor,	  even	  where	  MyoD,	  Pax7	   and	   desmin	   have	   been	   expressed	   previously	   (Asakura	   et	   al.	   2001).	  Therefore,	   primary	   muscle	   culture	   has	   the	   potential	   to	   include	   mixed	   cell	  populations.	  Whilst	  maintenance	  of	  heterogeneity	  in	  culture	  is	  required	  for	  the	  release	   of	   supportive	   growth	   factors	   (Husmann	   et	   al.	   1996),	   and	   may	   more	  accurately	  reflect	  the	  in	  vivo	  environment,	  it	  is	  important	  to	  optimise	  the	  culture	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environment	  to	  achieve	  the	  desired	  proportions	  of	  cell	  types	  in	  a	  reproducible	  fashion.	   In	   the	   context	   of	   these	   experiments,	   the	   characteristic	  morphology	  of	  the	  multinucleated	  myotube	  was	   identified	  as	  advantageous,	  particularly	  since	  this	  would	  allow	  imaging	  experiments,	  such	  as	  functional	  confocal	  microscopy,	  specific	   to	   myogenic	   cells	   without	   the	   need	   for	   potentially	   confounding	  additional	   fluorescent	   labeling.	   Since	   myotubes	   are	   post-­‐mitotic	   and	   possess	  active	  contractile	  machinery,	  these	  are	  clearly	  the	  most	  closely	  representative	  of	  muscle	   in	   vivo.	   Previous	   studies	   suggested	   that	   demonstrable	   myogenicity	   of	  greater	  than	  80%	  was	  achievable	  in	  non-­‐passaged	  primary	  satellite	  cell	  cultures	  (Park	  et	  al.	  2006).	  	  
3.1.6.2	  Culture	  Techniques	  Mechanical	   and	   enzymatic	   dissociation	   with	   collagenase	   or	   trypsin	   releases	  myogenic	  precursor	  cells	  from	  samples	  of	  fresh	  skeletal	  muscle.	  These	  cells	  can	  be	  identified	  by	  light	  microscopy	  and	  plated	  at	  the	  desired	  density,	  where	  they	  adhere	  within	  a	  few	  hours	  to	  an	  appropriate	  culture	  surface.	  During	  the	  first	  few	  days,	   the	   doubling	   time	   has	   been	   estimated	   as	   daily	   and	   this	   continues	   until	  approximately	   day	   four	   when	   alignment	   and	   fusion	   into	   myotubes	   occurs.	  Myotubes	   develop	   functional	   contractile	   machinery	   and	   appear	   striated	   on	  electron	  microscopy	  (Askanas	  et	  al.	  1975).	  	  Myotubes	   themselves	  are	  not	  mitotic	  but	  may	   incorporate	  additional	   adjacent	  satellite	  cells.	  Therefore	  the	  doubling	  time	  drastically	  reduces	  to	  approximately	  six	   further	  days	   (Le	  Moigne	  et	  al.	  1990).	  This	   is	  a	  potentially	  useful	   feature	   in	  the	   context	   of	   studies	   on	   IBM	   since	   the	   propensity	   of	   IBM	   tissue	   to	   display	  disordered	   homeostasis	   may	   well	   reflect	   the	   postmitotic	   nature	   of	   skeletal	  muscle	  and	  its	  consequent	  inability	  to	  reduce	  misfolded	  protein	  load	  by	  mitotic	  dilution.	  Therefore,	  the	  induction	  of	  IBM-­‐relevant	  conditions	  after	  the	  formation	  of	  myotubes	  appeared	  desirable.	   It	   is	  widely	  accepted	   that	  a	  step	  reduction	   in	  the	   concentration	  of	   serum	   in	   the	  growth	  medium	   is	   a	   stimulus	  of	   fusion	   into	  myotubes	  (Mau	  et	  al.	  2008).	  Therefore,	  most	  primary	  muscle	  culture	  protocols	  employ	  two	  growth	  media,	  the	  initial	  comprising	  by	  fetal	  serum	  that	  facilitates	  proliferation	  and	  a	  subsequent	  differentiation	  medium	  (Fig	  3.3).	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Figure	   3.3	   Light	  microscopy	   of	   satellite	   cell	   cultures	   forming	   distinctive	  
myotubes.	  Satellite	  cell	  cultures	  from	  various	   lines	  of	   laboratory	  mice	  at	  different	  days	  of	  cultivation	   in	   growth	   medium	   (A–D)	   or	   after	   a	   change	   from	   growth	   to	  maintenance	  medium	  at	  day	  6	  (E,	  F).	  Reproduced	  from	  (Rehfeldt	  et	  al.	  2002)	  
	  
3.1.7	  Choice	  of	  species	  Consideration	   was	   given	   to	   whether	   to	   use	   muscle	   derived	   from	   humans	   or	  rodents	   as	   the	   source	   of	   satellite	   cells.	   The	   principal	   advantages	   offered	   by	  human	  tissue	  are	  the	  presumed	  closer	  representation	  of	  human	  pathology	  and	  that	  the	  majority	  of	  relevant	  previous	  cellular	  work	  in	  IBM	  has	  occurred	  on	  cell	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cultures	   harvested	   from	   human	   muscle	   biopsies	   from	   subjects	   who	   were	  subsequently	  found	  to	  be	  free	  of	  muscle	  disease	  (Askanas	  1996,	  Schmidt	  2008).	  However,	  numerous	  disadvantages	  of	  using	  human	  tissue	  were	  also	   identified.	  There	  are	  considerable	  practical	  hurdles	  to	  overcome	  if	  a	  sustainable	  source	  of	  human	  myoblasts	  is	  to	  be	  maintained.	  These	  exceed	  the	  additional	  legal,	  ethical	  and	  regulatory	  requirements	  posed	  by	  study	  of	  human	  tissue.	  Based	  on	  the	  inevitability	  that	  any	  programme	  of	  study	  employing	  primary	  cell	  culture	  will	  require	  the	  use	  of	  multiple	  pieces	  of	  tissue	  from	  multiple	  donors,	  it	  is	   important	   to	   consider	   that	   human	  myoblast	   biobanks	   reflect	   an	   extremely	  heterogeneous	   population.	   They	   include	   patients	   of	  widely	   differing	   ages	   and	  genetic	   backgrounds,	   making	   cross-­‐muscle	   culture	   comparison	   difficult	   to	  validate.	   Alternatively,	   multiple	   passages	   of	   individual	   harvests	   are	   required,	  which	   represents	   selection	   of	   a	   subclone	   of	   cells	   that	   may	   not	   represent	   the	  majority.	   Furthermore,	   it	   is	   difficult	   to	   be	   certain	   that	   all	   individuals	   are	  absolutely	   free	  of	   any	   genetic	   or	   acquired	  muscle	   condition	  or	  predisposition.	  Even	   supposing	   this	   is	   the	   case,	   there	   are	   substantial	   differences	   in	   both	   the	  absolute	  numbers	  and	  inherent	  properties	  of	  myoblasts	  sourced	  from	  donors	  of	  different	   ages.	   Indeed,	   it	   is	   proposed	   that	   such	   differences	   contribute	   to	   the	  sarcopenia	   of	   ‘normal’	   ageing,	   which	   is	   a	   potentially	   crucial	   underlying	  susceptibility	  in	  the	  pathogenesis	  of	  IBM.	  Therefore,	  it	  was	  necessary	  to	  review	  these	   differences	   in	   consideration	   of	   whether	   to	   pursue	   a	   human	   source	   of	  satellite	  cells.	  Whereas	   approximately	   30%	   of	   sublaminar	   nuclei	   in	   neonatal	   rodent	  muscle	  represents	  satellite	  cells	  (Hawke	  et	  al.	  2001),	  the	  proportion	  of	  satellite	  cells	  in	  adult	   human	   muscle	   has	   been	   estimated	   at	   only	   1.3%	   (Mackey	   et	   al.	   2009).	  Satellite	   cell	  number	  does	  not	  appear	   to	  be	   influenced	  by	   type	  or	   size	  of	   fibre	  with	   which	   those	   satellite	   cells	   are	   associated	   (Kadi	   et	   al.	   2006).	   Despite	   the	  larger	  size	  of	  human	  biopsy	  samples	  than	  rodent	  muscles,	  any	  small	  advantage	  this	   presents	   is	   superseded	   by	   the	   greater	   availability	   of	   rodents	   for	  investigative	  use.	  Therefore,	  use	  of	  human	  tissue	  would	  provide	  a	  significantly	  reduced	  stock	  of	  satellite	  cells,	  a	  potential	  disadvantage	  to	  the	  development	  of	  a	  high	   throughput	   screening	   tool.	   The	   use	   of	   repeated	   passages	   to	   address	   this	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issue	  is	  also	  undesirable;	  changes	  in	  satellite	  cell	  function	  such	  as	  the	  propensity	  to	  accumulate	  amyloid	  species	  were	  observed	  when	  satellite	  cells	  derived	  from	  IBM	  patients	  were	  studied	  in	  this	  way	  (Morosetti	  et	  al.	  2010).	  The	  same	  study	  also	   demonstrated	   telomeric	   shortening,	   reduced	   proliferative	   ability	   and	  reduced	  differentiation	  in	  IBM	  patient	  satellite	  cells,	  which,	  is	  evidence	  against	  employing	   them	   in	   this	  work.	  Moreover,	   it	  was	   not	   a	   hypothesis	   of	   this	  work	  that	  IBM	  is	  a	  satellite	  cell	  mediated	  disease.	  It	  was	   foreseen	   that	   comparison	  between	   cultures	  would	   form	  a	   considerable	  part	   of	   this	   work.	   Therefore,	   it	   was	   important	   to	   minimise	   any	   inherent	  variability	   in	   the	   culture	   system	   itself	   that	   might	   mask	   or	   exaggerate	  experimental	   effect.	   Differences	   in	   satellite	   cell	   function	   between	   subjects	   of	  different	   ages	   and	   from	   different	   muscle	   groups	   were	   considered.	   Brack	   and	  colleagues	  demonstrated	  increased	  Wnt	  signaling	  during	  ageing	  of	  satellite	  cells,	  which	  were	  also	  associated	  with	  increased	  fibrogenicity	  (Brack	  et	  al.	  2007).	  This	  impaired	  myogenicity	  was	  not	  restored	  by	  exposure	  of	  aged	  satellite	  cells	   to	  a	  more	  youthful	  environment,	  which	  has	  important	  connotations	  for	  the	  sourcing	  of	  satellite	  cells	  in	  this	  work.	  It	  is	  clear	  that	  to	  study	  IBM	  using	  cultured	  muscle,	  whilst	   accepting	   the	   premise	   that	   underlying	   ageing	   of	   skeletal	   muscle	  contributes	  in	  some	  way	  to	  the	  disease,	  the	  age	  of	  the	  primary	  cell	  donor	  must	  be	  standardised	  as	  far	  as	  possible.	  For	   these	   reasons,	   the	   disadvantages	   associated	  with	   use	   of	   human	  myoblast	  cultures	   promoted	   the	   use	   of	   rodent	   cultures	   to	   the	   preferred	   initial	   choice.	  Such	   disadvantages	   presented	   by	   the	   use	   of	   human	   cultures	   may	   be	   largely	  superseded	  in	  the	  context	  of	  genetic	  conditions,	  where	  the	  direct	  representation	  of	   the	   disease	   by	   cells	   harvested	   from	   an	   affected	   donor	   confers	   a	   significant	  benefit.	   Although,	   as	   described	   above,	   genetic	   forms	   of	   ‘IBM’	   exist,	   these	   are	  substantially	   phenotypically	   and	   distinct	   to	   the	   sporadic	   condition.	   They	   are	  also	  extremely	  rare,	  precluding	  realistic	  use	  in	  this	  context.	  Upon	  deciding	  to	  pursue	  rodent	  derived	  cultures,	  it	  was	  apparent	  that	  neonatal	  pups	  would	  probably	  represent	  the	  most	  efficient	  source	  of	  satellite	  cells.	  Even	  accounting	   for	   the	   increasing	   size	  of	  muscle	  with	  age,	   the	   absolute	  number	  of	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satellite	  cells	  reduces	  with	  advancing	  age,	  reportedly	  from	  3.1x105	  in	  EDL	  aged	  one	  month	  versus	  1.3x105	  at	  24	  months	  (Gibson	  et	  al.	  1983).	  	  
	  
3.1.8	  Specific	  aims	  of	  this	  Chapter	  1.	   To	   optimise	   a	   protocol	   for	   primary	   myogenic	   cell	   culture,	   with	   high	  myogenicity	  and	  myotube	  formation.	  2.	  To	  determine	  whether	  IBM-­‐relevant	  pathology	  can	  be	  induced	  consistently	  in	  these	  cells.	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3.2	  Results	  The	  first	  step	  in	  the	  development	  of	  an	  in	  vitro	  model	  of	  IBM	  pathology	  was	  to	  optimise	  the	  technique	  of	  culturing	  satellite	  cells	  to	  differentiate	  into	  myocytes	  and	   myotubes	   that	   could	   then	   be	   maintained	   sufficiently	   for	   further	  experimentation.	  This	  process	  began	  with	  evaluation	  of	  mouse	  and	  rat	  primary	  satellite	  cell	  cultures	  before	  examination	  of	  various	  plating	  densities	  and	  media	  constituents.	  Subsequently,	  several	  myogenic	  cell	  purification	  techniques	  were	  compared,	   including	   pre-­‐plating,	   density	   centrifugation	   and	   fluorescently	  activated	  cell	  sorting	  (FACS).	  	  	  
3.2.1	  Neonatal	  mouse	  satellite	  cell	  cultures	  Using	   the	   standard	   culture	   protocol	   (see	   Chapter	   2:	   Methods),	   satellite	   cells	  harvested	  from	  the	  hindlimb	  muscles	  of	  wild-­‐type	  C57-­‐B6/SJLF1	  neonatal	  mice	  at	   postnatal	   day	   0-­‐4	  were	   plated	   at	   50	   to	   100,000	   /	   cm2.	   A	   variety	   of	   culture	  conditions	   were	   evaluated.	   First	   medium	   change,	   which	   removes	   debris	  remaining	   from	  the	  harvest	  process	  or	  detached	  cells,	  was	  evaluated	  at	  either	  24	  or	  48	  hours.	  Further	  examination	  was	  made	  on	  the	  effect	  of	  different	  media	  constituents	  (between	  20	  and	  30%	  fetal	  calf	  serum	  (FCS),	  between	  5	  and	  15%	  horse	   serum	   (HS),	   and	   with	   or	   without	   chick	   embryo	   extract).	   Demonstrable	  myogenicity	   of	   up	   to	   44%	   (±12%,	   n=5	   cultures	   per	   condition,	  minimum	   of	   6	  wells	   per	   culture)	   was	   achieved,	   with	   a	   myotube	   fusion	   index	   of	   23%	   (±8%,	  n=5)	   (Figure	   3.4)	   Based	   on	   cell	   morphology,	   the	   non-­‐myogenic	   fraction	  predominantly	  comprised	  fibroblasts,	  although	  imunocytochemical	  staining	  for	  fibroblast	   specific	   markers	   was	   inconsistent	   and	   some	   cells	   that	   assumed	   a	  fibroblastic	   morphology	   demonstrated	   myocytic	   features	   on	  immunocytochemistry,	   as	  has	  been	  described	  previously	   (Molnar	   et	   al.	   1996).	  Absolute	  variability	   in	  myogenicity	  between	   individual	  wells	  derived	   from	  the	  same	  harvest	  was	  up	   to	  27%.	  Comparison	  between	  harvests	  demonstrated	  an	  absolute	   variability	   in	  myogenicity	   of	   18%.	  Mouse	   satellite	   cell	   cultures	  were	  typically	  limited	  to	  approximately	  7	  days	   in	  vitro,	  primarily	  due	  to	  detachment	  from	  the	  coverslip.	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Figure	  3.4	  Immunocytochemisty	  of	  mouse	  satellite	  cell	  cultures	  Myogenic	   cells	   were	   manifest	   as	   elongated,	   multinucleated	   myotubes,	   or	   as	  myocytes.	  The	  latter	  were	  more	  common	  in	  most	  experiments.	  Co-­‐stained	  DAPI	  images	   suggested	  a	  high	  proportion	  of	   cells	  were	  not	  demonstrably	  myogenic	  (C).	  By	  7	  days	  in	  vitro,	  there	  was	  evidence	  of	  detached	  or	  fragmented	  myotubes	  (arrow	   in	  D).	  Anti-­‐myosin	  heavy	   chain	   (red).	  Nuclei	   labeled	  with	  DAPI	   (blue).	  Scale	  Bars	  =	  20μm	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3.2.2	  Neonatal	  rat	  cultures	  In	   light	   of	   the	   considerable	   variation	   in	  myogenicity	   demonstrated	   by	  mouse	  satellite	  cell	  cultures,	  the	  standard	  culture	  protocol	  was	  then	  applied	  to	  satellite	  cells	  harvested	  from	  neonatal	  wild-­‐type	  Sprague	  Dawley	  rats	  at	  postnatal	  day	  0-­‐3.	   Approximately	   6x106/ml	   cells	   for	   subsequent	   culture	   were	   yielded	   per	  animal.	  An	  isolated	  preliminary	  experiment	  demonstrated	  myogenicity	  of	  54%,	  superior	   to	   that	   demonstrated	   in	   neonatal	   mouse	   culture.	   Additionally,	   the	  fusion	  index	  of	  67%	  was	  greater,	  with	  the	  majority	  of	  cells	  forming	  distinctive,	  frequently	   aligned	   multinucleated	   myotubes.	   Fragmentation	   and	   detachment	  were	   less	   apparent	   than	   in	  mouse	   cultures.	   Indeed,	   cultures	  were	  maintained	  for	  14	  days	  in	  vitro	  (DIV)	  prior	  to	  detachment,	  which	  was	  approximately	  7	  days	  superior	   to	   neonatal	   mouse	   cultures.	   Continued	   culture	   beyond	   the	   point	   of	  detachment	   demonstrated	   that	   remaining	   plated	   cells	   were	   then	   apparently	  induced	  to	  differentiate	  to	  myotubes	  (Figure	  3.5).	  It	  was	  noted	  that	  the	  lack	  of	  hair	   on	   neonatal	   rat	   pups,	   unlike	   their	  mouse	   counterparts,	  might	   reduce	   the	  risk	   of	   subsequent	   culture	   infection.	   Therefore	   more	   detailed	   evaluation	   of	  different	   culture	   conditions	  was	  performed	   to	   optimise	   the	  protocol	   using	   rat	  satellite	  cells.	  	  	  
3.2.3	  Culture	  Medium	  Cultures	  were	  performed	  using	  a	  variety	  of	  different	  of	  medium	  constituents,	  in	  order	  to	  optimise	  the	  conditions	  for	  differentiation	  to	  myogenic	  lineage.	  Subtle	  differences	  in	  the	  constitution	  of	  growth	  medium	  and	  timing	  of	  medium	  changes	  had	   significant	   effects	   on	   both	   overall	   myogenicity	   and	   the	   differentiation	   of	  myogenic	   cells	   into	  mature	  myotubes	   (Table	   3.2).	   The	   highest	  myogenicity	   as	  assessed	  by	  desmin	  immunostaining	  (mean	  78%,	  ±7%,	  n=3)	  followed	  the	  initial	  use	  of	  25%	  Fetal	  Calf	  Serum,	  as	  proliferation	  medium,	  then	  10%	  Horse	  Serum,	  as	  differentiation	  medium,	  at	  48	  hours	  onwards,	  with	  inclusion	  of	  Chick	  Embryo	  Extract.	  This	  was	  significantly	  greater	  than	  in	  cultures	  using	  the	  same	  medium	  that	  were	  left	  for	  48	  hours	  prior	  to	  the	  first	  medium	  change	  (mean	  61%,	  ±6%,	  p<0.05).	  Non-­‐significant	   differences	  were	   observed	  between	   this	  medium	  and	  those	  employing	  subtly	  different	  concentrations	  of	  FCS	  or	  HS.	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Figure	  3.5	  Maturation	  of	  rat	  satellite	  cell	  cultures	  Light	  microscopy	   of	   satellite	   cells	   over	   time	   demonstrates	   differentiation	   into	  elongated	   myotubes.	   After	   detachment	   of	   the	   myotubes,	   typically	   at	   day	   14,	  continued	  culture	  of	   the	  remaining	  adherent	  cells	   leads	   to	   further	  myogenesis	  and	  differentiation	  to	  myotubes.	  Scale	  Bars=2mm	  	  	  	  	   	  

























24	   48	   20	   15	   -­‐	   72	  ±6	   72	  ±3	  
24	   48	   20	   10	   -­‐	   70	  ±5	   81	  ±3	  
24	   48	   20	   10	   +	   74	  ±4	   80	  ±5	  
24	   48	   25	   10	   +	   78	  ±7	   86	  ±4	  
24	   48	   30	   10	   +	   69	  ±5	   77	  ±4	  
24	   48	   25	   5	   +	   63	  ±4	   81	  ±7	  
24	   72	   25	   10	   +	   71	  ±5	   72	  ±7	  
48	   48	   20	   10	   +	   64	  ±7	   83	  ±5	  
48	   48	   25	   10	   +	   61	  ±6	   77	  ±3	  
Table	   3.2	   Effect	   of	   culture	   medium	   constitution	   on	   culture	   myogenicity	  
and	  differentiation	  All	  cultures	  subject	  to	  pre-­‐plating.	  Mean	  percentages	  for	  myogenicity	  and	  fusion	  index	  at	  7	  days	  are	  shown	  to	  2	  significant	  figures.	  (n=3)	  	  	  Nevertheless,	   this	   medium	   constitution	   was	   selected	   for	   application	   to	   all	  subsequent	  cultures.	  These	  media	  all	  conferred	  a	  high	  fusion	  index,	  the	  highest	  being	   86%	   (±4%,	   n=3)	   as	   demonstrated	   with	   light	   microscopy	   and	  immunocytochemistry	  by	  formation	  of	  characteristic	  elongated,	  multinucleated	  myotubes	  (Figure	  3.6).	  Regardless	  of	  medium,	  cultures	  could	  be	  maintained	  for	  up	  to	  14	  days,	  at	  which	  time	  spontaneous	  contraction	  of	  myotubes,	  viewable	  on	  light	  microscopy,	  precipitated	  detachment	  of	  cells	  from	  the	  culture	  well.	  
	  
3.2.4	  Plating	  density	  Plating	  density	  was	  also	  observed	  to	  increase	  the	  rapidity	  and	  extent	  of	  fusion	  to	  myotubes,	   proportionally	   up	   to	   100,000	   cells/cm2.	   Beyond	   this,	   confluence	  was	   demonstrated	   at	   approximately	   7	   days	   and	   detachment	   occurred	   by	   10	  days,	   thereby	   reducing	   the	   lifespan	   of	   the	   culture.	   Therefore,	   the	   100,000	  cells/cm2	  standard	  was	  subsequently	  applied	  routinely.	  	  	   	  




Figure	  3.6	  Comparison	  of	  different	  culture	  media	  on	  satellite	  cell	  cultures	  A:	  By	  7	   days	   in	  vitro,	  myocytes	   fuse	   to	   form	  multinucleated	  myotubes,	   visible	  with	   fluorescently	   labelled	   desmin	   immunostaining	   (red).	   Nuclei	   are	   labelled	  with	  DAPI	  (blue).	  (Scale	  Bar	  =	  100μm)	  B:	   Light	  microscopy	   at	   20x	  magnification	   of	   satellite	   cell	   culture	   at	   7	   days	   in	  
vitro	   demonstrating	   characteristic	   elongated	   structure	   and	   alignment	   of	  orientation.	  (Scale	  Bar	  =	  100μm)	  
	  	  
3.2.5	  Culture	  purification	  techniques	  After	   optimising	   culture	   medium	   and	   seeding	   densities,	   a	   high	   proportion	   of	  myogenic	   cells	   was	   achieved.	   However,	   for	   the	   purposes	   of	   future	   high	  sensitivity	   biochemical	   analysis,	   several	   established	   techniques	   for	   further	  purification	  of	  myogenic	  cultures	  were	  examined.	  	  
3.2.5.1	  Preplating	  Pre-­‐plating	   the	   cell	   suspension	   after	   completing	   the	   preparation	   of	   cells	   for	  culture	  within	  a	  plastic	  container,	  prior	  to	  transfer	  of	  the	  suspension	  to	  growth	  plates,	   is	   reported	   to	   increase	   the	  myogenic	   fraction	  by	   exploiting	   the	   greater	  propensity	   of	   fibroblasts	   to	   adhere	   to	   plastic	   surfaces.	   The	   impact	   of	   this	  technique	  was	  examined	  and	  preplating	  for	  15-­‐20	  minutes	  prior	  to	  final	  plating	  improved	  myogenicity.	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Preplating	  was	  associated	  with	  a	  change	  from	  69%,	  (±6%,	  n=3)	  myogenic	  purity	  to	  78%	  (±7%,	  n=3)	  (Figure	  3.7).	  This	  difference	  was	  not	  statistically	  significant,	  reflecting	  the	  fairly	  broad	  variance	  in	  purity	  between	  cultures	  under	  equivalent	  conditions.	   Nevertheless,	   since	   pre-­‐plating	   was	   a	   straightforward	   process	   to	  incorporate	   in	   the	   protocol,	   and	  was	   not	   associated	  with	   a	   decline	   in	   overall	  cellular	  yield,	  it	  was	  included	  in	  subsequent	  cultures.	  	  
	  
Figure	  3.7	  Effect	  of	  Preplating	  on	  Myogenicity	  The	  bar	   chart	   compares	  preplated	  and	  non-­‐preplated	   cultures.	  This	   technique	  did	  not	  significantly	  affect	  the	  proportion	  of	  myogenic	  cells.	  (Error	  bars	  =	  SEM,	  n=3)	  	  
3.2.5.2	  Differential	  centrifugation	  Various	   differential	   centrifugation	   gradients	   and	   centrifugation	   forces	   were	  tested	  on	  muscle	  cell	   suspensions	   to	   isolate	   fractions	  of	  high	  myogenicity	   (Fig	  3.8).	  Those	  which	  resulted	  in	  most	  consistent	  separation	  of	  cell	  subtypes	  were	  90%/40%/25%	  layers	  and	  70%/50%/35%	  layers,	  spun	  at	  1250g.	  Three	  bands	  of	   cellular	   material	   were	   collected	   and	   cultured	   separately	   to	   determine	  myogenicity.	   Band	   2	   (as	   indicated	   in	   Fig	   3.8)	   was	   that	   which	   consistently	  displayed	   the	   highest	   myogenicity	   on	   subsequent	   culture	   and	   was	   also	   the	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Figure	  3.8	  Effect	  of	  differential	  centrifugation	  on	  myogenicity	  Top:	   schematic	   representation	   of	   the	   layered	   density	   technique	   with	   cell	  fraction	  separation.	  Bottom:	   Bar	   chart	   demonstrates	   the	   effect	   of	   differential	   centrifugation	   on	  myogenicity	   of	   cultures.	   All	   represent	   cultures	   from	   cellular	   band	   2	   of	   the	  respective	  experiment.	  (Error	  Bars	  =	  SEM,	  n=3,).	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consistently	  largest	  band.	  Band	  1	  also	  demonstrated	  predominant	  myogenicity,	  at	   approximately	  11%	  absolute	   reduction	   compared	  with	  band	  2.	  Band	  3	  was	  typically	  smaller	  and	  displayed	  a	  reddish	  colour,	  in	  contrast	  to	  the	  white	  colour	  of	  the	  other	  two	  bands.	  It	  did	  not	  yield	  sufficient	  cell	  numbers	  to	  allow	  cultures	  of	   comparable	   plating	   densities.	   When	   cultures	   from	   band	   2	   were	   compared	  with	   those	   prepared	  without	   the	   use	   of	   Percoll®,	   no	   significant	   difference	   in	  myogenicity	   was	   detected	   (Fig	   3.8,	   bar	   graph).	   Furthermore,	   the	   use	   of	  differential	   centrifugation	   reduced	   the	   final	   cellular	   yield	   substantially,	   from	  approximately	   6	   million/ml	   per	   animal	   to	   2.5	   million/ml	   per	   animal,	  necessitating	   the	   use	   of	   more	   animals	   to	   achieve	   an	   equivalent	   number	   of	  culture	   wells.	   Therefore,	   this	   technique	   was	   not	   incorporated	   into	   the	   final	  culture	  protocol.	  	  
3.2.5.3	  Fluorescence	  Activated	  Cell	  Sorting	  (FACS)	  FACS	   allows	   highly	   specific	   identification	   or	   selection	   of	   a	   desired	   cell	   type	  through	   simultaneous	   detection	   of	   multiple	   surface	   antigens	   using	   antibody	  labelling.	  FACS	  has	  previously	  been	  applied	  to	  satellite	  cell	  populations,	  often	  in	  work	   examining	   subtypes	   of	   differentiating	   cells	   (Ieronimakis	   et	   al.	   2010).	  Briefly,	  cells	   in	  suspension	  are	  passed	  through	  a	  high	  flow	  stream	  in	  which	  an	  electrical	  charge	   is	  applied	  to	  the	   liquid	  droplet	  containing	  each	  cell	  according	  to	  it’s	  physical	  or	  fluorescent	  properties	  as	  it	  passes	  through	  the	  device,	  thereby	  allowing	   sorting	   on	   this	   basis.	   FACS	  was	   tested	   here	   to	   determine	  whether	   a	  subpopulation	   of	   myogenic	   specific	   cells	   could	   be	   isolated	   from	   overall	   cell	  population	   after	   initial	   harvesting.	   This	   would	   allow	   the	   selective	   culture	   of	  pure	  myogenic	  cells	  at	  a	  similar	  stage	  of	  maturation	  at	  the	  time	  of	  plating.	  
	  
3.2.5.4	  Unlabelled	  Cells	  Before	  FACS	  analysis,	  an	   initial	  examination	  of	   the	  cell	  population	  based	  upon	  size	  and	  morphology	  was	  performed	  on	  cell	  suspensions	  in	  order	  to	  identify	  any	  distinct	   subpopulations	   (Figure	   3.9).	   Examination	   of	   Side	   Scattering	   (SSC)	   of	  light	  and	  Forward	  Scattering	  (FSC)	   in	  unlabelled	  suspensions	  (i.e.	  not	  exposed	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to	  any	  antibody)	   suggested	   there	  might	  be	   two	  cell	  populations,	  distinguished	  by	   size	   and	   shape.	   Propidium	   Iodide	   (PI)	   staining	   identified	   a	   small	  minority	  (2.8%	  ±0.2%)	  of	  non-­‐viable	  cells	  within	  the	  original	  suspension.	  	  	  	  
	  	  
Figure	  3.9	  FACS	  analysis	  of	  unlabelled	  satellite	  cells	  in	  suspension	  Blue	  and	  red	  dots	  represent	  individual	  cells.	  SSC=side	  scatter	  (arbitrary	  units).	  FSC=forward	  scatter	  (arbitrary	  units).	  PI=Propidium	  Iodide.	  Scatter	  plots	  of	  the	  physical	  characteristics	  of	  cells	   (left)	   suggests	   two	   types	  constitute	   the	  overall	  cell	   population.	   PE-­‐Texas	   Red	   filtering	   (y-­‐axis,	   right)	   identifies	   PI	   staining	   of	  non-­‐viable	  cells	  (red	  dots),	  which	  represents	  approximately	  3%	  of	  all	  cells.	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3.2.5.5	  Antibody	  Labelling	  Some	  satellite	  cells	  are	  distinguished	  from	  other	  cell	   types	  by	  their	  expression	  of	   the	   sialomucin	   surface	   receptor	   CD34	   (Alfaro	   et	   al.	   2011).	   Therefore,	   to	  determine	   whether	   this	   sub-­‐group	   could	   be	   identified	   and	   isolated	   from	   the	  whole	  cell	  population,	  FACS	  analysis	  was	  conducted	  after	  exposure	  to	  anti-­‐CD34	  antibody.	  A	   very	   small	   proportion,	   approximately	  0.2%,	  of	   all	   suspended	   cells	  demonstrated	   positive	   CD34	   labelling	   (Fig	   3.10).	   There	   was	   no	   impact	   from	  increased	  incubation	  time	  up	  to	  1	  hour.	  Two	  possible	  reasons	  for	  the	  low	  yield	  of	  CD34	  positive	  cells	  were	  tested.	  First,	  whether	  expression	  of	  CD34	  required	  differentiation	   beyond	   the	   stage	   at	   which	   the	   cells	   were	   harvested	   from	   the	  animal	   and,	   secondly,	   whether	   the	   use	   of	   enzymatic	   digestion	   in	   the	   culture	  protocol	   might	   alter	   the	   expression	   of	   cell	   surface	   markers.	   The	   latter	  hypothesis	  has	  been	  described	  in	  other	  cell	  populations	   in	  vitro	  (Abuzakouk	  et	  al.	  1996).	  Therefore,	  cells	  were	  plated	  for	  24	  hours	  prior	  to	  FACS	  analysis.	  	  However,	  the	  process	  of	  extracting	  these	  cells	  from	  culture	  plates	  resulted	  in	  an	  intolerably	   high	   degree	   of	   cell	   death.	   Thereafter,	   the	   culture	   protocol	   was	  adjusted	  to	  replace	  the	  use	  of	  collagenase	  with	  trypsin	  and,	  subsequently,	  with	  purely	  mechanical	  dissociation	  of	  muscle	  using	  scissors	  and	  pipette	  trituration.	  Although	   mechanical	   dissociation	   was	   associated	   with	   an	   increased	   CD34	  positive	   fraction,	   the	   cells	   that	  were	   subsequently	   sorted	  and	  cultured	  on	   this	  basis	   failed	   to	   differentiate	   after	   seven	   days	   in	   vitro.	   Different	   established	  markers	  of	  myogenic	   lineage	  were	   tested	  using	   the	   same	   technique,	   including	  NCAM	   (Fig	   3.11)	   but	   very	   few	   cells	   demonstrated	   positive	   binding	   with	   the	  antibody.	  Therefore,	  FACS	  was	  not	  used	  as	  a	  method	   to	   increase	  cell	  purity	   in	  subsequent	  cultures.	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Figure	  3.10	  FACS	  analysis	  of	  CD34	  binding	  in	  a	  satellite	  cell	  suspension	  Standard	  thresholds	  were	  applied	  to	  detect	  the	  proportion	  of	  cells	  in	  suspension	  (represented	   by	   individual	   dots)	   bound	   by	   anti-­‐CD34	   antibody	   (identified	   by	  dots	  within	  black	  bordered	  rhomboids	  labeled	  P3).	  This	  represented	  only	  0.2%	  of	   the	   cell	   population.	   Concentrations	   of	   antibody	   exposure	   at	   1μg,	   2μg	   and	  5μg/ml	  are	  shown	  (clockwise	  from	  top	  left).	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Figure	  3.11	  FACS	  analysis	  of	  NCAM	  binding	  in	  a	  satellite	  cell	  suspension	  Dots	   represent	   individual	   cells.	   Those	   representing	   the	   small	   number	   of	   cells	  successfully	   labelled	   with	   anti-­‐NCAM	   antibody	   are	   contained	   in	   the	   black	  rhomboid.	  	  
3.2.6	  Induction	  of	  IBM-­‐like	  Pathology	  in	  Myogenic	  Cells	  Optimisation	   of	   medium	   constituents	   and	   the	   incorporation	   of	   pre-­‐plating	  allowed	  cultures	  of	  consistently	  highly	  myogenicity	  to	  be	  maintained.	  The	  next	  step	   was	   to	   determine	   how	   to	   recapitulate	   salient	   aspects	   of	   IBM	   pathology.	  	  The	   following	   histopathological	   features	   of	   IBM	   were	   considered	   particularly	  important	  characteristics:	  1. Upregulation	  of	  MHC	  Class	  I	  2. Cytoplasmic	  Translocation	  of	  TDP43	  3. The	  formation	  of	  proteinaceous	  intracellular	  inclusions	  4. Activation	  of	  NFκB	  The	  upregulation	  of	  MHC	  Class	  I	  was	  considered	  essential,	  on	  the	  grounds	  that	  absence	  of	  this	  feature	  on	  muscle	  biopsy	  in	  vivo	  is	  legitimately	  used	  as	  evidence	  to	  query	  the	  diagnosis	  of	  IBM	  and	  its	  potentially	  central	  pathogenic	  role.	  Previous	   studies	  on	  human	  satellite	   cells	   suggested	   two	  stimuli	  with	  which	   to	  trigger	  the	  development	  of	   IBM	  features	   in	  vitro.	  Over-­‐expression	  of	  βAPP	  had	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been	   shown	   to	   result	   in	   cytoplasmic	   inclusion	   formation,	   mitochondrial	  impairment	   and	   proteasomal	   inhibition	   (Askanas	   et	   al.	   1996;	   Askanas	   et	   al.	  1997).	   In	   turn,	   exposure	   to	   inflammatory	   cytokines	   IL1β,	   TNFα	   or	   IFNγ	   had	  been	  demonstrated	   to	  upregulate	  endogenous	  expression	  of	  βAPP	  (Schmidt	  et	  al.	   2008).	   Furthermore,	   IFNγ	   was	   a	   potent	   inducer	   of	   MHCI,	   including	   in	  cultured	   myocytes	   (Bao	   et	   al.	   1990).	   Therefore,	   both	   of	   these	   methods	   were	  evaluated	  further	  using	  primary	  rat	  satellite	  cell	  cultures.	  	  	  
3.2.7	  Overexpression	  of	  βAPP	  First,	  a	  variety	  of	  βAPP	  transfection	  conditions	  were	  examined	  to	  optimise	  the	  overexpression	   of	   βAPP	   and/or	   β-­‐amyloid	   oligomers	   with	   Lipofectamine™.	  Given	   the	   theoretical	   potential	   for	   selective	   cytotoxicity	   from	   the	   transfection	  process,	   the	   impact	  on	  myogenicity	  of	   each	   condition	  was	  also	   examined.	  The	  effect	  of	  βAPP-­‐containing	  vector	   transfection	  was	  compared	  against	   that	  of	  an	  empty	  vector	  as	  control.	  All	  conditions	  were	  also	  compared	  to	  a	  further	  control	  of	  non-­‐transfected	  cultures.	  	  
3.2.7.1	  The	  effect	  of	  βAPP	  transfection	  protocol	  on	  culture	  myogenicity	  Compared	   to	   untransfected	   cultures,	   transfection	   with	   βAPP	   reduced	   the	  percentage	  of	  myogenic	  cells	  at	  all	  DNA	  to	  Lipofectamine™	  	  ratios,	  but	  only	  to	  a	  significant	   extent	   at	   ratios	   of	   1:1,	   2:1	   and	   5:1	   (p<0.05,	   n=3)	   (Fig	   3.12).	   The	  greatest	  reductions	  were	  observed	  at	  ratios	  of	  1:1	  and	  2:1,	  where	  the	  myogenic	  proportion	  was	  23%	  ±7.2%	  and	  31%	  ±5.4%	  respectively	   (n=3).	  Only	   at	   these	  ratios	   was	   a	   significantly	   lower	   myogenicity	   observed	   compared	   to	   empty	  vector	   (p<0.05,	   n=3).	   The	   myogenicity	   associated	   with	   empty	   vector	  transfection	   itself	   (58%	  ±7.6%,	   n=3)	  was	   not	   significantly	   different	   to	   that	   of	  untransfected	   cultures,	   implying	   the	   βAPP-­‐independent	   aspects	   of	   the	  technique	   are	   not	   selectively	   cytotoxic	   to	   myogenic	   cells.	   The	   apparent	  reduction	  of	  myogenicity	  was	  attenuated	  at	  all	  ratios	  by	  transfecting	  at	  the	  later	  time	  point	  of	  96	  hours	  post-­‐plating	  rather	  than	  at	  48	  hours	  (Fig	  3.12).	  However,	  only	  at	   the	  2:1	   ratio	  was	   the	   comparison	  of	   these	   time	  points	   significant	  31%	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±2.3%	  to	  49%	  ±	  3.5%	  (n=3,	  p<0.05).	  Overall,	   the	  DNA:Lipofectamine	   ratios	  of	  3:1	  and	  4:1	  demonstrated	  greatest	  myogenic	  purity	  at	  both	  the	  48	  and	  96	  hour	  transfection	  time	  points.	  	  	  
	  
Figure	  3.12	  Effect	  of	  βAPP	  transfection	  conditions	  on	  culture	  myogenicity	  When	  applied	  to	  βAPP	  transfection,	  the	  DNA:Lipofectamine	  ratios	  of	  1:1	  and	  2:1,	  significantly	  reduced	  the	  subsequent	  proportion	  of	  myogenic	  cells	  compared	  to	  empty	  vector	  transfection	  and	  untransfected	  cultures.	  This	  was	  not	  observed	  at	  higher	  ratios	  between	  3:1	  and	  5:1.	  Transfection	  at	  96	  hours	  in	  vitro	  (grey	  bars),	  compared	   to	   at	   48	   hours	   (black	   bars)	   was	   generally	   associated	   with	   higher	  myogenicity,	  but	  this	  was	  only	  significant	  at	  the	  2:1	  transfection	  ratio.	  (Error	   Bars=SEM,	   n=3,	   Asterisk=p<0.05	   vs.	   untransfected	   cultures,	  Square=p<0.05	  vs.	  empty	  vector	  transfection,	  Star=p<0.05	  between	  transfection	  ratios,	  Diamond=p<0.05	  between	  time	  points)	  	  	  The	   distinctive	   morphology	   of	   the	   multinucleated	   myotube	   was	   considered	  potentially	  advantageous	   for	   subsequent	  experiments	   in	  which	  myogenic	   cells	  would	   need	   to	   be	   distinguished	   from	   non-­‐myogenic	   cells.	   Therefore,	   it	   was	  preferable	   to	   maintain	   a	   high	   fusion	   index	   (the	   proportion	   of	   myogenic	   cells	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represented	  by	  myotubes).	  Across	   all	   the	   conditions	   tested,	   transfection	  at	  48	  hours	  with	  empty	  vector	  or	  βAPP	  significantly	  reduced	  the	  fusion	  index	  (p<0.05,	  n=3	   per	   condition).	   This	   effect	   was	   most	   marked	   at	   the	   1:1	   DNA	   to	  Lipofectamine™	   transfection	   ratio,	   where	   17%	   (±6%)	   of	   myogenic	   cells	   were	  myotubes,	  compared	  to	  86%	  (±4%,	  p<0.05,	  n=3)	  in	  untransfected	  controls.	  This	  implies	   the	   transfection	   technique	   either	   delayed	   maturation	   of	   myocytes	   or	  their	   fusion	   directly,	   or	   affected	   these	   indirectly	   through	   cytotoxicity	   and	  reduced	   cell	   density.	   At	   the	   transfection	   ratios	   between	   3:1	   and	   5:1,	   no	  significant	  difference	   in	   fusion	   index	  was	  observed	  between	  βAPP	   transfected	  and	   empty	   vector	   transfected	   cultures,	   suggesting	   no	   effect	  was	   conferred	   by	  βAPP	  per	  se	  (Fig	  3.13).	  	  The	   reduction	   in	   myotube	   formation	   associated	   with	   transfection	   was	  attenuated	   by	   transfecting	   cultures	   at	   96	   hours	   after	   plating	   rather	   than	   48	  hours	   (Fig	   3.14).	   At	   the	   96-­‐hour	   time	   point,	   maturation	   to	   myotubes	  approached	   that	   of	   standard	   culture	   conditions	   and,	   for	   empty	   vector	   and	  DNA:Lipofectamine	   ratios	   between	   3:1	   and	   5:1,	   there	   was	   no	   significant	  difference	   to	   untransfected	   controls.	   Therefore,	   the	   96-­‐hour	   time	   point	  conferred	  some	  advantage	  over	  the	  48-­‐hour	  time	  point;	  myocyte	  differentiation	  was	   not	   significantly	   altered	   versus	   standard	   culture	   conditions,	   and	  demonstrated	  the	  high	  fusion	  index	  desired	  for	  further	  experimentation.	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Figure	   3.13	   Effect	   of	   transfection	   at	   48	   hours	   in	   vitro	   on	   myogenic	   cell	  
types	  	  Transfection	   reduced	   the	   fusion	   of	   myocytes	   to	   form	  myotubes	   compared	   to	  untransfected	  cultures.	  No	  significant	  difference	  was	  observed	  between	  empty	  vector	  and	  DNA:Lipofectamine	  ratios	  3:1,	  4:1	  and	  5:1.	  Blue	  bars=myocytes,	  Red	  bars=myotubes,	  EV=empty	  vector	  transfection,	  NT=not	  transfected.	  (Error	  Bars=SEM,	  n=3,	  Asterisk=p<0.05	  vs.	  NT,	  Diamond=p<0.05	  vs.	  EV)	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Figure	   3.14	   Effect	   of	   transfection	   at	   96	   hours	   in	   vitro	   on	   myogenic	   cell	  
types	  	  In	   contrast	   to	   transfection	   after	   48	   hours,	   transfection	   at	   96	   hours	   was	   not	  associated	  with	  significant	  alteration	  of	   the	  myogenic	  cell	  sub-­‐types	  compared	  to	  untransfected	  controls.	  Blue	  bars=myocytes,	  Red	  bars=myotubes,	  EV=empty	  vector	  transfection,	  NT=not	  transfected.	  (Error	  Bars=SEM,	  n=3,	  Asterisk=p<0.05	  vs.	  NT)	  	  
3.2.7.2	  The	  effect	  of	  βAPP	  transfection	  on	  expression	  of	  β-­‐Amyloid	  oligomers	  For	  western	  blot	  analysis,	   the	  optical	  density	  of	  bands	  corresponding	  to	  βAPP,	  Aβ42	  and	  Aβ40	  was	  determined	  relative	   to	   contemporaneous	  protein	   control,	  α-­‐tubulin	   (Fig	   3.15).	   Transfection	   with	   the	   βAPP	   plasmid	   significantly	  upregulated	  the	  expression	  of	  each	  of	   these	  proteins,	  compared	  to	  either	  non-­‐transfected	   cultures	   or	   empty	   vector	   (EV)	   control.	   Versus	   EV,	   after	   βAPP	  transfection	  the	  relative	  expression	  of	  βAPP	  increased	  2.51	  fold	  (p<0.01),	  Aβ42	  increased	  2.59	  fold	  (p<0.01)	  and	  Aβ40	  increased	  5.00	  fold	  (p<0.01).	  The	   increase	   in	   expression	  of	   amyloid	   species	  demonstrated	  by	  western	  blots	  was	  supported	  by	  quantification	  of	  the	  proportion	  of	  myogenic	  cells	  that	  were	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immunoreactive	   for	   βAPP,	  Aβ42	   and	  Aβ40.	   This	  was	   compared	   at	   the	   48	   and	  96-­‐hour	  transfection	  time	  points.	  	  	  
	  
Figure	  3.15	  Effect	  of	  βAPP	  transfection	  on	  amyloid	  expression	  i)	   Representative	   western	   blot	   comparing	   expression	   levels	   of	   βAPP	   and	  amyloid	  oligomers	  under	  non-­‐transfected	   (NT),	  empty	  vector	   transfected	   (EV)	  and	  βAPP	  transfected	  culture	  conditions.	  	  ii)	   Optical	   density	   of	   western	   blots	   for	   amyloid	   species.	   White	   bars=non-­‐transfected,	  Grey	  bars=Empty	  Vector,	  Black	  Bars=βAPP	  transfected	  (n=3,	  Error	  Bars=SEM,	  Stars=p<0.05)	  iii)	   Immunocytochemisty	   of	   myocytes	   and	   myotubes	   transfected	   with	   βAPP	  demonstrated	   intracellular	  protein	  aggregates.	  A:	  Positive	  desmin	   (green)	  and	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Aβ42	  staining	  (red)	  within	  a	  myotubes	  B:	  Colocalisation	  of	  ubiquitin	  and	  Aβ42	  (yellow	   inclusions)	   was	   observed	   in	   the	   cytoplasm.	   C/D/E:	   Frequently,	   Aβ42	  was	  demonstrated	  as	  discrete	  intracellular	  inclusions,	  of	  varying	  patterns	  such	  as	  large	  cytoplasmic	  bodies	  in	  C	  and	  E,	  or	  scattered	  cytoplasmic	  and	  perinuclear	  bodies	  in	  D.	  (Scale	  bar=50μM)	  	  	  Next,	  the	  proportion	  of	  myogenic	  cells	  demonstrating	  positive	  immunostaining	  for	  amyloid	  oligomers	  was	  quantified.	  Aβ40,	  the	  oligomer	  considered	  to	  be	  less	  cytotoxic	  than	  Aβ42,	  showed	  that	  there	  was	  a	  higher	  constitutive	  expression	  of	  this	   protein	   than	   Aβ42	   by	   untransfected	   cells	   (36%	   ±2.6%,	   n=3).	   After	  transfection	  at	  48	  hours,	  Aβ40	  expression	  was	  elevated	  fairly	  uniformly	  across	  the	   tested	   transfection	   conditions,	   with	   significant	   increases	   versus	   empty	  vector	   control	   demonstrated,	   in	   a	   broadly	   proportional	   manner,	   at	   all	  transfected	  ratios	  above	  1:1	  (Fig	  3.16).	  At	  3:1,	   the	  most	  effective	  ratio	  regards	  Aβ42	   expression,	   the	   proportion	   of	   cells	   demonstrating	   Aβ40	   positivity	   was	  elevated	  to	  57%	  (±3.7%,	  n=3,	  p<0.05).	  This	  increase	  was	  significant	  regardless	  of	   whether	   all	   myogenic	   cells	   or	   purely	   myocytes,	   rather	   than	   elongated	  multinucleated	  myotubes,	  were	  studied.	  Following	   transfection	   at	   96	   hours	   after	   plating,	   there	   was	   also	   significant	  elevation	   in	  Aβ40	  positivity	   across	   all	   transfection	   ratios	   (Fig	  3.17).	  However,	  compared	  with	  the	  48	  hour	  time	  point,	  the	  typical	  proportion	  of	  myogenic	  cells	  positive	  was	  slightly	  reduced,	   for	  example	  57%	  ±3.7%	  versus	  43	  ±4.1%	  at	  the	  3:1	  transfection	  ratio.	  At	  the	  majority	  of	  transfection	  ratios,	  this	  difference	  was	  less	  marked	  when	  only	  myocytes	  rather	   than	  the	  overall	  myogenic	  population	  were	   considered.	  This	   implies	   that	  multinucleated	  myotubes,	  which	   represent	  an	  increasing	  proportion	  of	  the	  myogenic	  culture	  population	  between	  the	  time	  points	   studied,	   are	   either	   less	   likely	   to	   be	   transfected	   than	  myocytes	   or	  more	  quickly	   undergo	   cell	   death	   if	   they	   are	   transfected,	   perhaps	   indicative	   of	  increased	   vulnerability	   to	   protein	   overexpression	   in	   the	   terminally	  differentiated,	  post-­‐mitotic	  state.	  	  Aβ42	   immunostaining	   revealed	   that	   transfection	  with	   the	  βAPP	  plasmid	  at	  48	  hours,	  using	  transfection	  ratios	  of	  1:1,	  3:1,	  4:1	  or	  5:1	  significantly	  increased	  the	  expression	   of	   Aβ42	   in	   myogenic	   cells	   versus	   empty	   vector	   transfection	   (Fig	  3.18).	   Compared	   with	   12%	   ±2.4%	   in	   non-­‐transfected	   cultures,	   a	   βAPP	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transfection	  ratio	  of	  3:1	  DNA	  (μL)	  to	  Lipofectamine	  (μL)	  resulted	  in	  63%	  ±8%	  of	  myogenic	   cells	   demonstrating	   positive	   Aβ42	   staining	   (p<0.01,	   n=3).	   	   Empty	  vector	   had	   no	   significant	   impact	   on	   Aβ42	   expression,	   indicating	   that	   the	  upregulation	  of	  Aβ42	  was	  not	  a	  byproduct	  of	  the	  transfection	  process	  per	  se.	  At	  the	  96-­‐hour	  transfection	  time	  point,	  there	  was	  also	  significant	  elevation	  of	  Aβ42	  positivity,	   at	   ratios	  between	  1:1	   and	  4:1	   (Fig	  3.19).	  As	  was	   the	   case	   at	   the	  48	  hour	  time	  point,	  the	  most	  significant	  increase	  was	  observed	  using	  the	  3:1	  ratio	  at	  approximately	  8-­‐fold	  that	  of	  empty	  vector	  (p<0.01,	  n=3).	  A	   consistent	   feature	   of	   cultures	  was	   the	   greater	   proportion	   of	  myocytes	   than	  mature	   multinucleated	   myotubes	   which	   appeared	   to	   express	   either	   or	   both	  amyloid	  oligomer.	  This	  was	  reflected	  across	  transfection	  conditions,	  notably	  at	  3:1,	  where	  over	  60%	  of	  myocytes	  demonstrated	  Aβ42	  positivity,	  whereas	  42%	  of	   the	   overall	   myogenic	   population	   were	   positive	   (p<0.05).	   The	   differential	  expression	  by	  myocytes	  and	  myotubes	  was	  less	  pronounced	  for	  Aβ40	  than	  for	  Aβ42	  staining	  but	  remained	  apparent	  (mean	  69%	  of	  myocytes	  at	  3:1).	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Figure	  3.16	  Effect	  of	  βAPP	  transfection	  at	  48	  hours	  in	  vitro	  on	  expression	  
of	  Aβ40	  in	  myogenic	  cells	  At	   transfection	   ratios	   between	   2:1	   and	   5:1,	   βAPP	   transfection	  was	   associated	  with	   a	   significantly	   elevated	   proportion	   of	   myogenic	   cells	   that	   were	   Aβ40	  immunopositive	   compared	   to	   empty	   vector	   transfection	   and	   untransfected	  controls.	  Grey	  bars	  =	  all	  myogenic	  cells,	  Black	  bars	  =	  myocytes	  only	  (Error	  Bars=SEM,	  n=3,	  Asterisk=p<0.05)	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Figure	   3.17	   Effect	   of	   transfection	   at	   96	   hours	   in	   vitro	   on	   expression	   of	  
Aβ40	  in	  myogenic	  cells	  At	   all	   transfection	   ratios	   tested,	   βAPP	   transfection	   was	   associated	   with	   a	  significantly	  elevated	  proportion	  of	  myocytes	   that	  were	  Aβ40	   immunopositive	  compared	  to	  empty	  vector	  transfection.	  At	   transfection	  ratios	  3:1	  and	  4:1,	   this	  effect	  was	  maintained	  when	  all	  myogenic	  cells	  were	  compared.	  Grey	  bars	  =	  all	  myogenic	  cells,	  Black	  bars	  =	  myocytes	  only	  (Error	  Bars=SEM,	  n=3,	  Asterisk=p<0.05)	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Figure	   3.18	   Effect	   of	   transfection	   at	   48	   hours	   in	   vitro	   on	   expression	   of	  
Aβ42	  in	  myogenic	  cells	  At	   transfection	   ratios	   between	   3:1	   and	   5:1,	   βAPP	   transfection	  was	   associated	  with	   a	   significantly	   elevated	   proportion	   of	   myogenic	   cells	   that	   were	   Aβ42	  immunopositive	   compared	   to	   empty	   vector	   transfection	   and	   untransfected	  controls.	  Grey	  bars	  =	  all	  myogenic	  cells,	  Black	  bars	  =	  myocytes	  only	  (Error	  Bars=SEM,	  n=3,	  Asterisk=p<0.05)	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Figure	   3.19	   Effect	   of	   transfection	   at	   96	   hours	   in	   vitro	   on	   expression	   of	  
Aβ42	  in	  myogenic	  cells	  At	  all	  transfection	  ratios	  between	  1:1	  and	  4:1,	  βAPP	  transfection	  was	  associated	  with	   a	   significantly	   elevated	   proportion	   of	   myocytes	   that	   were	   Aβ42	  immunopositive	   compared	   to	   empty	   vector	   transfection.	   At	   transfection	   ratio	  3:1,	   this	   effect	  was	  maintained	  when	   all	  myogenic	   cells	  were	   compared.	   Grey	  bars	  =	  all	  myogenic	  cells,	  Black	  bars	  =	  myocytes	  only	  (Error	  Bars=SEM,	  n=3,	  Asterisk=p<0.05)	  	  	  
3.2.7.3	  Overall	  analysis	  of	  transfection	  optimisation	  	  The	  effect	  of	  transfection	  DNA:Lipofectamine	  ratios	  and	  transfection	  time	  points	  on	  myogenic	   cell	   purity,	   differentiation	   and	   production	   of	   amyloid	   oligomers	  suggested	   that	   a	   DNA	   to	   Lipofectamine	   ratio	   of	   3:1	   at	   96	   hours	   after	   plating	  achieved	  the	  results	  most	  suited	  to	  subsequent	  investigation.	  High	  myogenicity	  was	  maintained,	  with	  no	   significant	   change	   in	   the	   apparent	  maturation	  of	   the	  cells,	   as	  evidence	  by	  a	   fusion	   index	  comparable	  with	  non-­‐transfected	  cultures.	  Significant	   elevation	   of	   βAPP,	   Aβ40	   and	   Aβ42	  was	   consistently	   demonstrated	  and	   was	   maximal	   at	   the	   3:1	   ratio,	   indicating	   successful	   transfection.	   In	   the	  context	  of	  modeling	   IBM,	   the	  production	  of	   the	  Aβ42	  oligomer	  was	  prioritised	  since	   due	   to	   the	   greater	   proposed	   significance	   of	   Aβ42	   in	   induction	   of	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downstream	   pathology	   such	   as	   proteasomal	   inhibition	   and	   ER	   dysfunction,	  reflected	  by	  its	  increased	  likelihood	  to	  aggregate.	  The	  3:1	  DNA	  to	  Lipofectamine	  ratio	  was,	  therefore,	  used	  in	  all	  subsequent	  experiments	  involving	  transfections.	  
3.2.8	  The	  effect	  of	  inflammatory	  cytokines	  on	  amyloid	  expression	  The	  inflammatory	  cytokines	  IL1β	  and	  IFNγ	  have	  previously	  been	  demonstrated	  to	  augment	  the	  expression	  of	  βAPP	  in	  human	  satellite	  cell	  cultures	  but	  not	  in	  rat.	  (Schmidt	  et	  al.	  2008)	  Together	  with	  TNFα,	  these	  inflammatory	  mediators	  were	  evaluated	  as	  potential	  inducers	  of	  IBM-­‐like	  pathology	  in	  myogenic	  cell	  cultures.	  Therefore,	   their	   impact	   on	   β-­‐amyloid	   expression	  was	   also	   examined.	  Western	  blot	   analysis	   demonstrates	   that,	   at	   various	   concentrations,	   exposure	   to	   IL1β,	  TNFα	  or	  IFNγ	  significantly	  elevated	  the	  expression	  of	  βAPP	  and	  Aβ42	  (p<0.05)	  (Figure	  3.20).	  The	  magnitude	  of	  this	  effect	  was	  less	  marked	  than	  that	  following	  βAPP	  transfection,	  at	  least	  throughout	  the	  range	  of	  concentrations	  tested.	  
Figure	  3.20	  Effect	  of	  cytokines	  on	  β-­‐amyloid	  proteins	  Representative	   western	   blot	   and	   corresponding	   optical	   densitometry	   for	   β-­‐amyloid	   proteins	   following	   exposure	   to	   inflammatory	   cytokines.	   Significant	  elevation	   of	   βAPP	   and	   Aβ42	   was	   observed.	   Control=unexposed	   cultures,	  expressed	  as	  a	  comparative	  value	  of	  1.	  Grey	  bars=βAPP,	  Black	  Bars=Aβ42	  (Error	  Bars=SEM,	  n=3,	  Star=p<0.05)	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A	   range	   of	   concentrations	   of	   each	   inflammatory	   cytokine	   was	   tested	   to	  determine	   which	   cytokines,	   and	   at	   which	   concentration,	   should	   be	   taken	  forward	  to	  further	  experiments.	  	  Western	  blot	  densitometry	  showed	  that	  exposure	  of	  myogenic	  cultures	  to	  IL1β	  between	  5	  and	  20ng/ml,	  elevated	  βAPP	  and	  Aβ42	  significantly	  (p<0.05).	  There	  was	  a	  strong	   logarithmic	  relationship	  between	  cytokine	  concentrations	  of	  1	  to	  20ng/ml	  and	  β-­‐amyloid	  protein	  expression	  (βAPP	  R2	  =	  0.96	  and	  Aβ42	  R2	  =	  0.98.	  Fig	   3.21,	   A).	   At	   40ng/ml,	   IL1β	   was	   associated	   with	   a	   paradoxically	   minimal	  effect	  on	  β-­‐amyloid,	  concentrations,	  perhaps	  indicating	  this	  was	  a	  cytotoxic	  dose	  (Fig	  3.21,	  B).	  Exposure	  of	  cultures	  to	  TNFα	  at	  2.5,	  10	  and	  20ng/ml	  was	  also	  associated	  with	  significant	  elevation	  of	  βAPP	  and	  Aβ42	  expression	  (p<0.05).	  There	  was	  a	  strong	  relationship	  between	   cytokine	   concentration	  and	  effect	  on	  β-­‐amyloid	  proteins	  (βAPP	  R2	  =	  0.65	  and	  Aβ42	  R2	  =	  0.72.	  Fig	  3.21,	  C).	  IFNγ	  was	  only	  associated	  with	  significant	  elevation	  either	  β-­‐amyloid	  protein	  at	  a	  concentration	  of	  1000	  U/ml,	  with	  a	  suggestion	  of	  a	  proportional	  dose	  response	  relationship	  on	  βAPP	  (βAPP	  R2	  =	  0.54	  and	  Aβ42	  R2	  =	  0.38.	  Fig	  3.21,	  D).	  	  Comparison	   of	   βAPP	   and	  Aβ42	  mean	   levels	   at	   all	   concentrations	   of	   cytokines	  (Figure	  3.22)	  demonstrated	  a	  strong	  correlation	  between	  the	  two	  proteins	  (R2	  =	  0.745),	  consistent	  with	  the	  βAPP	  being	  the	  predominant	  source	  of	  Aβ42	  here.	  Together,	   these	   data	   demonstrate	   that	   the	   cytokines	   IL1β	   and	  TNFα	   induce	   a	  concentration	  dependent,	   significant	   elevation	  of	  βAPP	  and	  Aβ42	   in	  myogenic	  cell	  cultures.	  IFNγ	  at	  higher	  concentration	  also	  elevated	  the	  expression	  of	  these	  proteins.	  The	  tight	  correlation	  between	  βAPP	  and	  Aβ42	  (Fig	  3.22)	  is	  consistent	  with	   the	   logic	   that	   Aβ42,	   as	   a	   breakdown	   produce	   of	   βAPP,	   is	   elevated	   as	   a	  consequence	  of	  the	  upregulation	  or	  reduced	  breakdown	  of	  βAPP	  that	  succeeds	  cytokine	   exposure.	   It	   is	   possible	   that	   other	   IBM-­‐relevant	   effects	   of	   IL1β	   and	  TNFα	  on	  myogenic	  cultures	  might	  be	  distinguished	  from	  those	  of	  IFNγ,	  at	  least	  at	   the	   lower	   concentrations	   tested,	   through	   mechanisms	   that	   respectively	  involve	  or	  are	  independent	  of	  β-­‐amyloid.	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Figure	   3.21	   Effect	   of	   cytokine	   concentration	   on	   β-­‐amyloid	   protein	  
expression	  After	   cultures	   were	   exposed	   to	   a	   range	   of	   cytokine	   concentrations,	   optical	  densitometry	   of	   western	   blots	   determined	   βAPP	   and	   Aβ42	   levels	   relative	   to	  untreated	   control	   cultures.	   A:	   Between	   0	   and	   20ng/ml,	   IL1β	   was	   associated	  with	  a	  closely	  proportional	  response	  of	  both	  β-­‐amyloid	  proteins,	  demonstrated	  by	  correlation	  coefficients	  (R2)	  that	  approach	  a	  value	  of	  1.	  B:	  40ng/ml	  IL1β	  was	  associated	   with	   a	   paradoxical	   reduction	   of	   β-­‐amyloid	   protein	   levels,	   perhaps	  due	   to	   cytotoxicity.	   C:	   Between	   0	   and	   20ng/ml,	   TNFα	   was	   associated	   with	   a	  proportional	   change	   in	   β-­‐amyloid	   protein	   levels.	   D:	   The	   change	   of	   β-­‐amyloid	  protein	  levels	  after	  exposure	  to	  IFNγ	  was	  less	  strongly	  correlated.	  Black	  squares	  and	   dashed	   best-­‐fit	   lines=βAPP,	   Open	   circles	   and	   solid	   best-­‐fit	   lines=Aβ42	  (Error	  Bars=SEM,	  n=3,	  Asterisk=p<0.05)	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Figure	   3.22	   Relationship	   between	   βAPP	   and	   Aβ42	   levels	   following	  
exposure	  to	  inflammatory	  cytokines	  Individual	  markers	  represent	  the	  βAPP	  and	  Aβ42	   levels,	  measured	  by	  western	  blot	  optical	  densitometry,	  after	  exposure	   to	  a	  given	  cytokine	  concentration,	  as	  charted	  in	  Figure	  3.22.	  This	  suggests	  that,	  regardless	  of	  the	  underlying	  cytokine	  stimulus,	   the	   elevation	   of	   Aβ42	   is	   strongly	   proportional	   to	   that	   of	   βAPP	  (R2=0.745).	  (n=3	  per	  cytokine	  concentration	  tested)	  	  	  
3.2.9	   MHC	   Class	   I	   expression	   following	   βAPP	   transfection	   and	   exposure	   to	  
inflammatory	  cytokines	  Since	   upregulation	   of	   Major	   Histocompatibility	   Class	   I	   protein	   (MHCI)	   is	  fundamental	  element	  of	  IBM	  histopathology,	  and	  a	  proposed	  central	  mechanism	  in	  IBM	  pathogenesis,	  it	  was	  important	  to	  determine	  what	  effects	  any	  proposed	  technique	  to	  induce	  IBM-­‐like	  pathology	  had	  on	  MHCI	  expression.	  Unlike	  mature	  skeletal	  muscle	   fibres,	  which	  do	  not	   constitutively	   express	  MHCI,	  myocytes	   in	  culture	  express	  this	  protein	  constitutively,	  albeit	  at	   low	  levels.	  (Michaelis	  et	  al.	  1993),	  Whilst	  inflammatory	  cytokines,	  particularly	  IL1β,	  are	  known	  inducers	  of	  MHCI	   expression	   in	   a	   variety	   of	   tissues,	   less	   was	   known	   about	   the	   impact	   of	  amyloid	  oligomers	  on	  MHCI	  expression.	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As	   expected,	  MHCI	   immunostaining	   of	   standard	   cultures	   revealed	   constitutive	  expression.	   Positive	   immunostaining	   also	   followed	   βAPP	   transfection	   or	  exposure	   to	   IL1β	   or	   TNFα	   (Figure	   3.23).	   Therefore,	   western	   blots	   were	  employed	  to	  quantify	  the	  differences	  in	  MHCI	  levels.	  As	  anticipated,	  exposure	  to	  inflammatory	  cytokines	  IL1β	  or	  TNFα	  induced	  significant	  upregulation	  of	  MHCI,	  where	  increases	  over	  control	  of	  5.48	  fold	  (±1.7,	  n=3)	  and	  5.14	  fold	  (±1.4,	  n=3)	  were	   demonstrated	   respectively	   (p<0.05).	   Interestingly,	   this	   effect	   was	   also	  observed	  following	  treatment	  with	  βAPP,	  where	  an	  increase	  of	  4.51	  fold	  (±0.98,	  n=3)	  was	  demonstrated	   in	  comparison	   to	  untreated	  cultures.	  However,	  empty	  vector	   transfection	   also	   induced	   a	   significant	   increase	   in	   MHCI	   of	   2.40	   fold	  (±0.33,	  n=3).	  Therefore,	  the	  true	  impact	  of	  βAPP	  transfection	  was	  likely	  subtler,	  with	   a	   1.74	   fold	   increase	   in	   MHCI	   compared	   to	   empty	   vector	   transfection.	  Nevertheless	  this	  difference	  remained	  significant	  (p<0.05).	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Figure	   3.23	   Effect	   of	   β-­‐APP	   transfection	   and	   inflammatory	   cytokines	   on	  
MHCI	  Cultures	  were	  immunostained	  for	  MHC	  Class	  I	  (Red)	  following	  exposure	  to:	  A)	  5ng/ml	  TNFα,	  B)	  10ng/ml	  IL1B,	  C)	  βAPP	  Transfection	  (Scale	  Bar=40μm)	  D:	  Western	  Blots	  for	  MHCI	  at	  50kDa.	  Ctrl	  =	  untreated	  cultures.	  Gluc	  =	  Cultures	  subject	  to	  2	  hours	  glucose	  deprivation.	  EV	  =	  empty	  vector	  E:	  MHC	   I	   levels	   by	   optical	   densitometry	   of	  western	   blots	   relative	   to	   standard	  culture	  control,	  expressed	  as	  nominal	  value	  of	  1	  (Error	  Bars=SEM,	  n=3,	  Star=p<0.05)	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3.2.10	  Formation	  of	  proteinaceous	  aggregates	  A	  characteristic	  feature	  of	  human	  muscle	  affected	  by	  IBM	  is	  the	  appearance	  of	  inclusion	  bodies	  that	  represent	  a	  number	  of	  aggregated	  proteins	  in	  addition	  to	  β-­‐amyloid	  products.	  In	  order	  to	  establish	  whether	  these	  pathological	  characteristics	  of	  IBM	  were	  modeled	  by	  these	  myogenic	  cultures,	  a	  number	  of	  these	  were	  examined	  in	  vitro.	  After	  over-­‐expression	  of	  βAPP,	  immunostaining	  demonstrated	  inclusions	  containing	  phosphorylated	  tau,	  p62	  and	  TDP-­‐43.	  Tau	  and	  TDP-­‐43	  inclusions	  were	  frequently	  ubiquinated.	  	  
	  	  
Figure	  3.24	  Inclusion	  and	  aggregate	  formation	  in	  cultured	  myotubes	  Following	  βAPP	  transfection,	  cytoplasmic	  proteinaceous	  aggregates,	  frequently	  ubiquinated,	  were	  demonstrated	  with	  immunocytochemistry.	  A:	   Phosphorylated	   tau	   (red),	   B:	   ubiquitin	   (green)	   and	   C:	   merged	   images	  demonstrate	   colocalisation	   (yellow).	   D:	   p62	   (red),	   E:	   TDP-­‐43	   (green)	   and	  ubiquitin	  (red)	  positive	  inclusions	  were	  observed	  within	  individual	  cells.	  Nuclear	  staining	  with	  DAPI	  (A-­‐D),	  arrows	  indicate	  inclusions	  (Scale	  Bars=20μm)	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3.2.11	  Summary	  of	  results	  1.	  Primary	  satellite	   cell	   cultures	   from	  mice	  demonstrated	   limited	  myogenicity,	  considerable	   variability	   between	   cultures	   and	   a	   restricted	   lifespan	   in	   vitro	  before	   detachment	   from	   the	   coverslip.	   These	   features	   precluded	   their	   use	   in	  further	  experiments	  2.	   Primary	   satellite	   cell	   cultures	   from	   rats	   displayed	   superior	   myogenicity,	  consistency	   and	   lifespan,	   particularly	   when	   the	   growth	   conditions	   were	  optimised.	  This	  involved	  refinement	  of	  the	  culture	  medium	  constituents,	  plating	  density	   and	   pre-­‐plating.	   Other	   purification	   techniques,	   density	   centrifugation	  and	   FACS,	   were	   not	   associated	  with	   significantly	   improved	   culture	   quality	   so	  were	  not	  incorporated	  into	  the	  final	  method	  used	  in	  subsequent	  experiments.	  3.	   IBM-­‐like	   pathology	   was	   induced	   with	   two	   types	   of	   stimuli,	   related	   to	   the	  proposed	   degenerative	   and	   inflammatory	   components	   of	   IBM	   pathogenesis.	  Overexpression	   of	   βAPP	   was	   successfully	   achieved	   using	   Lipofectamine™	  transfection	   and	  was	   optimal	   at	   a	   DNA	   (μg):Lipofectamine™	   (μL)	   ratio	   of	   3:1,	  where	   no	   significant	   impact	   was	   demonstrated	   on	   culture	   myogenicity	   or	  differentiation	   to	  myotubes.	   The	   overexpression	   of	   βAPP	  was	   associated	  with	  proportionately	  increased	  levels	  of	  Aβ40	  and	  Aβ42	  species.	  4.	   In	   turn,	  βAPP	  overexpression	  reproduced	  ubiquinated	  and	  non-­‐ubiquinated	  intracellular	   proteinaceous	   inclusions	   that	   contained	   several	   of	   the	  degenerative	   markers	   that	   characterise	   muscle	   affected	   by	   IBM,	   including	  amyloid	  proteins,	  TDP-­‐43,	  tau	  and	  p62.	  5.	  The	  exposure	  of	  myogenic	  cultures	  to	  inflammatory	  cytokines	  IL1β	  and	  TNFα	  was	  associated	  with	  a	  significant	  and	  strongly	  correlated	  increase	  in	  βAPP	  and	  Aβ42	  levels.	  6.	   Both	   βAPP	   overexpression	   and	   exposure	   to	   inflammatory	   cytokines	   were	  associated	  with	  significant	  upregulation	  of	  MHCI.	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3.3	  Discussion	  The	  aim	  of	  the	  experiments	  described	  in	  this	  chapter	  was	  to	  determine	  whether	  certain	  markers	  of	  IBM	  pathology	  could	  be	  reliably	  reproduced	  in	  vitro,	  in	  order	  to	  provide	   a	  preclinical	   disease	  model	   on	  which	  quantifiable,	   disease-­‐relevant	  pathological	   outcome	  measures	   could	   then	  be	  developed	  and,	   in	   turn,	  used	   to	  measure	  the	  impact	  of	  potential	  treatments.	  	  
3.3.1	  Optimisation	  of	  an	  in	  vitro	  model	  of	  IBM	  A	  number	  of	  cell	  culture	  conditions	  were	  first	  compared	  using	  primary	  satellite	  cells	  harvested	  from	  neonatal	  mouse	  and	  rat	  hindlimb	  muscles.	  Mouse	  satellite	  cell	  cultures	   lacked	  a	  number	  of	  properties	  required	  of	  a	  reliable	  model.	  First,	  myogenicity	   was	   limited,	   with	   only	   44%	   of	   cells	   displaying	   muscle	   specific	  immunocytochemical	  staining	   for	  desmin,	  reflecting	  that	  approximately	  half	  of	  the	  cultured	  cells	  were	  not	  demonstrably	  myogenic.	  Only	  around	  25%	  of	  these	  cells	   proceeded	   fuse	   to	   form	   multinucleated	   myotubes,	   the	   cell	   type	   of	   most	  interest	   for	   further	   experiments.	   	   Furthermore,	   the	   variability	   in	  myogenicity	  was	  large,	  up	  to	  27%	  between	  culture	  wells	  derived	  from	  the	  same	  satellite	  cell	  harvest.	  Finally,	  the	  longevity	  of	  these	  cultures	  was	  limited	  to	  approximately	  7	  days,	  which	  would	  preclude	  sufficient	  maturation	  for	  subsequent	  manipulation	  through	  transfection	  of	  βAPP	  or	  exposure	  to	  other	  compounds.	   	  Therefore,	  the	  superior	  myogenic	  yields	  provided	  by	  neonatal	   rat	   cultures	   supported	   further	  work	  using	  these	  animals.	  	  As	   there	   is	   no	   consensus	   on	   experimental	   protocol	   in	   the	   field	   of	   primary	  satellite	  cell	  culture,	  a	  number	  of	  purification	  techniques	  were	  then	  compared	  in	  order	   to	   achieve	   the	   highest	   reliable	   demonstrable	   myogenicity,	   without	  compromising	   the	   maturation	   or	   longevity	   of	   the	   cultures.	   Just	   as	   in	   mature	  skeletal	   muscle,	   a	   number	   of	   supportive	   cell	   types	   exist	   in	   addition	   to	   the	  myogenic	   majority	   and	   these	   are	   important	   both	   in	   vivo	   and	   in	   vitro.	  Furthermore,	   a	   significant	   proportion	   of	   myogenic	   cells	   exist	   as	   a	   ‘side	  population’	   (Hawke	   et	   al.	   2001)	   and	   do	   not	   express	   standard	   myogenic	   cell	  markers.	   Therefore,	   it	   was	   neither	   desirable	   nor	   realistic	   to	   attain	   absolute	  purity.	   More	   important	   was	   to	   attain	   consistency	   and	   high	   rate	   of	   fusion	   to	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myotubes,	  since	  these	  are	  the	  post-­‐mitotic	  cell	  type	  in	  vitro	  which	  most	  closely	  represent	   functional	   skeletal	  muscle	   and	   are	   also	   readily	   identifiable	   through	  their	  characteristic	  morphology.	  Modification	  of	   the	  growth	  medium	  had	  the	  greatest	   impact	  on	  these	  cultures,	  where	  the	  time	  of	  first	  medium	  change,	  spacing	  of	  subsequent	  medium	  changes,	  and	  proportions	  of	  constituents	  were	  all	  associated	  with	  changes	  to	  myogenicity	  or	   fusion	   index.	   	   The	   incorporation	   of	   a	   15-­‐minute	   pre-­‐plating	   step	   was	  supported	  by	  improved	  myogenic	  purity,	  using	  the	  optimal	  medium,	  from	  69%	  to	  78%	  and	  was,	  therefore,	  incorporated	  into	  the	  protocol	  used	  for	  subsequent	  experiments	  in	  this	  thesis.	  This	  is	  in	  keeping	  with	  previously	  described	  benefits	  of	  a	  pre-­‐plating	  step	  on	  myogenic	  purity	  (Park	  et	  al.	  2006).	  Differential	  centrifugation	  is	  a	  cell	  selection	  technique	  based	  on	  the	  principle	  of	  isopycnic	   separation,	  which	   exploits	   differences	   in	   density	   between	   given	   cell	  types.	  The	  application	  of	  high	  gravitational	   force	   facilitates	  density	  dependent	  separation	  and,	  when	  performed	  within	  a	  solution	  of	  graded	  densities,	  a	  given	  mass	   or	   cell	   type	   reaches	   a	   point	   of	   equilibrium	   beyond	   which	   it	   will	   not	  sediment	   further	   regardless	   of	  whether	   further	   centrifugation	   is	   applied.	   This	  has	  previously	  been	  effective	   in	   isolating	  satellite	   cell	   cultures	   (Bischoff	  1997;	  Mau	  et	  al.	  2008).	  Here,	  however,	  two	  different	  gradient	  compositions	  were	  not	  associated	  with	   a	   significant	   change	   in	   overall	   myogenicity.	   Furthermore,	   the	  incorporation	  of	   this	   step	   reduced	   the	   final	   satellite	   cell	   yield	  by	   almost	  50%.	  Therefore,	  this	  step	  was	  not	  incorporated	  in	  further	  experiments.	  Three	  distinct	  cellular	   bands	   were	   consistently	   isolated;	   that	   of	   greatest	   density	   appeared	  through	  a	  distinctive	  red	  colouration	  to	  include	  a	  significant	  number	  red	  blood	  cells.	   The	   largest	   two	   cellular	   bands,	   however,	   were	   both	   predominantly	  myogenic,	  implying	  that	  two	  broad	  groups	  of	  satellite	  cells,	  of	  different	  densities,	  exist	  in	  neonatal	  rat	  hindlimb	  muscles.	  This	  might	  reflect	  different	  coordinated	  stages	  of	  differentiation,	   as	   the	   satellite	   cell	  population	   is	  highly	  active	  during	  the	  muscle	   maturation	   of	   early	   life.	   Indeed,	   such	   distinct	   colonies	   of	   satellite	  cells,	  of	  differing	  sizes,	  have	  previously	  been	  described	  (Molnar	  et	  al.	  1996).	  Finally,	  fluorescence	  activated	  cell	  sorting	  was	  also	  evaluated.	  This	  allows	  highly	  specific	   identification	  or	   selection	  of	   a	  desired	   cell	   type	   through	   simultaneous	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detection	   of	   multiple	   surface	   antigens	   using	   antibody	   labelling.	   However,	   the	  physical	  or	  fluorescent	  characteristics	  on	  which	  sorting	  is	  based	  are	  continuous	  rather	   than	  nominal.	  Therefore,	   arbitrary	   selection	  margins	  must	  be	  manually	  applied	   to	   select	   a	   given	   cellular	   subpopulation	   from	   the	   overall	   suspension.	  FACS	   has	   previously	   been	   applied	   to	   satellite	   cell	   populations,	   often	   in	   work	  examining	   subtypes	   of	   differentiating	   cells	   (Ieronimakis	   et	   al.	   2010).	   It	   was	  investigated	   here	   in	   case	   near	   pure	   cultures	   were	   required	   for	   future	  experiments.	   Examination	   of	   satellite	   cells	   based	   on	   side	   and	   forward	   light	  scattering	   properties	   suggests	   the	   presence	   of	   two	   cell	   populations	   of	  approximately	   equal	   numbers,	   distinguished	   by	   shape	   and	   size.	   This	  corroborates	   the	   equivalent	   finding	   after	   density	   centrifugation.	   Fluorescent	  labeling	   with	   the	   satellite	   cell	   marker	   CD34	   was	   unsuccessful	   when	   applied	  immediately	   to	   the	  satellite	  cell	  suspension,	   implying	  either	   lack	  of	  expression	  of	   the	  protein	  due	   to	   relative	   cell	   immaturity	   or	   reduced	   expression	   resulting	  from	  the	  harvesting	  protocol.	  Indeed,	  removal	  of	  collagenase	  from	  the	  protocol	  was	  associated	  with	  increased	  CD34	  positivity	  but	  the	  resulting	  cells	  could	  not	  be	  cultured	  successfully.	  Additional	  satellite	  cell	  markers,	  including	  NCAM	  were	  associated	  with	  similar	  results.	  FACS	   sorting	   is	   limited	   by	   the	   need	   to	   apply	   a	   combination	   of	   cell	   surface	  markers	   in	   order	   to	   achieve	   the	   specificity	   intended,	  which	   is	   achieved	   at	   the	  price	  of	  subselecting	  a	  subpopulation	  of	  cells	  which	  may	  not	  fully	  represent	  the	  characteristics	   of	   all.	   Additionally,	   the	   effects	   of	   antibody	   binding	   or	   passage	  through	  the	  FACS	  machine	  on	  subsequent	  cell	  function	  are	  not	  fully	  appreciated.	  In	   summary,	   refinement	   of	   previously	   published	   protocols	   for	   satellite	   cell	  cultures	   achieve	   the	   desired	   outcome	   of	   consistent,	   highly	   myogenic	  populations,	  which	   could	  be	  maintained	   for	   sufficient	   time	   in	   culture	   to	   allow	  further	  experimentation.	  	  
3.3.2	  Induction	  of	  IBM-­‐like	  pathology	  in	  myogenic	  cultures	  In	   using	   βAPP	   transfection	   and	   exposure	   to	   cytokines,	   two	   distinct	   potential	  stimuli	   of	   IBM-­‐like	   changes	  were	   explored.	   The	   role	   of	   β-­‐amyloid	   proteins	   in	  IBM	   in	   vivo	   is	   debated	   and	   it	   is	   unclear	   whether	   primary	   over-­‐expression	   of	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βAPP	  is	  a	  significant	  upstream	  event	  in	  pathogenesis.	  (Greenberg	  2009;	  Schmidt	  et	  al.	  2013)	  However,	   it	  was	  evaluated	  here	  on	  the	  basis	  of	  previous	  data	   that	  suggest	   that	   it	   can	   induce	   certain	   downstream	   pathological	   changes,	   such	   as	  aggregate	   formation,	   mitochondrial	   dysfunction	   and	   proteasome	   inhibition	   in	  
vitro	   (Askanas	   et	   al.	   2003).	   Such	   an	   ‘overload’	   of	   cellular	   protein	   degradation	  mechanisms	  may	  be	  analogous	  to	  the	  limitation	  protein	  degradative	  capacity	  of	  aged	  muscle	  which	  is	  evidenced	  by	  the	  cytoplasmic	  accumulation	  of	  numerous	  proteins	  in	  IBM.	  This	  technique	  was	  therefore	  thought	  preferable	  to,	  and	  more	  relevant	   than,	   the	  application	  of	  a	  generic	  cell	   ‘stressor’	   such	  as	  application	  of	  direct	   cytotoxins	   or	   glucose	   deprivation.	   Similarly,	   the	   exposure	   to	  inflammatory	   cytokines	  has	  previously	  been	   shown	   to	   lead	   to	  upregulation	  of	  both	  β-­‐amyloid	  proteins	  (Schmidt	  et	  al.	  2008)	  and	  MHC	  Class	  I	  (Michaelis	  et	  al.	  1993)	   in	  cultured	  myotubes.	  Since	  a	  sustained,	  predominantly	  T-­‐cell	  mediated	  inflammatory	  response	  is	  a	  fundamental	  pathological	  component	  of	  IBM,	  it	  was	  logical	  to	  evaluate	  this	  further.	  	  
3.3.2.1	   Overexpression	   of	   βAPP	   can	   be	   achieved	   without	   reduction	   of	   culture	  
myogenicity	  	  The	  purpose	  of	  these	  experiments	  was	  to	  achieve	  a	  balance	  between	  a	  sufficient	  overall	  overexpression	  of	  βAPP	  in	  myogenic	  cells	  to	  allow	  both	  demonstration	  that	  the	  technique	  had	  worked	  and	  to	  produce	  downstream	  effects,	  but	  to	  avoid	  excessive	  cytotoxicity,	  particularly	  if	  predominant	  among	  myogenic	  cells.	  First,	  therefore,	  it	  was	  important	  to	  determine	  a	  protocol	  for	  transfection	  of	  the	  βAPP-­‐containing	   plasmid	   that	   was	   still	   associated	   with	   an	   acceptable	   degree	   of	  myogenicity	   in	   these	   cultures.	   It	  was	   anticipated	   that	   the	   postmitotic	   state	   of	  multinucleated	   myotubes	   might	   render	   them	   particularly	   susceptible	   to	   the	  toxicity	  of	  the	  technique	  per	  se,	  in	  addition	  to	  any	  toxic	  consequences	  of	  βAPP.	  	  Examination	   of	   βAPP	   transfection	   at	   different	   time	   points	   (48	   and	   96	   hours	  after	   plating)	   with	   different	   DNA	   to	   Lipofectamine™	   ratios	   (between	   1:1	   and	  5:1)	  revealed	  a	  significant	  effect	  in	  certain	  combinations	  on	  overall	  myogenicity	  and	  myotube	  formation.	  This	  could	  either	  represent	  direct	  selective	  toxicity	  on	  myogenic	   cells	   or	   delay	   in	   their	   maturation	   toward	   expression	   of	   myocyte	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specific	   proteins.	   Nevertheless,	   two	   transfection	   ratios,	   3:1	   and	   4:1	   were	   not	  associated	   with	   a	   significant	   reduction	   in	   overall	   myogenicity,	   demonstrating	  that	  the	  overall	  toxicity	  of	  the	  technique	  is	  acceptable	  in	  this	  context.	  The	  time	  point	  at	  which	  cells	  were	  transfected	  was	  of	  significance	  in	  myogenic	  maturation	  of	  the	  cultures.	  Following	  transfection	  at	  48-­‐hours,	  the	  proportion	  of	  myogenic	   cells	   represented	   by	   multinucleated	   myotubes	   was	   significantly	  attenuated	  across	  all	  transfection	  ratios	  with	  βAPP	  and	  empty	  vector.	  This	  effect	  was	   overcome	   by	   delaying	   transfection	   to	   96	   hours	   after	   plating,	   when	   no	  significant	  difference	  in	  myotube	  proportion	  was	  detected	  at	  three	  of	  the	  tested	  transfection	  ratios,	  including	  those	  (3:1	  and	  4:1)	  which	  also	  did	  not	  detract	  from	  overall	  myogenicity.	  As	   the	   time	  period	   between	  48	   and	  96	  hours	   is	   that	   in	  which	   the	  majority	   of	  myotube	   formation	   is	   observed,	   these	   results	   are	   likely	   to	   represent	   an	  inhibitory	   effect	   of	   the	   transfection	   process	   on	   the	   differentiation	   of	   satellite	  cells,	   particularly	   their	   fusion	   into	   myotubes,	   rather	   than	   a	   direct	   cytotoxic	  effect.	  	  
3.3.2.2	   Overexpression	   of	   βAPP	   in	   myogenic	   cells	   is	   associated	   with	   increased	  
formation	  of	  Aβ40/42	  oligomers	  Having	   determined	   the	   transfection	   conditions	   that	   appeared	   suitable	   for	  further	  experiments,	  the	  effects	  of	  βAPP	  transfection	  on	  the	  concentrations	  and	  handling	   of	   β-­‐amyloid	   proteins	   were	   next	   examined.	   Western	   blot	   analysis	  confirmed	   successful	   overexpression	   through	   significantly	   elevated	  concentration	   of	   βAPP	   compared	   to	   untransfected	   cultures.	   Furthermore,	   the	  significant	   increase	   compared	   to	   empty	   vector	   transfection	   implies	   that	   this	  effect	  did	  reflect	  increased	  expression	  of	  βAPP	  specific	  to	  the	  plasmid	  concerned,	  rather	   than	   being	   a	   generic	   response	   to	   the	   transfection	   technique	   itself.	  Untransfected	   cultures	  displayed	   relatively	   similar	  proportions	  of	  βAPP,	  Aβ42	  and	   Aβ40	   compared	   to	   control	   housekeeping	   proteins.	   However,	   this	   balance	  altered	  substantially	  following	  βAPP	  transfection,	  where	  far	  greater	  elevation	  of	  Aβ42	  was	   demonstrated	   than	  Aβ40.	  Although	  both	   proteins	   are	   implicated	   in	  human	   disease,	   the	   Aβ42	   oligomer	   is	   the	   more	   fibrillogenic	   and,	   therefore,	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cytotoxic,	  notably	  in	  Alzheimer’s	  Disease	  (AD)	  (Chen	  et	  al.	  2006).	  Therefore,	  the	  propensity	   of	   skeletal	   muscle	   to	   accumulate	   Aβ42	   in	   response	   to	  overexpression	  of	  βAPP	  might	  hint	  at	  a	  similar	  susceptibility	   to	   that	  displayed	  by	  cortical	  neurons	  in	  AD	  (Walsh	  et	  al.	  2007).	  The	  tissues	  are	  analogous	  in	  their	  postmitotic,	  highly	  metabolically	   active	   state.	  Extrapolating	   to	   IBM	   in	  vivo,	   the	  relatively	  acidotic	  environment	  represented	  by	  Type	  2	  fast-­‐twitch	  fibres	  of	  the	  forearm	   flexor	   compartment	   and	   quadriceps	  might	   alter	   βAPP	   processing,	   as	  has	  been	  demonstrated	  in	  neurons	  (Brewer	  1997).	  Correspondingly,	  proteomic	  analysis	   of	   IBM	  muscle	   through	  mass	   spectrometry	   demonstrated	   substantial	  loss	   of	   Type	   2	   fibre	   proteins,	   particularly	   ACTN3	   and	  MYBPC2,	   and	   glycolytic	  pathway	  proteins,	   in	   excess	   to	   that	   seen	   in	   comparable	   diseases	   and	   to	   other	  downregulated	   proteins	   in	   IBM	   tissue	   (Parker	   et	   al.	   2009).	   	   Altered	   βAPP	  processing	   in	   IBM	  muscle	   in	  vivo	   is	   suggested	   by	   accumulation	   of	   BACE1	   and	  BACE2	  proteins	  (beta-­‐site	  amyloid	  precursor	  protein	  cleaving	  enzymes),	  which	  release	   amyloidogenic	   proteins	   from	   cleavage	   of	   βAPP,	   in	   cytoplasmic	  inclusions	  and	  in	  increased	  concentration	  on	  western	  blot	  (Vattemi	  et	  al.	  2003).	  Furthermore,	  BACE1	  mRNA	  is	  significantly	  increased	  in	  IBM	  tissue	  (Nogalska	  et	  al.	  2010).	  Interestingly,	  approximately	  one	  third	  of	  myogenic	  cells	  grown	  under	  standard	  conditions	   were	   immunoreactive	   for	   the	   Aβ40	   oligomer.	   This	   compared	   to	  fewer	   than	   20%	   of	   cells	   positive	   for	   Aβ42.	   The	   normal	   constitutive	  characteristics	  of	  β-­‐amyloid	  proteins	   in	   skeletal	  muscle	   and	  myotubes	   in	  vitro	  are	  not	  well	  described.	  Nevertheless,	   formation	  of	  proteinaceous	   inclusions	   in	  individual	  myotubes	  grown	  under	  standard	  cultures	  conditions	  was	  extremely	  rare.	  Therefore,	  the	  expression	  level	  of	  β-­‐amyloid	  proteins	  per	  se	  may	  not	  be	  the	  only	  factor	  that	  leads	  to	  protein	  aggregation.	  Altered	  βAPP	  processing,	  and	  the	  underlying	  cellular	  milieu	  may	  dictate	  the	  degree	  of	  susceptibility	  to	  the	  further	  burdens	  of	  inflammation	  and	  other	  pathologies	  that	  coexist	  in	  IBM.	  	  	  
	   119	  
3.3.2.3	   Overexpression	   of	   βAPP	   in	   myogenic	   cells	   leads	   to	   formation	   of	  
proteinaceous	  aggregates	  βAPP	  transfection	  was	  associated	  with	  formation	  of	  cytoplasmic	  proteinaceous	  aggregates,	  mirroring	  the	  histological	  changes	  observed	  in	  IBM	  tissue	  and	  those	  seen	   in	   cultured	  human	  myocytes	   following	   the	   same	  stimulus	   (Askanas	  et	   al.	  2003).	   These	   changes	   were	   observed	   in	   both	   mononuclear	   myocytes	   and	  multinuclear	   myotubes,	   implying	   that	   the	   postmitotic	   state	   is	   not	   the	   sole	  susceptibility	   factor	   in	   aggregate	   formation.	   	   The	   formation	   of	   proteinaceous	  inclusions	   is	   a	   consistent	   feature	   of	   numerous	   neurodegenerative	   diseases	  including	   AD,	   Frontotemporal	   dementia,	   Lewy	   Body	   Dementia,	   Parkinson’s	  Disease,	   Huntington’s	   Disease	   and	   Motor	   Neuron	   Disease,	   in	   addition	   to	  systemic	  diseases	  including	  type	  2	  diabetes,	  inherited	  cataracts,	  some	  forms	  of	  atherosclerosis	   and	   amyloidosis	   (Reynaud	   2010).	   Briefly,	   they	   represent	   the	  consequence	   of	   inappropriate	   exposure	   of	   hydrophobic	   surfaces	   that	   are	  usually	  concealed	  internally	  or	  at	  the	  interface	  with	  other	  protein	  subunits.	  This	  is	   particularly	   relevant	   to	   membrane	   proteins,	   which	   often	   contain	   large	  hydrophobic	  domains	  that	  are	  normally	  contained	  in	  the	  lipid	  bilayer.	  Exposure	  of	   these	  hydrophobic	   regions	   leads	   to	   abnormal	   confirmations	   of	   protein	   that	  subsequently	   interact	   to	   form	   aggregates	   which	   are	   often	   resistant	   to	  degradation	  or	  refolding	  (Johnston	  et	  al.	  1998).	  	  The	  stimulus	  for	  this	  process	  is	  provided	   when	   a	   cell’s	   capacity	   to	   degrade	   or	   refold	   misfolded	   proteins	   is	  exceeded.	   This	   represents	   overwhelming	   of	   the	   numerous	   protective	  ‘chaperone’	   responses,	   primarily	   involving	   the	   ubiquitin-­‐proteasome	   or	  autophagic	   pathways	   that	   have	   evolved	   to	   minimise	   the	   likelihood	   of	   such	   a	  scenario.	   It	   is	   conceptually	   difficult,	   therefore,	   to	   determine	   whether	   the	  formation	   of	   proteinaceous	   inclusions	   represent	   another	   stage	   of	   cellular	  defence	  or	  are	  directly	  cytotoxic,	  and	  this	  question	  remains	  unanswered.	  Rather,	  their	   presence	   are	   best	   inferred	   as	   an	   imbalance	   between	   the	   production	   of	  abnormal	  proteins	  and	  the	  capacity	  to	  process	  them.	  The	  cytoplasmic	  proteinaceous	  inclusions	  identified	  in	  these	  experiments	  took	  a	  variety	  of	  appearances	  and	  sizes,	  as	  is	  well	  described	  in	  the	  literature	  (Narhi	  et	  al.	  2012).	  Immunocytochemical	  staining	  of	  the	  inclusions	  revealed	  a	  number	  of	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proteins	   that	   are	   also	   detected	   in	   IBM	   tissue,	   including	   phosphorylated	   tau,	  TDP-­‐43	  and	  p62	  (Nogalska	  et	  al.	  2009;	  Salajegheh	  et	  al.	  2009).	  Their	   frequent	  ubiquination	   implies	   identification	   for	   intended	  proteasomal	  degradation.	  The	  larger,	  well-­‐defined	  perinuclear	   inclusions	  might	  represent	  aggresomes,	  which	  are	   thought	   to	   have	   greater	   structural	   organisation	   than	   other	   forms	   of	  inclusion	  (Johnston	  et	  al.	  1998).	  Nevertheless,	  the	  presence	  of	  each	  type	  served	  to	  demonstrate	  here	  that	  the	  degree	  of	  βAPP	  over-­‐expression	  achieved	  with	  this	  transfection	  process	  did	  exceed	  the	  degradative	  capacities	  of	  myotubes	  in	  vitro,	  thereby	   reproducing	   one	   downstream	   element	   of	   IBM	   pathology.	   The	  accumulation	   of	   other	   typically	   ‘degenerative’	   proteins	   within	   the	   inclusions	  further	  suggests	  impairment	  of	  protein	  degradation	  by	  βAPP,	  Aβ40	  and	  Aβ42	  or	  the	  activation	  of	  pathogenic	  cascades	   that	  affect	   the	  production	  or	  breakdown	  of	  those	  proteins	  specifically.	  The	  induction	  of	  ER	  stress	  therefore	  appeared	  an	  attractive	  mechanism	  for	  further	  investigation.	  	  
3.3.2.4	   Inflammatory	   cytokines	   induce	   β-­‐amyloid	   expression	   in	   satellite	   cell	  
cultures	  In	   keeping	   with	   previous	   work	   on	   human	   myocytes	   (Schmidt	   et	   al.	   2008),	  exposure	  to	   inflammatory	  cytokines	  IL1β,	   IFNγ	  and	  TNFα	  was	  associated	  with	  increased	   concentrations	   of	   βAPP	   and	   Aβ42.	   The	   advantage	   of	   this	   technique	  over	   direct	   βAPP	   overexpression	   is	   the	   homogenous	   level	   of	   exposure	   to	   the	  stimulus,	   compared	   with	   typically	   heterogeneous	   success	   of	   transfection.	  Furthermore,	  following	  exposure	  to	  IL1β	  or	  TNFα,	  a	  dose	  dependent	  increase	  in	  βAPP	   and	   Aβ42	   was	   observed.	   This	   allows	   adjustment	   of	   the	   magnitude	   of	  induced	  expression	  of	  β-­‐amyloid	  proteins	  that	  is	  not	  possible	  with	  transfection.	  The	  observation	  of	  dose	  dependence	  strengthens	  the	  conclusion	  that	  increased	  expression	   β-­‐amyloid	   proteins	   are	   a	   consequence	   of	   the	   cytokines.	   	   Strong	  correlation	  between	  βAPP	  and	  Aβ42	  levels	  across	  the	  experimental	  conditions	  implies	   that	   the	   increase	   in	   Aβ42	   in	   these	   conditions	   is,	   indeed,	   the	   direct	  consequence	  of	  increased	  βAPP	  expression.	  The	  magnitude	  of	  increases	  in	  βAPP	  and	  Aβ42	  concentration	  following	  cytokine	  exposure	  was	  up	   to	  2.5	   times	   that	  of	  control,	  which	   is	   less	   than	   that	  observed	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following	  transfection	  where	  increases	  of	  βAPP	  and	  Aβ42	  were	  approximately	  4	  and	  6	  fold	  respectively.	  This	  might	  account	  for	  the	  relative	  lack	  of	  proteinaceous	  inclusion	  formation	  displayed	  by	  myotubes	  exposed	  to	  cytokines,	  in	  contrast	  to	  those	  transfected	  with	  βAPP.	  This	  would	  depend	  on	  a	  critical	  threshold	  of	  βAPP	  expression	  above	  which	  inclusion	  formation	  occurs.	  This	  may	  relate	  to	  absolute	  concentration	   of	   β-­‐amyloid,	   simultaneous	   upregulation	   of	   other	   proteins,	   or	  direct	  effects	  on	  protein	  degradation	  of	  either	  experimental	  technique	  used	  here.	  Alternatively,	   the	   rate	   of	   increase	   in	   βAPP	   or	   Aβ42	   expression	   might	   be	  important,	   and	   a	   more	   rapid	   induction	   associated	   with	   transfection	   might	  thereby	  account	  for	  the	  greater	  association	  with	  inclusion	  formation.	  	  
3.3.2.5	  MHC	  Class	  I	  upregulation	  can	  be	  driven	  by	  β-­‐amyloid	  proteins	  in	  addition	  
to	  inflammatory	  cytokines	  The	  expression	  of	  MHC	  Class	   I	   (MHCI)	  by	   skeletal	  muscle,	  which	   is	  one	  of	   the	  few	  tissues	  that	  does	  not	  constitutively	  express	  the	  protein,	  is	  a	  hallmark	  of	  IBM	  pathology.	   In	   addition	   to	   representing	   the	   chronic,	   self-­‐perpetuating	  inflammatory	  response	  of	   the	  disease,	   it	   is	   implicated	   in	  driving	  ER	  stress	  and	  activation	   of	   the	   NFκB	   cascade,	   which	   themselves	   are	   potentially	   central	  mechanisms	   in	   IBM	  pathogenesis.(Dalakas	   2006).	  Unsurprisingly,	   satellite	   cell	  cultures	   demonstrated	   significantly	   increased	   MHCI	   expression	   following	  exposure	   to	   IL1β	   and	   TNFα.	   This	   effect	   was	   not	   reproduced	   through	   glucose	  deprivation,	   implying	   that	   increased	  MHCI	   expression	   is	   not	   a	   generic	   ‘stress	  response’	  of	  myogenic	  cells	   in	  culture.	   Interestingly,	  even	  when	  accounting	  for	  the	   effect	   of	   empty	   vector	   transfection,	   βAPP	   transfection	  was	   also	   associated	  with	   significant	   elevation	   of	   MHCI	   expression.	   This	   implies	   a	   previously	  undescribed	  pathway	  of	  potential	  relevance	  to	  IBM,	  in	  which	  β-­‐amyloid	  proteins	  appear	   to	   contribute	   to	   a	   fundamentally	   pro-­‐inflammatory	   stimulus.	   The	  potential	  mechanisms	  of	   this	  are	  explored	   in	  Chapter	  4.	   	  The	   interpretation	  of	  MHCI	  results	  must,	  however,	  be	  cautious	  given	  the	  disparity	  between	  immature	  satellite	  cells	  in	  culture,	  which	  do	  constitutively	  express	  MHCI	  unlike	  the	  mature	  tissue.	  The	  protein	  may	  have	  additional	  roles	  in	  satellite	  cell	  maturation	  (Honda	  et	  al.	  1989).	  However,	  this	  effect	  is	  likely	  to	  be	  small	  since	  MHCI	  expression	  falls	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quickly	   upon	   formation	   of	   multinucleated	   myotubes,	   which	   represent	   the	  predominant	  cell	  type	  in	  the	  cultures	  described	  here.	  	  
3.3.3	  Overall	  Summary	  The	   experiments	  presented	   in	   this	  Chapter	  demonstrate	   that	  highly	  myogenic	  cell	   cultures,	   with	   high	   rates	   of	   multinucleated	   myotube	   formation,	   can	   be	  established	   consistently	   following	   harvest	   and	   plating	   of	   satellite	   cells	   from	  neonatal	   rats.	   The	   transfection	   of	   βAPP	   with	   Lipofectamine™	   successfully	  increases	  the	  cellular	  concentration	  of	  βAPP,	  Aβ42	  and	  Aβ40	  in	  myogenic	  cells,	  which,	   in	   turn,	   is	   associated	  with	   the	   formation	   of	   cytoplasmic	   proteinaceous	  inclusions	  containing	  degenerative	  proteins	  found	  in	  IBM	  tissue	  in	  vivo.	  It	  is	  also	  associated	  with	  upregulation	  of	  MHC	  Class	  I,	   indicating	  a	  further	  potential	   link	  between	   ‘inflammatory’	   and	   ‘degenerative’	  mechanisms.	  MHCI	   upregulation	   is	  reproduced	  by	  exposure	   to	   IL1β	  and	  TNFα,	  and	   these	   inflammatory	  cytokines	  are	   further	   associated	   with	   increased	   concentration	   of	   β-­‐amyloid	   proteins,	  albeit	   to	   a	   lesser	   degree	   than	   direct	   transfection	   and	   without	   consistent	  inclusion	  deposition.	  This	  work	  laid	  the	  required	  foundation	  to	  explore	  the	  pathological	  mechanisms	  associated	   with	   these	   two	   stimuli	   of	   IBM-­‐like	   pathology,	   and	   to	   investigate	  which	  might	  be	  used	  to	  test	  new	  therapeutic	  strategies.	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Chapter	  4:	  Characterisation	  of	  pathological	  outcome	  
measures	  of	  IBM	  in	  vitro	  to	  investigate	  a	  novel	  
therapeutic	  approach	  	  
	  
4.1	  Introduction	  Having	  established	  a	  reproducible	  cellular	  model	  in	  which	  salient	  degenerative	  and	   inflammatory	   features	  of	   IBM	  pathology	  were	  represented,	   the	  next	  set	  of	  experiments	  sought	   to	  characterise	   further	   IBM-­‐relevant	  markers	  and	   thereby	  develop	  a	  panel	  of	  pathological	  outcome	  measures	  on	  which	  potential	  therapies	  can	   be	   evaluated.	   Subsequently,	   a	   pre-­‐clinical	   in	   vitro	   evaluation	   of	   a	   novel	  therapeutic	   approach	  was	   undertaken	   using	   these	  measures;	   pharmacological	  augmentation	   of	   the	   cytoprotective	  Heat	   Shock	   Response	  with	   the	   co-­‐inducer	  Arimoclomol.	  First,	   consideration	   was	   given	   to	   those	   processes	   that,	   from	   reviewing	   the	  literature,	   are	   key	   distinguishing	   features	   or	   potentially	   central	   pathogenic	  mechanisms	   of	   IBM,	   particularly	   those	   that	   lie	   at	   the	   junction	   between	  inflammation	  and	  degeneration.	  These	  are:	  1. TDP-­‐43,	  which	  appears	  to	  be	  the	  most	  specific	  and	  sensitive	  histological	  marker	  of	  IBM	  (Salajegheh	  et	  al.	  2009).	  2. NFκB	   activation,	   which	   is	   activated	   by	   both	   ER	   stress	   and	   pro-­‐inflammatory	   stimuli,	   and	   appears	   well	   placed	   to	   perpetuate	   the	  inflammatory	   response	   in	   IBM,	   in	   addition	   to	   promoting	   muscular	  atrophy	  (Dalakas	  2006).	  3. Endoplasmic	   reticulum	   (ER)	   stress,	   which	   is	   a	   common	   feature	   of	  neurodegenerative	   diseases,	   intimately	   related	   to	   the	   cellular	  milieu	   of	  protein	   misfolding	   and	   aggregation,	   which	   distinguish	   IBM	   from	   the	  primary	  myositides	  (Roussel	  et	  al.	  2013;	  Schmidt	  et	  al.	  2013).	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4.1.1	  TDP-­‐43	  Tar	  DNA	  Binding	  Protein	  43	  (TDP-­‐43)	  is	  a	  414	  amino	  acid	  protein,	  the	  extent	  of	  whose	   normal	   cellular	   functions	   remain	   under	   investigation.	   It	   was	   initially	  investigated	  in	  a	  pathological	  context	  as	  the	  major	  constituent	  of	  proteinaceous	  intraneuronal	   aggregates	   characterised	   by	   ALS	   and	   FTD,	   now	   intriguingly	  connected	  at	  two	  ends	  of	  a	  TDP-­‐43-­‐opathic	  disease	  spectrum	  through	  common	  C9orf72	  mutations,	  which	  have	  not	  been	  detected	  thus	  far	  in	  IBM	  (Wood	  2011).	  Nevertheless,	   TDP-­‐43’s	   normal	   functions	   appear	   to	   relate	   primarily	   to	   RNA	  regulation,	  mediated	  chiefly	  via	  its	  RRM1	  domain	  (Figure	  4.1)	  (Lee	  et	  al.	  2012).	  	  
	  
Figure	   4.1	   Illustration	   of	   the	   structure	   of	   TAR	   DNA-­‐binding	   protein	   43	  
(TDP-­‐43)	  Key	   elements	   include	   two	   RNA-­‐recognition	   motifs;	   RNA-­‐recognition	   motif	   1	  (RRM1)	   and	   RRM2),	   a	   carboxy-­‐terminal	   glycine-­‐rich	   domain,	   nuclear	  localization	  signal	  (NLS)	  and	  a	  nuclear	  export	  signal	  (NES).	  Mutations	  linked	  to	  sporadic	  and	  familial	  forms	  of	  amyotrophic	  lateral	  sclerosis	  and	  frontotemporal	  lobar	  degeneration	  are	  almost	  exclusively	  located	  in	  or	  adjacent	  to	  the	  glycine-­‐rich	  domain.	  	  The	   RNA	   types	   to	   which	   TDP-­‐43	   possesses	   binding	   capability	   represent	  approximately	  one	  third	  of	  the	  transcriptome	  (Tollervey	  et	  al.	  2011).	  There	  is	  a	  preponderance	  of	  introns	  and	  non-­‐coding	  RNAs.	  Subsequent	  postulated	  nuclear	  functions	   include	   pre-­‐mRNA	   splicing,	   as	   a	   heterogeneous	   nuclear	  ribonucleoprotein	  (hnRNP)	  (Buratti	  et	  al.	  2005),	  and	  transcriptional	  repression	  via	   single	   stranded	   DNA	   promoter	   silencing.	   TDP-­‐43’s	   characteristic	   nuclear-­‐cytoplasmic	   shuttling	   may	   assist	   mRNA	   trafficking	   (Wang	   et	   al.	   2008),	   with	  further	   cytoplasmic	   roles	   in	   mRNA	   stability	   and	   protection,	   through	   stress	  granule	  sequestration	  (McDonald	  et	  al.	  2011).	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TDP-­‐43	   pathology	   is	   characterised	   by	   two	   features:	   translocation	   from	   the	  nucleus	  to	  the	  cytoplasm	  with	  consequent	  clearance	  of	  TDP-­‐43	  from	  the	  nucleus,	  and	  the	  formation	  of	  cytoplasmic	  proteinaceous	  aggregates	  as	  non-­‐ubiquinated	  ‘pre-­‐inclusions’	   or	   ubiquinated	   ‘inclusions’.	   Nuclear	   aggregates	   are	   less	  frequently	  demonstrated.	  TDP-­‐43	  appears	  to	  be	  inherently	  prone	  to	  aggregation,	  characteristic	  feature	  of	  an	  important	  neurodegenerative	  protein	  (Johnson	  et	  al.	  2009).	   However,	   the	   nuclear	   clearance	   phenomenon	   appears	   to	   be	   a	  distinguishing	   factor	   from	   other	   typical	   neurodegenerative	   proteins,	   such	   as	  Huntingtin	  or	  β-­‐amyloid	  (DiFiglia	  et	  al.	  1997).	  The	  lack	  of	  clarity	  on	  TDP-­‐43’s	  normal	  functions	  adds	  complexity	  to	  the	  puzzle	  of	  how	  it	  contributes	  to	  degenerative	  pathology.	  It	   follows	  that	  the	  majority	  of	  previous	  work	  has	  focussed	  on	  gain	  of	  toxic	  function	  rather	  than	  the	  loss	  of	  as	  yet	   undetermined	   physiological	   roles.	   Much	   of	   this,	   in	   turn,	   depends	   on	   the	  interpretation	   of	   whether	   TDP-­‐43	   cytoplasmic	   aggregates	   are	   pathogenic	   or	  cytoprotective.	   Certainly,	   it	   is	   rational	   to	   hypothesise	   that	   the	   loss	   of	   normal	  RNA	  binding	  in	  the	  nucleus	  disturbs	  a	  number	  of	  the	  processes	  with	  which	  TDP-­‐43	  has	  been	  linked	  through	  genomic	  studies	  (Lee	  et	  al.	  2012).	  If	  its	  RNA	  binding	  property	   is	  maintained	   upon	   translocation	   to	   the	   cytoplasm,	   this	  may	   lead	   to	  subsequent	   abnormalities	   of	   RNA	   processing.	   Nuclear	   clearance	   appears	   to	  occur	   early	   in	   ‘TDP-­‐43-­‐opathies’	   ALS	   and	   FTD	   (Giordana	   et	   al.	   2010).	  Furthermore,	   TDP-­‐43	   aggregates	   do	   not	   appear	   necessary	   for	   TDP-­‐43	   related	  neurodegeneration	   to	   occur.	   Further	   investigation	   of	   a	   ‘loss	   of	   function’	  hypothesis	  has	  been	  hindered	  by	  the	  fact	  that	  TDP-­‐43	  knockout	  is	  lethal	  in	  mice	  (Chiang	  et	  al.	  2010).	  
	  
4.1.1.1	  Relevance	  of	  TDP-­‐43	  to	  IBM	  Although	  TDP-­‐43	  has	  been	  studied	  primarily	   in	   the	  context	  of	  FTD	  and	  ALS,	   it	  appears	   that	   IBM	   tissue	   displays	   several	   similar	   features	   of	   TDP-­‐43	  degenerative	   pathology.	   Indeed,	   these	   features	   strongly	   distinguish	   IBM	   from	  PM	  and	  DM.	  Histopathological	  studies	  have	  demonstrated	  mislocalised	  TDP-­‐43,	  with	  characteristic	  loss	  of	  nuclear	  staining	  and	  formation	  of	  cytoplasmic	  TDP-­‐43	  aggregates	  (Figure	  4.2).	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Figure	  4.2	  Illustration	  of	  TDP-­‐43	  pathology	  in	  IBM	  tissue	  From	  (Salajegheh	  et	  al.	  2009)	  A1-­‐4:	  Fluorescent	  images	  of	  myonuclei	  in	  normal	  skeletal	   muscle	   demonstrate	   nuclear	   TDP-­‐43	   staining,	   evidenced	   by	  colocalisation	   with	   DAPI.	   B-­‐1	   and	   C:	   Skeletal	   muscle	   from	   IBM	   patients	  demonstrates	   redistribution	   of	   TDP-­‐43,	   with	   loss	   of	   nuclear	   staining	   and	  cytoplasmic	  translocation.	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Notably,	   such	   features	  were	   demonstrated	   in	   one	   study	  by	   up	   to	   a	   quarter	   of	  muscle	   fibres	   in	   IBM	   tissue,	   making	   this	   clearly	   the	   most	   common	  histopathological	   hallmark	   of	   IBM.	   By	   comparison,	   rimmed	   vacuoles	   were	  observed	  in	  fewer	  than	  3%	  of	  fibres	  in	  the	  same	  study.	  TDP-­‐43	  expression	  was	  also	  increased	  in	  IBM	  cases	  versus	  disease	  controls.	  Consistent	  with	  its	  relative	  absence	   in	   PM	   tissue,	   this	   TDP-­‐43	   pathology	   is	   far	   more	   characteristic	   of	  degenerative	   than	   inflammatory	  disease.	   Indeed,	   fibres	   of	   hereditary	   IBM	  and	  myofibrillar	  myopathies	  demonstrated	  similar	  features	  (Salajegheh	  et	  al.	  2009).	  IBM	  is	   linked	  to	  FTD,	  a	  characteristic	  TDP-­‐43-­‐opathy,	   through	  the	  VCP	  mutant	  condition	   IBM-­‐FTD-­‐PD	   (Watts	   et	   al.	   2007).	   This	   is	   among	   other	   factors	   that	  suggest	   IBM	  could	  be	   considered	   as	   the	  peripheral	   end	  of	   a	   disease	   spectrum	  that	  whose	  central	  nervous	  system	  phenotype	  is	  FTD,	  bridged	  by	  ALS	  (Chapter	  1,	   Section	   1.6.2).	   However,	   there	   are	   marked	   phenotypic	   and	   pathological	  differences	  between	  ‘IBM’	  in	  VCP	  mutations	  and	  the	  sporadic	  disease,	  and	  none	  of	  the	  genetic	  mutations,	  most	  notably	  C9Orf72,	  have	  yet	  been	  demonstrated	  in	  cases	  of	  apparently	  sporadic	  IBM.	  	  
4.1.2	  Endoplasmic	  reticulum	  pathophysiology	  The	   intracellular	  organelle	   endoplasmic	   reticulum	  (ER)	  has	   two	  broad	   related	  functions.	   First,	   it	   processes	   and	   modifies	   newly	   translated	   membrane	   and	  secretory	   proteins,	   serving	   a	   ‘quality	   control’	   purpose	   in	   determining	  what	   is	  passed	   on	   to	   the	   Golgi	   apparatus.	   Secondly,	   it	   is	   the	   principle	   intracellular	  calcium	   store,	   the	   regulation	   of	   which	   is	   fundamental	   to	   all	   cell	   functions	  through	   calcium	   signaling.	   Indeed,	   the	   regulation	   of	   intracellular	   calcium	   is	  demonstrated	   by	   all	   living	   cells.	   Close	   functional	   connectivity	   with	   cell	  membrane	   and	   mitochondria	   further	   convey	   the	   ER’s	   wide	   influence.	   The	  specialised	   ER	   in	   muscle,	   sarcoplasmic	   reticulum	   (SR),	   has	   a	   further	   key	  function	  in	  excitation-­‐contraction	  coupling.	  It	  follows	  that	  the	  ER’s	  own	  function	  is	   highly	   Ca2+-­‐dependent	   and	   its	   disturbance	   results	   in	   a	   cascade	   of	   highly	  conserved	  pathways	  that	  are	  collectively	  referred	  to	  as	  ‘ER	  stress’.	  Disturbance	  of	  the	  ER	  is	  associated	  with	  a	  wide	  variety	  of	  stimuli,	  is	  a	  common	  characteristic	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of	   all	   neurodegenerative	   diseases	   in	   which	   it	   has	   been	   studied,	   and	   is	   a	  potentially	  central	  component	  of	  IBM	  pathology.	  	  	  
4.1.2.1	  ER/SR	  Calcium	  Luminal	  ER/SR	  Ca2+	  is	  dynamic	  but	  tightly	  regulated	  at	  concentrations	  several	  thousand	   times	   that	   of	   the	   cytosol	   through	   homeostatic	   mechanisms	   that	  regulate	  the	  magnitude	  and	  velocity	  of	  ER	  Ca2+	  uptake	  and	  release	  according	  to	  both	  ER	  and	  cytosolic	  [Ca2+]	  (Burdakov	  et	  al.	  2005).	  Uptake	  is	  mediated	  by	  the	  Sarco/Endoplasmic	   Reticulum	   ATPase	   (SERCA)	   pump,	   which	   actively	  transports	   Ca2+	   against	   this	   concentration	   gradient,	   into	   the	   ER	   lumen.	   Ca2+	  release	   is	   dictated	   by	   the	   inositol	   1,4,5-­‐triphosphate	   (IP3)	   and	   ryanodine	  receptors.	   The	   rapid	   kinetics	   of	   ER	   Ca2+	   release	   rely	   on	   the	   low	   resting	  resistance	   of	   the	   ER	   membrane,	   which	   precludes	   the	   significant	   shift	   of	  membrane	  potential	  during	  Ca2+	  movement	  that	  slows	  or	  ceases	  the	  process	  in	  most	   other	   transmembrane	   ionic	   shifts.	   Broadly,	   the	   ryanodine	   receptor	  pathway	  represents	   the	  principle	  pathway	  of	  Ca2+	   induced	  Ca2+	  release	  (CICR),	  which	   underlies	   excitation	   contraction	   coupling	   and	   is	   demonstrated	   by	  excitable	  cells.	  IP3	  pathways,	  however,	  relate	  to	  ‘capacitative’	  or	  ‘store	  operated’	  calcium	  entry	  mechanisms	  via	   the	  plasma	  membrane	   that	   are	  signaled	  by	   the	  ER	   in	   response	   to	   depletion	   of	   its	   Ca2+	   through	   a	   variety	   of	   proteins	   such	   as	  transient	  receptor	  proteins	  (TRPs).	  This	  was	  initially	  thought	  to	  relate	  primarily	  to	   non-­‐excitable	   cells	   but	   it	   increasingly	   appears	   common	   to	   excitable	   tissues	  also.	  One	  putative	  mechanism	  depends	  upon	  the	  stromal	  interacting	  molecule	  1	  (STIM1),	  which	  may	   detect	   depleted	   ER	   Ca2+,	   including	   in	   skeletal	  muscle	   and	  myotubes	   (Stiber	   et	   al.	   2008).	   Upon	   stimulation,	   STIM1	   translocates	   to	   the	  membrane	  and	   facilitates	   the	   formation	  of	   functional	  Ca2+	  channels	  by	  TRPs	  or	  Orai1,	  through	  which	  cytosolic	  rises	  and	  ER	  Ca2+	  consequently	  repletes	  (Perez	  et	  al.	  2003;	  Prakriya	  et	  al.	  2006).	  	  Elevated	  cytosolic	  [Ca2+]	  is	  characteristic	  of	  cytotoxic	  conditions,	  in	  which	  the	  ER	  appears	   to	   serve	   as	   a	   protective	   buffer.	   Ca2+	   is	   sequestered	   from	   the	   cytosol,	  assisted	  by	  induced	  expression	  of	  SERCA2b	  (Wu	  et	  al.	  2001).	  However,	  implying	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dysfunction	   or	   insufficiency	   in	   this	   mechanism,	   the	   cellular	   milieu	   of	   most	  pathology	  appears	  to	  combine	  depleted	  ER	  Ca2+	  with	  elevated	  cytosolic	  [Ca2+].	  	  
	  
4.1.2.2	  Consequences	  of	  disturbed	  intraluminal	  ER	  Calcium	  In	   keeping	   with	   its	   protein	   trafficking	   role,	   a	   large	   number	   of	   chaperone	  proteins	   are	   resident	   in	   the	   ER.	   The	   majority	   of	   these	   display	   multiple	   Ca2+	  binding	  sites,	  which	  regulate	  their	  activity	  and	  expression	  (Michalak	  et	  al.	  2002).	  Therefore,	  the	  cytoprotective	  responses	  to	  accumulation	  of	  unfolded	  proteins	  in	  the	  ER,	  such	  as	  is	  typical	  of	  neurodegenerative	  diseases,	  are	  highly	  dependent	  on	  ER	   Ca2+.	   Indeed,	   the	   lectin	   group	   of	   ER	   chaperones,	   including	   calreticulin	   and	  calnexin,	  has	  ER	  Ca2+	  buffering	  properties.	  Consequently,	   it	   is	  unsurprising	  that	  depletion	  of	  ER	  Ca2+	   inhibits	  protein	   folding	  (Wetmore	  et	  al.	  1996).	  Sufficiently	  low	   concentrations	   of	   ER	   Ca2+	   appear	   to	   switch	   off	   ER	   chaperone	   responses	  completely	  (Corbett	  et	  al.	  2000).	  It,	  therefore,	  appears	  that	  disturbed	  ER	  Ca2+	  can	  both	   trigger	   ER	   dysfunction	   and	   also	   hinder	   the	   ER	   chaperone	   response,	  depending	  on	  the	  magnitude	  of	  the	  insult.	  Conversely,	  the	  initiation	  of	  ER	  stress	  also	   contributes	   to	   further	   ER	   Ca2+	  disturbance	   through	   induction	   of	   truncated	  SERCA1	   isoforms,	   which	   contribute	   to	   further	   ER	   Ca2+	   leak	   (Hammadi	   et	   al.	  2013).	  The	  resulting	  ER	  dysfunction,	  or	  ‘ER	  Stress’	  includes	  the	  unfolded-­‐protein	  response	   (UPR),	   ER	   overload	   response	   (EOR)	   and	   ER-­‐associated	   degradation	  (ERAD),	  the	  particular	  combination	  of	  which	  appears	  to	  depend	  on	  the	  nature	  of	  the	  underlying	  stimulus.	  	  	  
4.1.2.3	  The	  Unfolded	  Protein	  Response	  (UPR)	  The	   UPR	   (Figure	   4.3)	   is	   mediated	   by	   three	   ER	   membrane	   receptor	   proteins:	  pancreatic	   ER	   kinase	   (PERK),	   activating	   transcription	   factor	   6	   (ATF6)	   and	  inositol-­‐requiring	  enzyme	  1	  (IRE1).	  These	  are	  maintained	  in	  a	  quiescent	  state	  by	  the	   glucose-­‐regulated	   protein	   78,	   otherwise	   referred	   to	   as	   binding	  immunoglobulin	   protein	   (BiP),	   to	   which	   they	   are	   bound.	   The	   accumulation	   of	  unfolded	  protein	  in	  the	  ER	  leads	  to	  dissociation	  of	  BiP	  from	  these	  three	  receptors,	  and	  thereby	  the	  UPR	  activates,	  leading	  to	  processes	  that	  reduce	  the	  protein	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Figure	  4.3	  The	  three	  main	  pathways	  of	  the	  Unfolded	  Protein	  Response	  	  The	   UPR	   is	   initiated	   by	   the	   dissociation	   of	   BiP	   from	   three	   ER	  membrane	   proteins,	   which	   are	  maintained	   in	   a	   quiescent	   state	  when	   bound.	   BiP	  subsequently	  interacts,	  as	  a	  chaperone,	  with	  unfolded	  proteins	  in	  the	  ER	  lumen.	  Continued	  onto	  next	  page.	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Red	  pathway	  –	  dissociation	  of	  BiP	  from	  PERK	  leads	  to	  phosphorylation	  of	  eIF2	  and	   generalised	   inhibition	   of	   protein	   translation.	   ATF4	   is	   exempt	   from	   eIF2	  translational	   block,	   and	   indeed	   is	   translated	   more	   efficiently	   under	   such	  conditions,	   and	   translocates	   to	   the	   nucleus	   where	   it	   triggers	   expression	   on	  predominantly	  pro-­‐survival	  genes	  but	  is	  also	  a	  strong	  inducer	  of	  pro-­‐apoptotic	  CHOP	  pathways.	  	  
Purple	  pathway	  –	  after	  dissociation	  of	  BiP,	  ATF6	  is	  cleaved	  and	  then	  translocates	  to	  the	  nucleus	  where	  it	  induces	  expression	  of	  chaperone	  proteins.	  It	  also	  further	  upregulates	   BiP	   expression	   and,	   like	   ATF4,	   also	   CHOP.	   However,	   unlike	   that	  related	  to	  ATF4,	  this	  does	  not	  appear	  to	  trigger	  apoptotic	  signals.	  	  
Green	  pathway	  –	  inositol-­‐requiring	  enzyme	  (IRE1)	  also	  dissociates	  from	  BiP	  and	  splices	   X	   box	   binding	   protein	   (XBP1),	   leading	   to	   its	   nuclear	   translocation	   and	  upregulation	  of	  ER	  chaperones.	   It	  also	   triggers	  delayed	  expression	  of	  P58-­‐IPK,	  an	  HSP40	  protein,	  which	  has	  been	  postulated	  as	   representing	   the	  UPR-­‐ending	  signal,	   the	  absence	  of	  which	  leads	  to	  a	  shift	  towards	  pro-­‐apoptotic	  rather	  than	  cytoprotective	  signaling.	  Adapted	  from	  (Szegezdi	  et	  al.	  2006)	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accumulation	  responsible.	  Prolonged	  activation,	  however,	   triggers	  an	  apoptotic	  signal.	  Notably,	  the	  PERK	  and	  ATF6	  pathways	  both	  culminate	  in	  upregulation	  of	  CHOP	  (also	  known	  as	  GADD53).	  This	  is	  typically	  considered	  pro-­‐apoptotic	  and,	  indeed,	  CHOP	  knockout	  animals	  are	  resistant	  to	  ER	  stress	  induced	  cell	  death	  (Marciniak	  et	   al.	   2004).	   However,	   it	   appears	   that	   CHOP’s	   target	   genes	   are	   not	   actually	  directly	  apoptotic	  but,	   rather,	   relate	   to	  protein	  secretion.	   It	  may	  be	   that	  CHOP	  serves	  as	  an	  amplifier	  of	  the	  UPR	  such	  that,	  at	  milder	  levels	  of	  ER	  stress,	  it	  does	  not	   trigger	   cell	  death.	  Nevertheless,	  under	  prolonged	  or	   sufficient	   stimulation,	  CHOP	  is	  the	  primary	  connection	  between	  the	  UPR	  and	  apoptosis.	  	  	  
4.1.2.4	  Other	  ER	  Stress	  pathways	  ERAD	  refers	  to	  the	  elimination	  of	  misfolded	  or	  unassembled	  proteins	  from	  the	  ER,	  culminating	  in	  their	  degradation	  by	  the	  ubiquitin-­‐proteasome	  system	  (UPS).	  This	  is	  a	  critical	  pathway,	  particularly	  in	  post-­‐mitotic	  tissue,	  and	  loss	  of	  function	  mutations	   are	   associated	   with	   disease,	   such	   as	   in	   Parkin	   related	   familial	  Parkinson’s	  disease	   (Meusser	  et	   al.	   2005).	   Interestingly,	   the	  AAA-­‐ATPase	  VCP,	  mutations	   of	   which	   cause	   IBMPFD,	   appears	   to	   have	   an	   important	   role	   in	  dislocation,	   the	   element	   of	   ERAD	   in	  which	   the	   substrate	   is	   transported	   to	   the	  cytoplasm	  to	  undergo	  degradation.	  The	   EOR	   is	   less	   well	   characterised	   than	   the	   other	   ER	   stress	   responses	   but	  represents	  one	  of	  the	  distinguishing	  features	  of	  the	  mammalian	  response	  versus	  that	  observed	  in	  more	  primitive	  organisms	  such	  as	  yeast.	  Of	  note,	  it	  appears	  to	  induce	   pro-­‐inflammatory	   signaling,	   predominantly	   via	   activation	   of	   the	   NFκB	  cascade,	  and	  is	  frequently	  coactivated	  with	  the	  UPR,	  of	  which	  ATF6	  appears	  to	  further	  stimulate	  NFκB	  (Kaufman	  1999;	  Yamazaki	  et	  al.	  2009).	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4.1.2.5	  ER	  Stress	  in	  neurological	  disease	  and	  IBM	  ER	   dysfunction	   is	   widely	   implicated	   in	   neurodegenerative	   diseases,	   notably	  Huntington’s	  disease,	  ALS,	  Alzheimer’s	  disease,	  prion	  diseases	  and	  Parkinson’s	  disease.	  It	  is	  also	  considered	  important	  in	  the	  pathogenesis	  of	  several	  otherwise	  disparate,	   typically	   inherited,	   conditions	   including	   CMT1A/1B,	   tuberous	  sclerosis,	   Gaucher’s	   disease,	   Wolfram	   syndrome	   and	   Torsion	   dystonia	   1	  (Roussel	   et	   al.	   2013).	   Furthermore,	   there	   is	   evidence	   for	   ER	   stress	   playing	   a	  significant	  role	   in	  the	  common	  disease	  groups	  of	  autoimmunity,	  cancer,	  stroke	  and	   diabetes	   (Kim	   et	   al.	   2008).	   In	   the	   context	   of	   most	   diseases,	   it	   is	   still	  generally	  assumed	  that	  the	  initial	  participation	  of	  the	  ER,	  particularly	  the	  UPR,	  is	   appropriate	   and	   cytoprotective	   before	   the	   sustained	   activation	   ultimately	  contributes	  to	  apoptosis,	  having	  been	  unable	  to	  address	  the	  insult	  of	  misfolded	  protein.	  Interestingly,	   Familial	   encephalopathy	   with	   neuroserpin	   inclusion	   bodies	  (FENIB),	  which	  is	  characterised	  by	  intraneuronal	  inclusions,	  appears	  to	  result	  in	  selective	   induction	   of	   the	   EOR,	   with	   consequent	   NFκB	   activation,	   without	  coactivation	  of	  the	  UPR,	  before	  degradation	  of	  protein	  occurs	  via	  the	  ERAD	  and	  autophagic	   pathways	   (Roussel,	   Kruppa	   et	   al.	   2013).	   This	   phenomenon	   is	  postulated	   to	   arise	   from	   the	   accumulation	   of	   well	   folded	   protein	   in	   the	   ER,	  which	   draws	   parallels	   with	   the	   hypothesis	   in	   which	   upregulation	   of	   MHCI	   in	  IBM	   might	   lead	   to	   such	   a	   form	   of	   ER	   stress,	   perpetuating	   a	   self-­‐propagating	  cycle	  of	  pro-­‐inflammatory	  stimuli	  and	  ER	  overload	  that	  eventually	  overwhelms	  degradative	  mechanisms,	   leading	   to	  activation	  of	   the	  UPR	  and,	  eventually,	   cell	  death.	  Immunoelectron	   microscopy	   studies	   of	   IBM	   muscle	   have	   demonstrated	  increased	   expression	   of	   UPR	   markers,	   including	   chaperones	   BiP	   and	   GRP94,	  disulfide	  isomerase	  ERp72,	  and	  the	  lectins/calcium-­‐buffering	  proteins	  calnexin	  and	  calreticulin.	  Additional	  apparent	  colocalisation	  with	  degenerative	  proteins	  that	   subsequently	   form	   cytoplasmic	   aggregates,	   including	   βamyloid,	   implies	  insufficiency	   of	   this	   response	   (Vattemi	   et	   al.	   2004).	   In	   cultured	  myotubes,	   ER	  stress	   appears	   to	   induce	   the	   expression	   negative	   muscle	   growth	   regulator	  myostatin,	   which	   might	   also	   be	   a	   consequence	   of	   the	   NFκB	   activation	   that	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follows	  (Nogalska	  et	  al.	  2007).	  The	  primary	  trigger	  of	  ER	  stress	  in	  IBM	  remains	  unclear.	   This	   leaves	   open	   the	   possibility	   that	   ER	   stress	   is,	   itself,	   a	   triggering	  pathogenic	  event.	   Indeed,	  the	   ‘ER	  handicap’	  that	   is	  evidenced	  by	  aged	  tissue	  is	  an	  interesting	  concept.	  As	  approximately	  30%	  of	  cell	  synthesized	  proteins	  fail	  to	  acquire	  their	   fully	   folded	  conformation,	  post-­‐mitotic	   tissues	  are	  heavily	  reliant	  upon	   the	   ER	   protein	   processing	   functions	   of	   their	   constituent	   cells	   (Romisch	  2004).	   Aged	   tissue	   demonstrates	   reduced	   UPR	   responsiveness	   and	   a	   shift	  towards	   pro-­‐apoptotic	   signaling,	   with	   impaired	   enzymatic	   activity	   of	   key	   ER	  chaperones	   BiP,	   calnexin	   and	   GRP94,	   possibly	   due	   to	   progressive	   oxidation	  (Nuss	  et	  al.	  2008).	  Furthermore,	  expression	  of	  BiP	  and	  PERK	  falls	  with	  age	  (Paz	  Gavilan	   et	   al.	   2006;	  Naidoo	   et	   al.	   2008).	   ATF4-­‐mediated	   translational	   block	   is	  suppressed	  by	  increased	  expression	  of	  GADD34	  in	  aged	  mice,	  which	  reduces	  the	  efficiency	  of	  the	  UPR.	  This	  allows	  continuation	  of	  the	  protein	  stimulus	  which	  is	  likely	   to	   have	   triggered	   ER	   stress,	   and	   promotes	   CHOP-­‐mediated	   apoptosis	  (Hussain	  et	  al.	  2007).	  	  
4.1.3	  Nuclear	  Factor	  κB	  (NFκB)	  NFκB	   refers	   to	   a	   heterogeneous	   collection	   of	   five	   inducible	   dimeric	  transcription	   factors	   that	  comprises	  p65	  (or	   ‘RelA’),	  Rel	  B,	   c-­‐Rel,	  NFκB1	  (p50)	  and	  NFκB2	  (p52).	  Its	  activation	  cascade	  is	  ubiquitous	  and	  highly	  evolutionarily	  conserved	  with	   functions	   including	  pro-­‐inflammatory	   signalling	   and	   apoptotic	  modulation,	  particularly	  under	  conditions	  of	   immune	  and	   inflammatory	  stress	  (Fig	  4.4).	  The	  proinflammatory	  transcription	  functions	  of	  NFκB	  are	  of	  particular	  interest	  in	  IBM.	  Its	  products	  include	  the	  inflammatory	  cytokines	  IL1β	  and	  TNFα,	  inflammatory	  enzymes	  COX-­‐2	  and	   inducible	  nitric	  oxide	  synthase,	  chemotactic	  chemokines,	  adhesion	  molecules,	  and	  the	  T-­‐cell	  receptor	  (Barnes	  et	  al.	  1997).	  It	  is	  notable	  that	  IL1β	  and	  TNFα	  are	  both	  stimuli	  and	  products	  of	  the	  cascade	  and	  represent	   a	   positive	   feedback	   loop	   that	   is	   postulated	   to	   perpetuate	   local	  inflammatory	   responses.	   This	   represents	   one	  mechanism	   through	  which	   viral	  infection,	   which	   often	   exploits	   NFκB	   in	   its	   own	   replication,	   may	   trigger	   a	  prolonged	  inflammatory	  process	  of	  autoimmunity.	  Indeed,	  a	  viral	  trigger	  is	  one	  of	  several	  proposed	  stimuli	  in	  the	  pathogenesis	  of	  IBM	  (Dalakas	  2006).	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Figure	  4.4	  Illustration	  of	  canonical	  NFκB	  activation	  In	   its	   inactive	   form,	   NFκB	   (represented	   as	   its	   dominant	   p50/p65	   subunit)	   is	  mainly	  cytoplasmic,	  where	  it	  is	  maintained	  under	  inhibition	  of	  IκB	  proteins	  that	  mask	  its	  nuclear	  localisation	  signal.	  Successful	  stimuli,	  notably	  IL1β	  and	  TNFα,	  activate	  IκB	  kinase	  (IKK),	  which	  phosphorylates	  the	  complex.	  In	  turn,	  this	  leads	  to	  recognition	  by	  E3RS	  which	  ubiquinates	  IκB,	  leading	  to	  its	  rapid	  degradation	  by	   the	   26S	   proteasome.	   This	   exposes	   the	   p50/p65	  nuclear	   localisation	   signal,	  resulting	  in	  translocation	  to	  the	  nucleus	  where	  it	  adjusts	  transcription	  of	  target	  genes.	  	  	  Such	   is	   the	   influence	   that	   NFκB	   over	   the	   inflammatory	   and	   immune	   systems	  that	  it	  is	  implicated	  in	  most,	  if	  not	  all,	  chronic	  inflammatory	  conditions.	  Further,	  the	   effectiveness	   of	   glucocorticoids	   in	   such	   conditions	   is	   likely	   to	   reflect	   their	  inhibitory	  effect	  on	  NFκB.	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NFκB	   plays	   a	   significant	   role	   in	   myositis,	   not	   only	   that	   which	   represents	  primary	  autoimmunity,	  and	  this	  is	  an	  important	  consideration	  in	  the	  hypothesis	  that	   the	   inflammation	   observed	   in	   IBM	   may	   too	   be	   secondary.	   For	   example,	  dystrophinopathies,	   notably	   Duchenne	   muscular	   dystrophy	   (DMD),	   are	  classically	  associated	  with	  a	  considerable	  inflammatory	  response,	   in	  which	  the	  chronic	   NFκB	   activation	   displayed	   by	   the	   majority	   of	   myofibres	   has	   been	  strongly	   implicated	   (Messina	   et	   al.	   2011).	   Indeed,	   mdx	   transgenic	   mice	  haploinsufficient	  for	  the	  NFκB	  p65	  subunit	  demonstrate	  reduced	  inflammatory	  infiltrate	  and	  muscle	  necrosis	  (Messina	  et	  al.	  2006).	  NFκB	  activation	  does	  appear	  to	  occur	  in	  IBM	  muscle	  and	  is	  proposed	  to	  result	  from	  ER	  stress	  in	  addition	  to	  inflammatory	  stimuli	  (Nogalska	  et	  al.	  2007).	  This	  is	  similarly	  observed	  in	  transgenic	  mice	  overexpressing	  MHCI,	  via	  the	  ER	  overload	  response	  (Nagaraju	  et	  al.	  2005).	  NFκB	  also	  appears	  to	  be	  a	  unifying	  pathological	  mechanism	   through	   which	   VCP	   mutations	   cause	   the	   constellation	   of	   IBM,	  Frontotemporal	   Dementia	   and	   Paget’s	   disease	   of	   bone	   (Custer	   et	   al.	   2010).	   It	  may,	   therefore,	   represent	   an	   important	   point	   of	   interaction	   between	  degenerative	  and	  inflammatory	  processes	  in	  IBM.	  Finally,	  skeletal	  muscle	  atrophy,	  a	  defining	  component	  of	  IBM,	  may	  be	  driven	  by	  NFκB,	  via	  inhibition	  of	  Myo-­‐D	  and	  upregulation	  of	  Myostatin	  Precursor	  Protein	  (Wojcik	  et	  al.	  2008).	  Similarly,	  in	  cultured	  myotubes,	  the	  protein	  loss	  associated	  with	   exposure	   to	   TNFα	   appears	   to	   be	   mediated	   by	   NFκB.	   Muscle-­‐specific	  activation	  of	  NFκB	  causes	  profound	  muscle	  wasting	  in	  mice	  and	  inhibition	  of	  the	  cascade	  appears	  to	  reverse	  the	  atrophic	  phenotype.	  Conversely,	  muscle-­‐specific	  inhibition	  of	  NFκB	  is	  not	  associated	  with	  an	  altered	  phenotype	  (Jackman	  et	  al.	  2004).	  	  	  
4.1.4	  A	  novel	  therapeutic	  hypothesis	  in	  IBM	  The	   failure	   of	   all	   clinically	   tested	   drugs	   in	   IBM,	   all	   of	   which	   are	   primarily	  immune	   modulating	   treatments,	   supports	   consideration	   of	   alternative	  therapeutic	   avenues	   in	   this	   disabling	   condition.	   The	   combination	   of	  degenerative	   features,	   such	   as	   protein	   misfolding	   and	   ER	   stress,	   with	  inflammatory	   elements	   raised	   the	   hypothesis	   that	   cellular	   chaperone	   systems	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represented	  an	  attractive	   target.	   In	  particular,	  augmentation	  of	   the	  heat	  shock	  response	   (HSR)	   has	   translated	   to	   pathological	   and	   functional	   improvement	   in	  preclinical	  models	  of	  other	  conditions	  characterised	  by	  similar	  pathology,	  such	  as	  ALS	  (Kieran	  et	  al.	  2004).	  
	  
4.1.4.1	  The	  potential	  role	  of	  Heat	  Shock	  Proteins	  (HSPs)	  in	  IBM	  pathogenesis	  HSPs	  are	  a	   family	  of	  highly	  conserved,	  ubiquitously	  expressed	  stress	  response	  proteins	   that	   function	   as	   molecular	   chaperones,	   facilitating	   protein	   folding,	  preventing	   protein	   aggregation,	   or	   targeting	   improperly	   folded	   proteins	   to	  specific	  degradative	  pathways.	  The	  heat	  shock	  response	  (HSR)	  derives	  its	  name	  from	   the	   original	   description	   of	   this	   cytoprotective	   reaction	   to	   elevated	  temperature,	   although	   the	   spectrum	   of	   stimuli	   in	   vivo	   is	   far	   wider,	  encompassing	   ischaemia,	   infection,	   inflammation	   and	   degenerative	   disease	  (Fulda	  et	  al.	  2010).	  Common	  to	  the	  majority	  of	  these	  processes	  is	  the	  formation	  of	   misfolded	   proteins,	   which	   can	   culminate	   in	   the	   formation	   of	   nuclear	   and	  cytoplasmic	   aggregates	   or	   ubiquinated	   inclusions	   that	   are	   the	   hallmark	   of	  neurodegenerative	   conditions	   and,	   indeed,	   a	   distinguishing	   characteristic	   of	  IBM.	  HSPs	  are	  grouped	  according	  to	  their	  molecular	  weight	  and	  arbitrarily	  referred	  to	   as	   ‘small	   HSPs’	   when	   below	   30kDa.	   Common	   larger	   HSPs	   include	  HSP40/60/70	  and	  90	  (Lindquist	  et	  al.	  1988).	  	  After	  induction	  and	  considerable	  upregulation	   in	   response	   to	  cellular	   stress,	   they	  act	  on	  a	  number	  of	  processes	  that	  are	  chiefly	  anti-­‐apoptotic,	  notably	   those	   that	   result	   from	  diminishment	  of	  cytoplasmic	   protein	   aggregation.	   Indeed,	  HSPs	   are	   known	   to	   reduce	   cytotoxic	  intracellular	   accumulation	   of	   protein,	   as	   observed	   in	   IBM	   (Muchowski	   et	   al.	  2005).	   Further,	   they	   prevent	   inappropriate	   interactions	   within	   and	   between	  non-­‐native	  polypeptides,	  can	  enhance	  the	  efficiency	  of	  de	  novo	  protein	   folding,	  and	  promote	  refolding	  and	  repair	  of	  misfolded	  proteins	  (Sherman	  et	  al.	  2001).	  In	   addition	   to	   their	   protein	   repair	   activity,	   HSPs	   can	   mediate	   targeting	   of	  misfolded	   proteins	   to	   the	   proteasome,	   dysfunctional	   in	   IBM,	   or	   to	   lysosomes,	  resulting	   in	   selective	   degradation	   of	   the	   misfolded	   protein	   through	   ERAD	   or	  autophagy	   respectively.	   Of	   particular	   interest	   here,	   HSP70	   and	   90	   have	   been	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shown	   to	   inhibit	  early	   stages	  of	  Aβ42	  aggregation	   in	  vitro	   (Evans	  et	  al.	  2006).	  HSP70	   also	   promotes	   degradation	   and	   inhibits	   intracellular	   aggregation	   of	  amyloidogenic	   light	   chains	   (Dul	   et	   al.	   2001).	   One	   study	   determined	   that	  selective	   reduction	   of	   Aβ42	   delays	   progression	   of	   tau	   pathology,	   suggesting	   a	  close	  connection	  between	  βamyloid	  and	  tau	  pathology.	  βamyloid	  accumulation	  is	   known	   to	   decrease	   levels	   of	   the	  HSP70	   co-­‐chaperone	   CHIP,	   so	   it	   is	   notable	  that	   the	   Aβ42-­‐induced	   effects	   on	   tau	   can	   be	   rescued	   by	   restoration	   of	   CHIP	  levels	  (Oddo	  et	  al.	  2008).	  Further	   actions	   of	   HSPs	   are	   directly	   related	   to	   the	   inflammatory	   and	  degenerative	   mechanisms	   of	   IBM.	   Activation	   of	   the	   proinflammatory	  transcription	  factor	  NFκB	  is	  dependent	  upon	  activation	  of	  IkB	  kinase,	  which	  is	  inhibited	  by	  HSP70,	  possibly	  via	  interaction	  with	  IKK.	  This	  translates	  to	  reduced	  induction	  of	  iNOS,	  a	  chief	  contributor	  to	  oxidative	  stress	  (Feinstein	  et	  al.	  1996;	  Feinstein	  et	  al.	  1997;	  Ran	  et	  al.	  2004).	  Indeed,	  HSP-­‐induced	  down-­‐regulation	  of	  inflammatory	   gene	   transcription	   has	   been	   demonstrated	   through	   reduced	  metalloproteinase-­‐9	  mRNA	  (Lee	  et	  al.	  2004).	  Conversely,	  HSP	  induction	  or	  over-­‐expression	   reduces	   levels	   of	   inflammatory	   mediators	   (Hayashi	   et	   al.	   2002;	  Weiss	  et	  al.	  2002).	  In	  models	  of	  endotoxin-­‐induced	  cellular	  inflammation,	  this	  is	  reflected	  in	  reduced	  levels	  of	  cytokines	  TNFα,	  IL1β,	  IL-­‐10	  and	  IL-­‐12	  (Ding	  et	  al.	  2001).	   Finally,	   IKB	   induced	   NFκB	   activation	   can	   be	   inhibited	   by	   HSP27	   with	  consequent	  reduction	  of	  skeletal	  muscle	  atrophy	  (Dodd	  et	  al.	  2009).	  	  
4.1.4.2	  Pharmacological	  induction	  of	  Heat	  Shock	  Proteins	  A	  wide	  variety	  of	  cellular	  stresses	  can	  activate	  the	  HSR	  resulting	  in	  upregulation	  in	   HSP	   expression.	   However,	   under	   certain	   pathological	   conditions,	   such	   as	  prolonged	  exposure	  during	  chronic	  disease,	  genetic	  predisposition	  or	  otherwise,	  the	   HSR	   is	   insufficient	   to	   prevent	   accumulation	   of	   misfolded	   proteins,	   as	  observed	  in	  IBM.	  Notably,	  the	  endogenous	  inducibility	  of	  the	  HSR	  is	  thought	  to	  decline	  in	  normal	  ageing	  (Sherman	  et	  al.	  2001).	  Therefore,	  augmentation	  of	  the	  HSR	   appears	   an	   attractive	   approach	   for	   the	   treatment	   of	  many	   diseases.	   This	  has	   been	   investigated	   particularly	   extensively	   in	   the	   context	   of	   ALS,	   whose	  pathological	  and	  clinical	  similarities	  with	  IBM	  are	  considerable.	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Genetic	   upregulation	   of	   HSPs	   has	   been	   studied	   using	   a	   number	   of	   transgenic	  mice,	   in	   which	   HSP70	   concentrations	   approaching	   ten	   times	   that	   of	   normal	  controls	  have	  been	  demonstrated,	  and	  through	  direct	   injection	  of	  recombinant	  HSP70	  in	  the	  SOD1G93A	  mouse	  model	  of	  ALS.	  These	  approaches	  have	  had	  limited	  success,	  having	  failed	  to	  improve	  lifespan	  or	  motor	  neuron	  survival	  respectively	  (Liu	   et	   al.	   2005;	   Gifondorwa	   et	   al.	   2007).	   Furthermore,	   primary	   genetic	  manipulation	   is	   not	   currently	   clinically	   practical.	   Pharmacological	   HSR	  manipulation	   is	   more	   pragmatic	   and,	   indeed,	   has	   been	   more	   successful	   in	  preclinical	  models.	   Relevant	   compounds	   that	   upregulate	   the	  HSR,	   include	   17-­‐AAG	   (17-­‐N-­‐Allylamino-­‐17-­‐demethoxygeldanamycin),	   Celastrol	   and	  Arimoclomol	  (Kalmar	  et	  al.	  2014).	  Limited	  data	  exist	  on	  17-­‐AAG,	  which	  acts	  via	  activation	  of	  HSF1	  and	  ameliorates	  aggregation	  of	  polyglutamine	  proteins	  and	  α-­‐synuclein	   in	   vitro	   and	   in	   a	   mouse	   model	   of	   spinobulbar	   muscular	   atrophy	  through	   induction	   of	   autophagy	   (Waza	   et	   al.	   2006;	   Riedel	   et	   al.	   2010).	   It	   also	  appears	  to	  protect	  against	  TDP-­‐43	  mediated	  neurotoxicity	  (Gregory	  et	  al.	  2012).	  Celastrol,	   at	   high	   concentration,	   induces	  HSP70	   and	   has	   been	   associated	  with	  cytoprotective	   actions	   and	   functional	   improvement	   in	   animal	   models	   of	   ALS,	  Parkinson’s	  disease	  and	  Huntington’s	  disease,	  along	  with	  the	  demonstration	  of	  anti-­‐inflammatory	   effects	   through	   NFκB	   inhibition.	   However,	   its	   application	  appears	   to	   be	   limited	   by	   cytotoxicity	   at	   low	   concentration	   in	   in	   vitro	   toxicity	  studies,	  proteasomal	   inhibiting	  actions	  and	   its	   indiscriminate	  activation	  of	   the	  HSR,	   which	   is	   likely	   to	   be	   an	   undesirable	   effect	   in	   the	   treatment	   of	   human	  disease	  (Kalmar	  et	  al.	  2014).	  The	  most	  extensive	  pre-­‐clinical	  efficacy	  data	  and	  early	  clinical	  safety	  data	  exist	  for	   the	   hydroxylamine	   derivatives	   Bimoclomol	   and	   its	   analogue	   Arimoclomol	  (/+/−(2R),(Z)-­‐N-­‐[2-­‐hydroxy-­‐3-­‐(piperidin-­‐1-­‐yl)propoxy]-­‐pyridine-­‐1-­‐oxide-­‐3-­‐carbox-­‐imidoyl	  chloride	  citrate	  (1:1))	  (Figure	  4.5).	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Figure	  4.5	  The	  chemical	  structure	  of	  Arimoclomol	  	  These	  compounds	  stabilise	  the	  activated	  phosphorylated	  trimer	  of	  HSF1,	  which	  prolongs	   its	   binding	   to	   DNA	   binding	   regions,	   termed	   Heat	   Shock	   Elements,	  leading	  to	  increased	  translation	  of	  several	  HSPs	  under	  the	  conditions	  of	  cellular	  stress.	  The	  upregulated	  products	  include	  HSPs	  60/70/90	  and	  GRP94,	  but	  HSP70	  and	  HSP90	  are	  preferentially	  expressed.	  The	  critical	  element	  of	  this	  mechanism	  is	  the	  dependency	  on	  the	  pre-­‐activated	  form	  of	  HSF1	  since	  this	  targets	  the	  HSR	  augmentation	  function	  of	  Arimoclomol	  to	  those	  cells	  and	  tissues	  already	  subject	  to	  HSR	  stimulation	  (i.e.	  those	  under	  stress).	  This	  hypothesis	  has	  been	  confirmed	  by	   in	   vitro	   work	   that	   found	   Arimoclomol	   does	   not	   induce	   HSP	   expression	   in	  motor	  neurons	   in	  culture	  without	  contemporaneous	  pro-­‐apoptotic	  stimulation	  and	  in	  vivo	  studies	  which	  demonstrate	  a	  similar	  lack	  of	  effect	  of	  Arimoclomol	  in	  control	   animal	   tissue	   (Kalmar	   et	   al.	   2009).	   No	   comprehensive	   studies	   of	   HSP	  expression	   in	   IBM	   have	   been	   undertaken	   but	   HSP70	   is	   upregulated	   in	   IBM	  compared	   to	   normal	   controls	   (Parker	   et	   al.	   2009),	   indicating	   a	   suitable	  environment	  for	  Arimoclomol’s	  action.	  Several	   in	   vitro	   and	   in	   vivo	   studies	   have	   supported	   HSR	   manipulation	   with	  Arimoclomol	  in	  neurodegenerative	  disease.	  These	  include	  prolonged	  survival	  in	  SOD1G93A	   mice	   treated	   with	   Arimoclomol,	   with	   concurrent	   delay	   of	   disease	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onset,	   neuronal	   viability,	   hind	   limb	   muscular	   strength	   and	   reduction	   of	  proteinaceous	   aggregates.	   Importantly,	   these	   effects	   manifested	   when	  treatment	   was	   delayed	   after	   phenotypic	   manifestation	   (Kieran	   et	   al.	   2004).	  Similarly,	   Arimoclomol	   was	   effective	   in	   a	   mouse	   model	   of	   the	   trinucleotide	  expansion	   disorder	   spinobulbar	   muscular	   atrophy	   (Kennedy’s	   disease),	   with	  augmented	   HSP	   expression	   associated	   with	   delayed	   clinical	   onset,	   improved	  muscle	  function	  and	  improved	  neuronal	  survival	  (Malik	  et	  al.	  2013).	  Looking	   further	   forward,	   Arimoclomol	   had	   the	   additional	   advantage	   of	   being	  supported	   by	   early-­‐phase	   clinical	   safety	   and	   toxicity	   studies,	   facilitating	   the	  translation	   of	   laboratory	   work	   to	   examination	   in	   patients.	   This	   is	   discussed	  further	  in	  Chapter	  5.	  	  
4.1.5	  Summary	  and	  Specific	  Aims	  Several	  aspects	  of	  IBM	  pathogenesis	  warranted	  further	  characterisation	  in	  this	  cellular	   model,	   such	   that	   quantifiable	   disease-­‐relevant	   pathological	   outcome	  measures	  can	  be	  developed.	  The	  lack	  of	  such	  a	  system	  has	  contributed	  towards	  restriction	  of	  attempted	  drug	  treatments	  to	  the	  inflammatory	  component	  of	  IBM,	  which	   have	   been	   ineffective.	   A	   key	   element	   in	   the	   development	   of	   these	  measures	   is	   their	   feasibility	   of	   determining	   a	   pharmacological	   effect.	   There	   is	  considerable	  evidence	  to	  suggest	  that	  manipulation	  of	  the	  HSR,	  as	  it	  has	  done	  in	  models	  of	  comparable	  conditions,	  may	  counteract	  some	  pathogenic	  elements	  of	  both	   inflammation	  and	  degeneration	   that	  are	  active	   in	   IBM.	  Arimoclomol,	  as	  a	  co-­‐inducer	   of	   large	   HSPs,	   particularly	   HSP70,	   represents	   an	   attractive	   new	  therapeutic	  avenue.	  In	  order	   to	  determine	  whether	   this	   approach	  would	  be	   feasible,	   the	   following	  specific	  aims	  were	  addressed	  in	  the	  experiments	  described	  in	  this	  Chapter:	  	   1. Characterisation	   of	   the	   HSR	   in	   an	   in	   vitro	   model	   of	   IBM;	   since	  Arimoclomol	   functions	  as	   a	   co-­‐inducer	  of	   the	  HSR,	   it	  would	  only	  be	  maximally	  effective	  if	  the	  HSR	  were	  already	  be	  active	  in	  cultured	  cells.	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2. Determination	   of	   Baseline	   Cytotoxicity;	   although	   considerable	   data	  support	   Arimoclomol’s	   toxicity	   profile	   in	   vitro,	   no	   previous	   studies	  examined	   its	   effects	   on	   primary	   muscle	   satellite	   cell	   cultures.	  Furthermore,	   this	   step	   would	   represent	   an	   early	   component	   of	   an	  IBM	   screening	   system,	   since	   the	   significance	   of	   subtler	   effects	   on	  individual	   pathological	   elements	   would	   be	   reduced	   without	  demonstration	  of	  improved	  overall	  cellular	  viability.	  3. Characterisation	  and	  quantification	  of	  TDP-­‐43	  pathology,	  ER	  function	  and	   NFκB	   activity,	   to	   further	   understand	   the	   nature	   of	   these	  processes	   in	   IBM,	   to	   determine	   their	   feasibility	   as	   drug	   screening	  tools,	  and	  to	  examine	  the	  effect	  of	  Arimoclomol	  thereon.	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4.2	  Results	  
4.2.1	  The	  Heat	   Shock	  Response	   in	  myogenic	   cultures	  under	   IBM-­‐relevant	   stimuli	  
and	  treatment	  with	  Arimoclomol	  Immunocytochemistry	  and	  western	  blotting	  demonstrated	  that	  control	  cultures	  express	   a	   constitutive	   level	   of	   HSP70	   expression.	   This	   was	   not	   significantly	  altered	   by	   empty	   vector	   transfection.	   Exposure	   to	   IL1β	   (10ng/ml)	   was	  associated	   with	   significantly	   elevated	   HSP70	   concentration,	   to	   2.3	   fold	   of	  control	   (n=3,	   p<0.05).	   However,	   although	   a	   1.8	   fold	   increase	   in	   HSP70	   was	  observed	   following	   TNFα	   (10ng/ml)	   exposure,	   this	   was	   not	   significant.	   βAPP	  overexpression	  was	   the	  most	   potent	   stimulus	   of	  HSP70	   expression,	  where	   an	  increase	  of	  3.7	  fold	  was	  observed	  (n=3,	  p<0.05).	  Arimoclomol	  treatment	  (10μM,	  24	  hours	  after	  onset	  of	   IBM-­‐relevant	  stimulus)	  significantly	  augmented	   the	  expression	  of	  HSP70.	  The	  magnitude	  of	   this	  effect	  was	  similar	  across	  all	  conditions	  tested;	  by	  2.4	  fold	  after	  βAPP	  transfection,	  2.1	  fold	   after	   IL1β	   exposure	   and	   2.5	   fold	   after	   TNFα	   exposure	   (p<0.05,	   n=3	   per	  condition)	  (Figures	  4.6	  and	  4.7).	  	   	  




Figure	   4.6	   Augmentation	   of	   HSP70	   expression	   in	   myogenic	   cells	   with	  
Arimoclomol,	   following	   transfection	   with	   βAPP	   or	   exposure	   to	  
inflammatory	  cytokines	  	  
A-­‐E:	  HSP70	   immunocytochemistry	  (red)	  was	  positive	   in	  cultures	  grown	  under	  control	  conditions	  (A),	  and	  more	  pronounced	  following	  exposure	  to	  IL1β	  (B)	  or	  transfection	   with	   βAPP	   (C),	   and	   when	   these	   conditions	   were	   succeeded	   by	  Arimoclomol	   treatment	   (following	   βAPP	   transfection	   in	   D	   and	   IL1β	   in	   E).	  Nuclear	  co-­‐staining	  with	  DAPI	  (blue).	  	  
F-­‐H:	   HSP70	   representative	   western	   blots.	   C=control,	   EV=empty	   vector	  transfection,	  APP=βAPP	  transfection,	  +A	  or	  Ari+	  indicates	  Arimoclomol	  treated	  cultures.	  (Scale	  Bars=10μm)	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Figure	   4.7	   Quantification	   of	   HSP70	   upregulation	   in	   myogenic	   cells	  
following	   transfection	   of	   βAPP	   or	   exposure	   to	   inflammatory	   mediators	  
and	  treatment	  with	  Arimoclomol	  A:	   HSP70	   expression	   relative	   to	   control	   protein	   (GAPDH)	  was	   determined	   by	  optical	  densitometry	  of	  western	  blots.	  This	  indicated	  significant	  upregulation	  of	  HSP70	  levels	  after	  exposure	  to	  IL1β	  and,	  compared	  to	  empty	  vector	  transfection,	  βAPP	  overexpression.	  B:	   Arimoclomol	   treatment	   (indicated	   by	   suffix	   +A)	   was	   associated	   with	  significant	   additional	   increase	   in	   HSP70	   levels,	   following	   each	   pathological	  stimulus.	  (Error	   Bars=SEM,	   n=3,	   Asterisk=p<0.05	   vs.	   untreated	   control,	   Star=p<0.05	   vs.	  empty	  vector	  transfection)	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4.2.2	  MTT	  cell	  viability	  assays	  First,	   to	   determine	   whether	   cell	   viability	   could	   be	   examined	   in	   primary	  myogenic	   cultures	   by	   MTT	   assay,	   reduced	   glucose	   concentration	   in	   growth	  media	  for	  2	  hours,	  as	  a	  known	  inducer	  of	  cellular	  stress	  in	  vitro,	  was	  examined	  as	   a	   positive	   control.	   At	   50%	   glucose	   concentration,	   MTT	   reduction	   was	  significantly	   reduced	   to	   23.1%	   ±8.6%	   of	   standard	   cultures	   (n=5,	   p<0.01)	  thereby	   supporting	   the	   further	   use	   of	   the	   MTT	   assay	   to	   then	   determine	   the	  impact	  of	  IBM-­‐like	  conditions	  on	  the	  viability	  of	  myogenic	  cell	  cultures.	  MTT	   assays	   were	   then	   performed	   on	   βAPP	   over-­‐expressing	   cultures.	   The	  cultures	  were	  examined	  at	   two	   time	  points:	  48	  or	  96	  hours	  after	   transfection.	  These	   correspond	   to	   the	  midpoint	   and	  endpoint	   in	   the	   typical	   overexpression	  period	   associated	   with	   Lipofectamine™	   mediated	   transfection.	   At	   48	   hours,	  
βAPP	   overexpression	   induced	   significant	   cytotoxicity	   compared	   with	   EV,	  reflected	   by	   impaired	   MTT	   reduction,	   measured	   at	   53%	   ±4.3%	   versus	   68%	  ±5.2%	   of	   control	   cultures	   (n=5,	   p<0.05).	   By	   96	   hours,	   this	   effect	   was	  exacerbated,	  where	  absorbance	  fell	  to	  47%	  ±4.9%	  of	  control,	  compared	  to	  74%	  ±7.2%	   of	   control	   with	   empty	   vector	   (n=5,	   p<0.05).	   EV	   transfection	   was	  associated	   with	   significantly	   lower	   MTT	   reduction	   compared	   to	   standard	  cultures	   (p<0.05)	   but	   there	   was	   no	   significant	   difference	   between	   the	  magnitude	  of	  this	  effect	  at	  48	  and	  96	  hours	  (Fig	  4.8).	  Exposure	   to	   the	   cytokines	   IL1β,	   TNFα	   also	   each	   resulted	   in	   significant	  attenuation	   of	   MTT	   reduction,	   reflecting	   cytotoxicity.	   A	   variety	   of	  concentrations	   were	   employed	   to	   establish	   a	   suitable	   panel	   for	   subsequent	  testing	   and	   to	   determine	   whether	   the	   cytotoxic	   effect	   was	   proportional.	   For	  either	   mediator,	   the	   effect	   indeed	   occurred	   in	   a	   dose-­‐dependent	   fashion.	  Between	  5ng/ml	  and	  20ng/ml,	   IL1β	  was	  associated	  with	  absorbance	  between	  69%	  ±4.4%	  and	  48%	  ±5.1%	  of	  control	  (n=5,	  p<0.01).	  Between	  5	  ng/ml	  and	  15	  ng/ml,	   TNFα	   attenuated	  MTT	   reduction	   significantly,	   to	   between	   87%	   ±6.8%	  (p<0.05)	  and	  65%	  ±5.9%	  of	  control	  (n=5,	  p<0.01)	  (Fig	  4.8).	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Next,	   the	   effect	   of	   Arimoclomol	   treatment	   on	   cell	   viability	   following	   βAPP	   or	  exposure	  to	  cytokines	  was	  examined.	  At	  concentrations	  between	  0.1	  and	  100μM,	  Arimoclomol	   had	   no	   significant	   effect	   on	   the	   MTT	   reduction	   in	   untreated	  standard	   control	   cultures	   (n=5).	   	   Arimoclomol	   (10μM)	   was	   applied	   to	  experimental	   cultures	   24	   hours	   after	   induction	   of	   the	   respective	   condition	   of	  cellular	   stress.	   In	   βAPP	   overexpressing	   cultures,	   no	   significant	   difference	   in	  MTT	   reduction	   was	   detected	   after	   a	   further	   24	   hours	   (i.e.	   48	   hours	   post-­‐transfection).	   However,	   by	   96	   hours	   post-­‐transfection,	   Arimoclomol	   treated	  cultures	  demonstrated	  significantly	  greater	  MTT	  reduction	  than	  untreated	  βAPP	  overexpressing	   cultures,	   at	   76%	   ±6.1%	   versus	   47%	   ±4.9%	   of	   control	  respectively	   (n=5,	   p<0.01).	   	   Therefore,	   subsequent	   analyses	   of	   cultures	   were	  undertaken	  at	  the	  96-­‐hour	  time	  point.	  Following	   IL1β	   exposure,	   Arimoclomol	   was	   associated	   with	   a	   mean	  improvement	   in	   absorbance	   across	   concentrations	  of	   13.25%,	  with	   significant	  differences	   demonstrated	   at	   5,	   15	   and	   20ng/ml	   concentrations.	   The	   largest	  increase,	   from	   48%	   ±5.1%	   to	   69%	   ±5.9%	   of	   control	   absorbance,	   was	  demonstrated	  at	  20ng/ml	  (n=5,	  p<0.01).	  	  The	   impact	   of	   Arimoclomol	   on	   TNFα-­‐induced	   cytotoxicity	   was	   more	   modest,	  with	  a	  mean	  improvement	  of	  6.75%	  across	  the	  tested	  concentrations.	  However,	  the	   lowest	   concentration	   of	   TNFα	   did	   not	   induce	   significant	   change	   in	   MTT	  reduction	   compared	   to	   control.	   Some	  of	   this	   apparent	   lack	  of	   treatment	  effect	  may	  reflect	   the	   limited	  action	  of	  Arimoclomol,	  as	  a	  co-­‐inducer,	  on	   ‘unstressed’	  cells.	  Nevertheless,	  a	  significant	  treatment	  effect	  was	  demonstrated	  at	  10ng/ml	  TNFα,	  where	   absorbance	   increased	   from	  69%	  ±4.9%	   to	   82%	  3.8%	   of	   control	  (n=5,	  p<0.05)	  (Fig	  4.8).	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Figure	   4.8	   Cell	   viability	   following	   βAPP	   transfection	   or	   exposure	   to	  
inflammatory	  cytokines	  and	  the	  effect	  Arimoclomol	  treatment	  As	   determined	   by	   MTT	   assays,	   the	   reduction	   of	   cell	   viability	   associated	   with	  βAPP	   transfection	   and	   cytokine	   exposure	   was	   significantly	   attenuated	   by	  Arimoclomol	  treatment.	  White	  markers=control	  cultures	  without	  Arimoclomol,	  Grey=Empty	  Vector	  control,	  Black	  markers=with	  Arimoclomol	  (Error	  Bars=SEM,	  n=5,	  Star=p<0.05)	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4.2.3	  TDP-­‐43	  The	  evidence	  that	  TDP-­‐43	  mislocalisation	  distinguishes	  IBM	  from	  its	  differential	  diagnoses	   is	   stronger	   than	   that	   for	   other	   proteins	   that	   constitute	   the	  cytoplasmic	   inclusions	   observed	   in	   affected	   muscle.	   Additionally,	   IBM	   tissue	  demonstrates	  increased	  TDP-­‐43	  concentration,	  which	  has	  not	  been	  established	  with	   for	   other	   proteins.	   Therefore,	   these	   experiments	   prioritised	   the	  development	   of	   an	   assay	   of	   TDP-­‐43	   pathology	   over	   other	   inclusion-­‐forming	  proteins.	  Furthermore,	  it	  was	  noted	  in	  preliminary	  experiments	  that	  TDP-­‐43	  C-­‐terminus	  staining	  exhibited	  a	  fairly	  predictable	  spectrum	  of	  change,	  which	  was	  conducive	   to	   quantification.	   Normal	   nuclear	   staining	   evolved,	   under	  pathological	   conditions,	   to	   cytoplasmic	   inclusion	   formation	   with	   retained	  nuclear	   staining,	   to	   loss	   of	   nuclear	   staining	   with	   or	   without	   cytoplasmic	  inclusions.	   This	   cytoplasmic	   translocation	   mirrors	   the	   pattern	   of	   TDP-­‐43	  pathology	  described	  in	  other	  tissues	  (Janssens	  et	  al.	  2013).	  	  
4.2.3.1	  TDP-­‐43	  immunostaining	  in	  untreated	  primary	  myogenic	  cultures	  Under	   normal	   culture	   conditions,	   TDP-­‐43	   immunostaining	   in	   myotubes	   was	  predominantly	   nuclear,	   which	   was	   readily	   identifiable,	   with	   some	   largely	  homogenous	  cytoplasmic	  staining	  at	   lower	   intensity.	  Comparison	  with	  nuclear	  staining	   using	   DAPI	   demonstrated	   that	   only	   exceptionally	   rarely	   were	  myotubular	  nuclei	  TDP-­‐43	   immunonegative	  (Figure	  4.9).	  Therefore,	  additional	  DAPI	  staining	  was	  not	  employed	  in	  the	  further	  determination	  of	  TDP-­‐43	  nuclear	  immunoreactivity.	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Figure	  4.9	  TDP-­‐43	  under	  normal	  culture	  conditions	  Under	   normal	   conditions,	   TDP-­‐43	   (green)	   immunostaining	   is	   predominantly	  nuclear,	  with	  cytoplasmic	  staining	  of	  lower	  intensity.	  Comparison	  with	  matched	  images	   including	   additional	   DAPI	   staining	   (overlayed	   blue	   in	   C,	   D)	   reveals	  almost	   100%	   concordance	   of	   nuclear	   identification.	   On	   rare	   occasions,	  myotubular	  nuclei	   identified	  by	  DAPI	  staining	  lacked	  TDP-­‐43	  staining	  (such	  as	  nucleus	  arrowed	  in	  D).	  	  (Scale	  Bars=20μm)	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4.2.3.2	  Quantification	  of	  TDP-­‐43	  immunostaining	  The	  overexpression	  of	  βAPP	  or	  exposure	   to	   inflammatory	  cytokines	   induced	  a	  range	  of	  pathological	  features	  in	  cultured	  myotubes.	  The	  loss	  of	  nuclear	  TDP-­‐43	  staining	   was	   examined	   as	   the	   primary	   measure	   in	   quantifying	   the	   TDP-­‐43	  response	  to	  IBM-­‐relevant	  conditions.	  Counting	  the	  absolute	  number	  of	  TDP-­‐43	  cytoplasmic	  inclusions	  was	  impractical	  due	  to	  their	  small	  size,	  high	  number	  and	  frequent	   clustering.	   Furthermore,	   since	   it	   remains	   unclear	   whether	   such	  structures	  represent	  a	  cytoprotective	  or	  cytotoxic	  response,	  it	  is	  difficult	  to	  use	  this	   parameter	   as	   an	   indicator	   of	   the	   beneficial	   effect	   of	   potential	   therapeutic	  compounds.	   Rather,	   the	   presence	   or	   absence	   of	   cytoplasmic	   inclusions	   was	  noted	  after	  determination	  of	  the	  nuclear	  staining	  pattern.	  	  
4.7.3.3	  Cytoplasmic	  translocation	  and	  nuclear	  depletion	  of	  TDP-­‐43	  Under	   normal	   culture	   conditions,	   fewer	   that	   10%	   of	  myotubes	   demonstrated	  absence	   of	   normal	   nuclear	   TDP-­‐43	   immunoreactivity.	   However,	   over-­‐expression	  of	  βAPP	  or	  exposure	  to	  cytokines	  produced	  a	  significant	  increase	  in	  translocation	  of	  TDP-­‐43	  from	  the	  nucleus	  to	  the	  cytoplasm	  (Fig	  4.10).	  	  Compared	   to	   EV	   transfection,	   βAPP	   overexpression	   was	   associated	   with	   an	  increase	  in	  non-­‐nuclear	  TDP-­‐43	  staining	  from	  7.31%	  ±0.78%	  to	  75.28%	  ±6.9%	  (n=5,	   p<0.001),	   an	   absolute	   increase	   of	   67.97%	   and	   relative	   increase	   of	   10.3	  fold.	  IL1β	  exposure,	  between	  5	  ng/ml	  and	  20	  ng/ml	   increased	  non-­‐nuclear	  TDP-­‐43	  staining	   in	   a	   dose-­‐dependent	   manner,	   from	   4.53%	   ±0.67%	   to	   a	   maximum	   of	  47.56%	  ±2.76%	  (n=5,	  p<0.01)	  at	  20	  ng/ml.	  The	  maximal	  effect	  represented	  an	  absolute	  increase	  of	  43.03%	  and	  relative	  increase	  of	  10.5	  fold.	  TNFα	   exposure	   was	   also	   associated	   with	   a	   significant	   reduction	   of	   TDP-­‐43	  nuclear	   immunoreactivity	  between	  5	  ng/ml	  and	  20	  ng/ml.	  The	  maximal	  effect	  was	  observed	  at	  20	  ng/ml,	  where	  non-­‐nuclear	  TDP-­‐43	  staining	  increased	  from	  2.32%	   ±0.31%	   to	   62.18%	   ±3.31%	   (n=5,	   p<0.001),	   an	   absolute	   increase	   of	  59.86%	  and	  relative	  increase	  of	  26.8	  fold.	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Figure	  4.10	  Spectrum	  of	  TDP-­‐43	  pathology	  after	  overexpression	  of	  βAPP	  
or	  exposure	  to	  inflammatory	  cytokines	  Immunostaining	  of	  TDP-­‐43	  (green)	  following	  exposure	  to	  TNFα	  (A),	  IL1β	  (B)	  or	  βAPP	  overexpression	  (C	  and	  D)	  demonstrated	  that	  loss	  of	  nuclear	  staining	  was	  the	  most	  characteristic	  finding	  under	  all	  conditions.	  This	  was	  observed	  with	  and	  without	  the	  appearance	  of	  cytoplasmic	  TDP-­‐43	  aggregates	  (arrows	  in	  B,	  C	  and	  D).	  More	   rarely,	   nuclear	   staining	  was	   retained	   in	   the	   presence	   of	   cytoplasmic	  aggregates	  (C),	  perhaps	  indicating	  an	  earlier	  stage	  of	  the	  pathological	  spectrum	  (Scale	  Bars=20μm)	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The	  absence	  of	  significant	  TDP-­‐43	  pathology	  following	  the	  non-­‐specific	  ‘stressor’	  of	  empty	  vector	  transfection	  implies	  a	  degree	  of	  specificity	  to	  the	  IBM-­‐relevant	  stimuli	  examined	  in	  the	  other	  experiments.	  To	  examine	  this	  hypothesis	  further,	  the	   generic	   stimulus	   of	   glucose	   deprivation,	   which	   had	   previously	   been	  demonstrated	   to	   produce	   a	   quantifiable	   proportional	   reduction	   of	   overall	   cell	  viability	   in	  myogenic	  cultures,	  was	  examined.	  At	  concentrations	  between	  20%	  and	   80%	   of	   control	   medium	   glucose	   concentration,	   no	   significant	   impact	   on	  TDP-­‐43	  staining	  was	  observed	  (n=3).	  	  
4.7.3.4	  The	  effect	  of	  Arimoclomol	  on	  TDP-­‐43	  localisation	  Arimoclomol	   treatment	   attenuated	   the	   effect	   of	   βAPP	   and	   cytokines	   on	   the	  localisation	  of	  TDP-­‐43	  immunoreactivity	  (Figs	  4.11	  and	  4.12).	  Following	   βAPP	   over-­‐expression,	   treatment	  with	   Arimoclomol	  was	   associated	  with	   a	   reduction	   in	   the	   proportion	   of	   myotubes	   demonstrating	   non-­‐nuclear	  TDP-­‐43	   from	   75.28%	   ±6.9%	   to	   57.67%	   ±6.1%	   (n=5,	   p<0.05),	   an	   absolute	  reduction	  of	  17.61%	  and	  relative	  reduction	  of	  23.3%.	  Arimoclomol	  significantly	  attenuated	  the	  effect	  of	  IL1β	  exposure,	  at	  5	  ng/ml	  and	  20	   ng/ml,	   on	   TDP-­‐43	   localisation.	   Across	   all	   IL1β	   concentrations	   tested,	   the	  mean	   absolute	   reduction	   in	   the	   number	   of	   myotubes	   demonstrating	   non-­‐nuclear	  TDP-­‐43	  was	  11%.	  The	  maximum	  effect	  was	  observed	  at	  20	  ng/ml,	  with	  an	  absolute	  reduction	  of	  23.27%	  and	  relative	  reduction	  of	  48.9%.	  Arimoclomol	  also	  reduced	  the	  impact	  of	  TNFα	  on	  TDP-­‐43	  localisation,	  at	  a	  mean	  absolute	  reduction	  of	  16%	  across	  all	  TNFα	  concentrations	  (n=5).	  The	  maximum	  significant	  effect	  was	  demonstrated	  at	  10	  ng/ml,	  with	  an	  absolute	  reduction	  of	  29.34%	  and	  relative	  reduction	  of	  51.1%.	  Notably,	   Arimoclomol	   had	   no	   effect	   on	   the	   localisation	   of	   TDP-­‐43	   in	   control	  cultures.	  This	   implies	  the	  low	  frequency	  of	  TDP-­‐43	  changes	  seen	  in	  those	  cells	  either	   reflect	   normal	   variation	   or	   are	   dependent	   on	   another	   pathway	   that	  Arimoclomol	  does	  not	  affect.	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Figure	   4.11	   Effect	   of	   Arimoclomol	   treatment	   on	   the	   pattern	   of	   TDP-­‐43	  
immunoreactivity	  in	  myogenic	  cultures	  Following	  Arimoclomol	  treatment	  of	  cultures	  under	  conditions	  of	  IL1β	  exposure	  (A),	   TNFα	   (B)	   or	   βAPP	   overexpression	   (C),	   TDP-­‐43	   immunostaining	  demonstrated	   a	   significant	   increase	   of	   cells	   with	   the	   predominantly	   nuclear	  staining	   characteristic	   of	   normal	   control	   cultures,	   and	   reduction	   of	   cells	   with	  loss	   of	   nuclear	   staining.	   Some	   myotubes	   that	   retained	   nuclear	   staining	   also	  displayed	  elements	  of	  mislocalisation	  such	  as	  cytoplasmic	  aggregates	  (arrowed	  in	  C).	  (Scale	  Bars=20μm)	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Figure	  4.12	  Quantification	  of	  TDP-­‐43	  mislocalisation	  in	  myogenic	  cultures	  
following	   overexpression	   of	   βAPP,	   exposure	   to	   inflammatory	   cytokines	  
and	  treatment	  with	  Arimoclomol	  The	  proportion	  of	  myotubes	  that	  displayed	  mislocalised	  (non-­‐nuclear)	  TDP-­‐43	  was	   significantly	   increased	   by	   overexpression	   of	   βAPP	   versus	   empty	   vector	  control	  and	  by	  exposure	  to	  cytokines	  versus	  unexposed	  control	  cultures	  (white	  bars).	   Treatment	   with	   Arimoclomol	   (black	   bars)	   significantly	   attenuated	   the	  mislocalisation	  of	  TDP-­‐43	  associated	  with	  these	  conditions.	  (Error	  Bars=SEM,	  n=5	  per	  condition,	  Asterisk=p<0.05)	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Next,	  it	  was	  determined	  whether	  the	  magnitude	  of	  the	  effect	  of	  Arimoclomol	  to	  attenuate	  TDP-­‐43	  mislocalisation	   simply	   reflected	   the	   comparative	  magnitude	  of	  that	  mislocalisation	  in	  the	  corresponding	  untreated	  control	  culture.	  Plotting	  the	  relative	  change	  associated	  with	  Arimoclomol	  treatment	  against	  the	  absolute	  values	   of	   TDP-­‐43	   suggests	   there	   is	   not	   a	   proportional	   relationship	   between	  these	  two	  factors	  (Figure	  4.13).	  In	  turn,	  this	  strengthens	  the	  likelihood	  that	  the	  effect	  of	  Arimoclomol	  is	  not	  a	  generic	  action	  but,	  in	  combination,	  depends	  on	  the	  other	  major	   variable	   in	   these	   experiments,	   the	  means	   through	  which	   TDP-­‐43	  pathology	  was	  induced.	  	  
	  
Figure	  4.13	  Examination	  of	  the	  specificity	  of	  Arimoclomol’s	  effect	  The	   mean	   change	   in	   TDP-­‐43	   mislocalisation	   after	   Arimoclomol	   treatment	   is	  plotted	   against	   the	   mean	   proportion	   of	   TDP-­‐43	   mislocalisation	   under	   all	  experimental	  conditions	  without	  Arimoclomol	  (the	  data	  in	  Fig	  4.13).	  The	  lack	  of	  proportional	  relationship	  (R2=0.04)	  implies	  the	  effect	  of	  Arimoclomol	  does	  not	  simply	  reflect	  the	  pre-­‐treatment	  state	  of	  TDP-­‐43	  localisation	  in	  a	  given	  culture.	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4.2.3.5	  The	  effect	  of	  βAPP	  overexpression,	  exposure	  to	  inflammatory	  cytokines	  and	  
Arimoclomol	  treatment	  on	  TDP-­‐43	  expression	  Next,	   the	   impact	   of	   βAPP	   over-­‐expression	   and	   exposure	   to	   inflammatory	  cytokines	   on	   TDP-­‐43	   concentration	   was	   examined	   using	   western	   blotting.	  Compared	   to	   control	   cultures,	   empty	   vector	   transfection	   did	   not	   significantly	  affect	   the	   level	   of	   TDP-­‐43	   expression.	   However,	   βAPP	   transfection	   was	  associated	  with	   a	   significant	   increase	   in	   TDP-­‐43	   expression,	   at	   2.53	   fold	   over	  that	   of	   control	   (n=3,	   p<0.01).	   Glucose	   deprivation	   also	   produced	   a	   small,	   but	  significant,	  effect	  of	  a	  1.36	  fold	  increase	  over	  control	  (n=3,	  p<0.05)	  (Fig	  4.14).	  Exposure	   to	   the	   cytokines	   TNFα	   and	   IFNγ	   significantly	   increased	   TDP-­‐43	  concentration,	   at	   2.01	   and	   1.77	   fold	   greater	   than	   control	   respectively	   (n=3,	  p<0.05).	  However,	  IL1β	  was	  not	  associated	  with	  a	  significant	  increase	  in	  TDP-­‐43	  expression	  (Fig	  4.15).	  Treatment	   of	   βAPP	   transfected	   or	   cytokine	   exposed	   myogenic	   cultures	   with	  Arimoclomol	  was	  associated	  with	  a	  significant	  reduction	  in	  the	  level	  of	  TDP-­‐43	  expression.	   Typically	   this	   reflected	   attenuation	   of	   the	   increase	   in	   TDP-­‐43	  associated	  with	  the	  given	  IBM-­‐relevant	  stimulus,	  rather	  than	  a	  reduction	  versus	  unexposed	   control	   cultures.	   After	   βAPP	   over-­‐expression,	   Arimoclomol	   treated	  cultures	  demonstrated	  TDP-­‐43	  expression	  at	  59.9%	  of	  the	  untreated	  population.	  This	   level	  of	  expression	  was	  not	  significantly	  different	  to	  that	  of	  untransfected	  control	  cultures	  (n=3,	  p=0.051)	  (Fig	  4.14).	  Although	  the	  impact	  of	  inflammatory	  cytokines	  was	  generally	  less	  marked	  than	  that	  of	  βAPP,	  the	  effect	  of	  Arimoclomol	  appeared	  proportionately	  greater	  under	  these	   conditions.	   Indeed,	   after	   Arimoclomol	   treatment	   of	   cultures	   exposed	   to	  each	  cytokine,	  TDP-­‐43	  concentration	  was	  lower	  than	  that	  of	  unexposed	  control.	  Relative	   to	   the	   untreated	   comparator,	   the	   TDP-­‐43	   expression	   levels	   after	  Arimoclomol	   treatment	  of	   IL1β,	  TNFα	  and	  IFNγ	  exposed	  cultures	  were	  51.2%,	  35.8%	  and	  24.3%	  respectively	  (n=3,	  p<0.05)	  (Fig	  4.15).	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Figure	  4.14	  TDP-­‐43	  expression	  in	  myogenic	  cultures	  following	  βAPP	  over-­‐
expression	  and	  Arimoclomol	  treatment	  A:	  Representative	  western	  blot	  for	  TDP-­‐43	  in	  myogenic	  cultures	  under	  control	  conditions	  (C),	  2	  hours	  of	  Glucose	  Deprivation	  (GD),	  Empty	  Vector	  transfection	  (EV),	  βAPP	  overexpression	  (APP)	  and	  βAPP	  overexpression	  with	  Arimoclomol	  treatment	  (Ari).	  B:	   Mean	   optical	   densitometry	   of	   western	   blots	   demonstrates	   that	   βAPP	  overexpression	  significantly	  elevates	  TDP-­‐43	  concentration	  compared	  to	  empty	  vector	   control.	   Arimoclomol	   treatment	   prevents	   this	   effect	   and,	   here,	   TDP-­‐43	  concentration	  is	  not	  significantly	  different	  to	  control.	  (Error	   Bars=SEM,	   n=3,	   Star=p<0.05	   vs.	   corresponding	   control	   culture,	  Asterisk=p<0.05	  vs.	  βAPP	  overexpression)	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Figure	  4.15	  TDP-­‐43	  expression	  in	  myogenic	  cultures	  following	  exposure	  to	  
inflammatory	  cytokines	  and	  treatment	  with	  Arimoclomol	  A:	  Representative	  western	  blot	  for	  TDP-­‐43	  in	  myogenic	  cultures	  under	  control	  conditions	   (C)	   or	   exposure	   to	   IL1β	   (IL1),	   TNFα	   (TNF)	   or	   IFNγ	   (IFN).	   The	  addition	   of	   Arimoclomol	   treatment	   to	   these	   conditions	   is	   indicated	  with	   plus	  sign.	  B:	   Mean	   optical	   densitometry	   of	   western	   blots	   demonstrates	   that	   TNFα	   and	  IFNγ	   were	   associated	   with	   significant	   increases	   in	   TDP-­‐43	   expression.	   IL1β,	  however,	   was	   not.	   Arimoclomol	   treatment	   (indicated	   by	   +A)	   was	   associated	  with	   a	   significant	   reduction	   of	   TDP-­‐43	   expression	   compared	   to	   the	   relevant	  untreated	  control	  condition.	  	  (Error	   Bars=SEM,	   n=3,	   Star=p<0.05	   versus	   control	   culture	   not	   exposed	   to	  cytokines,	  Asterisk=p<0.05	  vs.	  same	  condition	  minus	  Arimoclomol	  treatment)	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4.2.4	  Endoplasmic	  reticulum	  function	  and	  calcium	  homeostasis	  As	  described	  above	  (Chapter	  4,	  Section	  4.3),	  ER	  stress	  and	  its	  close	  association	  with	  disturbed	  intracellular	  calcium	  (Ca2+)	  signalling	  are	  proposed	  as	  a	  central	  and	   early	   indicators	   of	   IBM	   pathology.	   Therefore,	   these	   represent	   attractive	  therapeutic	   targets.	  The	  next	   set	  of	  experiments	   sought	   to	  determine	  whether	  ER	  stress	  or	  Ca2+	  dyshomeostasis	  were	  evident	  in	  myogenic	  cultures	  exposed	  to	  IBM-­‐relevant	  stimuli	  and	  to	  what	  degree	  these	  pathological	  processes	  could	  be	  quantified.	  This	  was	  examined	  using	  live	  confocal	  imaging	  of	  intracellular	  Ca2+,	  with	  the	  fluorescent	  dye	  Fluo4-­‐AM,	  and	  the	  determination	  of	  the	  expression	  of	  ER	  stress	  markers	  using	  western	  blots.	  	  
4.2.4.1	  Live	  cell	  Ca2+	  Imaging:	  baseline	  fluorescence	  It	  was	  first	  necessary	  to	  determine	  whether	  the	  proposed	  experimental	  protocol	  could	   be	   completed	   within	   a	   period	   during	   which	   a	   stable	   fluorescent	   signal	  corresponding	  to	  Ca2+-­‐bound	  Fluo-­‐4AM	  could	  be	  obtained,	  independently	  of	  any	  pharmacological	   manipulation.	   Therefore,	   myotubes	   were	   observed	   for	  approximately	   twice	   the	  maximum	   anticipated	   time	   required	   to	   complete	   the	  proposed	   protocol.	   Myotubes	   did	   not	   demonstrate	   a	   significant	   persistent	  deviation	   from	   baseline	   during	   this	   period	   (Figure	   4.16)	   (n=27	   cells,	  corresponding	  to	  3	  cells	  from	  3	  random	  coverslips	  from	  3	  cultures).	  	  	  
4.2.4.2	  Determination	  of	  cell	  types	  used	  for	  analysis	  of	  intracellular	  Ca2+	  Elongated	   myotubes	   were	   readily	   identifiable	   and	   distinguishable	   from	   the	  circular	   conformation	   of	   contracted	   myotubes	   or	   myocytes,	   meaning	  experimental	  data	   could	  be	   restricted	  purely	   to	   this	   cell	   type	  of	   interest.	  Only	  myotubes	   that	   obeyed	   predetermined	   characteristics	   were	   included	   in	   the	  analysis	  of	  Ca2+	  response	  (Figure	  4.17).	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Figure	  4.16	  Baseline	  Ca2+	  fluorescence	  with	  Fluo-­‐4AM	  in	  a	  myotube	  from	  a	  
control	  culture	  Representative	  Fluo4-­‐AM	  fluorescence	  trace	  (red	  line)	  of	  an	  individual	  myotube,	  grown	  under	  standard	  culture	  conditions,	  observed	  for	  approximately	  twice	  the	  anticipated	  length	  of	  the	  experimental	  protocol	  intended	  to	  examine	  ER	  Ca2+	  in	  myogenic	  cultures.	  Dotted	  black	  line	  indicates	  the	  anticipated	  time	  limit	  of	  this	  protocol.	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Figure	  4.17	  Identification	  of	  myotubes	  for	  Ca2+	  analysis	  A:	   Four	  myotubes	   labelled	  with	   region	   of	   interest	   (ROI)	   rectangles.	  Myocytes	  are	   indicated	   by	   white	   arrows.	   ROI	   13	   (orange	   rectangle)	   demonstrates	  myotubes	  with	   two	   closely	   adjacent	  myocytes,	  which	  would	  preclude	   this	   cell	  from	  analysis.	  B:	  Representative	  example	  trace	  of	  myotube	  throughout	  experimental	  protocol,	  with	  administration	  of	   thapsigargin	  and	   ionomycin	  as	   indicated.	  This	  myotube	  demonstrates	   spontaneous	   spikes	   in	   fluorescence	   prior	   to	   administration	   of	  experimental	  compounds.	  This	  would	  exclude	  this	  cell	  from	  analysis.	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To	  minimise	  other	  potentially	  confounding	  variables,	  parameters	  were	  set	  with	  which	   myotubes	   were	   selected	   for	   inclusion	   in	   the	   analysis.	   The	   following	  characteristics	  excluded	  a	  cell	  from	  use	  in	  analysis:	  1. Overlapping	  with	  another	  other	  cell	  or	  with	  other	  cells	  in	  close	  proximity	  meaning	  the	  region	  of	  interest	  box	  could	  include	  more	  than	  one	  cell	  (Fig	  4.18,	  A)	  2. Morphology	   other	   than	   that	   of	   the	   distinctive,	   elongated,	   multinuclear	  myotube	  3. Any	   cell	  which	   appeared	   disproportionately	   bright	   to	   initial	   inspection	  compared	   to	   other	   cells	   within	   the	   field	   (i.e.	   that	   might	   represent	  bleaching	  of	  dye)	  4. Any	  cell	  with	  spontaneous	  changes	  in	  fluorescence,	  either	  on	  microscopy	  or	  subsequent	  plotted	  data	  analysis	  (Fig	  4.17,	  B).	  	  It	   was	   noted,	   in	   keeping	  with	   the	   expected	  maturation	   of	   calcium	   dependent	  excitation	   contraction	   coupling	   machinery,	   that	   spontaneous	   changes	   in	  fluorescence	   became	   markedly	   more	   common	   after	   10	   days	   in	   culture.	  Therefore	  all	  calcium	  fluorescence	  imaging	  experiments	  were	  conducted	  before	  this	   time	  point.	   Figure	   4.18	   illustrates	   the	   typical	   Ca2+	   response	   of	   a	   group	   of	  myotubes	  using	  the	  optimised	  experimental	  protocol.	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Figure	  4.18	  Experimental	  protocol	   for	  determination	  of	   cytosolic	  and	  ER	  
calcium	  A-­‐C:	  representative	  images	  of	  one	  viewing	  region	  of	  myotubes	  during	  different	  stages	   of	   the	   protocol.	   A=at	   baseline,	   B=after	   administration	   of	   Thapsigargin,	  C=after	   administration	   of	   Ionomycin.	   Contracted	   myotubes	   such	   as	   that	  indicated	  (arrow	  in	  C)	  were	  not	  included	  in	  the	  analysis.	  (Scale	  Bar=100μm)	  D:	   corresponding	   representative	   trace	   of	   fluorescence	   within	   individual	  myotubes	   from	   one	   experiment	   (each	   myotube	   represented	   by	   one	   coloured	  trace).	   Each	   myotube	   demonstrated	   increased	   fluorescence	   (reflecting	  increased	   cytosolic	   [Ca2+])	   after	   the	   administration	   of	   Thapsigargin,	   a	   non-­‐competitive	  inhibitor	  of	  the	  SERCA.	  This	  approximates	  the	  discharge	  of	  ER	  Ca2+	  into	   the	   cytosol.	   After	   this	   response	   completed,	   the	   calibration	   point	   for	  maximal	  fluorescence	  (required	  to	  calculate	  [Ca2+]	  from	  fluorescence	  readings)	  was	  acquired	  through	  the	  administration	  of	  ionomycin.	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4.2.4.3	  Baseline	  cytosolic	  Calcium	  Fluorescence	  prior	  to	  the	  administration	  of	  thapsigargin	  was	  used	  to	  determine	  the	   baseline	   mean	   cytosolic	   calcium	   concentration,	   [Ca2+]Cyto,	   of	   myotubes	  across	  experimental	  conditions	  (Figure	  4.19).	  Under	   standard	   culture	   conditions,	   [Ca2+]Cyto	   was	   262.42	   nM	   ±28.5nM.	   After	  βAPP	  over-­‐expression,	  this	  increased	  significantly	  to	  373.49	  nM	  ±21.2nM	  (n=5,	  p<0.05).	  Empty	  vector	  was	  not	  associated	  with	  a	  significant	  change	  in	  [Ca2+]Cyto.	  	  At	   each	   concentration	   tested	   between,	   5	   and	   20	   ng/ml,	   IL1β	   exposure	   was	  associated	  with	  a	   significant	   increase	   in	   [Ca2+]Cyto.	  This	  did	  not	  appear	   to	  be	  a	  concentration	   dependent	   effect.	   Mean	   [Ca2+]Cyto	   across	   concentrations	   was	  354.45	  nM	  (n=5,	  p<0.01).	  At	  5	  and	  10	  ng/ml,	  TNFα	  exposure	  also	  significantly	  increased	  [Ca2+]Cyto	  but,	  at	  20	  ng/ml,	  was	  not	   associated	  with	   a	   significant	   change.	  Mean	   [Ca2+]Cyto	  across	  concentrations	  was	  316.89	  nM	  (n=5,	  p<0.01).	  Treatment	  with	  Arimoclomol	  was	  not	  associated	  with	  a	  significant	  difference	  in	  [Ca2+]Cyto	   after	   application	   to	   control	   cultures	   or	   to	   the	   single	   experimental	  condition	  (TNFα	  20	  ng/ml)	  that	  was	  not	  associated	  with	  a	  significant	  change	  to	  [Ca2+]Cyto.	   However,	   Arimoclomol	   attenuated	   the	   elevation	   of	   [Ca2+]Cyto	  associated	   with	   IBM-­‐relevant	   stimuli.	   Following	   βAPP	   over-­‐expression,	  [Ca2+]Cyto	  was	  reduced	   from	  373.49	  nM	  ±21.2	  nM	  to	  282.5	  nM	  ±	  17.5	  nM	  (n=5,	  p<0.01),	  which	   is	   a	   concentration	  not	   significantly	  different	   to	   that	   of	   control.	  Further	   significant	   effects	   of	   Arimoclomol	   were	   demonstrated	   in	   association	  with	  IL1β,	  at	  each	  concentration	  tested	  between	  5	  and	  20	  ng/ml.	  Mean	  [Ca2+]Cyto	  fell	   from	  354.35	  nM	  to	  253.5	  nM	  (n=5,	  p<0.01),	  a	   relative	  reduction	  of	  28.5%.	  Following	   TNFα	   exposure,	   other	   than	   at	   20	   ng/ml	   which	   had	   not	   been	  associated	  with	  a	  change	   in	   the	  underlying	   [Ca2+]Cyto,	  Arimoclomol	  produced	  a	  significant	   reduction	   of	   [Ca2+]Cyto.	   Across	   the	   concentrations	   tested,	   mean	  [Ca2+]Cyto	  fell	  from	  316.89	  nM	  to	  268.92	  nM	  (n=5,	  p<0.01),	  a	  relative	  reduction	  of	  14.8%.	   As	   observed	   after	   βAPP	   over-­‐expression,	   the	   effect	   of	   Arimoclomol	  following	   cytokine	   exposure	   restored	   [Ca2+]Cyto	   to	   a	   level	   not	   significantly	  different	  to	  control	  cultures.	  




Figure	  4.19	  Effect	  of	  Arimoclomol	  on	  baseline	  cytosolic	  Calcium	  following	  
βAPP	  overexpression	  or	  exposure	  to	  inflammatory	  cytokines	  A:	  Overexpression	  of	  βAPP	  significantly	  elevated	  [Ca2+]Cyto	  versus	  empty	  vector	  transfected	   controls	   (white	   bars).	   Arimoclomol	   treatment	   after	   βAPP	  overexpression	   inhibited	   this	   effect	   and	   was	   associated	   with	   a	   [Ca2+]Cyto	   not	  significantly	   different	   to	   empty	   vector	   control	   (black	   bars).	   Arimoclomol	  treatment	  had	  no	  significant	  effect	  on	  empty	  vector	  control.	  B/C:	   Arimoclomol	   treatment	   (black	   symbols)	   significantly	   attenuated	   the	  elevation	  of	  [Ca2+]Cyto	  that	  followed	  exposure	  to	  cytokines	  IL1β	  or	  TNFα	  (white	  symbols).	   [Ca2+]Cyto	  was	   restored	   to	   levels	   insignificantly	   different	   to	   control	  cultures.	  	  (Error	   Bars=SEM,	   n=5	   per	   condition,	   Star=p<0.05	   vs.	   empty	   vector	   or	  unexposed	  cultures,	  Asterisk=p<0.05	  vs.	  control	  not	  treated	  with	  Arimoclomol)	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4.2.4.4	  Inferred	  ER	  Calcium	  under	  IBM-­‐like	  conditions	  ER	   calcium	   concentration	   [Ca2+]ER,	   inferred	   from	   the	   change	   in	   cytosolic	  fluorescence	  after	  SERCA	  inhibition	  by	  thapsigargin,	  was	  significantly	  altered	  by	  IBM-­‐like	  conditions	  (Figure	  4.20).	  Compared	   to	   contemporaneous	   control	   cultures,	   where	   mean	   [Ca2+]ER	   was	  350.89	   nM	   ±22.3	   nM,	   empty	   vector	   transfection	   (EV)	   was	   associated	   with	   a	  consistently	  lower	  [Ca2+]ER	  but	  this	  was	  not	  significant	  280.4	  nM	  ±20.8	  nM	  (n=5,	  p=0.09).	   βAPP	   overexpression,	   however,	   was	   associated	   with	   a	   significantly	  lower	   [Ca2+]ER	   compared	   to	   EV,	   at	   190.58	   nM	   ±22.8	   nM	   (n=5,	   p<0.05).	   This	  equated	  to	  a	  relative	  reduction	  of	  32%.	  IL1β	   exposure	   was	   associated	   with	   a	   dose	   dependent	   reduction	   in	   [Ca2+]ER	  (R2=0.89),	  which	  was	   significant	  at	   each	  concentration	   tested	  when	  compared	  to	  contemporaneous	  control	  cultures.	  At	  the	  lowest	  concentration,	  IL1β	  5ng/ml,	  [Ca2+]ER	   fell	   to	  226.4	  nM	  ±18.5	  nM	  (n=5,	  p<0.01),	  which	  represented	  a	  relative	  reduction	  of	  37.2%.	  At	  the	  highest	  concentration,	  IL1β	  20	  ng/ml,	  [Ca2+]ER	  fell	  to	  122.4	  nM	  ±18.9	  nM	  (n=5,	  p<0.01),	  a	  greater	  relative	  reduction	  of	  66%.	  The	  effect	  of	  TNFα	  exposure	  was	  also	  broadly	  dose	  dependent,	  but	   less	  tightly	  so	  than	  with	  IL1β	  (R2=0.645).	  Significant	  reductions	  of	  [Ca2+]ER	  were	  observed	  at	   2.5,	   5	   and	   20	   ng/ml	   concentrations.	   At	   the	   lowest	   concentration,	   TNFα	   2.5	  ng/ml,	  [Ca2+]ER	  fell	  to	  260.56	  nM	  ±25.2	  nM	  (n=5,	  p<0.05),	  a	  relative	  reduction	  of	  26.7%.	  At	  the	  highest	  concentration,	  TNFα	  20	  ng/ml,	  [Ca2+]ER	  fell	  to	  190.54	  nM	  ±19.3	  nM	  (n=5,	  p<0.01),	  a	  greater	  relative	  reduction	  of	  46%.	  	  
4.2.4.5	  The	  effect	  of	  Arimoclomol	  on	  inferred	  ER	  Calcium	  	  Arimoclomol	   attenuated	   the	   impact	   of	   IBM-­‐like	   conditions	   on	   [Ca2+]ER.	  Arimoclomol	  did	  not	  affect	  [Ca2+]ER	  the	  control	  cultures	  significantly	  (339.5	  nM,	  ±20.7nM,	  p=0.72).	  Similarly,	  EV	  cultures	  were	  not	  affected	  significantly	   (320.9	  nM,	  ±21.4nM,	  p=0.25).	  However,	   following	  βAPP	  overexpression,	  Arimoclomol	  significantly	   attenuated	   the	   reduction	   of	   [Ca2+]ER	   to	   290.2	   nM	   ±26.1nM	   (n=5,	  p<0.05).	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Figure	   4.20	   Effect	   of	   Arimoclomol	   on	   [Ca2+]ER	   following	   βAPP	  
overexpression	  or	  exposure	  to	  inflammatory	  cytokines	  A:	  [Ca2+]ER	  was	  estimated	  by	  measuring	  the	  increase	  in	  cytosolic	  [Ca2+]	  following	  administration	   of	   thapsigargin.	   Transfection	   with	   empty	   vector	   did	   not	  significantly	   affect	   [Ca2+]ER	   relative	   to	   untransfected	   control.	   However,	  overexpression	   of	   βAPP	   significantly	   reduced	   [Ca2+]ER	  in	  myotubes	   relative	   to	  empty	   vector	   transfected	   cultures	   (white	   bars).	   Treatment	   with	   Arimoclomol	  (black	   bars)	   had	   no	   significant	   effect	   on	   untransfected	   or	   empty	   vector	  transfected	  cultures	  but	  significantly	  attenuated	  the	  effect	  of	  βAPP	  transfection	  on	  [Ca2+]ER.	  B/C:	  The	  reduction	  of	  [Ca2+]ER	  associated	  with	  exposure	  to	  IL1β	  or	  TNFα	  (white	  bars)	  was	  significantly	  attenuated	  by	  treatment	  with	  Arimoclomol	  (black	  bars).	  (Error	   Bars=SEM,	   n=5	   per	   condition,	   Star=p<0.05	   vs.	   empty	   vector	   or	  unexposed	  cultures,	  Asterisk=p<0.05	  vs.	  control	  not	  treated	  with	  Arimoclomol)	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Furthermore,	   this	   effect	   was	   sufficiently	   marked	   that	   [Ca2+]ER	   in	   the	  Arimoclomol	   treated	   group	   did	   not	   differ	   significantly	   from	   standard	   control	  cultures	  (p=0.15).	  Arimoclomol	   also	   attenuated	   the	   effect	   of	   IL1β	   on	   [Ca2+]ER.	   The	  magnitude	   of	  this	   effect	  was	   not	   linearly	   dependent	   upon	   the	   degree	   to	  which	   [Ca2+]ER	  was	  depressed	  by	  the	  respective	  experimental	  condition.	  Rather,	  between	  IL1β	  at	  5	  and	   15	   ng/ml,	   there	   was	   a	   restoration	   of	   [Ca2+]ER	   to	   concentration	   not	  significantly	  different	   to	   those	  of	   control	   cultures	   (5	  ng/ml,	  p=0.16;	  10	  ng/ml,	  p=0.21;	   15	   ng/ml,	   p=0.0699).	   At	   each	   of	   these	   concentrations,	   the	   difference	  between	   Arimoclomol	   treated	   cultures	   and	   the	   corresponding	   untreated	  comparator	   was	   significant	   	   (5	   ng/ml,	   p=0.03;	   10	   ng/ml,	   p=0.01;	   15	   ng/ml,	  p=0.027).	   The	   greatest	   effect	   was	   observed	   at	   10ng/ml	   IL1β,	   where	  Arimoclomol	  treatment	  increased	  [Ca2+]ER	  to	  314.4	  nM	  	  ±12.4	  nM	  compared	  to	  176.7	   nM	   ±	   14.5	   nM	   (n=5,	   p<0.01).	   At	   20	   ng/ml,	   the	   highest	   concentration	  tested,	   Arimoclomol	   was	   not	   associated	  with	   a	   significant	   impact	   on	   [Ca2+]ER.	  However,	   [Ca2+]ER	   after	   IL1β	   20ng/ml	   was	   not	   significantly	   different	   to	   that	  after	  IL1β	  15ng/ml,	  on	  which	  Arimoclomol	  did	  have	  a	  significant	  impact.	  After	   TNFα	   exposure,	   Arimoclomol	   had	   a	   similar	   effect	   to	   that	   observed	   after	  IL1β.	   At	   concentrations	   between	   2.5	   ng/ml	   and	   20	   ng/ml,	   there	   was	   a	  significant	  elevation	  of	  [Ca2+]ER	  (2.5	  ng/ml,	  p=0.03,	  5	  ng/ml,	  p=0.046;	  10	  ng/ml,	  p=0.034;	  20	  ng/ml,	  p=0.006).	  At	  each	  concentration,	  [Ca2+]ER	  was	  increased	  to	  a	  concentration	  not	  significantly	  different	  to	  control	  cultures	  (2.5	  ng/ml,	  p=0.523,	  5	   ng/ml,	   p=0.718;	   10	   ng/ml,	   p=0.466;	   20	   ng/ml,	   p=0.678).	   The	   largest	   effect	  was	  observed	  at	  TNFα	  15	  ng/ml,	  where	  Arimoclomol	  treatment	  was	  associated	  with	  an	  increased	  [Ca2+]ER	  of	  341.5	  nM	  ±11.1	  nM	  versus	  190.5	  nM	  ±9.3	  nM	  in	  the	  untreated	  control	  (n=5,	  p<0.01).	  	  
4.2.4.6	  Protein	  markers	  of	  ER	  Stress	  (UPR)	  To	   investigate	   further	   the	   nature	   of	   ER	   stress	   under	   experimental	   IBM-­‐like	  conditions	   in	  myogenic	   cultures,	   and	   the	   influence	   of	  Arimoclomol,	   a	   panel	   of	  proteins	   with	   important	   functions	   in	   the	   unfolded	   protein	   response	   (UPR)	  element	  of	  ER	  stress	  was	  examined.	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First,	   it	   was	   determined	   that	   there	   was	   no	   significant	   difference	   in	  concentration	  of	  ER	  stress	  markers	  across	  the	  control	  groups:	  cultures	  grown	  in	  standard	   conditions	   with	   or	   without	   Arimoclomol	   and	   empty	   vector	  transfection	   (Fig	   4.21).	   Therefore,	   myogenic	   cultures	   unexposed	   to	   either	  cytokines	  or	  transfection	  were	  used	  as	  controls	  for	  the	  subsequent	  experiments	  comparing	  expression	  of	  UPR	  proteins.	  	  
	  
Figure	  4.21	  Determination	  of	  a	  suitable	  control	  for	  ER	  stress	  experiments	  
using	  empty	  vector	  transfection	  and	  Arimoclomol	  treatment	  	  Representative	  western	  blot	  demonstrates	  that	  treatment	  of	  myogenic	  cultures	  (C)	  with	  Arimoclomol	   (C	  Ari+)	  or	   transfection	  with	  empty	  vector	   (EV)	  had	  no	  significant	  effect	  on	  the	  expression	  of	  ER	  stress	  proteins	  BiP,	  ATF	  or	  CHOP.	  	  	  βAPP	   overexpression	   was	   associated	   with	   significant	   elevation	   of	   the	  expression	   of	   BiP,	  where	   the	   increase	  was	   2.58	   ±0.68	   fold	   over	   control	   (n=3,	  p<0.05)	  and	  CHOP,	  at	  2.56	  ±0.58	  fold	  over	  control	  (n=3,	  p<0.05).	  Although	  ATF	  expression	   was	   consistently	   higher	   following	   βAPP,	   the	   magnitude	   of	   this	  increase	  was	  not	  significant.	  Exposure	  of	  myogenic	  cultures	  to	  IL1β	  had	  a	  similar	  effect	  to	  βAPP;	  there	  was	  significant	   elevation	   of	   BiP	   of	   3.33	   ±0.93	   fold	   of	   control	   (n=3,	   p<0.05)	   and	   of	  CHOP	  of	   2.47	  ±0.62	   fold	   (n=3,	   p<0.05).	   TNFα	   exposure	  was	   associated	  with	   a	  significant	  elevation	  of	  CHOP	  of	  2.32	  ±0.54	  fold	  (n=3,	  p<0.05).	  Treatment	  with	  Arimoclomol	  appeared	  comparatively	  to	  reduce	  the	  expression	  of	  ER	  stress	  markers	  induced	  by	  βAPP	  overexpression	  or	  cytokine	  exposure.	  A	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consistently	  lower	  band	  densitometry	  was	  observed	  across	  each	  western	  blots	  performed	   (n=3).	   However,	   this	   apparent	   reduction	   only	   reached	   statistical	  significance	   for	   CHOP	   following	   βAPP	   overexpression,	   where	   expression	   was	  reduced	   to	   49.6%	   ±4.3%	   of	   control	   (n=3,	   p<0.05)	   and	   following	   exposure	   to	  IL1β,	   where	   CHOP	   expression	   was	   reduced	   to	   62.7%	   ±6.4%	   of	   control	   (n=3,	  p<0.05)	  (Fig	  4.22).	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Figure	  4.22	  Effect	  of	  Arimoclomol	  of	  UPR	  Markers	  under	  IBM	  conditions	  A:	   Representative	  western	   blots	   examining	   Bip,	   ATF	   and	   CHOP	   expression	   in	  myogenic	   cultures	   under	   control	   conditions	   (C),	   overexpression	   of	   βAPP	   or	  exposure	  to	  IL1β/TNFα.	  Arimoclomol	  treatment	  is	  indicated	  by	  plus	  sign.	  B:	   Overexpression	   of	   βAPP	   or	   exposure	   to	   IL1β/TNFα	   were	   each	   associated	  with	  significant	  elevation	  of	  UPR	  markers.	  C:	   Arimoclomol	   treatment	   significantly	   reduced	   the	   expression	   of	   CHOP	  following	  overexpression	  of	  βAPP	  and	  exposure	  to	  IL1β.	  (Error	  Bars=SEM,	  n=3,	  Asterisk=p<0.05)	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4.2.5	  NFκB	  activation	  in	  myogenic	  cultures	  under	  IBM-­‐like	  conditions	  The	   status	   of	   NFκB	   activation	   in	   myogenic	   cultures	   was	   examined	   by	  determining	   the	   extent	   of	   nuclear	   staining	   for	   the	  p65	   subunit.	   Positive	  NFκB	  activation	  was	  defined	  as	  a	  multinucleated	  cell	  in	  which	  greater	  than	  50%	  of	  the	  nuclei	  were	  immunoreactive	  for	  NFκB.	  As	  a	  positive	  control,	  lipopolysaccharide	  exposure	  at	  concentrations	  between	  20	  and	  100	  ng/ml	  resulted	  in	  mean	  NFκB	  activation	   at	   close	   to	   100%	  of	   cells	   (between	  92.6%	  and	  95.9%	   respectively).	  Under	   standard	   culture	   conditions,	   between	   4%	   and	   9%	   of	   myotubes	  demonstrated	  NFκB	  activation.	  Although	   this	  apparent	  difference	  between	   the	  control	  populations	  of	  different	  experiments	  was	  not	  significant,	  each	  cytokine	  and	   the	   effect	   of	   APP	   overexpression	   were	   compared	   against	   their	   own	  contemporaneous	   control	   population	   cultured	   in	   different	   wells	   of	   the	   same	  plate,	  thereby	  minimizing	  the	  impact	  of	  inter-­‐culture	  variability	  on	  the	  apparent	  effect	  of	  each	  condition.	  The	  generic	  stressor	  of	  glucose	  deprivation	  for	  2	  hours	  was	   not	   associated	  with	   a	   significant	   change	   in	   the	   extent	   of	   NFκB	   activation	  (n=3).	  Exposure	  of	  cultures	  to	  cytokines	  was	  associated	  with	  a	  significant	   increase	   in	  the	   proportion	   of	   cells	   that	   demonstrated	   NFκB	   activation.	   Following	   IL1β	  exposure,	   between	   5ng/ml	   and	   20ng/ml,	   the	   significant	   increase	   in	   the	  proportion	  of	  cells	  demonstrating	  NFκB	  activation	  occurred	  in	  a	  concentration	  dependent	  manner.	  Compared	  to	  4.4%	  ±1.3%	  of	  cells	  in	  the	  control	  population,	  NFκB	   activation	   was	   detected	   in	   49.3%	   ±2.9%	   cells	   following	   exposure	   at	   5	  ng/ml	   (n=5,	   p<0.01)	   and	   88.1%	   ±6.3%	   cells	   following	   exposure	   at	   20ng/ml	  (n=5,	   p<0.01).	   TNFα	   exposure	   also	   induced	   NFκB	   activation.	   Against	   9.2%	  ±1.3%,	   of	   cells	   grown	   in	   standard	   conditions,	   this	   proportion	   increased	   to	  between	  46.6%	  ±3.7%	  at	  5	  ng/ml	  (n=5,	  p<0.01)	  and	  67.2%	  ±4.6%	  at	  20	  ng/ml	  (n=5,	  p<0.01).	  Interestingly,	   βAPP	   overexpression	  was	   also	   associated	  with	   NFκB	   activation.	  Compared	  with	  empty	  vector	  transfection,	  the	  proportion	  of	  cells	  in	  which	  most	  nuclei	  stained	  for	  the	  p65	  subunit	  increased	  from	  8.8%	  ±1.2%	  to	  43.1%	  ±6.2%	  (n=5,	  p<0.01)	  (Figs	  4.23	  and	  4.24).	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Figure	  4.23	  Effect	  of	  βAPP	  or	  exposure	  to	  inflammatory	  cytokines	  on	  NFκB	  
activation	  in	  myogenic	  cultures	  Myogenic	   cultures	   grown	   under	   standard	   conditions	   (A)	   demonstrate	   diffuse	  homogenous	  cytoplasmic	  NFκB	  p65	  staining,	  in	  contrast	  to	  a	  lack	  of	  associated	  nuclear	   immunopositivity.	   	   Exposure	   to	   IL1β	   (B)	   or	   TNFα	   (C),	   or	   βAPP	   over-­‐expression	  (D)	  induced	  nuclear	  translocation,	  confirmed	  by	  colocalisation	  with	  DAPI	   (D).	   In	   each	   condition,	   Arimoclomol	   treatment	   was	   associated	   with	   a	  reduction	   of	   nuclear	   translocation	   (following	   βAPP	   overexpression	   in	   E	   or	  exposure	  to	  IL1β	  in	  F).	  (Scale	  Bars=20μm)	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Figure	  4.24	  Effect	  of	  Arimoclomol	  on	  NFκB	  activation	  in	  myogenic	  cultures	  
following	  overexpression	  of	  βAPP	  or	  exposure	  to	  inflammatory	  cytokines	  Overexpression	  of	  βAPP	  (A)	  or	  exposure	   to	   IL1β	   (B)	  or	  TNFα	  (C)	   significantly	  increased	  NFκB	  activation	  compared	  to	  cultures	  transfected	  with	  empty	  vector	  or	   unexposed	   to	   cytokines	   respectively	   (white	   bars).	   In	   each	   condition,	   this	  effect	  was	  significantly	  inhibited	  by	  Arimoclomol	  treatment	  (black	  bars).	  (Error	   Bars=SEM,	   n=5,	   Star=p<0.05	   vs.	   untransfected	   or	   unexposed	   control	  cultures,	   Asterisk=p<0.05	   vs.	   corresponding	   condition	   minus	   Arimoclomol	  treatment)	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4.2.5.1	  The	  effect	  of	  Arimoclomol	  on	  NFκB	  activation	  in	  myogenic	  cultures	  under	  
IBM-­‐like	  conditions	  Treatment	   of	   myogenic	   cells	   cultured	   under	   standard	   conditions	   with	  Arimoclomol	  was	  not	  associated	  with	  a	  significant	  change	  in	  the	  extent	  of	  NFκB	  activation.	   This	   might	   reflect	   a	   small	   percentage	   of	   non-­‐specific	  immunocytochemical	   positivity	   that	   is	   not	   amenable	   to	   pharmacological	  manipulation,	   or	   that	   the	   mechanism	   of	   Arimoclomol’s	   effect	   depends	   on	   an	  NFκB	   activation	   pathway	   that	   is	   only	   active	   under	   the	   IBM-­‐like	   conditions	  tested.	  This	  is	  consistent	  with	  Arimoclomol’s	  known	  property	  as	  a	  coinducer	  of	  the	  HSR,	  which	  relies	  upon	  existing	  HSR	  activation	  at	  the	  time	  of	  treatment.	  In	  contrast,	  following	  βAPP	  overexpression	  or	  exposure	  to	  inflammatory	  cytokines,	  Arimoclomol	   treatment	   was	   associated	   with	   significant	   reduction	   of	   the	  proportion	  of	  myogenic	  cells	  with	  positive	  p65	  nuclear	  staining.	  Following	   IL1β	   exposure,	   the	   maximal	   effect	   of	   Arimoclomol	   treatment	   was	  observed	  at	  10ng/ml	   IL1β,	  where	  nuclear	  p65	  staining	  was	   reduced	   to	  35.7%	  ±5.2%	  compared	   to	  84.9%	  ±4.6%	   in	   the	  untreated	   comparator	   (n=5,	   p<0.01).	  Across	   all	   IL1β	   concentrations,	   the	   mean	   absolute	   reduction	   following	  Arimoclomol	  treatment	  was	  42.2%	  and	  mean	  relative	  reduction	  was	  57.8%.	  Following	   TNFα	   exposure,	   the	   maximal	   effect	   of	   Arimoclomol	   treatment	   was	  observed	  at	  20ng/ml	  TNFα.	  Here,	  nuclear	  p65	  staining	  was	  reduced	  from	  67.2%	  	  ±4.6%	   to	   45.3%	   ±4.8%	   (n=5,	   p<0.05).	   Across	   the	   concentrations	   tested,	   the	  mean	   absolute	   reduction	   following	   Arimoclomol	   treatment	   was	   17.9%	   and	  mean	  relative	  reduction	  was	  35.9%.	  Following	   βAPP	   over-­‐expression,	   Arimoclomol	   also	   significantly	   reduced	  apparent	  NFκB	  activation.	  Compared	  to	  43.1%	  ±6.2%,	  nuclear	  p65	  staining	  was	  reduced	   to	   23.6%	   ±4.2%	   of	   cells	   (n=5,	   p<0.05).	   This	   equates	   to	   an	   absolute	  reduction	  of	  19.5%	  and	  relative	  reduction	  45.2%.	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4.2.6	  The	  effect	  of	  Arimoclomol	  on	  βAPP	  or	  MHCI	  expression	  in	  myogenic	  cultures	  	  Two	   of	   the	   notable	   effects	   of	   both	   βAPP	   transfection	   and	   exposure	   to	  inflammatory	  cytokines	  were	   the	  consequent	  upregulation	  of	  βAPP	  and	  MHCI.	  In	   these	   experiments,	   the	   upregulation	   of	   βAPP	   was	   an	   evidently	   upstream	  effect	  through	  direct	  overexpression.	  In	  IBM	  in	  vivo,	  the	  upregulation	  of	  MHCI	  is	  postulated	  to	  be	  an	  upstream	  and	  central	  pathogenic	  feature.	  Therefore,	  it	  was	  hypothesised	   that	   Arimoclomol’s	  mechanism	   could	   depend	   on	   either	   of	   these	  two	   features.	  However,	  western	  blots	  demonstrated	   that	  Arimoclomol	  did	  not	  significantly	  affect	  the	  concentration	  of	  either	  βAPP	  or	  MHCI,	  when	  either	  was	  upregulated	   following	   βAPP	   overexpression	   or	   exposure	   to	   IL1β	   or	   TNFα	  (Figure	  4.25).	  	  
	  
Figure	  4.25	  Effect	  of	  Arimoclomol	  on	  βAPP	  and	  MHC	  Class	  I	  expression	  Representative	  western	   blots	   demonstrate	   that	  Arimoclomol	   treatment	   (+Ari)	  has	  no	  significant	  effect	  on	  the	  expression	  of	  βAPP	  (A)	  or	  MHCI	  (B)	  in	  myogenic	  cultures	  after	  transfection	  of	  βAPP	  or	  exposure	  to	  inflammatory	  cytokines.	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4.2.7	  Summary	  of	  Results	  1.	  The	  Heat	  Shock	  Response	  (HSR),	  determined	  by	  expression	  of	  key	  Heat	  Shock	  Protein,	   HSP70,	   is	   activated	   in	   primary	   myogenic	   cell	   cultures	   by	  overexpression	  of	  βAPP	  or	  exposure	  to	  cytokines	  IL1β	  and	  TNFα.	  This	  effect	  can	  be	   significantly	   augmented	   through	   treatment	   with	   the	   HSR	   co-­‐inducer	  Arimoclomol.	  2.	   Overexpression	   of	   βAPP	   or	   exposure	   to	   cytokines	   IL1β	   and	   TNFα	   are	  cytotoxic	   to	   myogenic	   cells,	   determined	   by	   the	   MTT	   cell	   viability	   assay.	  Arimoclomol	   treatment	   significantly	   improves	   cell	   viability	   under	   these	  conditions.	  3.	   TDP-­‐43	   translocation	   from	   the	   nucleus	   to	   the	   cytoplasm	   can	   be	   induced	  through	  overexpression	  of	  βAPP	  or	  exposure	  to	  cytokines	  IL1β	  and	  TNFα.	  This	  is	   quantifiable	   through	   the	   phenomenon	   of	   loss	   of	   normal	   nuclear	  immunostaining.	   Arimoclomol	   treatment	   significantly	   attenuates	   this	   TDP-­‐43	  mislocalisation.	  4.	  TDP-­‐43	  expression	  is	  increased	  by	  the	  same	  IBM-­‐relevant	  stimuli	  and	  can	  be	  restored	  to	  levels	  of	  control	  cultures	  by	  Arimoclomol	  treatment.	  5.	  	  Calcium	  dyshomeostasis	  is	  evidenced	  in	  myogenic	  cultures	  following	  βAPP	  or	  exposure	  to	  cytokines	  IL1β	  and	  TNFα	  through	  elevated	  basal	  cytosolic	  calcium	  concentration	   and	   reduced	   ER	   calcium	   concentration.	   Arimoclomol	   treatment	  confers	  significant	  protection	  against	  these	  effects.	  6.	   ER	   stress	   is	   further	   evidenced	   in	   these	   conditions	   through	   elevated	  expression	   of	   key	   markers	   of	   the	   UPR.	   Arimoclomol	   treatment	   reduces	   this	  evidence	  of	  ER	  stress	  in	  myogenic	  cultures.	  7.	   NFκB	   activation	   is	   demonstrated	   by	   myogenic	   cultures	   following	   βAPP	   or	  exposure	   to	   cytokines	   IL1β	   and	   TNFα.	   This	   is	   inhibited	   by	   Arimoclomol	  treatment.	  8.	   The	   effects	   of	   Arimoclomol	   to	   reduce	   these	   features	   of	   IBM	   pathology,	  recapitulated	  in	  primary	  myogenic	  cultures,	  are	  not	  dependent	  on	  alteration	  of	  βAPP	  or	  MHCI	  expression.	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4.3	  Discussion	  	  
4.3.1	  Augmentation	  of	  the	  Heat	  Shock	  Response	  by	  Arimoclomol	  The	  baseline	  HSP70	  expression	  demonstrated	  by	  control	  cultures	  could	  reflect	  a	  number	   of	   scenarios.	   It	   is	   unlikely	   that	   this	   reflects	   non-­‐specific	   antibody	  staining	   since	   there	   is	   consistency	   between	   immunocytochemical	   and	  immunoblotting	   techniques.	   There	   may	   be	   a	   constitutive	   level	   of	   HSP70	  expression	  in	  myotubes	  and,	  as	  is	  the	  case	  in	  MHC	  Class	  I	  expression,	  this	  may	  reflect	   normal	   upregulation	   during	   maturation	   rather	   than	   in	   response	   to	   a	  cytotoxic	   stimulus.	   The	   normal	   concentration	   of	   HSP70	   in	   skeletal	   muscle	   in	  
vivo	   has	   not	   been	   examined	   so	   estimation	   of	   a	   comparable	   baseline	   here	   is	  difficult.	   Nevertheless,	   it	   is	   reasonable	   to	   consider	   even	   ‘control’	   in	   vitro	  conditions	   as	   representing	   an	   element	   of	   cellular	   stress,	   which	   would	   be	  expected	  to	  trigger	  a	  cytoprotective	  heat	  shock	  response.	  	  Transfection	  of	  primary	  myogenic	  cultures	  with	  βAPP	  or	  exposure	  to	  cytokines	  results	   in	   a	   number	   of	   pathological	   features	   that	   indicate	   cellular	   stress,	  therefore	  it	  is	  unsurprising	  that	  these	  conditions	  are	  associated	  with	  increased	  expression	   of	   HSP70.	   This	   is	   consistent	   with	   the	   upregulation	   of	   HSP70	  observed	  in	  IBM	  tissue	  in	  vivo	  (Parker	  et	  al.	  2009).	  	  Treatment	  with	  Arimoclomol	  augmented	  the	  upregulation	  of	  HSP70	  after	  βAPP	  over-­‐expression	   or	   exposure	   to	   cytokines,	   in	   keeping	   with	   its	   known	  pharmacological	   action.	   Interestingly,	   this	   effect	   was	   not	   uniform.	   Whilst	   a	  comparable	  magnitude	  of	  upregulation,	  of	  4	  to	  5	   fold	  of	  control,	  was	  observed	  following	  exposure	  to	  cytokines,	  the	  effect	  was	  more	  pronounced	  in	  association	  with	  βAPP	  over-­‐expression,	  to	  approximately	  8	  fold.	  Clearly,	  as	  the	  ‘strength’	  of	  the	  stimulus	  cannot	  be	  standardised	  between	  these	  two	  quite	  different	  stresses,	  inferences	   about	   the	   significance	   of	   this	   differential	   response	   depended	   on	  further	   information	   regards	   the	  magnitude	  of	   other	  pathological	   outcomes,	   as	  examined	  in	  subsequent	  experiments.	  However,	  this	  does	  suggest	  that	  the	  effect	  of	  Arimoclomol	  might	  depend	  on	  other	  factors	  beyond	  only	  the	  extent	  to	  which	  the	  HSR	  is	  activated	  at	  the	  time	  of	  treatment.	  In	  the	   in	  vitro	  environment,	   it	  would	  be	  useful	  to	  determine	  the	  impact	  of	  HSR	  inhibition	   or	   HSP70	   down-­‐regulation	   on	   the	   susceptibility	   to	   the	   various	  
	   180	  
pathological	  features	  described	  in	  Chapter	  3	  and	  below.	  This	  may	  help	  to	  clarify	  whether	   physiological	   activation	   of	   the	   HSR	   confers	   cytoprotective	   benefit,	  which	   is	   particularly	   relevant	   in	   considering	   the	   role	   of	   ageing	   in	   IBM.	   This	  could	  be	   further	  studied	  through	  examination	  of	   the	   inducibility	  of	   the	  HSR	   in	  IBM	  tissue	  compared	  to	  age-­‐matched	  and	  non-­‐age	  matched	  controls.	  	  
4.3.2	   Exposure	   to	   IBM-­‐relevant	   stress	   induces	   cell	   death	   in	   primary	   myogenic	  
cultures	  	  A	  high	  throughput	  viability	  assay	  represents	  an	  important	  component	  of	  a	  cell	  model	  based	  technique	  for	  analysing	  the	  effect	  of	  drugs.	  The	  MTT	  assay,	  through	  its	  broad	  dependence	  of	  mitochondrial	   reduction	  enzyme	  activity	   represented	  an	   IBM-­‐relevant	   selection	   from	   the	   standard	   panel	   of	   assays.	   This	   could	   form	  the	  primary	  ‘screening’	  tool	  for	  selection	  of	  promising	  compounds	  from	  a	  given	  selection,	   before	  more	   disease	   specific	   tools	   are	   employed	   to	   provide	   greater	  detail	  on	  mechanism	  of	  action	  (van	  Meerloo	  et	  al.	  2011).	  Control	   experiments	   using	   the	   generic	   stimulus	   of	   glucose	   deprivation	  demonstrated	   that	   the	   technique	   was	   both	   reproducible	   and	   sufficiently	  sensitive	   to	   detect	   the	   impact	   of	   a	   pathological	   insult	   of	   graded	   magnitude.	  Furthermore,	   the	   correlation	   between	   the	   outcome	   of	   the	  MTT	   assay	   and	   the	  magnitude	   of	   the	   insult	   (i.e.	   degree	   of	   glucose	   deprivation)	   appeared	   strong,	  implying	   that	   the	  MTT	  assay	  could	  be	  used	   to	  estimate	   the	  magnitude	  of	  both	  the	  subsequent	  IBM-­‐relevant	  insults	  and	  effect	  of	  drug	  treatment.	  However,	  the	  relatively	   large	   inter-­‐experimental	   variance	   in	   absolute	   MTT	   reduction	   was	  noted	  as	  a	  potential	  limitation	  of	  the	  technique.	  Although	   the	   dependence	   of	   the	  MTT	   assay	   on	  mitochondrial	   enzyme	   activity	  implies	   mitochondrial	   dysfunction	   as	   a	   mechanism	   of	   the	   cytotoxicity	  demonstrated	   by	   the	   tested	   conditions,	   this	   may	   simply	   represent	   a	   final	  common	   pathway	   phenomenon	   and	   does	   not	   prove	   that	   mitochondrial	  dysfunction	   is	   either	   a	   central	   or	   upstream	   component	   of	   the	   corresponding	  pathological	  mechanism.	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4.3.2.1	  βAPP	  over-­‐expression	  in	  myogenic	  cells	  is	  cytotoxic	  	  Since	   Lipofectamine™	   transfection	   achieves	   transient	   overexpression	   of	   the	  corresponding	  gene,	  the	  effect	  of	  βAPP	  overexpression	  was	  examined	  at	  both	  48	  and	   96	   hours	   after	   transfection.	   By	   48	   hours,	   βAPP	   overexpression	   was	  associated	  with	  significantly	  reduced	  cell	  viability	  and	  this	  effect	  was	  greater	  by	  96	   hours,	   implying	   accumulation	   of	   cytotoxic	   processes.	   It	   is	   likely	   this	  represents	   either	   an	   increase	   in	   concentration	   of	   βAPP	   which,	   if	   directly	  cytotoxic,	   would	   reduce	   cell	   viability	   or	   that	   the	   initial	   trigger	   of	   βAPP	  overexpression	   triggers	   a	   pathological	   cascade	   that	   advances	   for	   at	   least	   96	  hours	  after	   initial	   transfection.	   	  Although	  EV	  transfection	  was	  also	  cytotoxic	   in	  comparison	   to	  non-­‐transfected	  controls,	   this	  was	  not	  a	  progressive	  effect.	   It	   is	  known	  that	  plasmid	  transfection	  can	  be	  associated	  with	  inherent	  cytotoxicity,	  in	  addition	  to	  any	  effects	  of	  the	  transfected	  product.	  However,	  the	  effects	  of	  βAPP	  were	   significantly	   greater	   than	   EV,	   suggesting	   a	   specific	   cytotoxic	   impact	  through	  βAPP	  itself.	  	  	  
4.3.2.2	  Exposure	  of	  myogenic	  cells	  to	  inflammatory	  mediators	  is	  cytotoxic	  	  Inflammatory	   mediators	   were	   characterised	   by	   a	   dose	   dependent	   and	  significant	  reduction	  in	  cell	  viability,	  indicated	  by	  the	  MTT	  assay.	  However,	  the	  character	  of	  this	  effect	  differed	  between	  mediators,	  such	  as	  the	  flatter	  response	  observed	  with	  LPS	  and	  steeper	  response	  observed	  with	  TNFα.	  Nevertheless,	  the	  proportional	  nature	  of	  each	  relationship	  suggests	  that	  LPS,	  IL1β	  and	  TNFα	  elicit	  a	  direct	   and	   specific	   cytotoxic	   effect	   on	  myotubes	   in	  vitro.	   Furthermore,	   these	  experiments	   demonstrate	   that	   the	   concentrations	   of	   cytokines	   used	   are	  appropriate	  in	  this	  context,	  where	  a	  significant	  pathological	  stimulus	  is	  required,	  but	   not	   to	   the	   extent	   that	   its	   effects	   are	   uniformly	   cytotoxic.	   Interestingly,	   a	  comparable	   magnitude	   of	   cytotoxicity	   was	   associated	   with	   βAPP	   transfection	  and	   exposure	   to	   cytokines	   at	   these	   concentrations.	   This	   permits	   some	  comparison	  to	  be	  made	  in	  subsequent	  investigation	  of	  pathological	  mechanisms,	  which	  may	  otherwise	  have	  simply	  reflected	  different	  magnitudes	  of	  stimuli.	  	  
	   182	  
4.3.2.3	   Treatment	   with	   Arimoclomol	   improves	   cell	   viability	   in	   myogenic	   cells	  
exposed	  to	  IBM-­‐relevant	  stress	  Treatment	  of	  control	  cultures	  with	  Arimoclomol	  had	  no	  significant	  effect	  on	  cell	  viability,	   as	   would	   be	   expected	   of	   a	   co-­‐inducer	   of	   the	   HSR	  whose	   function	   is	  restricted	   to	   environments	   of	   existing	   HSR	   activation	   through	   cellular	   stress	  (Kalmar	   et	   al.	   2014).	   Furthermore,	   the	   absence	   of	   effect	   on	   control	   cultures	  demonstrates	  that	  Arimoclomol’s	  effects	  under	  IBM-­‐like	  stresses	  are	  not	  simply	  the	   consequence	   of	   non-­‐specific	   elevation	   in	   MTT	   activity	   by	   Arimoclomol.	  Rather,	   Arimoclomol	   appeared	   to	   attenuate	   the	   cytotoxic	   impact	   of	   IBM-­‐relevant	  stimuli.	  Following	   βAPP	   overexpression,	   the	   effect	   of	   Arimoclomol	  was	   dependent	   on	  the	   time	  at	  which	   the	  cells	  were	  analysed.	  By	  48	  hours,	  a	   significant	  cytotoxic	  effect	  was	  evident	  but	  this	  was	  not	  significantly	  attenuated	  by	  Arimoclomol.	  By	  96	  hours,	   the	  magnitude	  of	   the	  cytotoxic	  effect	  was	  more	  pronounced	  and	  the	  impact	  of	  Arimoclomol	  considerably	  greater,	  restoring	  cell	  viability	  to	  that	  of	  EV	  control.	   The	   discrepancy	   in	   this	   effect	   of	   Arimoclomol	   at	   various	   time	   points	  after	  transfection	  could	  reflect	  one	  or	  more	  of	   three	  factors.	  First,	   the	  effect	  of	  Arimoclomol	  might	  depend	  on	  the	  degree	  of	  underlying	  cell	  stress.	  Secondly,	  the	  cytotoxic	   effects	   of	   the	   stimulus	   or	   cytoprotective	   effects	   of	  Arimoclomol	  may	  not	  manifest	  within	  the	  shorter	  time	  frame	  of	  48	  hours.	  Thirdly,	  the	  additional	  medium	   change	   and	   thereby	   additional	   provision	   of	   Arimoclomol	   included	   in	  the	  96-­‐hour	  experiment	  may	  enhance	  cytoprotection.	  Regardless	  of	  the	  nature	  of	   the	  phenomenon,	  Arimoclomol	   is	  clearly	  cytoprotective	  under	  conditions	  of	  IBM-­‐relevant	   cellular	   stress.	   These	   experiments	   also	   supported	   the	   use	   of	   the	  96-­‐hour	   post-­‐transfection	   time-­‐point	   for	   subsequent	   experiments	   involving	  Arimoclomol.	  Arimoclomol	  also	  significantly	  attenuated	  the	  cytotoxic	  impact	  of	  inflammatory	  mediators	   on	   myogenic	   cells.	   The	   magnitude	   of	   this	   effect	   was	   not	   simply	  proportional	  to	  the	  degree	  of	  cytotoxicity,	  implying	  specificity	  of	  the	  drug	  action	  to	  the	  mechanisms	  of	  the	  pathological	  stimuli.	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4.3.3	  IBM-­‐relevant	  stress	  induces	  TDP-­‐43	  pathology	  in	  myogenic	  cells	  As	  observed	  in	  control	  cultures,	  TDP-­‐43	  was	  normally	  located	  in	  the	  cell	  nuclei.	  When	   cells	  were	   exposed	   to	   inflammatory	   cytokines	   or	   βAPP	   overexpression,	  TDP-­‐43	   translocated	   to	   the	   cytoplasm.	   There	   was	   subsequent	   loss	   of	   nuclear	  staining	  and	  formation	  of	  discrete	  TDP-­‐43	  cytoplasmic	  aggregates,	  which	  were	  both	  ubiquinated	   inclusions	  and	  non-­‐ubiquinated.	  Western	  blots	  revealed	   that	  the	  concentration	  of	  TDP-­‐43	  rose	  in	  response	  to	  IL1β,	  TNFα	  and	  βAPP.	  The	   overwhelming	   predominance	   of	   nuclear	   based	   TDP-­‐43	   immunostaining	  under	  control	  conditions,	  with	  subsequent	  cytoplasmic	  translocation	  following	  pathological	   stimuli,	   is	   in	   keeping	   with	   previous	   work	   on	   muscle	   and	   other	  tissues	   (Salajegheh	   et	   al.	   2009;	   Giordana	   et	   al.	   2010).	   The	   additional	   low	  intensity	  homogenous	  cytoplasmic	  staining	  under	  normal	  conditions	  may	  either	  reflect	   non-­‐specific	   staining	   or	   known	   low-­‐level	   nuclear-­‐cytoplasmic	   TDP-­‐43	  shuttling	  (Ayala	  et	  al.	  2008).	  It	  is	  unclear	  whether	  the	  marked	  redistribution	  of	  TDP-­‐43,	  under	  IBM-­‐relevant	  stress	  represents	  a	  physiological	  change	  in	  shuttling	  or	  a	  pathogenic	  factor.	  The	  cytoplasmic	  proteinaceous	  aggregates	  of	  TDP-­‐43	  observed	  in	  these	  experiments	  are	   likely	   to	   represent	   a	   combination	   of	   the	   non-­‐ubiquinated	   ‘pre-­‐inclusions’	  and	  more	  typical	  ubiquinated	  inclusions	  that	  characterise	  TDP-­‐43	  pathology	  in	  muscle	  and	  other	   tissues	  (Lee	  et	  al.	  2012).	  Most	  notably,	  a	  comparison	  can	  be	  drawn	  with	  work	  on	  skeletal	  muscle	  biopsies	  that	  demonstrated	  a	  highly	  similar	  phenomenon	   in	   IBM	   muscle	   (Chapter	   4	   Introduction,	   Figure	   4.2).	   The	  reproduction	  of	   this	   feature,	  which	  appears	   to	  be	  highly	  specific	   to	   IBM	   in	   the	  context	   of	   skeletal	   muscle	   disease,	   in	   myotubes	   in	   vitro	   is	   an	   important	  component	  of	  this	  model.	  The	  results	  here	  also	  shed	  further	  light	  on	  the	  pattern	  through	  which	  this	  cytoplasmic	  redistribution	  occurs,	  in	  that	  cytoplasmic	  TDP-­‐43	  aggregates	   typically	  preceded	   loss	  of	  nuclear	  staining.	  However,	   the	   loss	  of	  nuclear	  staining	  in	  some	  cells	  without	  contemporaneous	  cytoplasmic	  inclusions	  is	   intriguing.	  This	  might	  reflect	  sufficient	  UPS	  or	  autophagic	  processing	  among	  certain	  cells	  that	  prevents	  accumulation	  of	  TDP-­‐43	  inclusions	  or	  facilitates	  their	  breakdown.	  Equally,	   the	  presence	  of	   cytoplasmic	  TDP-­‐43	  does	  not	  necessarily	  appear	  to	  be	  fundamental	  to	  its	  pathogenic	  effects	  (Igaz	  et	  al.	  2011).	  The	  various	  
	   184	  
morphologies	   observed	   in	   these	   experiments	   may	   simply	   reflect	   the	   broad	  spectrum	  of	  TDP-­‐43	  pathological	  characteristics.	  In	  models	  of	  TDP-­‐43	  pathology	  in	  neurons,	  loss	  of	  nuclear	  TDP-­‐43	  has	  appeared	  to	  be	  both	  a	  consistent	  feature	  and,	   through	   its	   association	   with	   the	   ‘pre-­‐inclusions’	   or	   ubiquitin-­‐negative	  inclusions	   that	  precede	  other	   types	  of	  proteinaceous	  aggregate,	   an	  apparently	  early	  component	  of	  the	  TDP-­‐43	  pathological	  spectrum	  (Walker	  et	  al.	  2013).	  Further	   work	   could	   determine	   what	   proportion	   of	   mislocalised	   TDP-­‐43	  represents	   stress	   granules,	   pre-­‐inclusion	   or	   mature	   inclusions,	   which	   would	  help	   determine	   the	   time	   course	   of	   morphological	   changes	   demonstrated	   in	  these	  experiments.	  It	  would	  also	  be	  interesting	  to	  determine	  whether	  the	  25kDa	  C-­‐terminal	  fragments	  are	  detectable	  in	  this	  model.	  A	  corresponding	  protein	  was	  not	  detected	  in	  significant	  quantity	  on	  western	  blotting,	  implying	  that	  this	  is	  not	  a	  predominant	  form	  here.	  	  Despite	   the	   variety	   of	   morphological	   patterns	   detected,	   those	   cells	   within	   an	  individual	   culture	   were	   typically	   consistent	   in	   their	   appearance.	   This	   is	  most	  likely	  to	  reflect	  consistency	  of	  the	  response	  to	  a	  controlled	  stimulus.	  However,	  the	  notion	  of	  intercellular	  influence,	  through	  prion-­‐like	  cell-­‐to-­‐cell	  propagation	  of	   TDP-­‐43	   pathology,	   is	   increasingly	   entertained	   as	   a	   mechanism	   in	  neurodegenerative	  disease	   in	  vivo.	  A	  prion-­‐like	  domain	  was	  detected	   in	   the	  C-­‐terminus	   of	   TDP-­‐43	   (Cushman	   et	   al.	   2010).	   There	   is	   evidence	   to	   support	   the	  TDP-­‐43	  being	  transferred	  between	  neuronal	  cell	  types	  via	  exosomes	  (Nonaka	  et	  al.	  2013).	  The	  phenomenon	  has	  not	  yet	  been	  demonstrated	   in	  skeletal	  muscle.	  However,	   this	  would	   be	   an	   interesting	   concept	   in	   the	   context	   of	   degenerative	  muscle	   diseases,	   each	   of	   whose	   particular	   anatomical	   distribution	   remains	  largely	  unexplained.	  This	  might	  mirror	  the	  predilection	  of	  certain	  degenerative	  diseases	  of	  the	  central	  nervous	  system	  for	  particular	  lobes	  of	  the	  brain,	  such	  as	  fronto-­‐temporal	   dementia.	   If	   a	  mechanism	   such	   as	   TDP-­‐43	   pathology	  were	   to	  spread	  akin	  to	  an	  infectious	  agent,	  conditions	  specific	  to	  myofibres	  of	  individual	  muscles	   (for	   example	   subtle	   pH	   differences	   or	   fibre	   type	   distributions)	   could	  initiate	  a	  pathogenic	  cascade	  that	  would	  evolve	  geographically	  from	  the	  original	  focus,	   thereby	   involving	   an	   increasing	   proportion	   of	   each	  muscle.	   This	  would	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ultimately	  explain	  the	  more	  pronounced	  clinical	  manifestations	  in	  those	  regions	  rather	  than	  in	  others.	  	  
4.3.3.1	  TDP-­‐43	  concentration	  increases	  under	  IBM-­‐relevant	  stress	  Several	  stimuli	  have	  previously	  been	  shown	  to	  increase	  TDP-­‐43	  concentration,	  including	  axotomy	  (Moisse	  et	  al.	  2009),	  oxidative	  stress	  (Colombrita	  et	  al.	  2009),	  heat	  shock	  and	  thapsigargin	  treatment	  (McDonald	  et	  al.	  2011).	  Therefore,	   it	   is	  unsurprising	  that	  what	  appears	  to	  be	  a	  generic	   ‘stress’	  response	  was	  activated	  in	  by	  IBM-­‐like	  conditions	   in	  these	  experiments,	  and	  by	  the	  generic	  stimulus	  of	  glucose	   deprivation.	  No	   direct	   response	   has	   previously	   been	   demonstrated	   to	  IL1β,	  TNFα	  or	  overexpression	  of	  βAPP	  although	  the	  coexistence	  of	  TDP-­‐43	  and	  amyloid	   pathology	   in	   neurodegenerative	   diseases	   such	   as	  Alzheimer’s	   disease	  suggests	  overlap	  in	  their	  pathogenic	  mechanisms.	  In	  general,	  overexpression	  of	  full-­‐length	  TDP-­‐43	   in	  other	   cell	  models	  has	  not	  produced	   cytoplasmic	  TDP-­‐43	  aggregation	   (Ash	   et	   al.	   2010).	   If	   that	   applies	   here,	   a	   deficiency	   of	   cellular	  breakdown	  machinery	   rather	   than	   the	   increased	   concentration,	   demonstrated	  by	  the	  western	  blots,	  could	  account	  the	  morphological	  features	  detected.	  Indeed,	  inhibition	   of	   the	   UPS	   has	   been	   shown	   to	   increase	   TDP-­‐43	   aggregates	   in	   vitro	  (Winton	   et	   al.	   2008).	   This	   mechanism	   is	   likely	   to	   be	   augmented	   by	   the	  proteasomal	   inhibition	   that	   results	   from	   intracellular	   accumulation	  of	  TDP-­‐43	  (Nonaka	  et	   al.	  2013).	  Consistently,	   the	  overexpression	  of	  p62	   reduces	  TDP-­‐43	  aggregation	  through	  autophagic	  and	  proteasomal	  breakdown	  pathways	  (Brady	  et	   al.	   2011).	   Cytoplasmic	   redistribution	   of	   TDP-­‐43,	   through	   sequestration	   and	  nuclear	   loss,	   has	   also	   been	   proposed	   to	   disturb	   its	   autoregulation	   by	  upregulating	  TDP-­‐43	  expression,	   thereby	  establishing	  a	  potentially	  pathogenic	  positive	   cycle	   (Lee	   et	   al.	   2012).	   Regardless,	   increased	   concentration	   of	   full-­‐length	  of	  TDP-­‐43,	  whether	  contributory	  to	  the	  cytoplasmic	  aggregation	  load	  or	  otherwise,	   appears	   to	  be	   cytotoxic	   (Li	   et	   al.	   2010)	  and,	   indeed,	   is	   sufficient	   to	  reproduce	  disease	  phenotypes	  such	  as	  FTD	  (Tsai	  et	  al.	  2010).	  	  
4.3.3.2	  Consequences	  of	  TDP-­‐43	  translocation	  These	  data	  support	  the	  hypothesis	  that	  TDP-­‐43	  mislocalisation	  in	  IBM	  could	  be	  a	  consequence	  of	  upstream	  degenerative	  or	   inflammatory	   triggers,	  which	  may	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not	  be	  specific	  to	  IBM.	  However,	  it	  is	  useful	  to	  consider	  the	  additional	  possibility	  that	   TDP-­‐43	   pathology	   could	   represent	   an	   early	   event	   in	   IBM	   in	   vivo,	   which	  cannot	  be	  tested	  in	  the	  cellular	  model	  used	  here.	  Further	  understanding	  of	  the	  potential	   consequences	  of	  TDP-­‐43	  mislocalisation	  and	  aggregation	  would	  help	  clarify	   its	   position	   in	   IBM	   pathogenesis,	   particularly	   with	   respect	   to	  inflammation.	   For	   example,	   the	   distinction	   between	   PM	   and	   IBM	   might	  represent	   a	   different	   threshold	   for	   initiation	   of	   TDP-­‐43	   pathology	   under	  inflammatory	  mediated	  ‘stress’,	  due	  to	  underlying	  genetic	  predisposition	  or	  the	  relatively	  more	  aged	  cellular	  milieu.	  Alternatively,	  activation	  of	  NFκB	  in	  TDP-­‐43	  disease	  states	  such	  as	  IBM-­‐FTD-­‐PD	  may	  contribute	  to	  a	  secondary	  inflammatory	  response,	   such	   as	   that	   observed	   in	   myofibrillar	   myopathy,	   in	   which	   TDP-­‐43	  pathology	   is	   also	   observed,	   or	   in	   Duchenne	   muscular	   dystrophy	   (Olive	   et	   al.	  2009;	  Messina	   et	   al.	   2011).	   Intriguingly,	   increased	   prevalence	   of	   autoimmune	  diseases	   has	   been	   observed	   in	   the	   semantic	   variants	   of	   FTD	   and	   progranulin	  mutation	   carriers	   (Miller	   et	   al.	   2013).	   Progranulin	   appears	   to	   have	   several	  inflammatory	   functions,	   notably	   TNFα	   antagonism,	   meaning	   its	   deficiency	  through	  mutation	  might	  augment	  the	  TNFα	  immune	  response.	  Indeed,	  there	  is	  
in	   vitro	   evidence	   that	   TDP-­‐43	   can	   induce	   neuroinflammation,	   increasing	  concentrations	  of	  IL-­‐6	  and	  TNFα	  (Herman	  et	  al.	  2012).	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4.3.3.3	  Arimoclomol	  attenuates	  TDP-­‐43	  pathology	  following	  IBM-­‐relevant	  stress	  in	  
myogenic	  cells	  	  A	   small	   proportion	  of	   cells	   in	   control	   populations,	   including	   those	   transfected	  with	   empty	   vector,	   demonstrated	   TDP-­‐43	   pathology.	   This	   implies	   either	   that	  this	  process	  of	  culture	  induces	  a	  degree	  of	  TDP-­‐43	  pathology	  or	  that	  myotubes	  
in	   vitro,	   unlike	   skeletal	   muscle	   in	   vivo,	   display	   a	   constitutive	   level	   of	   TDP-­‐43	  mislocalisation.	   Treatment	   with	   Arimoclomol	   did	   not	   affect	   this	   background	  phenomenon.	   Although	   this	   might	   suggest	   that	   it	   is	   not	   the	   result	   of	   cellular	  stress,	   Arimoclomol	   attenuated,	   rather	   than	   fully	   reversed	   the	   more	  pronounced	  TDP-­‐43	  pathology	  observed	  under	   IBM-­‐like	   conditions.	  Therefore	  multiple	  pathways	  might	  contribute	  towards	  TDP-­‐43	  mislocalisation,	  not	  all	  of	  which	  are	  influenced	  or	  entirely	  blocked	  by	  Arimoclomol	  or	  the	  HSR.	  	  Notably,	  Arimoclomol	  was	  found	  to	  confer	  significant	  protection	  against	  TDP-­‐43	  pathology,	   whether	   induced	   by	   degenerative	   or	   inflammatory	   stimuli.	   The	  magnitude	  of	   this	   effect	  was	  not	   simply	  proportional	   to	   the	  degree	  of	  TDP-­‐43	  mislocalisation	  related	  to	  the	  untreated	  comparator	  population,	  implying	  some	  selectivity	   of	   effect.	   However,	   following	   TNFα	   and	   IL1β	   exposure,	   there	   the	  extent	  of	  TDP-­‐43	  pathology	  after	  Arimoclomol	   treatment	  remained	  dependent	  on	   the	   cytokine	   dose.	   This	  may	   reflect	   a	   limitation	   of	  Arimoclomol’s	   action	   in	  this	  context	  or,	  again,	  that	  it	  does	  not	  influence	  all	  the	  processes	  that	  contribute	  to	  TDP-­‐43	  pathology.	  It	  was	  notable	  that	  cells	  within	  an	  individual	  culture	  well	  tended	  to	  display	  a	  relatively	  homogenous	  TDP-­‐43	  pattern,	  particularly	  whether	  nuclear	   staining	   was	   retained	   or	   lost.	   The	   numerical	   differences	   described	  between	   conditions	   thereby	   reflect	   a	   tendency	   to	   pathology	   within	   defined	  groups	   of	   cells	   rather	   than	   of	   random	   individual	   cells	   within	   the	   overall	  population.	   This	   might	   reflect	   subtle	   differences	   between	   conditions	   in	   given	  wells	   related	   to	  a	   threshold	  at	  which	  TDP-­‐43	  mislocalisation	  occurs	  or	   can	  be	  reversed.	  A	   likely	   mechanism	   through	   which	   Arimoclomol	   attenuates	   TDP-­‐43	  mislocalisation	   is	   augmented	   chaperoning	   through	   increased	   expression	   of	  HSPs	  such	  as	  HSP70.	  HSP70,	  in	  addition	  to	  HSP40,	  has	  been	  shown	  to	  regulate	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nuclear	   aggregation	   of	   TDP-­‐43	   in	   response	   to	   heat	   shock	   (Udan-­‐Johns	   et	   al.	  2014),	  which	  could	  influence	  its	  propensity	  to	  translocate	  and	  form	  cytoplasmic	  inclusions.	  The	  cytoprotective	  effect	  of	  Arimoclomol	  described	  in	  other	  models	  of	  proteinaceous	  aggregation,	  discussed	  above,	  indicate	  that	  Arimoclomol’s	  anti-­‐aggregation	  properties	  are	  likely	  to	  contribute	  to	  the	  reduced	  cytoplasmic	  TDP-­‐43	   aggregation	   observed	   in	   these	   experiments.	   These	   properties	   appear	   to	  depend	   primarily	   on	   upregulation	   of	   HSPs.	   The	   auto-­‐feedback	   loop	  demonstrated	  by	  TDP-­‐43	  (Lee	  et	  al.	  2012)	  might	  explain	  the	  associated	  decline	  in	  concentration.	  Down-­‐regulation	  of	  TDP-­‐43	  gene	  expression,	  either	  by	  HSPs	  or	  Arimoclomol	   directly,	   is	   also	   possible	   and	   this	   may,	   in	   turn,	   minimise	   the	  amount	  that	  subsequently	  translocates	  or	  aggregates.	  Finally,	   it	   is	   also	   possible	   that	   Arimoclomol	   exerts	   an	   HSR-­‐independent	  mechanism	   on	   TDP-­‐43	   pathology,	   which	   could	   be	   explored	   through	   HSP	  knockdown	  or	  contemporaneous	  inhibition.	  Indeed,	  hydroxylamine	  derivatives	  such	  as	  Arimoclomol	  have	  been	  suggested	  to	  alter	  the	  metabolism	  of	  membrane	  lipid	   rafts,	   resulting	   in	   an	  HSF-­‐independent	  mechanism	  of	  HSR	  activation	   that	  improves	   resistance	   to	   cellular	   stress	   (Kalmar	   et	   al.	   2014).	   Equally,	   an	  inhibitory	   action	   on	   reactive	   oxygen	   species	   has	   been	   postulated,	   which	  may	  contribute	  to	  attenuating	  the	  stimulus	  for	  TDP-­‐43	  translocation.	  	  	  
4.3.4	  ER	  stress	  and	  Calcium	  dyshomeostasis	  
4.3.4.1	  IBM-­‐relevant	  stress	  increases	  cytosolic	  Calcium	  in	  myogenic	  cells	  The	   significantly	   elevated	   cytosolic	   calcium	   concentration,	   [Ca2+]Cyto,	   of	  myotubes	   following	   βAPP	   over-­‐expression	   or	   exposure	   to	   IL1β	   or	   TNFα	   is	  consistent	   with	   the	   pathogenic	   nature	   of	   these	   stimuli,	   supported	   by	   their	  impact	   on	   other	   parameters	   investigated	   here.	   	   Interestingly,	   the	   response	   of	  [Ca2+]Cyto	   to	   inflammatory	   mediators	   did	   not	   appear	   to	   be	   dose	   dependent,	  implying	  either	  an	  upper	  threshold	  beyond	  which	  cells	  died	  (and	  therefore	  were	  not	   detectable	   by	   the	   technique	   employed	   here)	   or	   that	   ER	   buffering	  mechanisms	  remained	  successful	  in	  limiting	  the	  magnitude	  of	  this	  phenomenon	  under	   the	   conditions	   tested.	   The	   mechanism	   of	   elevated	   [Ca2+]Cyto,	   which	   is	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demonstrated	  by	  cells	   in	  various	  pathological	  conditions,	   is	   likely	  to	  be	  closely	  related	   to	   the	   depleted	   [Ca2+]ER	   contemporaneously	   demonstrated	   by	   these	  myotubes,	   discussed	   below.	   Indeed,	   ER	   Ca2+	   leak	   via	   ryanodine	   and	   IP3	  receptors	   is	   a	   commonly	   postulated	   process.	   Interestingly,	   however,	   basal	   ER	  Ca2+	   leak	   does	   not	   appear	   to	   rely	   on	   either	   of	   these	   channels,	   and	   alternative	  suggested	   pathways	   include	   an	   ATP-­‐induced	   leak	   and	   BCL2	   pores,	   or	   a	  ribosome-­‐translocon	  complex	  (Camello	  et	  al.	  2002).	  Additionally,	  other	  ‘non-­‐ER’	  purported	   mechanisms	   of	   raised	   [Ca2+]Cyto	   in	   skeletal	   muscle	   disease	   include	  increased	   permeability	   to	   Ca2+	   of	   the	   cell	   membrane,	   entry	   through	   TRPC1	  channels	  and	  hyperactive	  store-­‐operated	  uptake	  (Altamirano	  et	  al.	  2012).	  In	  the	  context	   of	   skeletal	   muscle,	   the	   MCK-­‐βAPP	   transgenic	   mouse	   displays	   similar	  calcium	   dyshomeostasis	   to	   that	   observed	   here,	   with	   significantly	   elevated	  [Ca2+]Cyto,	   thought	   to	   result	   from	   Aβ42	   modulation	   of	   ryanodine	   receptors	   to	  increase	  their	  open	  probability.	  This	  translates	  to	  reduction	  of	  contraction	  force	  in	  fast-­‐twitch	  muscles	  (Moussa	  et	  al.	  2006;	  Shtifman	  et	  al.	  2010).	  	  The	  pathological	  consequences	  of	  elevated	  [Ca2+]Cyto	  are	   likely	   to	  be	  broad	  and	  can	  impair	  numerous	  fundamental	  cellular	  functions,	  leading	  to	  necrosis	  and/or	  apoptosis.	  Mitochondrial	  disturbance	   is	  a	  notable	  outcome,	   thought	   to	   include	  Ca2+-­‐mediated	   opening	   of	   the	  mitochondrial	   permeability	   transition	   pore,	   and	  release	  of	   cytochrome	  C	   to	   the	   cytoplasm,	  which	   is	   a	  potent	  apoptotic	   trigger,	  via	  the	  calpain	  pathway	  (Brustovetsky	  et	  al.	  2002;	  Millay	  et	  al.	  2008).	  Of	  further	  relevance	  of	  other	  IBM	  pathogenesis	  is	  that	  elevated	  [Ca2+]Cyto	  induces	  the	  NFκB	  cascade	  (Altamirano	  et	  al.	  2012).	  The	   impact	   of	   Arimoclomol	   was	   restricted	   to	   myotubes	   under	   IBM-­‐relevant	  conditions,	   such	   that	   it	   only	   impacted	   upon	   [Ca2+]Cyto	   when	   significantly	  disturbed	   from	   baseline.	   This	   implies	   that	   Arimoclomol	   does	   not	   have	   a	   non-­‐specific	   action	   to	   reduce	   [Ca2+]Cyto	   generally,	   but	   rather	   mitigates	   one	   of	   the	  mechanisms	   through	  which	   elevated	   [Ca2+]Cyto	  is	   triggered	   or	  maintained.	   The	  magnitude	   of	   the	   effect	   was	   significant	   and,	   under	   several	   of	   the	   tested	  conditions,	  approached	  normalisation	  of	  the	  disturbance.	  Figure	   4.26	   summarises	   potential	   contributors	   to	   and	   consequences	   of	  	  [Ca2+]Cyto.	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Figure	  4.27	  Illustration	  of	  intracellular	  calcium	  dyshomeostasis	  Ca2+	   entry	   via	   TRPC1	   channels	   or	   store	   operated	   calcium	   entry	   (SOCE)	  combines	  with	  SR	  Ca2+	   leak	   through	   IP3	  and	  RyR	  channels.	   IP3	   is	   replenished	  via	   hydrolysis	   of	   PIP2	   by	   PLC	   on	   the	   plasma	   membrane.	   The	   consequent	  elevation	   of	   intracellular	   Ca2+	   activates	   NFκB,	   leading	   to	   expression	   of	   pro-­‐inflammatory	   factors	   and	   oxidative	   stress	   via	   inducible	   nitric	   oxide	   synthase	  (iNOS).	  NFκB	  mediated	  upregulation	  of	  MHCI	  sets	  up	  a	  self-­‐perpetuating	  cycle	  via	  added	  ER	  overload.	  
4.3.4.2	  IBM-­‐like	  conditions	  induce	  ER	  stress	  in	  myogenic	  cells	  The	   significant	   reduction	   of	   [Ca2+]ER	   following	   βAPP	   over-­‐expression	   or	  exposure	   to	   IL1β	  or	  TNFα	   indicates	   that	   these	   IBM-­‐relevant	  stimuli	   induce	  ER	  stress.	  This	  is	  corroborated	  by	  the	  upregulation	  of	  UPR	  markers	  demonstrated	  by	  western	  blotting.	  These	  effects	  may	  reflect	  a	  direct	  influence	  of	  βAPP,	  IL1β	  or	  TNFα	  on	  the	  ER	  but	  may	  be	  secondary	  to	  other	  effects.	  βAPP	   overexpression	   reduced	   inferred	   [Ca2+]ER	   by	   more	   than	   one	   third	   of	  control	   and	   significantly	  upregulated	   the	  ER	   stress	  markers	  BiP	   and	  CHOP,	   to	  approximately	   2.5	   times	   that	   of	   control.	  Most	   studies	   that	   have	   examined	   the	  effects	   of	   βAPP	   on	   ER	   stress	   have	   been	   in	   the	   context	   Alzheimer’s	   disease,	   in	  which	   several	  markers	   of	   UPR	   activity	   are	   demonstrated,	   including	   increased	  disulphide	   isomerase,	   PERK	   and	   XBP1	   mRNA	   (Roussel	   et	   al.	   2013).	   More	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specifically,	   application	   of	   βamyloid	   to	   cortical	   neurons	   in	   vitro	   activates	   ER	  stress	  directly	  (Resende	  et	  al.	  2008),	  and	  increases	  expression	  of	  PERK	  and	  eIF2,	  and	  the	  subsequent	  expression	  of	  CHOP	  (Ghribi	  et	  al.	  2001;	  Lee	  do	  et	  al.	  2010).	  It	   is	   likely	   that	   the	   effect	   of	   βAPP,	   and	   particularly	   Aβ42,	   to	   induce	   ER	   Ca2+	  depletion	  via	  increased	  ryanodine	  receptor	  leak	  is	  relevant	  to	  the	  combination	  of	  low	  [Ca2+]ER	  and	  high	  [Ca2+]Cyto	  observed	  here.	  	  The	   effect	   of	   inflammatory	   cytokines	   to	   induce	   ER	   stress	   may	   reflect	   MHCI	  upregulation,	  both	   in	  vitro	  here	  and	  also	   in	   IBM	   in	  vivo.	  Through	  the	  nature	  of	  burdening	   the	   ER	   with	   normally	   folded	   protein,	   this	   process	   is	   likely	   to	  selectively	  trigger	  the	  Endoplasmic	  Reticulum	  Overload	  Response	  (EOR),	  which	  is	   a	   further	   potent	   inducer	   of	   NFκB,	   thereby	   leading	   to	   a	   self	   perpetuating	  degenerative	   and	   inflammatory	   cycle.	   Indeed,	   in	   human	   primary	   myositic	  conditions,	   and	  mice	   over-­‐expressing	  MHCI,	   ER	   stress	   and	   NFκB	   are	   strongly	  evident	   (Nagaraju	  et	  al.	  2005).	  This	   serves	  an	   interesting	  point	  of	   comparison	  with	   IBM,	   which	   displays	   the	   additional	   canonical	   degenerative	   hallmarks	   of	  protein	   aggregation	   and	   nuclear	   degeneration	   that	   are	   conspicuously	   absent	  from	  the	  primary	  myositides.	  Such	  a	  distinction	  further	  highlights	  the	  potential	  contribution	   of	   the	   aged	   cell	   environment	   and	   molecular	   chaperones	   to	  determining	  the	  final	  pathological	  makeup.	   	  However,	  relatively	  little	  is	  known	  on	   the	   direct	   influence	   of	   cytokines	   on	   ER	   function	   in	   skeletal	   muscle.	   In	  pancreatic	   islet	   cells,	   also	   post-­‐mitotic,	   IL1β	   and	   TNFα	   down-­‐regulate	  expression	   SERCA2b,	   thereby	   reducing	   ER	   calcium,	   and	   inducing	   ER	   stress	  (Cardozo	  et	  al.	  2005).	  Such	  a	  mechanism	  is	  certainly	  possible	  in	  the	  experiments	  described	  here.	  Additionally,	   through	   their	   action	   to	   increase	  βAPP	  and	  Aβ42,	  the	  effect	  of	  cytokines	  could	  also	  include	  the	  mechanisms	  attributed	  to	  amyloid.	  None	   of	   the	   experimental	   conditions	   described	   here	   affected	   ATF6	  concentration	  significantly.	  This	  could	  reflect	  a	  relatively	  selective	  effect	  of	  IBM	  pathology	   on	   other	   elements	   of	   the	   UPR	   but	   the	   transient	   nature	   of	   ATF	  upregulation	  means	  it	  may	  simply	  not	  be	  significantly	  upregulated	  at	  the	  point	  of	  testing	  and	  these	  data	  do	  not	  prove	  the	  absence	  of	   its	   involvement.	  Equally,	  its	   cleavage	   as	   part	   of	   the	   activation	   process	   may	   reduce	   detection	   by	   the	  antibody,	  thereby	  underestimating	  its	  concentration.	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Limitations	  of	  Ca2+	  fluorescence	  imaging	  must	  be	  considered	  and	  this	  technique,	  by	  the	  nature	  of	  detecting	  secondary	  alterations	  in	  	  [Ca2+]Cyto,	  does	  not	  examine	  	  [Ca2+]ER	   directly.	   Therefore,	   dilution	   of	   the	   ER	   Ca2+	   release	   in	   the	   cytosol	   in	  response	   to	   thapsigargin	   may	   underestimate	   the	   magnitude	   of	   the	   effect.	  Additionally,	   this	  method	  could	  be	  confounded	  by	  contemporaneous	  effects	  of	  altered	  plasma	  membrane	  Ca2+	  handling,	  albeit	  that	  existing	  evidence	  suggests	  these	   are	   unlikely	   to	   be	   significant.	   There	   are	   also	   inherent	   limitations	   of	   all	  fluorescent	   dyes	   such	   as	   heterogeneous	   cell	   or	   organelle	   loading,	   leakage	   and	  bleaching.	   Direct	   measurement	   of	   [Ca2+]ER	   is	   difficult	   and	   impractical	   in	   this	  context.	  	  	  
4.3.4.3	  Arimoclomol	  treatment	  attenuates	  ER	  stress	  in	  myogenic	  cells	  The	  treatment	  of	  primary	  myogenic	  cell	  cultures	  with	  Arimoclomol	  attenuated	  the	   ER	   stress	   induced	   by	   IBM-­‐like	   conditions.	   The	   association	   of	   reduced	  [Ca2+]ER	   with	   raised	   [Ca2+]Cyto	   and	   the	   contemporaneous	   attenuation	   of	   both	  disturbances	  with	  Arimoclomol	  implies	  that	  the	  underlying	  disturbance	  caused	  by	   IBM-­‐like	   conditions	   primarily	   relates	   to	   ER-­‐cytosolic	   Ca2+	   signaling	   rather	  than	   mechanisms	   dependent	   on	   plasma	   membrane	   permeability.	   This	   is	  consistent	  with	  existing	  evidence	  that	  ER	  Ca2+	  leak	  is	  a	  fundamental	  component	  of	  ER	  stress.	  The	   significant	   attenuation	   of	   [Ca2+]ER	   disturbance	   under	   IBM-­‐like	   conditions	  following	   treatment	  with	   Arimoclomol	   implies	   it	   offers	   protection	   against	   ER	  stress.	  This	  is	  further	  supported	  by	  the	  significant	  reduction	  in	  CHOP	  expression	  when	  associated	  with	  βAPP	  over-­‐expression	  or	   IL1β	  exposure.	   In	  comparison,	  the	  lack	  of	  significant	  effect	  on	  CHOP	  following	  TNFα	  exposure	  further	  suggests	  that	  the	  mechanism	  by	  with	  Arimoclomol	  attenuates	  ER	  stress	  is	  not	  dependent	  on	  alteration	  of	  MHCI	  processing	  since	   this	  was	  similarly	  upregulated	  by	   IL1β	  and	   TNFα.	   The	   lack	   of	   significant	   impact	   by	   Arimoclomol	   on	   BiP	   and	   ATF6	  concentrations	  suggests	  its	  action	  may	  lie	  downstream	  of	  these	  components	  in	  the	   UPR	   pathway.	   Indeed,	   it	   is	   not	   surprising	   that	   Arimoclomol	   had	   no	  significant	   effect	   on	  BiP	   and	  ATF6	   concentration.	   As	   a	   chaperone	  protein,	   BiP	  could	   even	   be	   expected	   to	   have	   increased	   in	   concentration	   under	   HSR	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augmentation.	   Indeed,	   there	   is	   some	   evidence	   to	   suggest	   this	   is	   the	   case	   in	   a	  transgenic	  mouse	  model	  of	  retinitis	  pigmentosa	  (Parfitt	  et	  al.	  2014).	  However,	  the	  response	  of	  the	  ER	  to	  Arimoclomol	  or	  heat	  shock	  proteins	  in	  the	  context	  of	  contemporaneous	   ER	   dysfunction	   may	   be	   different.	   Models	   in	   which	   HSR	  augmentation	   has	   apparently	   enhanced	   UPR	   have	   not	   been	   shown	   to	   have	  coexistent	  alteration	  of	  [Ca2+]ER,	  as	  is	  the	  case	  here.	  	  Modulation	  of	  BiP	  chaperone	   function	  remains	   is	  a	   tempting	  hypothesis,	   since	  this	  has	  been	   shown	   to	  dictate	   the	   conformation	  of	   the	  ER	   translocon	  protein	  complex,	   through	   which	   ER	   Ca2+	   leak	   is	   postulated	   to	   occur	   in	   this	   context.	  Indeed,	   BiP-­‐mediated	   reduction	   of	   this	   leak	   appears	   to	   be	   anti-­‐apoptotic	   and	  associated	  with	  maintained	  protein	  folding	  (Hammadi	  et	  al.	  2013).	  	  Nevertheless,	  the	  effect	  of	  Arimoclomol	  to	  reduce	  expression	  of	  CHOP,	  and	  attenuate	  [Ca2+]ER	  disturbance	  could	  also	  reflect	  an	  indirect	  consequence	  of	  downstream	  actions	  of	  HSPs	   to	   reduce	   ER	   load.	   This	   could	   occur,	   for	   example,	   through	   cytoplasmic	  refolding	  of	  misfolded	  proteins	  or	  augmentation	  of	  ERAD	  (Liu	  et	  al.	  2008).	  A	  direct	  effect	  of	  Arimoclomol	  on	  the	  ER/SR	  calcium	  channels	   is	  also	  possible.	  Bimoclomol,	   from	   which	   Arimoclomol	   is	   derived,	   has	   been	   shown	   to	   act	   on	  cardiac	   ryanodine	   receptors,	   thereby	   affecting	   ER/SR	   calcium	   handling.	  However,	  the	  skeletal	  muscle	  ryanodine	  receptor	  represents	  a	  different	  isoform,	  on	  which	  no	  such	  effect	  is	  described	  (Nanasi	  et	  al.	  2001).	  Finally,	   upregulation	   of	   HSP70	   by	   Arimoclomol	   may	   ameliorate	   ER	   stress	   by	  direct	   HSP70	   binding	   to	   and	   stabilisation	   of	   the	   SERCA,	   thereby	   maintaining	  calcium	  homeostasis	  (Tupling	  et	  al.	  2004).	  	  
4.3.5	  Exposure	  to	  IBM-­‐like	  stress	  induces	  NFκB	  activation	  in	  myogenic	  cells	  The	   pro-­‐inflammatory	   and	   pro-­‐atrophic	   NFκB	   cascade	   is	   a	   potentially	   central	  component	  of	  IBM	  pathology.	  Existing	  evidence	  suggested	  this	  process	  could	  be	  inhibited	   by	   HSPs,	   supporting	   the	   rationale	   for	   testing	   Arimoclomol	   in	   this	  context.	  	  Although	   normal	   muscle	   maturation	   includes	   NFκB	   activation,	   this	  phenomenon	   appeared	   to	   be	  minimal	   among	  multinucleated	  myotubes,	   fewer	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than	  10%	  of	  which	  demonstrated	  it.	  It	  is	  not	  clear	  whether	  the	  nuclear	  staining	  for	  NFκB	  demonstrated	  by	  some	  cells	  in	  control	  cultures	  reflects	  a	  basal	  level	  of	  NFκB	  activation,	  residual	  activation	  from	  activation	  during	  myocytic	  maturation	  or	  non-­‐specific	  staining.	  It	  could,	  therefore,	  be	  argued	  that	  this	  background	  level	  of	   could	   be	   subtracted	   from	   the	   absolute	   values	   demonstrated	   by	   the	   IBM-­‐representative	   populations.	   This	   measure	   would	   increase	   the	   strength	   of	  statistical	   significance	   in	   the	   difference	   demonstrated	   after	   Arimoclomol	  treatment.	  It	   is	   not	   surprising	   that	   exposure	   to	   inflammatory	   cytokines	   IL1β	   and	   TNFα	  activated	   NFκB.	   A	   concentration	   dependent	   response	   could	   be	   demonstrated	  here,	   which	   represents	   an	   advantage	   of	   the	   nuclear	   translocation	  immunostaining	   assay	   over	   the	   other	   commonly	   used	   electrophoretic	   shift	  assay	  that	  provides	  a	  binary	  result.	  A	  further	  advantage	  of	  this	  technique	  is	  its	  specificity	  to	  myotubes,	  removing	  the	  potentially	  confounding	  influence	  of	  non-­‐specific	  NFκB	   activation	  by	   immature	  myogenic	   cells,	   or	   of	   non-­‐myogenic	   cell	  types.	   Further,	   the	   demonstration	   of	   a	   concentration	   dependent	   activation	   of	  NFκB	   by	   IL1β	   and	   TNFα	   strengthens	   the	   arguments	   that	   this	   represents	   a	  specific	   effect.	   	   Taken	   together,	   the	   results	   indicate	   that	   NFκB	   activation	   in	  myotubes	   can	   be	   stimulated	   and	   quantified	   in	   vitro	   using	   inflammatory	  cytokines.	  	  The	  mechanism	  of	  NFκB	  activation	  by	  these	  cytokines	  is	  likely	  to	  reflect	  a	  well-­‐established	  direct	  effect	  (Feldmann	  et	  al.	  2002).	  However,	  additional	  pathways	  of	  activation,	  notably	  via	  MHC	  Class	  I	  upregulation	  and	  ER	  stress	  must	  also	  be	  considered	   in	   the	   context	   of	   IBM.	   Indeed,	   the	   relative	   contributions	   of	   these	  direct	  and	  indirect	  pathways	  are	  of	  interest	  in	  determining	  the	  role	  of	  NFκB	  in	  IBM.	   In	   these	   experiments,	   βAPP	   overexpression	   also	   led	   to	   significant	   NFκB	  activation,	  which	  confirms	  the	  potential	  significance	  of	  such	  an	  indirect	  pathway,	  in	  which	  not	  only	  classically	  immune	  stimuli	  are	  responsible	  for	  maintenance	  of	  an	  immune	  response.	  Treatment	   with	   Arimoclomol	   inhibited	   the	   activation	   of	   NFκB	   following	  cytokine	  exposure	  or	  βAPP	  overexpression.	  A	  comparison	  of	  the	  effect	  between	  TNFα	  (5ng/ml)	  and	  βAPP	  overexpression,	  which	  demonstrated	  similar	  degrees	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of	   NFκB	   activation,	   shows	   that	   Arimoclomol	   had	   a	   similar	   impact	   in	   each	  condition.	  A	   similar	  pattern	   is	  demonstrated	  by	  comparable	  experiments	  with	  IL1β	  and	  TNFα.	  This	   implies	   that	   the	  effect	  of	  Arimoclomol,	  at	   least	  under	   the	  conditions	   tested	   here,	   is	   not	   reliant	   on	   the	   nature	   of	   NFκB	   activation.	   The	  mechanism	  of	  activation	  is	  likely	  to	  be	  largely	  direct	  in	  the	  case	  of	  cytokines	  but	  more	  likely	  to	  be	  indirect	  following	  βAPP,	  where	  is	  likely	  relies	  on	  MHC	  Class	  I	  upregulation	   or	   ER	   stress.	   Therefore,	   these	   results	   imply	   a	   direct	   inhibitory	  effect	   of	   Arimoclomol	   on	   the	  NFκB	   pathway	  per	   se	   rather	   than	   this	   being	   the	  result	   of	   other	   upstream	   actions.	   Such	   an	   effect	   would	   be	   in	   keeping	   with	  previous	   work	   that	   has	   demonstrated	   the	   inhibitory	   properties	   of	   HSP70	   on	  NFκB	   activation	   (Feinstein	   et	   al.	   1996).	   Nevertheless,	   the	   extent	   of	   NFκB	  activation	   following	  Arimoclomol	   treatment	   remains	   significantly	  greater	   than	  in	  control	  populations	  so	  the	  effect	  is	  an	  attenuation	  rather	  than	  full	  restoration.	  Further	   work	   could	   determine	   whether	   more	   aggressive	   upregulation	   of	   the	  HSR	  is	  able	  to	  suppress	  the	  NFκB	  cascade	  to	  a	  greater	  extent.	  	  Notably,	   Arimoclomol	   had	   no	   significant	   effect	   on	   control	   cultures,	   in	   which	  fewer	   than	  10%	  of	   cells	   demonstrated	  nuclear	  NFκB	   staining.	   If	   such	   staining	  does,	   indeed,	   represent	   NFκB	   activation	   in	   those	   cells,	   this	   implies	   that	  Arimoclomol’s	  inhibitory	  effect	  is	  restricted	  to	  stress	  induced	  NFκB	  activation.	  	  	  
4.3.6	  Potential	  mechanisms	  of	  Arimoclomol	  action	  In	  these	  experiments,	  the	  use	  of	  βAPP	  as	  an	  inducer	  of	  IBM-­‐relevant	  conditions	  and	  the	  proposed	  central	  role	  of	  MHCI	  in	  disease	  pathogenesis	  warrant	  specific	  consideration	  of	  how	  each	  of	  these	  is	  affected	  by	  Arimoclomol.	  	  
4.3.6.1	  Effect	  of	  Arimoclomol	  on	  βAPP	  As	   Arimoclomol	   was	   applied	   after	   the	   induction	   of	   βAPP	   over-­‐expression	  through	  transfection,	  any	  impact	  on	  transfection	  efficiency	  would	  be	  unlikely	  to	  manifest	   in	   these	  experiments.	  However,	   if	  Arimoclomol	  were	   found	   to	  down-­‐regulate	   βAPP,	   this	   would	   imply	   that	   it	   functions	   at	   a	   potentially	   upstream	  location,	   thereby	   attenuating	   the	   numerous	   consequences	   of	   βAPP	   over-­‐
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expression	   described	   here.	   However,	   Arimoclomol	   did	   not	   demonstrate	   a	  significant	   effect	   on	   βAPP	   concentration,	   either	   when	   induced	   through	  transfection	  or	  when	  as	  a	  consequence	  of	  cytokine	  exposure.	  Concentration	  per	  
se	  may	  not	   indicate	   the	  conformational	  state	  of	   the	  protein	  and,	   therefore,	  not	  be	   proportionate	   to	   its	   degree	   of	   pathological	   stimulus.	   However,	   this	   could	  equally	   mean	   that	   Arimoclomol’s	   effects	   on	   ER	   stress,	   TDP-­‐43	   and	   NFκB	   are	  more	  direct.	  The	   lack	   of	   reliance	   on	   a	   directly	   βAPP-­‐dependent	   mechanism	   perhaps	   adds	  further	  support	  to	  the	  significance	  of	  Arimoclomol’s	  cytoprotective	  effects.	  First,	  if	  βAPP	  does	  transpire	  to	  be	  an	  early	  pathogenic	  trigger	  in	  IBM,	  it	  is	  difficult	  to	  envisage	   that	   patients	   could	   receive	   treatment	   in	   the	   earliest	   stage	   of	   the	  disease	   as	   they	   would	   likely	   be	   either	   presymptomatic	   or	   without	   a	   formal	  diagnosis.	   Secondly,	   if	   βAPP	   is	   not	   pathogenic	   in	   IBM	   in	   vivo,	   but	   rather	   can	  simply	  be	  used	  to	  induce	  IBM-­‐relevant	  pathological	  features	  in	  vitro,	   it	   is	  more	  likely	  that	  Arimoclomol’s	  in	  vitro	  effects	  in	  this	  context	  would	  translate	  in	  vivo.	  	  The	   lack	   of	   impact	   by	   Arimoclomol	   on	  βAPP	   upregulation	   following	   cytokine	  exposure,	   despite	   contemporaneous	   attenuation	   of	   ER	   stress,	  NFκB	   activation	  and	   TDP-­‐43	  mislocalisation	   implies	   that	   βAPP	   upregulation	   in	   this	   context	   is	  independent	   of	   these	   three	   mechanisms.	   Indeed,	   the	   nature	   through	   which	  cytokines	  seem	  to	  affect	  βAPP	  metabolism	  remains	  unclear.	  It	  remains	  possible	  that	   this	   is	   mediated	   through	   altered	   APP	   processing	   by	   BACE-­‐1	   or	  macroautophagy	   (Vattemi	   et	   al.	   2001;	   Lunemann	   et	   al.	   2007).	   Again,	   the	  (mis)folding	   and	   aggregation	   of	   βamyloid	   oligomers	   is	   likely	   to	   be	   of	   greater	  importance	  in	  this	  context	  that	  the	  overall	  concentration	  of	  the	  proteins.	  	  
4.3.6.2	  Effect	  of	  Arimoclomol	  on	  MHC	  Class	  I	  The	   anticipated	   upregulation	   of	   MHCI	   in	   response	   to	   IL1β	   or	   TNFα	   was	  confirmed	   and	  was	  not	   affected	  by	  Arimoclomol.	  As	   this	   process	   represents	   a	  direct	  effect	  of	   cytokines,	   this	   lack	  of	  effect	  was	  unsurprising.	  However,	   in	   the	  context	   of	   Arimoclomol-­‐induced	   inhibition	   of	   NFκB,	   ER	   stress	   and	   calcium	  dyshomeostasis,	  it	  does	  suggest	  that	  MHCI	  upregulation	  observed	  here	  does	  not	  depend	   significantly	   on	   any	   of	   these	   three	   processes.	   It	   would	   be	   useful	   to	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determine	  whether	   the	  specific	  augmentation	  or	   inhibition	  of	   the	  ER	  overload	  response	  affects	  MHCI	  expression	  since	  this	  is	  likely	  to	  be	  the	  most	  relevant	  ER	  stress	   pathway	   on	   the	   assumption	   that	   MHCI	   is	   overexpressed	   but	   correctly	  folded.	   Conversely,	   that	   inhibition	   of	   NFκB	   and	   amelioration	   of	   ER	   stress	   are	  maintained	   despite	   ongoing	   MHCI	   upregulation	   suggest	   Arimoclomol	   acts	  downstream	  of	   the	   primary	   inflammatory	   intracellular	   insult,	   in	   keeping	  with	  its	  known	  functions.	  The	  situation	  in	  vivo	  may	  be	  different,	  given	  the	  additional	  factor	   of	   a	   systemic	   immune	   response	   to	  MHCI	   and	  NFκB.	   Equally,	   given	   that	  MHCI	   upregulation	   is	  widespread	   in	   IBM	   and	   does	   not	   respond	   to	   any	   of	   the	  immunotherapies	   exhibited	   thus	   far,	   any	   dependence	   of	   Arimoclomol’s	   other	  effects	   on	   this	   factor	   would	   diminish	   the	   likelihood	   of	   translation	   to	   a	  meaningful	   effect	   in	   vivo.	   Furthermore,	   if	   Arimoclomol	   were	   to	   restrict	   IBM	  pathology	  towards	  a	  more	  polymyositic	  milieu,	  restricted	  to	  MHCI	  upregulation	  and	  inflammation,	  current	  clinical	  distinctions	  imply	  this	  may	  represent	  highly	  effective	  treatment.	  The	   upregulation	   of	   MHCI	   following	   βAPP	   over-­‐expression	   (see	   Chapter	   3)	  differs	  from	  that	  related	  to	  cytokines	  since	  this	  is	  both	  a	  novel	  finding	  and	  is	  less	  likely	   to	   represent	   a	   direct	   response.	   It	   is,	   therefore,	   more	   difficult	   to	   make	  inferences	   from	   the	   impact	   of	   Arimoclomol.	   Nevertheless,	   in	   this	   context,	   the	  lack	   of	   impact	   of	  Arimoclomol	   implies	   that	  NFκB	   activation	   consequent	   to	  ER	  stress	   is	   unlikely	   to	   be	   the	   predominant	   stimulus	   of	   MHCI	   expression.	  Interestingly,	   ER	   stress	   in	   other	   scenarios	   appears	   to	   reduce	   MHCI	   surface	  expression,	  although	  it	  is	  not	  clear	  whether	  this	  reflects	  an	  underlying	  change	  in	  overall	   concentration,	   through	   reduction	   of	   synthesis,	   which	   could	   represent	  ATF4	   translation	   block,	   or	   increased	   ERAD	   breakdown	   (Ulianich	   et	   al.	   2011).	  Furthermore,	   the	   unusual	   characteristic	   of	   muscle	   in	   its	   lack	   of	   constitutive	  MHCI	   expression	   means	   its	   regulation	   may	   differ	   markedly	   to	   that	   in	   other	  tissues.	  Finally,	   its	  expression	  in	  maturing	  myotubes	   in	  vitro	  may	  represent	  an	  additional	  non-­‐inflammatory	  role	  that	  is	  outside	  the	  influence	  of	  Arimoclomol.	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4.4	  Summary	  The	  experiments	  described	  in	  this	  chapter	  show:	  i) The	  HSR	  can	  be	  induced	  in	  primary	  myotube	  cultures	  through	  over-­‐expression	  of	  βAPP	  or	  exposure	  to	  cytokines	  IL1β	  and	  TNFα.	  ii) These	   stimuli	   induce	   IBM-­‐like	   pathology	   including	   TDP-­‐43	  mislocalisation,	   ER	   stress,	   calcium	   dyshomeostasis	   and	   NFκB	  activation,	   each	   of	  which	   represents	   an	   important	   or	   distinguishing	  element	  of	   IBM	  pathology.	  The	  magnitude	  of	   these	  disturbances	  can	  be	   quantified	   using	   a	   variety	   of	   techniques,	   thereby	   allowing	   pre-­‐clinical	  determination	  of	  therapeutic	  efficacy.	  iii) Cell	   viability	   assays	   reveal	   that	   these	   pathological	   changes	   are	  associated	  with	  increased	  cytotoxicity.	  iv) Treatment	   with	   the	   hydroxylamine	   derivative	   Arimoclomol	  significantly	   attenuates	   of	   these	   interlinking	   processes	   through	  augmentation	  of	   the	  HSR	  chaperone	   response	  and	   this	   translates	   to	  improved	  cell	  viability.	  These	   findings	   represent	   the	   first	   dedicated	   pre-­‐clinical	   evaluation	   of	   a	  hypothesis-­‐driven	   therapeutic	   strategy	   in	   IBM	   and	   the	   first	   in	   pre-­‐clinical	   or	  clinical	   studies	   not	   to	   focus	   on	   immunomodulation.	   The	   contemporaneous	  induction	   of	   the	   IBM-­‐like	   pathological	   elements	   in	   these	   experiments	   adds	  further	   weight	   to	   the	   argument	   that	   they	   are	   intimately	   related.	   Their	  recapitulation	   in	   vitro	   highlights	   that	   many	   of	   them	   can	   be	   generated	   at	   a	  cellular	   level,	   absent	   from	   the	   influence	   of	   a	   systemic	   immune	   system.	   The	  nature	   of	   Arimoclomol’s	   effect	   in	   successfully	   ameliorating	   these	   elements	   is,	  therefore,	   justification	   for	   a	   therapeutic	   approach	   that	   considers	   the	   non-­‐inflammatory	  elements	  of	   IBM	  pathology.	   If	   the	   likely	  pathways	  of	   interaction	  are	  considered,	   those	  that	  Arimoclomol	  affects	  may	  well	   lie	  at	   the	  heart	  of	   the	  disease	  (Fig	  4.28).	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Figure	  4.28	  Illustration	  of	  how	  Arimoclomol	  relates	  to	  central	  pathogenic	  
mechanisms	  in	  IBM.	  A	   predominantly	   inflammatory	   phase	   (blue	   elements),	   interlinks	   with	   a	  predominantly	   degenerative	   one	   (red	   elements).	   Sites	   of	   Arimoclomol	   action	  are	  represented	  by	  yellow	  circles.	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Chapter	  5:	  Translating	  the	  Effects	  of	  Arimoclomol	  to	  
IBM	  Patients;	  Establishing	  a	  Phase	  IIa	  Clinical	  Trial	  
	  
5.1	  Introduction	  
5.1.1	  Translational	  research	  pathway	  The	  translational	  research	  pathway	  depends	  on	  the	  advancement	  of	  pre-­‐clinical	  scientific	   discoveries	   to	   early	   then	   late	   phase	   clinical	   trials	   (Fig	   5.1).	   Each	  condition	  presents	   individual	  challenges	  to	  this	  process.	   In	  the	  context	  of	   IBM,	  the	   limitations	   at	   pre-­‐clinical	   level	   relate	   to	   the	   lack	   of	   either	   a	   clearly	  established	  primary	   cause	   for	   the	  disease	   or	   the	   identification	   of	   a	   significant	  genetic	   influence,	   either	   of	   which	   would	   significantly	   reduce	   the	   inherent	  difficulty	   in	   developing	   pre-­‐clinical	   models	   of	   IBM.	   This,	   in	   turn,	   slows	   pre-­‐clinical	   development	   and,	   in	   particular,	   the	   lack	   of	   a	   suitable	   animal	   model	  means	  reliance	  on	  in	  vitro,	  computational	  or	  human	  studies.	  At	  the	  clinical	  level,	  in	  addition	  to	  generic	  ethical	  and	  financial	  considerations,	  the	  relative	  rarity	  and	  heterogeneity	  of	  IBM,	  combined	  with	  its	  relatively	  slow	  pace	  of	  clinical	  change	  and	  lack	  of	  validated	  outcome	  measures	  or	  biomarkers	  to	  quantify	  that	  change,	  make	   large	   efficacy	   trials	   very	   difficult.	   Previous,	   unsuccessful,	   studies	   of	  pharmacological	   agents	   for	   IBM	   have	   employed	   immune	   therapies	   already	  licensed	   for	   other	   conditions,	   typically	   in	   small	   and	   usually	   underpowered	  clinical	   trials	   (Section	   5.1.2).	   The	   lack	   of	   detectable	   effect	   in	   these	   trials,	  therefore,	   cannot	   be	   taken	   as	   definitive	   evidence	   of	   the	   absence	   of	   an	   effect.	  Equally,	   these	   trials	  were	   initiated	  without	   significant	   pre-­‐clinical	   evidence	   to	  support	  their	  use	  and	  were	  largely	  based	  on	  the	  hypothesis	  that	  attenuation	  of	  inflammation	  might	  be	  of	  benefit.	  	  As	   described	   in	   Chapters	   3	   and	   4,	   the	   development	   of	   an	   in	  vitro	  model	  with	  quantifiable	  IBM-­‐relevant	  pathological	  outcome	  measures	  allowed	  the	  testing	  of	  Arimoclomol,	   which	   proved	   to	   be	   effective	   in	   attenuating	   several	   disease	  markers.	  	  	  
201	  
Figure	  5.1	  Translational	  research	  pathway	  of	  drug	  development	  The	   process	   of	   advancement	   from	   laboratory	   research	   in	   a	   given	   condition,	  through	   to	   clinical	   studies	   of	   drug	   efficacy	   culminating	   in	   licensed	   treatments	  (Blue).	   Contemporaneous	   drug	   development	   contributes	   to	   pre-­‐clinical	  development	   and	   clinical	   outcome	   measures	   both	   rely	   upon	   and	   contribute	  towards	  early	  phase	  clinical	  studies	  (Red).	  IBM	  represents	  specific	  challenges	  at	  each	  stage	  of	  the	  process	  (Purple).	  
5.1.2	  Previous	  clinical	  trials	  of	  IBM	  To	   determine	   how	   to	   advance	   Arimoclomol	   in	   the	   translational	   pathway,	  consideration	  was	  given	  to	  the	  potential	  next	  steps.	  The	  lack	  of	  a	  suitable	  animal	  model	   is	   discussed	   above	   in	   this	   thesis	   (see	   Chapter	   3	   Introduction,	   Section	  3.1.2).	  Therefore,	  the	  feasibility	  of	  a	  human	  study	  was	  assessed	  by	  undertaking	  a	  review	  of	  previous	  clinical	  trials	  in	  IBM	  and	  the	  existing	  evidence	  supporting	  Arimoclomol’s	   suitability	   in	   this	   context.	   	   Nine	   randomised	   pharmacological	  trials	  of	  efficacy	  have	  been	  undertaken	  in	  IBM,	  of	  which	  seven	  were	  blinded	  and	  placebo	  controlled	  (Table	  5.1).	  Several	  smaller	  observational	  studies	  have	  also	  been	  performed	  (Table	  5.2).	  None	  of	  these	  lasted	  more	  than	  one	  year,	  with	  the	  typical	   duration	   being	   far	   shorter	   and	   usually	   fewer	   than	   six	   months.	   It	   is	  unsurprising,	  therefore,	  that	  very	  few	  statistically	  or	  clinically	  significant	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Outcomes	   Results	  
Oxandrolone	  in	  IBM	  
(Rutkove	  et	  al.	  2002)	  
12	  weeks	   R,	  DB,	  PC,	  CO	   13	   MVICT	   MVICT,	  MMT	   1. Increased	  MVICT	  of	  upper-­‐extremity
2. No	  significant	  difference	  in	  MRC	  scores
High	  Dose	  IvIg	  	  
(Walter	  et	  al.	  2000)	  
6	  months	  
(monthly)	  






time,	  EMG,	  CK	  
1. Small	  improvement	  in	  MRC	  score	  over
12	  months	  (in	  both	  groups)	  
2. Improvement	  or	  stabilisation	  in	  90%
patients	  
3. Improved	  Neuromuscular	  Symptom
score	  in	  IvIg	  over	  placebo	  
IvIg	  combined	  with	  
Prednisone	  	  
(Dalakas	  et	  al.	  2001)	  
IvIg+Pred	  or	  
Placebo+Pred	  
(monthly	  for	  3	  
months)	  






1. No	  significant	  difference	  in	  MRC/QMT
2. Reduced	  number	  of	  necrotic	  fibres,
CD3+	  cells,	  foci	  of	  inflammation	  in	  
IvIg/Pred	  group	  
Treatment	  with	  IvIg	  
(Dalakas	  et	  al.	  1997)	  
3	  months	  
(monthly)	  





1. Non-­‐significant	  gain	  in	  function
2. Improved	  swallowing	  function	  in	  IvIg
group	  
High	  Dose	  βINF1a	  	  
(MuscleStudyGroup	  
2004)	  
24	  weeks	   R,	  DB,	  PC	   30	   S+T	   MVICT,	  MMT,	  
DEXA,	  	  
1. No	  significant	  difference	  in	  AEs
2. No	  significant	  difference	  in	  efficacy
Pilot	  Trial	  of	  βINF1a	  	  
(MuscleStudyGroup	  
2001)	  
24	  weeks	   R,	  DB,	  PC	   30	   S+T	   MVICT,	  MMT,	  
MRC,	  DEXA,	  
Neopterin	  levels	  
1. AE	  profile	  similar	  to	  that	  of	  βIFN	  in	  MS
2. No	  significant	  change	  in	  efficacy
measures	  
3. Insignificant	  change	  in	  Neopterin	  levels
(marker	  of	  βIFN	  activity)	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Table	  5.1	  Previous	  drug	  trials	  in	  IBM	  Statistically	   significant	   findings	   are	   highlighted	   in	   bold.	   Treatments:	   IvIg=	   Intravenous	   immunoglobulin,	   Pred=prednisolone,	  AZA=azathioprine,	   MTX=methotrexate,	   TAC=tacrolimus,	   Ciclo=ciclosporin,	   ATG=Anti-­‐T-­‐lymphocyte	   globulin,	   IFN=interferon.	   Study	  
Designs:	  R=randomised,	  DB=double	  Blind,	  PC=placebo	  controlled,	  CO=crossover,	  RA=retrospective	  analysis,	  CR=case	  reports.	  Outcome	  
Measures:	  MMT=manual	  muscle	  testing,	  MRC=Medical	  Research	  Council	  power	  grade,	  MVICT=maximal	  voluntary	  isometric	  contraction	  testing,	   QMT=Quantitative	   muscle	   testing,	   S+T=safety	   and	   tolerability,	   (S)AE=(serious)	   adverse	   event,	   EMG=electromyography,	  DEXA=dual	  energy	  x-­‐ray	  absorptiometry,	  	  CK=creatine	  kinase,	  ND=not	  defined	  
Anti-­‐T-­‐lymphocyte	  
globulin	  




R	   11	   MVICT	   Muscle	  Biopsy	   1. Mean	  strength	  increased	  1.4%	  in	  ATG





(Badrising	  et	  al.	  2002)	  





1. 8/21	  patients	  dropped	  out	  of	  MTX	  arm
due	  to	  AEs	  
2. Greater	  CK	  drop	  in	  MTX	  group
Alemtuzumab	  in	  IBM	  
(Dalakas	  et	  al.	  2009)	  
4	  doses	   Open	   13	   QMT	  sum	  
score	  
Muscle	  biopsy	   1. QMT	  Strength	  declined	  14.9%	  in	  12
months	  prior	  to	  treatment,	  then	  by	  1.9%	  
in	  6	  months	  after	  treatment	  
2. Reduction	  of	  lymphocytic	  infiltrate	  on
biopsy	  
3. No	  drug	  related	  SAEs
Etanercept	  in	  IBM	  






9	   MVIC	   Grip	  strength	   1. No	  difference	  between	  etanercept	  	  and
control	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Table	  5.2	  Small	  clinical	  studies	  of	  pharmacological	  treatments	  of	  IBM	  Statistically	   significant	   findings	   are	   highlighted	   in	   bold.	   Treatments:	   IvIg=	   Intravenous	   immunoglobulin,	   Pred=prednisolone,	   AZA=azathioprine,	  MTX=methotrexate,	   TAC=tacrolimus,	   Ciclo=ciclosporin.	   Study	  Designs:	   R=randomised,	   DB=double	   Blind,	   PC=placebo	   controlled,	   RA=retrospective	  analysis,	  CR=case	  reports.	  Outcome	  Measures:	  MMT=manual	  muscle	  testing,	  MRC=Medical	  Research	  Council	  power	  grade,	  MVICT=maximal	  voluntary	  isometric	  contraction	  testing,	  S+T=safety	  and	  tolerability,	  CK=creatine	  kinase,	  ND=not	  defined.	  




Outcomes	   Results	  
Explanation	  of	  poor	  
response	  to	  
immunosuppressive	  therapy	  
(Barohn	  et	  al.	  1995)	  
Pred	   No	  control	   8	   ND	   CK,	  Muscle	  
strength	  
1. Reduce	  serum	  creatine	  kinase
2. Muscle	  strength	  reduced	  after
prednisone	  treatment	  
Retrospective	  view	  and	  
randomised,	  prospective	  
trial	  of	  immunosuppressive	  
therapy.	  
(Leff	  et	  al.	  1993)	  






and	  R,	  Open	  
25	   ND	   ND	   1. Prednisone	  ‘of	  modest	  benefit’	  in
40%	  patients	  
2. Other	  therapy	  (AZA/MTX)	  ‘halted
progression’	  in	  23%	  
Drug	  Therapy	  of	  the	  
Idiopathic	  Inflammatory	  
Myopathies:	  	  
(Joffe	  et	  al.	  1993)	  




RA	   14	   ND	   ND	   1. IBM	  patients	  less	  likely	  to	  respond
to	  all	  treatments	  than	  PM/DM	  
2. Approximately	  40%	  IBM	  patients
had	  no	  response	  to	  prednisone	  
Treatment	  with	  Ciclosporin-­‐
A	  or	  Tacrolimus	  
(Quartuccio	  et	  al.	  2007)	  
TAC	  or	  Ciclo	  in	  
combination	  with	  
Pred	  
Observational	   3	   ND	   ND	   1. Unquantified	  clinical	  improvement
reported	  
IvIg	  for	  Dysphagia	  
(Cherin	  et	  al.	  2002)	  
IvIg	  or	  IvIg	  and	  
Steroids	  
CR	   4	   ND	   ND	   1. Insignificant	  change	  in	  severe
dysphagia	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outcomes	   have	   been	   described.	   With	   the	   possible	   exception	   of	   apparent	  improvement	  of	  dysphagia	  with	  IvIg	  (Walter	  et	  al.	  2000),	  it	  could	  be	  argued	  that	  no	  meaningful	   treatment	   response	  has	  been	  observed	   in	  any	   IBM	   trial.	  Whilst	  this	   does	   fit	   with	   the	   anecdotal	   evidence	   that	   IBM	   does	   not	   respond	   to	  immunotherapies,	   which	   are	   the	   only	   group	   of	   compounds	   to	   have	   been	  explored,	   it	   is	   unlikely	   that	   any	   of	   these	   studies	  were	   adequately	   powered	   to	  detect	  clinical	  changes	  of	  a	  realistic	  magnitude.	  This	  challenge	  reflects	  the	  lack	  of	  agreed	  clinical	  outcome	  measures	  and	  biomarkers	  in	  IBM.	  Nevertheless,	   the	  absence	   of	   evidence	   generated	  by	   these	   studies	   has	   appeared	   to	  motivate	   the	  examination	  of	  alternative	  drugs,	  implying	  negative	  outcomes	  of	  underpowered	  trials	  might	  be	  unfairly	   inferred	   as	  proving	   a	   lack	  of	   effect.	   This	   could	   lead	   to	  potentially	  effective	  treatments	  being	  overlooked.	  A	  further	  criticism	  of	  the	  vast	  majority	   of	   previous	   trial	   in	   IBM	   is	   the	   absence	   of	   any	   attempt	   to	   clarify	   a	  potential	  mechanism	  of	   action;	   very	   few	   studies	   have	   included	  muscle	   biopsy	  analysis,	   although	   it	   is	   notable	   that	   even	   in	   studies	   where	   inflammation	   has	  apparently	   reduced	   histologically,	   a	   clinical	   correlation	   was	   not	   necessarily	  detected	  (Barohn	  et	  al.	  1995).	  Therefore,	  a	  review	  of	  previous	  trials	  in	  IBM	  suggests	  that	  future	  studies	  could	  be	   improved	  by	   following	   a	  more	   step-­‐wise	   approach	   to	   advance	   through	   the	  standard	   phases	   of	   drug	   development.	   In	   the	   absence	   of	   a	   pre-­‐clinical	   animal	  model,	   this	   should	   include	   analysis	   of	   drug	   action	   in	   trial	   subjects	   and	   also	  establish	  safety,	  tolerability	  and,	  ideally,	  tendency	  to	  placebo	  effect	  (which	  may	  be	   particularly	   strong	   with	   drugs	   intravenously	   administered	   such	   as	  immunoglobulin).	  This	  would	  minimise	   the	   likelihood	  of	  advancing	  unsuitable	  compounds	  towards	  premature	  efficacy	  studies.	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5.1.3	  A	  clinical	  study	  of	  Arimoclomol	  in	  IBM	  As	  an	  unlicensed	  compound,	  the	  feasibility	  to	  advance	  Arimoclomol	  to	  a	  clinical	  study	  required	  consideration	  of	  its	  existing	  safety	  and	  toxicity	  profile	  to	  assess	  the	   appropriateness	   of	   a	   human	   study.	   In	   addition	   to	   satisfactory	   pre-­‐clinical	  toxicology	   studies,	   Arimoclomol	   had	   undergone	   six	   phase	   I	   trials	   in	   healthy	  volunteers	  and	  two	  phase	  II	  trials	  of	  patients	  with	  ALS	  (Tables	  5.3	  and	  5.4).	  In	  total	   261	   human	   subjects	   had	   received	   the	   drug	   through	   oral	   administration,	  with	  no	  reported	  serious	  adverse	  events	  or	  deaths,	  no	  clinically	  meaningful	  or	  statistically	  significant	  changes	   in	   laboratory	  parameters	  and	  low	  frequency	  of	  adverse	  events	  of	  mild	  or	  moderate	  severity.	  These	  early	  phase	  clinical	  studies	  also	   to	   supported	   the	   use	   of	   a	   100mg	   three	   times	   daily	   regimen,	   which	   was	  determine	  by	  a	  multicenter	  dose-­‐ranging	  pharmacokinetic	  study	  in	  ALS	  patients.	  A	  review	  of	  the	  corresponding	  evidence	  by	  the	  US	  Federal	  Drug	  Administration	  and	   UK	   Medicines	   and	   Healthcare	   Regulatory	   Agency	   supported	   a	   trial	  incorporating	   a	   4-­‐month	   Arimoclomol	   treatment	   phase	   in	   IBM	   patients.	  Accordingly,	  a	  trial	  was	  designed,	  with	  four	  key	  objectives.	  
5.1.4	  Objectives	  of	  the	  clinical	  trial	  1. To	   assess	   the	   safety	   and	   tolerability	   of	   Arimoclomol	   in	   a	   cohort	   of	   patientswith	   IBM.	   Arimoclomol	   had	   already	   satisfied	   Phase	   I	   studies	   in	   healthy	  volunteers	   as	   well	   and	   been	   deemed	   safe	   and	   well	   tolerated	   in	   a	   study	   of	  population	   of	   patients	   with	   Amyotrophic	   Lateral	   Sclerosis	   (Cudkowicz	   et	   al.	  2008).	  To	  advance	  drug	  development	  in	  IBM,	  satisfactory	  safety	  data	  is	  essential	  prior	  to	  any	  efficacy	  study.	  2. To	   determine	   the	   impact	   of	   Arimoclomol	   treatment	   on	   a	   variety	   of	   clinicalmeasures	  relevant	  to	  IBM,	  such	  as	  muscle	  strength	  and	  a	  functional	  rating	  scale.	  A	   safety	   study,	   such	   as	   the	   one	   described	   in	   this	   Chapter,	   is	   not	   statistically	  powered	   to	   detect	   significant	   changes	   in	   outcome	   measures	   of	   treatment	  efficacy	  based	  on	  the	  anticipated	  natural	  history	  of	  the	  disease.	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Phase	  1	  Studies	  of	  Arimoclomol	  
Study	  
Purpose/Design	  
Population	   Arimoclomol	  Regimen	   Endpoints	  
Single	  oral	  doses	  
(SC,	  R,	  DB,	  P)	  
10	  healthy	  
males	  
50-­‐600mg	  single	  doses	  
or	  placebo	  
7	  days	  
PK,	  AEs,	  Labs,	  Clinical,	  
ECG	  
Multiple	  oral	  doses	  
(SC,	  R,	  DB,	  P)	  
18	  healthy	  
males	  
50mg	  od	  to	  100mg	  tds	  
10	  days	  
PK,	  AEs,	  Labs,	  Clinical,	  
ECG	  
Radiolabelled	  mass	  








14C-­‐BRX-­‐345	  PK	  and	  
metabolites	  in	  serum,	  
urine	  and	  faeces,	  AEs,	  
Labs,	  Clinical,	  ECG	  
Bioavailability	  and	  
food	  effect	  




100mg	  single	  dose	  
PK	  in	  plasma	  (fed	  vs.	  
fasted),	  AEs,	  Labs,	  
Clinical,	  ECG	  
Safety,	  tolerability	  
and	  maximum	  dose	  
range	  




100mg	  od	  to	  600mg	  tds	  
7	  days	  
PK,	  urinary	  creatinine	  
and	  B2-­‐microglobulin,	  
protein	  and	  
microalbumin,	  AEs,	  Labs,	  
Clinical,	  ECG	  	  
Extended	  Safety	  and	  
tolerability	  plus	  
renal	  evaluation	  










and	  microalbumin,	  AEs,	  
Clinical,	  ECG	  
Table	  5.3	  Phase	  I	  human	  studies	  of	  Arimoclomol	  Six	   studies	   of	   Arimoclomol	   in	   healthy	   human	   volunteers	   demonstrated	   satisfactory	  pharmacokinetic,	  bioavailability	  and	  safety	  data	  to	  allow	  further	  evaluation	  in	  patients	  (CytRxCorp	  2009).	  (SC=single	  centre,	  R=randomised,	  D=double-­‐blind,	  P=placebo,	  OL=open	  label,	  od=once	  daily,	   tds=three	   times	  daily,	  PK=pharmacokinetics,	  AEs=adverse	  events,	   Labs=routine	  clinical	  laboratory	  tests,	  ECG=electrocardiogram).	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CSF	  penetration	  in	  
ALS	  





25mg	  tds	  to	  
100mg	  tds	  
12	  weeks	  
PK,	  AEs,	  Labs,	  Clinical,	  
ECG,	  interaction	  with	  
riluzole,	  ALSFRS-­‐R,	  vital	  
capacity,	  weight,	  BMI,	  
survival	  
Extended	  safety	  and	  








PK,	  AEs,	  Labs,	  Clinical,	  
ECG,	  interaction	  with	  
riluzole,	  ALSFRS-­‐R,	  vital	  
capacity,	  weight,	  BMI,	  
survival	  
Table	  5.4	  Previous	  Phase	  IIa	  human	  studies	  of	  Arimoclomol	  Two	  previous	  Phase	   IIa	   studies	  of	  Arimoclomol	   in	  patients	  with	  Amyotrophic	  Lateral	  Sclerosis	   demonstrated	   satisfactory	   safety	   and	   tolerability	   over	   up	   to	   6	   months.	  (CytRxCorp	  2009)	  (MC=multicentre,	   DB=double-­‐blind,	   P=placebo	   controlled,	   ALS=Amyotrophic	   Lateral	  Sclerosis,	   tds=three	   times	   daily,	   PK=pharmacokinetics,	   AEs=adverse	   events,	  Labs=routine	   clinical	   laboratory	   tests,	   ECG=electrocardiogram,	   ALSFRS-­‐R=ALS	  functional	  rating	  scale,	  BMI=body	  mass	  index)	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Nevertheless,	   the	   opportunity	   to	   obtain	   such	  data	  was	   taken	   since	   this	  would	  evaluate	  the	  suitability	  of	  such	  measures	  for	  use	  in	  future	  studies,	  estimate	  the	  practicality	   of	   performing	   such	   a	  measurement	   panel	   on	   a	   cohort	   of	   patients,	  provide	  data	  to	  inform	  future	  power	  calculations	  could	  and	  provide	  a	  means	  to	  detect	  any	   large	   impact,	  either	  positive	  or	  negative,	  of	  Arimoclomol	   treatment	  on	  important	  features	  of	  IBM.	  3.	  To	  determine	  the	  effect	  of	  Arimoclomol	  treatment	  on	  the	  expression	  of	  Heat	  Shock	  Protein	  expression	  in	  IBM	  muscle.	  Having	  determined	  that	  Arimoclomol	  augments	   the	  expression	  of	  HSP70	  under	   IBM-­‐relevant	   conditions	   in	  vitro,	  we	  sought	   to	  examine	  whether	  a	   similar	  effect	   could	  be	  detected	   in	  patients	  with	  IBM.	  4.	  To	  determine	  the	  impact	  of	  Arimoclomol	  on	  histopathological	  features	  of	  IBM	  tissue.	  Only	  one	  previous	  study	  of	  IBM	  has	  included	  serial	  muscle	  biopsies.	  We	  sought	   to	   evaluate	   the	  histological	   features	  of	   the	  disease	  using	   an	  up-­‐to-­‐date	  panel	   of	   markers.	   This	   also	   provided	   opportunity	   to	   determine	   markers	   that	  appeared	  promising	  as	  potential	  biomarkers	  of	  disease.	  
5.2	  Methods	  
5.2.1	  Contributors	  to	  the	  clinical	  trial	  A	  transatlantic	  clinical	  trial	  requires	  the	  input	  of	  numerous	  people.	  The	  US	  and	  UK	   sites	   were	   led	   respectively	   by	   Dr	   Richard	   Barohn	   at	   Kansas	   University	  Medical	  Centre	  and	  Professor	  Michael	  Hanna	  at	  University	  College	  London	  and	  each	  site	  employed	  a	  team	  of	  people.	  My	  specific	  involvement	  was:	  
i)	  Trial	  design	  and	  set-­‐up	  
• I	   wrote	   the	   trial	   protocol	   for	   the	   UK	   site	   to	   meet	   local	   and	   EU	   trial	  directive	   regulations.	   This	   was	   required	   to	   achieve	   sponsorship	   from	  UCL	  Joint	  Biomedical	  Research	  Unit.	  This	   involved	  extensive	  adaptation	  of	   the	  methodology	   and	   trial-­‐reporting	   framework	   from	   an	   original	  US	  draft.	  
• I	   wrote	   the	   application	   to	   the	   Local	   Research	   Ethics	   Committee	   and	  defended	   the	   application	   at	   the	   corresponding	   meeting	   of	   the	   Ethics	  Committee.	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• I	  wrote	  the	  documents	  supporting	  approval	  of	  the	  trial	  by	  the	  Medicines	  and	  Healthcare	  Regulatory	  Agency.	  I	  was	  assisted	  in	  this	  process	  by	  Miss	  Emma	   Lee	   of	   ChoicePharma,	   a	   third-­‐party	   Contract	   Research	  Organisation.	  
• I	  wrote	   the	   grant	   application	   to	   the	  Arthritis	  Research	  Campaign	   (now	  Arthritis	  Research	  UK),	  who	  kindly	  funded	  this	  trial.	  
• I	   was	   the	   primary	   point	   of	   liaison	   with	   CytRx	   Corporation	   (the	  manufacturing	   drug	   company),	   UCL	   JBRU	   and	   UCL	   Trials	   Pharmacy	  throughout	   the	   trial	   set-­‐up	   period.	   This	   included	   the	   processes	   of	  achieving	   sponsorship,	   inspection	   of	   the	   IMP	  manufacturing	   site	   by	   an	  EU	   qualified	   person,	   preparation	   of	   Investigational	   Medicinal	   Product	  Dossier,	   statistical	  evaluation	  and	  approval,	  and	  receipt	  and	  dispending	  of	  trial	  medication.	  
• I	   received	   valuable	   administrative	   support	   from	   Ms	   Gisela	   Barreto	  (Clinical	  Trials	  Coordinator)	  during	  this	  period.	  	  
ii)	  Trial	  conduct	  
• For	  consistency,	  Dr	  Pedro	  Machado	  (Physician,	  clinical	  assessments)	  and	  Ms	   Lis	   Dewar	   (Physiotherapist,	   quantitative	   myometry)	   and	   Dr	   Fion	  Bremner	   (Ophthalmologist,	   slit	   lamp	  examination)	  performed	   trial	  visit	  assessments	   of	   UK	   subjects	   wherever	   possible.	   I	   performed	   clinical	  assessments	  when	  this	  was	  not	  possible.	  
• After	   completion	   of	   the	   surgical	   procedure,	   I	   processed	  muscle	   biopsy	  tissue	  taken	  at	  the	  UK	  site	  (i.e.	  retrieval,	  sectioning	  and	  provision	  to	  the	  relevant	   laboratories	   at	   the	   National	   Hospital	   for	   Neurology	   and	  Neurosurgery	   or	   Institute	   of	  Neurology,	  UCL).	   I	  was	   posted	   sections	   of	  frozen	   muscle	   biopsies	   from	   the	   US	   site	   through	   the	   Fedex™	   clinical	  sample	  service.	  	  
• I	   performed	   the	   analysis	   and	   scoring	   of	   the	   histology	   of	   trial	   muscle	  tissue	  described	  in	  this	  thesis.	  Additional	  analysis	  of	  the	  same	  slides	  was	  undertaken	   by	   Dr	   Janice	   Holton,	   Neuropathologist	   at	   the	   National	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Hospital	   for	  Neurology	  and	  Neurosurgery	   for	  purposes	  of	   the	   final	   trial	  reporting	   and	   local	   clinical	   governance.	   As	   an	   NHS	   clinical	   report	   was	  generated	   for	   all	   biopsies,	   all	   histology	   samples	   at	   the	   UK	   site	   were	  mounted	  and	   immunostained	  by	   the	  Department	  of	  Neuropathology,	   in	  accordance	  with	  its	  established	  standard	  operating	  procedures.	  
• I	  conducted	  the	  ELISA	  analysis	  of	  Heat	  Shock	  Proteins	  described	  in	  this	  thesis.	  Additional	  analysis	  was	  undertaken	  by	  Dr	  Bernadette	  Kalmar	  and	  Dr	  Ching-­‐Hua	  Lu	  at	   the	   Institute	  of	  Neurology	   for	   the	  purposes	  of	   final	  trial	  reporting.	  
• I	  amalgamated	  and	  analysed	  the	  data	  described	  in	  this	  thesis	  (additional	  analysis	  was	  performed	  by	  investigators	  in	  both	  sites	  as	  part	  of	  the	  final	  trial).	   Data	   from	   the	   UK	   was	   manually	   transcribed	   from	   the	  corresponding	   written	   case	   report	   forms	   (maintained	   by	   Ms	   Gisela	  Baretto)	  into	  electronic	  format.	  Data	  from	  US	  site	  was	  amalgamated	  and	  provided	   to	   me	   in	   digital	   format	   by	   Ms	   Laura	   Herbelin	   (Trials	  Coordinator	  at	  Kansas	  University	  Medical	  Centre).	  
• I	  attended	  trial	  safety	  committee	  meetings.	  
	  
5.2.2	  Trial	  design	  In	  the	  United	  Kingdom,	  the	  necessary	  sponsorship	  was	  obtained	  from	  the	  UCL	  Joint	   Biomedical	   Research	   Unit.	   Approval	   was	   then	   received	   from	   the	   local	  ethics	  committee	  and	  Medicines	  and	  Healthcare	  Regulatory	  Agency	  (MHRA).	  In	  the	  United	  States	  of	  America,	  the	  equivalent	  approvals	  were	  received	  from	  the	  local	  ethics	  committee	  and	  Food	  and	  Drug	  Administration	  (FDA).	  The	  trial	  was	  conducted	   at	   University	   College	   London,	   UK	   and	   Kansas	   University	   Medical	  Centre,	   USA.	   A	   randomised,	   double	   blind	   placebo-­‐controlled	   structure	   was	  employed.	  At	  each	  site,	  8	  participants	  were	  allocated	  oral	  Arimoclomol	  100mg	  three	  times	  per	  day	  and	  4	  participants	  matching	  placebo.	  This	  generated	  a	  total	  of	  24	  participants,	  16	  of	  whom	  received	  Arimoclomol	  and	  8	  received	  placebo.	  After	   determination	   of	   eligibility	   and	   provision	   of	   informed	   consent,	  participants	  entered	  a	  treatment	  phase	  lasting	  four	  months	  and	  then	  underwent	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a	  further	  eight	  months	  of	  clinical	   follow-­‐up.	  The	  duration	  of	  total	  participation	  was	   one	   year	   (Fig	   5.2).	   During	   the	   treatment	   phase,	   assessments	   were	  made	  fortnightly	   and	   during	   the	   follow-­‐up	   phase	   this	   was	   extended	   to	   monthly.	   In	  total,	  each	  participant	  made	  18	  trial	  visits.	  The	  nature	  of	  each	  visit	  depended	  on	  the	   stage	   of	   the	   trial,	   but	   always	   included	   determination	   of	   Adverse	   Events	  (Table	  5.5).	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Figure	  5.2	  Study	  design	  for	  participants	  each	  of	  the	  two	  sites	  Each	   site	   recruited	   12	   eligible	   participants	   who	   then	   underwent	   a	   4-­‐month	  treatment	   phase	   (8	   on	   Arimoclomol	   and	   4	   on	   placebo)	   before	   completing	   a	  further	  8	  months	  of	  clinical	  evaluation.	  
Placebo	  Controlled	  Drug	  Phase	   Clinical	  Endpoints	  Phase	  
Visit	  Number	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   11	   12	   13	   14	   15	   16	   17	  
18
Month	   0	  (Screen)	  
0	  
	  (Base)	   0.5	   1	   1.5	   2	   2.5	   3	   3.5	   4	   5	   6	   7	   8	   9	   10	   11	   12	  
History/Exam	   •	   •	   •	   •	   •	   •	   •	   •	   •	   •	   •	   •	  
Neurological	  
Examination	   •	   •	   •	  
Safety	  Labs*	   •	   •	   •	   •	   •	   •	  
Safety	  Labs**	   •	   •	   •	   •	  
Dispensing	  of	  
Medication	   •	   •	   •	   •	  
DEXA	  scan	   •	   •	   X	  
Muscle	  Biopsy	   •	   •	  




•	   •	   •	   •	   •	   •	   •	   •	   •	   •	   •	   •	   •	   •	  
Ophthalmic	  exam	   •	   •	  
Side	  Effects	  of	  
medication	   •	   •	   •	   •	   •	   •	   •	   •	  
Adverse	  Events	   •	   •	   •	   •	   •	   •	   •	   •	   •	   •	   •	   •	   •	   •	   •	   •	   •	  
Table	  5.5	  Outline	  of	  trial	  visit	  schedule	  for	  each	  participant.	  Components	  of	  each	  trial	  visit	  are	  indicated.*=Full	  laboratory	  profile,	  **=Partial	  laboratory	  profile	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5.2.3	  Patient	  eligibility	  Participants	  were	  required	  to	  fulfill	  a	  number	  of	  inclusion	  and	  exclusion	  criteria,	  detailed	  below.	  	  
5.2.3.1	  Inclusion	  criteria	  Eligible	  study	  subjects	  had	  to	  meet	  all	  of	  the	  following	  criteria:	  1. Meet	  the	  Griggs	  diagnostic	  criteria	  for	  definite	  or	  probable	  IBM	  (Griggs	  et	  al.	  1995)	  2. At	   least	  8	  of	   the	   following	  16	  muscle	   groups	  must	  have	  a	  MMT	  muscle	  grade	   >	   3-­‐	   or	   greater	   on	   the	  modified	  Medical	   Research	   Council	   Scale:	  Shoulder	   Abductors,	   Elbow	   Flexors,	   Elbow	   Extensors,	   Wrist	   Flexors,	  Knee	   extensors,	   Knee	   flexors,	   Ankle	   dorsiflexors,	   Neck	   flexors,	   Neck	  extensors.	  3. Age	  >	  50	  years.	  4. Women	  must	   be	  post-­‐menopausal	   (no	  menses	   in	   >12	  months)	   or	   have	  undergone	  hysterectomy.	  
	  
5.2.3.2	  Discussion	  of	  diagnostic	  criteria	  The	  most	  widely	  accepted	  and	  stringent	  criteria	  for	  the	  diagnosis	  of	  IBM	  remain	  Griggs’	   criteria	   (Table	   5.6).	   There	   is	   likely	   to	   be	   a	   significant	   cohort	   of	   IBM	  patients	  who	  demonstrate	  the	  stereotypical	  clinical	  phenotype	  but	  lack	  the	  full	  range	  of	  histological	  features	  required	  of	  these	  criteria	  (Hilton-­‐Jones	  et	  al.	  2010).	  As	   these	   patients	   may	   logically	   represent	   those	   in	   the	   earlier	   phase	   of	   the	  disease,	   they	   may	   represent	   those	   most	   likely	   to	   benefit	   from	   treatment.	  Nevertheless,	  as	  this	  trial	  did	  not	  seek	  to	  evaluate	  drug	  efficacy	  but,	  rather,	  drug	  safety	   and	   activity,	   stringency	   of	   diagnosis	   was	   prioritised,	   at	   the	   risk	   of	  excluding	  that	  cohort	  of	  ‘clinically	  defined’	  patients.	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I.	  Diagnostic	  classification	  
A.	  Definite	  inclusion	  body	  myositis	  
Patients	  must	  exhibit	  all	  muscle	  biopsy	  features	  including	  invasion	  of	  nonnecrotic	  fibers	  by	  mononuclear	  cells,	  
vacuolated	  muscle	  fibers,	  and	  intracellular	  (within	  muscle	  fibers)	  amyloid	  deposits	  or	  15–18	  nm	  
tubulofilaments.	  None	  of	  the	  other	  clinical	  or	  laboratory	  features	  are	  mandatory	  if	  muscle	  biopsy	  features	  are	  
diagnostic.	  
B.	  Probable	  inclusion	  body	  myositis	  
If	  the	  muscle	  shows	  inflammation	  (invasion	  of	  non-­‐necrotic	  muscle	  fibers	  by	  mononuclear	  cells)	  and	  vacuolated	  
fibers	  but	  without	  other	  pathological	  features	  of	  inclusion	  body	  myositis,	  then	  a	  diagnosis	  of	  probable	  inclusion	  
body	  myositis	  can	  be	  given	  if	  the	  patient	  exhibits	  the	  characteristic	  clinical	  (A1,2,3)	  and	  laboratory	  (B1,3)	  
features.	  
II.	  Characteristic	  features	  
A.	  Clinical	  features	  
1.	  Duration	  of	  illness	  >	  6	  months	  
2.	  Age	  of	  onset	  >	  30	  years	  of	  age	  
3.	  Muscle	  weakness	  
Must	  affect	  proximal	  and	  distal	  muscles	  of	  arms	  and	  leg	  and	  Patient	  must	  exhibit	  at	  least	  one	  of	  the	  following	  
features:	  
a.	  Finger	  flexor	  weakness	  
b.	  Wrist	  flexor	  >	  wrist	  extensor	  weakness	  
c.	  Quadriceps	  muscle	  weakness	  (MRC	  grade	  4)	  
B.	  Laboratory	  features	  
1.	  Serum	  creatine	  kinase	  <	  12	  times	  upper	  limit	  of	  normal	  
2.	  Muscle	  biopsy	  
a.	  Inflammatory	  myopathy	  characterized	  by	  mononuclear	  cell	  invasion	  of	  nonnecrotic	  muscle	  fibers	  
b.	  Vacuolated	  muscle	  fibers	  
c.	  Either	  
(I)	  Intracellular	  amyloid	  deposits	  (must	  use	  fluorescent	  method	  of	  identification	  before	  excluding	  the	  presence	  
of	  amyloid)	  or	  (II)	  15–18	  nm	  tubulofilaments	  by	  electron	  microscopy	  
3.	  Electromyography	  must	  be	  consistent	  with	  features	  of	  an	  inflammatory	  myopathy	  (however,	  long-­‐duration	  
potentials	  are	  commonly	  observed	  and	  do	  not	  exclude	  diagnosis	  of	  sporadic	  inclusion	  body	  myositis).	  
	  
Table	  5.6	  Griggs’	  diagnostic	  criteria	  for	  IBM	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Minimum	  muscle	  power	  Quantitative	   muscle	   testing	   by	   myometry	   represents	   a	   useful	   trial	   outcome	  measure	   in	  muscular	   diseases.	   To	   ensure	   this	   could	   be	   performed	   and,	   as	   an	  estimate	   of	   the	   level	   of	   function	   that	   would	   be	   required	   to	   complete	   the	  intensive	   trial	   visit	   schedule,	   only	   patients	   who	   were	   able	   to	   demonstrate	   at	  least	   Grade	   3-­‐	   on	   the	   MRC	   scale	   in	   at	   least	   eight	   major	   muscle	   groups	   were	  considered.	  	  
Minimum	  age	  To	  minimise	  the	  chance	  that	  patients	  with	  genetic	  diseases,	  such	  as	  myofibrillar	  myopathy,	   that	   can	  mimic	   IBM	  were	   included	   in	   the	   study,	   a	  minimum	  age	  of	  participation	  of	  50	  years	  was	  incorporated.	  
Infertile	  female	  participants	  Due	   to	   the	   unclear	   safety	   profile	   of	   Arimoclomol	   in	   pregnancy,	   only	  postmenopausal	  women	  were	  included	  in	  the	  trial.	  
	  
	  
5.2.3.3	  Exclusion	  criteria	  A	   variety	   of	   exclusion	   criteria	  were	   applied	   to	  minimise	   exposure	   of	   patients	  with	  coexistent	  medical	  conditions	  related	  to	  any	  previous	  potential	  side	  effects	  of	  Arimoclomol.	  These	  also	  prevented	   inclusion	  of	  patients	  unable	   to	  undergo	  muscle	  biopsy	  safely.	  Given	  animal	  data	  suggesting	  a	  potential	  interaction	  with	  Riluzole,	   the	   receipt	   of	   drug	   was	   a	   specified	   exclusion	   criterion	   (CytRx	  Corporation	  communication,	  unpublished	  toxicity	  data).	  The	  presence	  of	  any	  of	  the	  following	  excluded	  subject	  participation	  in	  the	  study:	  1. Presence	   of	   any	   one	   of	   the	   following	   medical	   conditions:	   diabetes	  mellitus	   or	   patients	   taking	   anti-­‐diabetic	   medications,	   chronic	   infection,	  chronic	   renal	   insufficiency,	   cancer	   other	   than	   skin	   cancer	   less	   than	  5	   years	  previously,	   multiple	   sclerosis	   or	   prior	   episode	   of	   central	   nervous	   system	  demyelination,	  or	  other	  chronic	  serious	  medical	  illnesses.	  2. Presence	   of	   any	   of	   the	   following	   on	   routine	   blood	   screening:	   WBC	   <	  3000/cm3,	   Platelets	   <	   100,000/cm3,	   haematocrit	   <	   30%,	   urea	   >	   10mmol/l,	  creatinine	   >	   150μmol/l,	   symptomatic	   liver	   disease	   with	   serum	   albumin	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<30g/L,	  prothrombin	  time	  or	  activated	  partial	  thromboplastin	  time	  >	  upper	  range	  of	  control	  values.	   	  3. Currently	  taking	  riluzole	  4. Women	  who	  are	  pregnant	  or	  lactating	   	  5. History	  of	  non-­‐compliance	  with	  other	  therapies	   	  6. Coexistence	  of	  other	  neuromuscular	  disease	  7. Drug	  or	  alcohol	  abuse	  within	  last	  3	  months	  8. Inability	  to	  give	  informed	  consent	  9. Known	  bleeding	  disorder	  (e.g.	  Haemophilia,	  Von	  Willebrand’s	  Disease)	  10. Use	  of	  potentially	  nephrotoxic	  drugs	  11. Prior	  difficulties	  with	  local	  anaesthetic	  	  
5.2.4	  Randomisation	  and	  blinding	  An	  independent	  statistician	  at	  the	  Kansas	  University	  Medical	  Centre	  performed	  randomisation	  of	  treatment	  allocation	  using	  computer	  generated	  random	  codes.	  These	  codes	  were	  provided	  to	  the	  respective	  research	  pharmacies.	  Investigators	  and	  participants	  were	  blinded	   to	   treatment	   allocation.	   In	   accordance	  with	   the	  intention-­‐to-­‐treat	   principle,	   all	   randomised	   participants	   were	   included	   in	   the	  analysis	   according	   to	   the	   treatment	   group	   to	   which	   they	   were	   originally	  assigned.	  	  All	  randomised	  participants	  were	  evaluated	  for	  tolerability	  and	  safety	  measures.	  	  	  
5.2.5	  Primary	  outcome	  measure	  Consistent	  with	   the	   principle	   aim	  of	   the	   study	  being	   safety	   and	   tolerability	   of	  Arimoclomol	  in	  IBM	  patients,	  the	  primary	  outcome	  measure	  was	  adverse	  events.	  As	   the	   significance	   of	   one	   serious	   adverse	   event	   may	   exceed	   that	   of	   several	  minor	   adverse	   events,	   this	   required	   quantification	   of	   severity	   in	   addition	   to	  frequency.	  Additionally,	  the	  relationship	  of	  any	  adverse	  event	  to	  the	  provision	  of	  Arimoclomol	  was	  important	  so	  that	  likelihood	  of	  causation	  could	  be	  established.	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5.2.5.1	  Definition	  of	  adverse	  events	  An	  Adverse	  Event	   (AE)	  was	  defined	  as	  any	  untoward	  medical	  occurrence	   in	  a	  subject	   to	   whom	   a	   medicinal	   product	   had	   been	   administered,	   including	  occurrences	  which	  are	  not	  necessarily	  caused	  by	  or	  related	  to	  that	  product.	  Accordingly,	  an	  adverse	  event	  incorporated	  any	  of	  the	  following:	  	  
• intercurrent	  illnesses	  	  
• physical	  injuries	  	  
• events	  possibly	  related	  to	  concomitant	  medications	  	  
• significant	   worsening	   (change	   in	   nature,	   severity,	   or	   frequency)	   of	   the	  disease	   under	   study	   or	   other	   preexisting	   conditions	   .	   Therefore,	  progression	   of	   the	   disease	   as	   judged	   by	   the	   clinical	   investigators	   to	  represent	   the	   natural	   course	   of	   the	   condition	   was	   not	   considered	   an	  adverse	  event.	  
• drug	  interactions	  	  
• events	  occurring	  during	  diagnostic	  procedures	  	  
• a	   laboratory	   or	   diagnostic	   test	   abnormality	   occurring	   after	   the	   start	   of	  the	   study	   (once	   confirmed	   by	   repeat	   testing)	   that	   resulted	   in	   the	  withdrawal	   of	   the	   participant	   from	   the	   study,	   required	   medical	  treatment	  or	  further	  diagnostic	  work-­‐up,	  or	  was	  considered	  by	  the	  study	  investigator	  to	  be	  clinically	  significant.	  	  A	  Serious	  adverse	  event	  (SAE)	  was	  defined	  as	  any	  adverse	  event	  that:	  
• resulted	  in	  death,	  
• was	  life-­‐threatening,	  
• required	  hospitalisation	  or	  prolongation	  of	  existing	  hospitalisation,	  
• resulted	  in	  persistent	  or	  significant	  disability	  or	  incapacity,	  or	  
• consisted	  of	  a	  congenital	  anomaly	  or	  birth	  defect;	  Adverse	  Events	  were	  also	  scored	  according	  to	  the	  US	  National	  Cancer	  Institute	  Common	   Terminology	   criteria	   (CTC	   version	   3.0,	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http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm)	  that	   set	   out	   clinical	   parameters	   required	   to	   classify	   each	   event	   as	   Grade	   1	  	  (mild),	   Grade	   2	   (moderate),	   Grade	   3	   (severe),	   Grade	   4	   (life-­‐threatening)	   or	  Grade	   5	   (death).	   This	   ensured	   objectivity	   to	   the	   scoring	   of	   Adverse	   Event	  severity.	  
	  
5.2.5.2	  Relationship	  of	  Adverse	  Events	  to	  Arimoclomol	  For	  each	  adverse	  event,	  the	  relationship	  to	  the	  study	  drug	  was	  recorded	  as	  one	  of	  the	  choices	  on	  the	  following	  scale:	  	  	  
Definite	  -­‐	  Causal	  relationship	  is	  certain	  The	   temporal	   relationship	   between	   drug	   exposure	   and	   the	   adverse	   event	  onset/course	   is	   reasonable,	   other	   causes	  have	  been	   eliminated,	   and	   the	   event	  must	  be	  definitive	  pharmacologically	  or	  phenomenologically.	  
Probable	  -­‐	  High	  degree	  of	  certainty	  for	  causal	  relationship	  The	   temporal	   relationship	   between	   drug	   exposure	   and	   the	   adverse	   event	  onset/course	   is	   reasonable,	   and	   other	   causes	   have	   been	   eliminated	   or	   are	  unlikely.	  	  
Possible	  -­‐	  Causal	  relationship	  is	  uncertain	  The	   temporal	   relationship	   between	   drug	   exposure	   and	   the	   adverse	   event	  onset/course	  is	  reasonable	  or	  unknown,	  and	  while	  other	  potential	  causes	  may	  or	   may	   not	   exist,	   a	   causal	   relationship	   to	   the	   study	   drug	   does	   not	   appear	  probable.	  
Unlikely	  -­‐	  Not	  reasonably	  related,	  although	  a	  causal	  relationship	  cannot	  be	  
ruled	  out	  While	  the	  temporal	  relationship	  between	  drug	  exposure	  and	  the	  adverse	  event	  onset/course	  does	  not	  preclude	  causality,	  there	  is	  a	  clear	  alternate	  cause	  that	  is	  more	  likely	  to	  have	  caused	  the	  adverse	  event	  than	  the	  study	  drug.	  	  
Not	  Related	  -­‐	  No	  possible	  relationship	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The	   temporal	   relationship	   between	   drug	   exposure	   and	   the	   adverse	   event	  onset/course	  is	  unreasonable	  or	  incompatible,	  or	  a	  causal	  relationship	  to	  study	  drug	  is	  implausible.	  
	  
5.2.5.3	  Classification/description	  of	  Adverse	  Events	  The	   clinical	   description	   or	   diagnosis	   related	   to	   each	   adverse	   event	   was	  categorised	   according	   to	   trial	   standard	   World	   Health	   Organisation	   MedDRA	  nomenclature	  (Brown	  et	  al.	  1999).	  	  
5.2.5.4	  Detection	  of	  Adverse	  Events	  and	  relationship	  to	  safety	  and	  tolerability	  Adverse	  events	  (AEs)	  were	  detected	  through	  participant	  reporting	  and	  at	   trial	  visits,	   where	   potential	   asymptomatic	   events	   were	   assessed	   through	   clinical	  examination,	   blood	   sample	   laboratory	   testing,	   electrocardiogram	   and	  ophthalmological	  review.	  Participants	   were	   instructed	   to	   contact	   the	   relevant	   Investigators	   to	   report	  events	   that	   occur	   between	   study	   visits.	   At	   each	   visit,	   participants	   were	  questioned	  directly	  regards	  symptoms	  of	  potential	  adverse	  events.	  	  Regards	   any	   ‘non-­‐serious’	   adverse	   event	   (NCI	   grade	   1	   or	   2)	   the	   protocol	  dictated	   that	   the	   principal	   investigator	   could	   determine	   whether	   the	   study	  medication	  should	  be	  continued.	  This	  could	  be	  performed	  without	  unblinding.	  For	   Serious	   Adverse	   Events	   (SAEs)	   and	   AEs	   of	   Grade	   3	   and	   above,	   the	  investigator	   informed	   the	   independent	   safety	   monitor	   to	   make	   this	  determination.	   This	   decision	   would	   include	   restricted	   unblinding	   of	   that	  participant’s	  treatment	  allocation	  to	  the	  safety	  monitor.	  The	   independent	   safety	   monitor	   reviewed	   safety	   and	   tolerability	   data	   every	  month	   and	   any	   SAE	   immediately.	   	   The	   predetermined	   criteria	   for	   an	  unacceptable	   safety	   profile,	   in	   which	   case	   the	   safety	   monitor	   would	   halt	   the	  study,	  were	  as	  follows:	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1.	  A	  rate	  of	  AEs	  (regardless	  of	  any	  severity)	  considered	  possibly	  or	  probably	  to	  trial	  medication	  that	  leads	  to	  discontinuation	  of	  the	  study	  in	  over	  25%	  of	  subjects	  (more	  than	  3	  participants	  at	  either	  site).	  	  2.	  Any	  SAE,	  Grade	  3,	  4,	  or	  5	  judged	  by	  the	  independent	  safety	  monitor	  to	  be	  secondary	  to	  the	  trial	  medication.	  3.	  An	  acceleration	  of	  cataract	  formation	  in	  two	  subjects	  that	  was	  believed	  to	  be	  related	  to	  trial	  medication.	  	  Pre-­‐trial	  power	  calculations	  suggested	  that	  observing	  0	  or	  1	  treatment	  related	  AE	   among	   the	   16	   recipients	   of	   Arimoclomol	   would	   allow	   conclusion	   that	   the	  true	  rate	  of	   treatment	   related	  AEs	   is	   less	   than	  23%,	   through	  a	  90%	  one-­‐sided	  confidence	  interval.	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5.2.6	  Secondary	  outcome	  measures	  
5.2.6.1	  Manual	  muscle	  testing	  Manual	  Muscle	  Testing	  (MMT)	  is	  a	  scored	  neurologic	  examination,	  derived	  from	  the	  widely	  employed	  Medical	  Research	  Council	  (MRC)	  scale.	  	  It	  allocates	  scores	  between	   0	   and	   10	   based	   on	   the	   examination	   of	   34	  muscles:	   neck	   flexors	   and	  extensors;	   shoulder	  abduction,	   external	   rotation;	   elbow	   flexion	  and	  extension;	  wrist	   extension	   and	   flexion;	   abductor	   pollicis	   brevis;	   flexor	   digiti	  minimi;	   hip	  flexors,	   extensors	   and	   abductors;	   knee	   extension	   and	   flexion;	   and	   ankle	  dorsiflexion,	  plantar	  flexion	  and	  extensor	  hallucis	  longus.	  	  Each	  muscle	  is	  scored	  from	  0	  to	  5,	  with	  0	  representing	  paralysis	  and	  5	  representing	  normal	  strength.	  	  There	   are	  modifications	   to	   this	   scale,	   by	   adding	   either	   a	  minus	   or	   plus	   to	   the	  score.	  	  For	  example,	  a	  4-­‐	  represents	  a	  muscle	  that	  is	  slightly	  weaker	  than	  a	  score	  of	  4,	  and	  likewise	  a	  4+	  would	  be	  a	  muscle	  that	  is	  slightly	  stronger	  than	  a	  score	  of	  4.	  	  The	  +/-­‐	  scores	  are	  only	  employed	  for	  MRC	  score	  scores	  3	  and	  above.	  	  	  	  	  	  	  	  	  	  	  	  	  
Table	  5.7	  Quantification	  of	  manual	  muscle	  testing	  (MMT)	  for	  power	  To	  minimise	  variability,	  MMT	  was,	  whenever	  possible,	  performed	  by	  the	  same	  investigator	   on	   a	   given	   participant.	   Preceding	   the	   trial,	   all	   site	   investigators	  conducted	   a	   blinded	   evaluation	   of	   their	   MMT	   scoring	   to	   minimise	   inter-­‐
MRC	  Grade	  
MMT	  
(10	  Point	  System)	  
5	   10	  
5-­‐	   9	  
4+	   8	  
4	   7	  
4-­‐	   6	  
3+	   5	  
3	   4	  
3-­‐	   3	  
2	   2	  
1	   1	  
0	   0	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observer	   variability.	   All	   investigators	   were	   provided	   detailed	   information	   to	  ensure	   standardisation	   of	   the	   technique	   used	   to	   evaluate	  MMT	   and	  minimise	  inter-­‐observer	  variability	  (see	  Chapter	  7,	  Appendix).	  
	  
5.2.6.2	  Myometry	  The	   Cybex™	  myometry	   system	  was	   employed	   to	   provide	  maximum	   isometric	  voluntary	   contraction	   testing	   (MVICT),	   which	   has	   good	   reliability	   and	  reproducibility	  (FSH-­‐DY-­‐Group	  1997).	  The	  specific	  protocols	  used	  are	  described	  in	   Chapter	   7	   Appendix,	   Section	   7.1.1.2).	   Briefly,	   equipment	   was	   calibrated	  according	   to	   manufacturer’s	   instructions.	   Twelve	   muscles	   were	   tested,	   six	  muscles	   on	   each	   side.	   The	   joint	   tested	   was	   placed	   in	   a	   specific	   position.	   90°	  angles	   were	   used	   in	   joint	   and	   strap	   alignment	   for	   reliability	   purposes.	   Each	  muscle	  group	  was	  tested	  three	  times	  for	  at	  least	  3	  seconds	  while	  the	  patient	  was	  vigorously	   encouraged	   to	   push	   or	   pull	   in	   the	   desired	   direction.	   At	   least	   10	  seconds	   rest	  were	   allowed	   between	   contractions.	   The	   patients	  were	   tested	   in	  the	   supine	   position	   for	   the	   shoulder	   abduction,	   elbow	   flexion,	   and	   elbow	  extension,	  and	  sitting	  upright	  at	  the	  end	  of	  the	  table	  for	  the	  knee	  extension,	  knee	  flexion	  and	  hand	  grip.	  
 
5.2.6.3	  IBM	  Functional	  Rating	  Scale	  The	  IBM	  Functional	  Rating	  Scale	  (Table	  5.8)	  is	  a	  validated	  scoring	  system	  used	  to	   assess	   functional	   parameters	   relevant	   to	   daily	   life	   in	   patients	   with	   IBM	  (Jackson	   et	   al.	   2008).	   	   It	   was	   previously	   demonstrated	   to	   have	   greater	  sensitivity	   of	   change	   compared	   to	   measures	   of	   muscle	   power,	   including	  handgrip	  dynamometry	  and	  has	  been	  employed	  in	  one	  previous	  clinical	  trial	  of	  IBM	   (MuscleStudyGroup	   2004).	   Evaluators	   administered	   the	   scale	   in	  accordance	   with	   written	   guidance	   reproduced	   in	   the	   Appendix	   (Chapter	   7,	  Section	  7.1.2).	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1.	  	  SWALLOWING	  
4	   Normal	  eating	  habits	  
3	   Early	  eating	  problems	  –	  
occasional	  choking	  
2	   Dietary	  consistency	  changes	  
1	   Frequent	  choking	  
0	   Needs	  tube	  feeding	  
	  
2.	  HANDWRITING	  (with	  dominant	  hand	  prior	  to	  IBM	  
onset)	  
4	   Normal	  
3	   Slow	  or	  sloppy:	  all	  words	  legible	  
2	  	  	  	  	  	  	  	  	  	   Not	  all	  words	  are	  legible	  	  
1	   Able	  to	  grip	  pen	  but	  unable	  to	  
write	  
0	   Unable	  to	  grip	  pen	  
	  
3.	  CUTTING	  FOOD	  AND	  HANDLING	  UTENSILS	  	  
4	   Normal	  
3	   Somewhat	  slow	  and	  clumsy,	  but	  
no	  help	  needed	  
2	   Can	  cut	  most	  foods,	  slow	  and	  
clumsy;	  some	  help	  needed	  
1	   Food	  must	  be	  cut	  by	  someone,	  
but	  can	  still	  feed	  slowly	  
0	   Needs	  to	  be	  fed	  	  
	  
4.	  FINE	  MOTOR	  TASKS	  (opening	  doors,	  using	  keys.	  
Picking	  up	  small	  objects)	  
	   4	  	   Independent	  
3	  	   Slow	  or	  clumsy	  in	  completing	  
task	  	  
2	   Independent	  but	  requires	  
modified	  techniques	  or	  device	  
1	  	  	   Frequently	  requires	  assistance	  
from	  caregiver	  
	   0	  	   Unable	  to	  perform	  
	  
5.	  	  DRESSING	  
	   4	  	   Normal	  
3	  	   Independent	  but	  with	  increased	  
effort	  or	  decreased	  efficiency	  
2	  	   Independent	  but	  assistive	  
device	  or	  modified	  technique	  
1	  	   Requires	  assistance	  from	  
caregiver	  for	  some	  clothing	  
items	  
	   0	   Total	  dependence	   	  
	  
	  
6.	  	  HYGIENE	  
4	   Normal	  function	  
3	   Independent	  but	  with	  increased	  
effort	  or	  decreased	  activity	  
2	   Independent	  but	  requires	  use	  of	  
assistive	  devices	  
1	   Requires	  occasional	  assistance	  	  
0	   Completely	  dependent	  
	  
	  
7.	  	  TURNING	  IN	  BED	  AND	  ADJUSTING	  COVERS	  
4	   Normal	  	  
3	   Somewhat	  slow	  and	  clumsy,	  but	  
no	  help	  needed	  
2	   Can	  turn	  alone,	  or	  adjust	  sheets,	  
but	  with	  great	  difficulty	  
1	   Can	  initiate,	  but	  not	  turn	  or	  
adjust	  sheets	  alone	  
0	   Unable	  or	  requires	  total	  
assistance	  
	  
8.	  	  SIT	  TO	  STAND	  
4	   Independent	  (without	  use	  of	  the	  
arms)	  
3	   Performs	  with	  substitute	  
motions	  but	  without	  use	  of	  
arms	  
	   2	   Requires	  of	  use	  of	  arms	  
1	   Requires	  assistance	  	  
	   0	   Unable	  to	  stand	  
	   	  
9.	  	  WALKING	  
4	  	   Normal	   	  
3	   Slow	  or	  mild	  unsteadiness	  
2	   Intermittent	  use	  of	  an	  assistive	  
	   device	  	  
1	   Dependent	  on	  assistive	  device	  
0	   Wheelchair	  dependent	  	  
	  
10.	  	  CLIMBING	  STAIRS	  	  
4	   Normal	  
3	   Slow,	  hesitation,	  increased	  
effort;	  uses	  hand	  rail	  
intermittently	  
2	  	   Dependent	  on	  handrail	  	  
1	   Dependent	  on	  handrail	  and	  
additional	  support	  (cane	  or	  
person)	  
0	  	   Cannot	  climb	  stair
Table	  5.8	  The	  IBM	  Functional	  Rating	  Scale	  (FRS)	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5.2.6.4	  Dual	  Energy	  X-­‐Ray	  Absorptiometry	  (DEXA)	  Body	   composition	   was	   obtained	   using	   a	   standard	   DEXA	   whole	   body	   scan	   to	  assess	   total	  body	   fat-­‐free	  mass	  as	  well	   as	   total	  body	   fat	  mass.	  The	  scans	  were	  performed	  in	  the	  departments	  of	  radiology	  at	  Kansas	  University	  Medical	  Centre	  and	  University	  College	  London	  Hospital.	  The	  DEXA	  technique	  provides	  a	  reliable	  estimate	   of	   muscle	   mass	   because	   lean	   body	   mass	   is	   primarily	   composed	   of	  muscle.	   Indeed,	  DEXA	  measured	   lean	  body	  mass	   in	  neuromuscular	  patients	   is	  highly	   correlated	   with	   a	   standard	   method	   for	   estimation	   of	   muscle	   mass,	  urinary	  creatinine	  excretion	  (Tawil	  R	  1994).	   	  DEXA	  has	  been	  used	  to	  measure	  muscle	  mass	   in	   previous	   studies	   of	   IBM	   (MuscleStudyGroup	  2004),	  Duchenne	  dystrophy,	  and	  FSHD	  (Kissel	  et	  al.	  1998).	  The	  technique	  is	  easily	  performed	  and	  safe,	  using	  a	  very	  small	  quantity	  of	  X-­‐ray	  energy	  to	  measure	  body	  composition.	  The	   effective	   dose	   to	   an	   adult	   for	   a	   whole	   body	   study	   performed	   on	   this	  instrument	   to	   be	   4.2	   μSv,	   less	   than	   that	   of	   a	   plain	   chest	   radiograph.	   Thus	   the	  total	  effective	  dose	   for	  all	   three	  whole	  body	  DXA	  procedures	   in	   the	  study	  was	  12.6	  μSv.	  	  
	  
5.2.6.5	  Skeletal	  muscle	  biopsy	  Informed	   consent	   for	  muscle	   biopsy	  was	   incorporated	   into	   the	   initial	   consent	  process	   for	   the	   trial.	   	   Procedure-­‐specific	   consent	   was	   repeated,	   according	   to	  local	  protocols,	  by	  the	  operating	  surgeon	  prior	  to	  each	  biopsy,	  which	  was	  then	  performed	   under	   sterile	   conditions	   in	   an	   operating	   theatre.	   Open	   biopsy	  was	  performed	   in	   all	   cases,	   and	   three	   pieces	   of	   skeletal	   muscle,	   each	   of	  approximately	  0.5cm3,	  were	  taken	  via	  a	  small	  incision	  under	  sterile	  conditions.	  The	   primary	   biopsy	   site	   the	   first	   biopsy	   for	   all	   patients	  was	   biceps.	   If	   clinical	  examination	  implied	  this	  was	  impossible,	  the	  secondary	  site	  for	  the	  first	  biopsy	  was	  quadriceps.	  In	  all	  patients,	  the	  site	  of	  the	  second	  biopsy	  was	  the	  equivalent	  muscle	  of	  the	  contralateral	  side	  to	  that	  used	  in	  the	  first	  biopsy.	  The	  tissue	  was	  transferred	  immediately	  by	  vacuum	  chute	  to	  the	  histopathology	  laboratory	  and	  processed	   for	   histology	   or	   frozen	   in	   liquid	   nitrogen	   then	   stored	   at	   -­‐80	   °C	   for	  subsequent	  ELISA.	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5.2.6.6	  Muscle	  histology	  Muscles	  biopsies	  were	  frozen	  and,	  until	  sectioning,	  were	  stored	  at	  −80°C.	  Serial	  tissue	  sections	  were	  cut	  in	  a	  cryostat	  to	  a	  thickness	  of	  8	  μm,	  mounted	  on	  glass	  slides,	  allowed	  to	  air	  dry	  and	  stored	  at	  −80°C	  until	  staining.	  For	  histochemistry,	  tissue	   sections	   were	   stained	   with	   haematoxylin	   and	   eosin	   (H&E),	   combined	  cytochrome	   oxidase	   (COX)	   succinate	   dehydrogenase	   (SDH)	   or	   Gomori	  Trichrome.	   The	   tissue	   sections	   for	   immunohistochemistry	   were	   fixed	   for	   10	  minutes	   and,	   if	   required,	   washed	   for	   5	  minutes	   in	   running	  water.	   They	  were	  then	  incubated	  in	  0.5%	  hydrogen	  peroxide	  for	  20	  minutes	  to	  block	  endogenous	  peroxidase.	   After	   further	  washing,	   the	   sections	  were	   incubated	   in	   5%	  normal	  goat	   serum	  (Vector	  Laboratories,	  Burlingame,	  California,	  USA)	   for	  30	  minutes.	  Primary	   antibody	   binding	   was	   visualised	   using	   the	   Dako	   REAL	   EnVision	  Detection	   System:	   following	   incubation	  with	   the	   particular	   primary	   antibody,	  tissue	  sections	  were	  washed	  in	  phosphate-­‐buffered	  saline	  (PBS),	   incubated	  for	  30	   minutes	   with	   Horse-­‐radish-­‐peroxidase-­‐labelled	   goat	   anti-­‐rabbit/mouse	  secondary,	  washed	  in	  PBS	  and	  incubated	  for	  3–	  5	  minutes	  in	  a	  1:50	  solution	  of	  3,3′-­‐	  diaminobenzidine	  (DAB).	  The	  primary	  antibodies	  used	  were:	  MHC	  Class	  I	  (Dako™,	  Clone:	  W6/32,	   dilution	   1:800),	   p62	   (BD	   Transduction™,	  Clone:	   3/P62	  LCK	   Ligand,	   dilution	   1:200),	   CD3	   (Leica	   Novocastra™,	   NCL-­‐L-­‐CD3-­‐565,	   Clone:	  LN10,	   Dilution	   1:180),	   CD4	   (Leica	   Novocastra™,	   NCL-­‐CD4-­‐368,	   Clone:	   4B12,	  Dilution	  1:300),	  CD8	  (Dako™,	  M7103,	  Clone:	  C8/144B,	  Dilution	  1:60)	  and	  CD20	  (Leica	  Novocastra™,	  NCL-­‐CD20-­‐7D1,	  Clone:	  L26,	  Dilution	  1:100).	  Slides	   were	   assessed	   blind	   to	   the	   participant	   identity.	   Five	   non-­‐overlapping	  regions	  of	  x20	  magnification	  (or	  two	  x20	  regions	  in	  the	  context	  of	  COX	  staining	  or	  determination	  of	  inflammatory	  clusters)	  were	  scored	  in	  each	  specimen	  using	  a	   system	   adapted	   from	   a	   validated	   system	   for	   evaluation	   of	   biopsies	   in	  Dermatomyositis	  (Wedderburn	  et	  al.	  2007).	  The	  number	  of	  fibres	  displaying	  the	  following	   degenerative	   features	   was	   counted:	   Eosinophilic	   hyaline	   inclusions,	  granular	   basophilic	   inclusions,	   rimmed	   vacuoles,	   non-­‐rimmed	   vacuoles,	   red	  ragged	   fibres,	   COX	   deficient	   fibres	   and	   p62	   positive	   inclusions.	   Inflammation	  was	   characterised	   by	   counting	   the	   number	   of	   endomysial	   and	   perimysial	  inflammatory	  cell	   clusters	   	   (defined	  as	  a	   constellation	  of	  10	  cells	  or	  more)	   for	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each	  CD	  stain.	  A	  further	  score	  of	  0,	  1	  or	  2	  was	  made	  for	  each	  CD	  stain	  according	  to	  the	  following	  criteria:	  	   0	  =	  fewer	  than	  4	  cells	  in	  a	  x20	  field	  	   1	  =	  4-­‐20	  cells	  in	  a	  x20	  field	  and/or	  1	  cluster	  in	  five	  x20	  fields	  2	  =	  2	  or	  more	  clusters	   in	  five	  x20	  fields	  and/or	  diffuse	  infiltration	  (>20	  cells	  in	  a	  x20	  field)	  	  
5.2.6.7	  Determination	  of	  Heat	  Shock	  Protein	  70	  concentration	  in	  muscle	  biopsies	  HSP70	   concentration	   in	  muscle	   biopsy	   tissue	  was	   determined	   by	   quantitative	  Enzyme	   Linked	   Immunosorbent	   Assay	   (ELISA)	   (Stressgen™,	   EKS-­‐700,	  StressXpress®	   HSP70	   ELISA	   Kit).	   A	   mouse	   monoclonal	   antibody	   specific	   for	  inducible	   Hsp70	   (Stressgen™	   700-­‐P1)	   was	   pre-­‐coated	   on	   the	   wells	   of	   the	  provided	   Hsp70	   Immunoassay	   Plate.	   Inducible	   Hsp70	   was	   captured	   by	   the	  immobilized	   antibody	   and	   detected	   with	   a	   Hsp70	   specific	   rabbit	   polyclonal	  antibody	   (Stressgen™,	   Anti-­‐HSP	   Biotin	   Conjugate,	   700-­‐P6).	   The	   rabbit	  polyclonal	   antibody	   was	   subsequently	   bound	   by	   a	   horseradish	   peroxidase	  conjugated	   anti-­‐rabbit	   IgG	   secondary	   antibody	   (Stressgen™,	   HRP	   Conjugate,	  700-­‐P8)	  The	  assay	  was	  developed	  with	   tetramethylbenzidine	  (TMB)	  substrate	  and	  a	  blue	  color	  develops	  in	  proportion	  to	  the	  amount	  of	  captured	  Hsp70.	  The	  color	   development	   was	   stopped	   with	   acid	   stop	   solution	   that	   converts	   the	  endpoint	   color	   to	   yellow.	   The	   intensity	   of	   the	   color	   was	   measured	   in	   a	  microplate	   reader	   at	   450nm.	   Hsp70	   concentrations	   from	   the	   sample	   were	  quantitated	   by	   interpolating	   absorbance	   readings	   from	   a	   standard	   curve	  generated	  with	  the	  calibrated	  Hsp70	  protein	  standard	  provided.	  Samples	  were	  diluted	   and	   100μL,	   in	   duplicate,	   of	   each	   of	   the	   following	   were	   added	   to	  preplated	  wells:	   prepared	  Hsp70	   standards	   (0.78ng/ml	   to	   50ng/ml),	   samples	  prepared	   in	  diluent	   and	   standard	  of	   pure	   sample	  diluent.	  Wells	  were	   covered	  with	   plastic	   wrap	   and	   incubated	   at	   room	   temperature	   for	   2	   hours.	   All	   wells	  were	  then	  washed	  4	  times	  with	  wash	  buffer	  and	  pat	  dried	  on	  clean	  paper	  towels.	  100μL	  of	  the	  Hsp70	  antibody	  were	  added	  to	  each	  well	  before	  further	  wrapping	  and	   incubation	   room	   temperature	   for	   1	   hour.	   After	   washing,	   100μL	   of	   the	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Hsp70	   Conjugate	  were	   added	   to	   each	  well	   and	   incubated	   for	   1	   hour	   at	   room	  temperature.	  After	  washing,	  100μL	  of	  TMB	  Substrate	  were	  added	  to	  each	  well	  and	   colour	   development	   was	   observed.	   After	   30	  minutes	   incubation	   at	   room	  temperature,	   100μL	   of	   the	   Stop	   Solution	   (Hydrochloric	   Acid)	   were	   added	   to	  each	  well	  in	  the	  same	  order	  that	  the	  TMB	  Substrate	  was	  added.	  Absorbance	  was	  then	  measured	  at	  450nm.	  A	  logarithmic	  curve	  was	  fitted	  to	  the	  HSP70	  standard	  absorbances	  to	  allow	  determination	  of	  HSP70	  concentration	  in	  samples.	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5.3	  Results	  
5.3.1	  Fulfilment	  of	  trial	  protocol	  24	  participants	  were	  enrolled,	  12	  at	  each	  study	  site	   in	  London	  and	  Kansas.	  All	  participants	  successfully	  completed	  the	  pre-­‐defined	  treatment	  phase	  of	  the	  trial	  other	   than	   in	   one	   case	  where	   the	   participant	   lost	   their	   final	   (fourth)	  monthly	  supply	  of	  treatment	  and	  the	  decision	  was	  taken	  by	  the	  Principal	  Investigator	  to	  curtail	   the	   treatment	   phase	   in	   this	   case	   to	   three	  months.	   The	   second	  muscle	  biopsy	  was	  performed	  at	  this	  stage,	  rather	  than	  incurring	  a	  period	  of	  one	  month	  without	   treatment	   prior	   to	   the	   biopsy.	   Due	   to	   long	   travelling	   distances,	   two	  patients	   in	   Kansas	   were	   unable	   to	   complete	   the	   follow-­‐up	   phase	   (after	  successful	   completion	   of	   the	   treatment	   phase)	   but	   one	   returned	   for	   the	   final	  month	  12	  visit.	  There	  were	  no	  major	  deviations	  from	  the	  protocol.	  	  
	  
5.3.2	  Clinical	  baseline	  characteristics	  Participants	   included	   17	   males	   and	   7	   females,	   with	   a	   mean	   age	   of	   66.8	   ±7.5	  years	   and	  mean	   disease	   duration	   of	   8.4	   ±4.3	   years.	   Five	   participants	   (20.8%)	  suffered	  coexistent	  autoimmune	  disease;	  two	  patients	  had	  Sjogren’s	  disease	  and	  there	   was	   one	   case	   each	   of	   Rheumatoid	   Arthritis,	   Ulcerative	   Colitis	   and	  Hypothyroidism.	  In	  keeping	  with	  the	  stereotypical	  phenotype,	  91.7%	  of	  patients	  presented	  with	  weakness	  of	  either	  proximal	   lower	   limb	  (quadriceps)	  or	  distal	  upper	  limb	  (forearm	  flexors)	  disease.	   	  No	  statistically	  significant	  differences	  in	  baseline	  clinical	  parameters	  were	  demonstrated	  between	  the	  Arimoclomol	  and	  Placebo	   groups,	   including	   the	   proportion	   of	   Griggs	   ‘definite’	   versus	   ‘positive’	  patients	  or	  IBM-­‐FRS	  score	  (Table	  5.9).	  	  
5.3.3	  Safety	  and	  Adverse	  Events	  160	  AEs	  were	  recorded	  during	  the	  study.	  108	  AEs	  occurred	  in	  the	  Arimoclomol	  group	  and	  52	  in	  the	  placebo	  group.	  This	  corresponds	  to	  a	  mean	  of	  6.8	  AEs	  per	  patient	   in	   the	   Arimoclomol	   group	   (range	   1-­‐27)	   and	   6.5	   per	   patient	   in	   the	  Placebo	  group	  (range	  2-­‐10),	  which	  is	  not	  a	  significant	  difference.	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   All	  Patients	  	   Arimoclomol	  	   Placebo	  	  
Male	  Sex,	  n	  (%)	   17	  (70.8)	   12	  (75.0)	   5	  (62.5)	  
Age	  (years)	  ±	  SD	   66.8	  ±	  7.5	   65.9	  ±	  7.9	   68.8	  ±	  6.7	  
Disease	  duration	  
(years)	  ±	  SD	   8.4	  ±	  4.3	   7.7	  ±	  4.5	   9.8	  ±	  3.5	  
Griggs	  diagnostic	  
category,	  n	  (%)	   	   	   	  
Definite	  IBM	   10	  (41.7)	   7	  (43.8)	   3	  (37.5)	  
Probable	  IBM	   14	  (58.3)	   9	  (56.3)	   5	  (62.5)	  
Presenting	  
features,	  n	  (%)	   	   	   	  
Dysphagia	   1	  (4.2)	   1	  (6.3)	   0	  (0)	  
Prox.	  upper	  limb	  	   1	  (4.2)	   1	  (6.3)	   0	  (0)	  
Distal	  upper	  limb	  	   4	  (16.7)	   3	  (18.8)	   1	  (12.5)	  
Prox.	  lower	  limb	  	   18	  (75.0)	   11	  (68.8)	   7	  (87.5)	  
Distal	  lower	  limb	  	   1	  (4.2)	   1	  (6.3)	   0	  (0)	  
IBMFRS	  score	  ±	  SD	   26.6	  ±	  6.4	   27.5	  ±	  7.0	   24.6	  ±	  5.1	  
Table	  5.9	  Baseline	  clinical	  characteristics	  of	  participants	  	  A	  significantly	  higher	  number	  of	  AEs	  were	  reported	  patients	  at	  the	  US	  site	  (116	  ±6.8,	  n=12)	  compared	  to	  the	  UK	  site	  (52	  ±3.2,	  n=12,	  p<0.01).	  14	  AEs	   in	  the	  Arimoclomol	  group	  were	  classed	  as	   ‘possibly’	   treatment	  related,	  compared	   to	   8	   in	   the	   Placebo	   group.	   This	   corresponds	   to	   a	  mean	   of	   0.88	   per	  patient	  and	  1	  per	  patient	  respectively,	  which	  is	  also	  not	  a	  significant	  difference.	  No	   AEs	   were	   assessed	   as	   being	   ‘definitely’	   or	   ‘probably’	   related	   to	   either	  treatment.	  The	  nature	  of	  AEs	   ‘possibly’	  related	  Arimoclomol	  (bold	  elements	   in	  Table	  5.10)	  was	  predominantly	  gastrointestinal,	  which	  represented	  8	  of	  the	  14	  AEs.	  No	  AEs	   clinically	   persisted.	   The	   two	   cases	   of	   hyponatraemia	  detected	   on	  laboratory	   testing	   were	   not	   clinically	   significant	   and	   normalised	   on	   repeat	  testing.	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WHO MedDRA Class Arimoclomol (16 patients) Placebo (8 patients) 
Blood and lymphatic 
system  
- - 
Cardiac  Palpitations (n=1)  
Congenital, familial 
and genetic  
- - 
Ear and labyrinth  Dizziness/tinnitus (n=2)  
Endocrine  - - 
Eye Conjunctivitis (n=1), ocular pain 
(n=1) 
Dry eyes (n=1) 
Gastrointestinal  Constipation (n=4), loose 
stools (n=2), nausea (n=2), 
bowel motion symptoms 
(n=1), abdominal pain (n=2), 
pyrosis (n=1),  vomiting (n=1), 
sore throat (n=4), glossitis 
(n=1), ), dry mouth (n=2), 
Constipation (n=4), loose stools 
(n=4), painful parotids (n=2) 
General disorders and 
administration site  
Weight loss (n=1), dizziness 
(n=1), loss of consciousness 
(n=1) 
Fatigue (n=1) 
Hepatobiliary  - - 
Immune system - - 
Infections and 
infestations  
Sinus infection (n=2), upper 
respiratory tract infection (n=7), 
lower respiratory tract infection 
(n=2), erysipelas (n=1), dental 
infection (n=1) 
Dental infection (n=4), upper 
respiratory tract infection (n=3), 
cellulitis (n=1), leg ulcer infection 
(n=1) 
Injury, poisoning and 
procedural 
complications 
Fall (n=23), post-biopsy pain 
(n=3), post-biopsy fatigue (n=1) 
Fall (n=9), post-biopsy pain 
(n=1), pruritus in biopsy scar 
(n=1), finger cut (n=1) 
Investigations  Hyponatraemia (n=2), high 
serum thyroxine (n=1) 
Spinal stenosis (n=1), herniated 
disk (n=1)  
Metabolism and 
nutrition disorders  
- - 
Musculoskeletal and Musculoskeletal pain (n=10), Musculoskeletal pain (n=2) 
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connective tissue  cramps (n=1), rheumatoid 
arthritis flare (n=1), pain in 




cysts and polyps) 
- - 
Nervous system  Headache (n=7), worsening of 
restless leg syndrome (n=1), 
paraesthesia (n=1) 
Headache (n=3), paraesthesia 





Psychiatric  - - 
Renal and urinary  Haematuria (n=1)  - 
Reproductive system 
and breast  
- 
Decreased libido (n=1) 
Respiratory, thoracic 
and mediastinal  
Cough (n=2) Cough (n=1) 
Skin and 
subcutaneous tissue  
Rash (n=2), worsening of 
rosacea (n=1), insect bite (n=1), 
cold sore (n=1) 
Rash (n=1) 
Social circumstances - - 
Surgical and medical 
procedures  
Tooth extraction (n=1), sinus 
surgery (n=1), solar lentigines 
removal (n=1) 
Tooth extraction (n=1) 
Vascular Hypertension (n=3), peripheral 
oedema (n=2)  
Hypertension (n=3), peripheral 
oedema (n=3)  




related to treatment 
14 8 	  
Table	  5.10	  The	  nature	  of	  reported	  Adverse	  Events	  (AEs)	  	  	  
	   234	  
One	  serious	  AE	  (SAE)	  occurred	  in	  the	  Arimoclomol	  treated	  group,	  at	  the	  UK	  site.	  After	   the	   first	   trial	  muscle	  biopsy	  and	   initiation	  of	   trial	   treatment,	   the	  patient,	  who	   had	   poorly	   controlled	   underlying	   hypertension,	   developed	   elevation	   of	  blood	   pressure	   to	   approximately	   200	   mmHg,	   which	   responded	   to	   oral	  antihypertensive	  treatment	  and	  did	  not	  recur	  throughout	  the	  remainder	  of	  the	  study.	   This	   qualified	   as	   an	   SAE	   as	   it	   met	   the	   criterion	   of	   “prolonged	  hospitalisation”	   (for	   one	   night)	   and	   Grade	   3	   on	   the	   NCI	   scale.	   Restricted	  unblinding	  to	  the	  safety	  monitor	  occurred	  in	  accordance	  with	  the	  protocol	  and	  the	   event	  was	   assessed	   as	   being	   unlikely	   related	   to	   trial	   treatment.	   Rather,	   it	  was	   attributed	   to	   the	   discomfort	   related	   to	   the	   muscle	   biopsy	   undertaken	  earlier	  that	  day.	  Two	  patients	  in	  the	  placebo	  group	  developed	  less	  pronounced	  hypertension	  after	  muscle	  biopsy.	  No	  SAEs	  occurred	  in	  the	  placebo	  group.	  
	  
5.3.4	  Tolerability	  (medication	  adherence)	  All	  participants	  in	  both	  groups	  completed	  the	  treatment	  phase.	  Tolerability	  was	  inferred	   by	  measuring	   adherence	   to	   the	   prescribed	   regimen.	   The	   duration	   of	  one	   participant’s	   treatment	   phase	   was	   reduced	   to	   three	   months	   following	  accidental	   loss	  of	   their	  medication.	  Adherence	  was	  measured	  by	  evaluation	  of	  participant	  medication	  diaries	  and	  counting	  the	  number	  of	  tablets	  remaining	  in	  their	   prescription	   box	   at	   monthly	   intervals	   during	   the	   treatment	   phase.	   The	  mean	   adherence	   to	   the	   regime	   was	   99%	   (range	   96.5%	   to	   100%),	   with	   no	  difference	   between	  Arimoclomol	   and	  Placebo	   groups.	  No	   participant	   at	   either	  trial	  site	  requested	  early	  withdrawal	  from	  the	  treatment	  phase	  of	  the	  trial.	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5.3.5	  Secondary	  outcome	  measures	  
5.3.5.1	  Manual	  muscle	  testing	  At	   baseline,	   the	   Arimoclomol	   group	   average	   MMT	   score	   was	   4.2	   ±0.5	   and	  Placebo	   group	   average	   MMT	   score	   was	   3.6	   ±1.4,	   which	   represented	   an	  insignificant	   difference.	   After	   baseline	   assessment,	   the	   change	   in	   MMT	   was	  determined	  at	  three	  4-­‐month	  intervals.	  There	  was	  a	  strong	  correlation	  between	  time	  and	  the	  observed	  change	  of	  MMT	  in	   both	   treatment	   groups	   (Fig	   5.3),	   (Arimoclomol	   group	   R2=0.967,	   Placebo	  group	  R2=0.999).	  The	  rate	  of	  decline	  appeared	  slower	  in	  the	  Arimoclomol	  group	  but	  no	  significant	  difference	  was	  observed	  between	  groups.	  	  
	  
Figure	  5.3	  Change	  in	  manual	  muscle	  testing	  (MMT)	  Following	   treatment	   initiation	   at	   Month	   0,	   MMT	   declined	   steadily	   over	   12	  months	  in	  both	  the	  placebo	  group	  (white	  icons)	  and	  Arimoclomol	  group	  (black	  icons).	  (Error	  bars	  =	  SEM,	  n=24)	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5.3.5.2	  Quantitative	  myometry	  At	  baseline,	  the	  mean	  Maximal	  voluntary	  isometric	  contraction	  testing	  (MVICT)	  sum	  score	  was	  130.4N	  ±70.4N	  in	  the	  Arimoclomol	  Group	  and	  94.4N	  ±39.8N	  in	  the	  Placebo	  group,	  which	  is	  not	  a	  significant	  difference.	  	  Unlike	  MMT,	  the	  change	  in	  MVICT	  was	  very	  weakly	  correlated	  with	  time	  in	  both	  treatment	   groups,	   indicating	   there	   was	   no	   appreciable	   trend.	   Furthermore,	  there	   was	   no	   significant	   difference	   between	   treatment	   groups	   and	   standard	  deviations	  were	  considerable;	   for	  example,	   these	  represented	  over	  50%	  of	  the	  population	  mean	  value	  in	  the	  Arimoclomol	  group	  (Fig	  5.4).	  Subgroup	   analysis	   for	   individual	   IBM-­‐relevant	  muscle	   groups,	   knee	   extension	  and	   handgrip	   (finger	   flexors)	   also	   did	   not	   demonstrate	   any	   significant	  differences	  between	  treatment	  groups.	  Interestingly,	  however,	  analysis	  of	  right	  hand	   grip	   implied	   a	   divergent	   trend	   between	   treatment	   groups	   (Fig	   5.5).	   The	  Arimoclomol	  group	  demonstrated	  a	   fairly	  strong	  correlation	  of	   increasing	  grip	  strength	   with	   time	   (R2=0.799),	   compared	   to	   an	   apparent	   reduction	   in	   the	  placebo	   group.	   However,	   within	   the	   time	   frame	   of	   this	   study,	   the	   greatest	  disparity	  between	  treatment	  groups,	  which	  fell	  at	  8	  months,	  was	  not	  significant	  (p=0.064).	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Figure	  5.4	  Change	  in	  QMVICT	  sum	  score	  There	   was	   no	   significant	   change	   in	   myometry	   measurements	   between	   the	  Arimoclomol	   group	   (black	   icons)	   and	   placebo	   group	   (white	   icons),	   not	   was	  there	   a	   trend	   in	   either	   group	   over	   time.	   Standard	   deviations	   were	   very	   high	  relative	  to	  mean	  values	  at	  each	  data	  point.	  (Error	  Bars=SEM,	  n=24)	  	  
	  
Figure	  5.5	  Change	  in	  right	  hand	  grip	  MVICT	  sum	  score	  (Newtons)	  At	   9	   and	   12	   months,	   right	   hand	   grip	   strength	   increased	   slightly	   in	   the	  Arimoclomol	   group	   (black	   icons)	   but	   declined	   to	   slightly	   less	   than	   the	   pre-­‐treatment	  baseline	  in	  the	  placebo	  group	  (white	  icons).	  No	  significant	  differences	  were	  detected	  at	  any	  of	  the	  three	  time	  points.	  (Error	  bars	  =	  SEM,	  n=24)	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5.3.5.3	  IBM	  Functional	  Rating	  Scale	  (IBMFRS)	  The	   change	   in	   IBMFRS	   observed	   in	   both	   groups	  was	   strongly	   correlated	  with	  time	   elapsed	   (Arimoclomol	   group	   R2=0.785,	   Placebo	   group	   R2=0.999).	   There	  was	  a	  trend	  towards	  a	  slower	  rate	  of	  decline	  in	  the	  Arimoclomol	  group,	  but	  no	  significant	  difference	  was	  displayed	  between	  the	  groups	  at	  any	  of	  the	  4-­‐monthly	  time	  points	  (Fig	  5.6).	  	  	  
	  
Figure	  5.6	  Change	  in	  IBM	  Functional	  Rating	  Scale	  The	  IBMFRS	  declined	  predictably	  in	  both	  the	  Arimoclomol	  group	  (black	  icons),	  and	   placebo	   group	   (white	   icons)	   but	   no	   significant	   difference	   was	   detected	  between	  treatment	  groups.	  (Error	  bars	  =	  SEM,	  n=24)	  	  
5.3.5.4	  DEXA	  At	  baseline,	  the	  mean	  lean	  body	  mass	  (LBM),	  determined	  by	  DEXA,	  was	  49.3kg	  (±9.7kg)	  in	  the	  Arimoclomol	  group	  and	  42.6kg	  (±13.6kg)	  in	  the	  Placebo	  group,	  which	   is	   not	   significantly	   different.	   At	   the	   first	   subsequent	   measurement	   (4	  months),	  LBM	  marginally	  increased	  in	  both	  treatment	  groups,	  before	  declining	  to	   below	   the	   baseline	   by	   12	  months	   in	   both	   groups.	   No	   significant	   difference	  was	  detected	  between	  treatment	  groups	  at	  either	  time	  point	  (Fig	  5.7).	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Figure	  5.7	  Change	  in	  Lean	  Body	  Mass	  Determined	  by	  DEXA,	   there	  was	  no	  significance	   in	  LBM	  between	  Arimoclomol	  treated	   (black	   icons)	   and	   placebo	   treated	   (white	   icons)	   groups	   at	   either	   time	  point.	  	  (Error	  Bars=SEM,	  n=24)	  	  
5.3.5.5	  Muscle	  histopathology	  Muscle	  biopsies	  corresponding	  to	  the	  beginning	  and	  end	  of	  the	  treatment	  phase	  were	   successfully	   collected	   from	   all	   subjects.	   All	   samples	   were	   taken	   from	  biceps	  other	  than	  in	  one	  subject,	  in	  whom	  muscle	  wasting	  precluded	  this,	  where	  quadriceps	  was	   biopsied.	   Detailed	   histological	   analysis	  was	   performed	   on	   UK	  site	  biopsies	  (12	  subjects),	  to	  determine	  degenerative	  (inclusions,	  vacuoles,	  p62	  aggregates	  and	  red	  ragged	  fibres)	  and	  inflammatory	  markers	  (MHCI,	  CD3,	  CD4,	  CD8	   and	   CD20).	   Only	   histological	   stains	   previously	   validated	   in	   the	   routine	  assessment	   of	   muscle	   biopsies	   at	   the	   Department	   of	   Neuropathology,	   NHNN,	  were	  employed.	  At	  the	  time	  of	  this	  analysis,	  these	  stains	  did	  not	  include	  TDP-­‐43	  or	  NFκB,	  meaning	  these	  characteristics	  of	  the	  in	  vitro	  experiments	  described	  in	  this	  thesis	  could	  not	  be	  examined	  here.	  Three	   biopsies	   from	   the	   placebo	   group	   were	   uninterpretable	   as	   they	   were	  characterised	   by	   fatty	   replacement	   or	   ‘end	   stage’	   tissue	   and	   only	   occasional	  identifiable	   myofibres.	   This	   included	   both	   biopsies	   from	   one	   subject	   and	   the	  pre-­‐treatment	  biopsy	  from	  another.	  	  This	  made	  statistical	  comparison	  between	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treatment	  groups	  impossible,	  since	  the	  placebo	  group	  comprised	  only	  two	  pairs	  of	  biopsies	  accordingly.	  As	   subjects	   required	   existing	   histopathological	   evidence	   of	   IBM,	   sufficient	   to	  meet	  Griggs’	   criteria,	   it	  was	  unsurprising	   that	  all	  biopsies	  obtained	  during	   the	  trial	   demonstrated	   features	   stereotypical	   of	   IBM.	   Inflammation	   was	  characterised	  by	  endomysial	  and	  perimysial	  infiltration	  by	  CD8+	  T-­‐cells,	  with	  a	  smaller	   proportion	   of	   CD4+	   T-­‐cells.	   Rimmed	   vacuoles,	   cytoplasmic	   inclusions,	  red	  ragged	  fibres	  and	  COX	  negative	  fibres	  were	  all	  observed	  in	  keeping	  with	  the	  degenerative	  stereotype	  in	  IBM.	  Nevertheless,	   no	   significant	   differences	   were	   demonstrated	   between	   pre	   and	  post	  treatment	  biopsies	  in	  either	  treatment	  group	  or	  between	  treatment	  groups	  (Figs	   5.8	   and	   5.9).	   There	  were	   high	   degrees	   of	   variance	   for	  most	   histological	  markers,	  both	  between	  patients	  and	  between	  the	  biopsies	  of	  individual	  patients.	  For	  example,	  one	   subject’s	  pre-­‐treatment	  biopsy	  displayed	  9	   fibres	   containing	  rimmed	   vacuoles	   compared	   to	   119	   fibres	   in	   the	   post-­‐treatment	   biopsy.	   This	  contrasts	   markedly	   with	   another	   subject,	   whose	   pre-­‐treatment	   and	   post-­‐treatment	   biopsies	   each	   displayed	   2	   rimmed	   vacuoles.	   Similar	   patterns	   were	  observed	   with	   p62	   and	   COX	   staining.	   The	   inflammatory	   characteristics	   also	  demonstrated	  this	  high	  variability	  and	  no	  significant	  differences	  were	  detected	  whether	   the	   absolute	   number	   of	   inflammatory	   clusters	   or	   effect	   on	   the	  inflammation	  score	  (0-­‐2)	  were	  examined.	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Figure	  5.8	  Quantification	  of	  inflammatory	  histopathological	  markers	  before	  and	  after	  treatment	  phase	  No	  significant	  difference	  was	  observed	  between	  pre-­‐	  and	  post-­‐treatment	  biopsies	  from	  the	  placebo	  group	  (black	  or	  white	  bars)	  or	  Arimoclomol	  group	  (blue	  or	  red	  bars),	  nor	  was	  there	  a	  significant	  difference	  between	  the	  two	  treatment	  groups.	  This	  reflects	  high	  intra-­‐	  and	  inter-­‐subject	  variance	  in	  the	  majority	   of	   biopsy	   characteristics.	   	   (Endo/perimys	   –	   endomysial/perimysial	   inflammation,	   Perivasc	   –	   perivascular	   inflammation)	   (Error	   Bars=SEM,	  n=12)	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Figure	  5.9	  Quantification	  of	  degenerative	  histopathological	  markers	  before	  and	  after	  treatment	  phase	  No	  significant	  difference	  was	  observed	  between	  pre-­‐	  and	  post-­‐treatment	  biopsies	  from	  the	  placebo	  group	  (black	  or	  white	  bars)	  or	  Arimoclomol	  group	  (blue	  or	  red	  bars),	  nor	  was	  there	  a	  significant	  difference	  between	  the	  two	  treatment	  groups.	  This	  reflects	  high	  intra-­‐	  and	  inter-­‐subject	  variance	  in	  the	  majority	  of	  biopsy	  characteristics.	  	  (RRFs=Red	  Ragged	  Fibres,	  COX	  Negative=Fibres	  lacking	  COX	  staining)	  (Error	  Bars=SEM,	  n=12)	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5.3.5.6	  HSP70	  concentration	  in	  muscle	  biopsies	  In	   the	   pretreatment	   muscle	   biopsies,	   mean	   HSP70	   concentration	   was	   7.44	  μg/ml	   ±4.14	   μg/ml	   in	   the	   placebo	   group	   and	   9.26	   μg/ml	   ±8.57	   μg/ml	   in	   the	  Arimoclomol	   group,	   which	   is	   not	   a	   significant	   difference.	   Neither	   group	  demonstrated	  a	  significant	  change	  in	  [HSP70]	  in	  the	  post-­‐treatment	  biopsy	  (Fig	  5.10).	  There	  was	  considerable	  variation	  in	  [HSP70]	  between	  subjects;	  5.8	  μg/ml	  to	  30.3	  μg/ml	  in	  pre-­‐treatment	  biopsies	  and	  1.29	  μg/ml	  to	  23.6	  μg/ml	  in	  post-­‐treatment	  biopsies.	  Exclusive	  of	  concentration,	  the	  likelihood	  of	  observing	  a	  rise	  of	  [HSP70]	  in	  the	  second	  biopsy	  was	  no	  greater	  in	  the	  Arimoclomol	  group	  than	  the	  Placebo	  group.	  As	  part	  of	  a	  second	  round	  of	  tissue	  evaluation	  in	  the	  trial,	  Dr	  Bernadette	  Kalmar	  and	   Dr	   Ching-­‐hua	   Lu	   repeated	   HSP70	   ELISAs	   with	   contemporaneous	  measurement	   of	   myosin	   concentration	   to	   determine	   whether	   any	   differential	  response	  of	  non-­‐myogenic	  components	  of	  the	  biopsies	  contributed	  towards	  the	  overall	   result.	   This	   demonstrated	   a	   reduction	   of	   [HSP70],	   between	   first	   and	  second	  biopsies,	  of	  34.7	  ng/100ng	  ±336.3	   in	   the	  Placebo	  group	  and	  of	  100.72	  ng/100ng	  myosin	  ±757	  in	  the	  Arimoclomol	  group,	  which	  was	  not	  a	  significant	  difference.	  Again,	   there	  was	  considerable	  variation	   in	  baseline	  [HSP70]	  among	  biopsies	  and	  in	  the	  change	  of	  [HSP70]	  between	  biopsies.	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Figure	  5.10	  HSP70	  concentration	  in	  IBM	  muscle	  There	  was	  no	  significant	  difference	  in	  [HSP70]	  between	  Arimoclomol	  (blue	  bar)	  and	  placebo	  (white	  bar)	  groups	  before	  the	  treatment	  phase.	  After	  the	  treatment	  phase,	  there	  remained	  no	  significant	  difference	  between	  groups.	  There	  was	  also	  no	  significant	  change	  within	  either	  group.	  (Error	  Bars=SEM,	  n=24)	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5.4	  Discussion	  
5.4.1	  Arimoclomol	  appears	  safe	  and	  tolerable	  in	  IBM	  patients	  The	   combination	   of	   fulfillment	   of	   the	   intensive	   trial	   treatment	   phase	   by	   all	  participants,	  in	  combination	  with	  adverse	  event	  data,	  suggests	  Arimoclomol	  (at	  100mg	  tds)	  is	  safe	  in	  patients	  with	  IBM.	  The	  primary	  outcome	  measure,	  adverse	  events	   (AEs),	   revealed	  no	   significant	  difference	  between	   the	  Arimoclomol	  and	  placebo	   groups.	   Furthermore,	   the	   nature	   of	   AEs	   was	   predominantly	  gastrointestinal	   in	   both	   groups,	   implying	   a	   lack	   of	   direct	   causation	   through	  Arimoclomol.	  The	  fact	  the	  AE	  rate	  was	  significantly	  different	  between	  trial	  sites,	  in	  which	  the	  direct	  demands	  of	  the	  trial	  on	  participants	  were	  identical,	  but	  not	  significant	   between	   treatment	   groups,	   suggests	   that	   local	   clinical	   or	   cultural	  factors	   were	   a	   more	   relevant	   predictor	   of	   AE	   occurrence	   than	   treatment	  allocation.	   Furthermore,	   blood	   laboratory	   analysis,	   electrocardiograms	   and	  ophthalmological	  slit	  lamp	  examinations	  did	  not	  detect	  any	  clinically	  significant	  asymptomatic	  disturbance	  of	  haematological,	  renal	  or	  hepatic,	  cardiac	  or	  ocular	  function.	  	  Clearly,	  the	  rate	  of	  AEs	  must	  be	  balanced	  with	  any	  apparent	  risk,	  however	  low,	  of	   a	   clinically	   serious	  AE	   related	   to	   the	  medication.	   It	   is,	   therefore,	   reassuring	  that	   no	   such	   event	   occurred.	   Indeed,	   the	   lack	   of	   any	   treatment	   related	  AEs	   is	  encouraging	   and	   is	   consistent	   with	   the	   existing	   early	   phase	   data	   from	   other	  clinical	   trials	   of	   Arimoclomol	   in	   healthy	   volunteers	   and	   patients	   with	   ALS	  (Cudkowicz	  et	  al.	  2008).	  Further	  safety	  specific	  to	  the	  IBM	  population	  is	  implied	  by	   the	   lack	   of	   clear	   clinical	   deterioration	   in	   any	   of	   the	   secondary	   outcome	  measures	  in	  this	  study.	  	  In	   addition	   to	   100%	   fulfillment	   of	   the	   treatment	   phase,	   the	   near	   100%	  adherence	  rate	  to	  trial	  medication	  is	  strong	  evidence	  to	  support	  Arimoclomol’s	  tolerability	  in	  this	  patient	  group.	  Therefore,	   it	   is	   reasonable	   to	   conclude	   that	   Arimoclomol	   was	   safe	   and	   well	  tolerated	   in	   this	  group	  of	   IBM	  patients.	   In	  combination	  with	  similar	  data	   from	  other	   early	   phase	   trials	   (Tables	   5.2	   and	   5.3),	   it	   is	   reasonable	   to	   infer	   that	  Arimoclomol’s	  safety	  and	  tolerability	  profile	  lies	  within	  the	  acceptable	  range	  for	  medications	   at	   this	   stage	   of	   development.	   Notwithstanding	   any	   debate	   about	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clinical	   effectiveness,	   the	   safety	   profile	   is	   therefore	   appropriate	   for	  advancement	  of	  Arimoclomol	  to	  larger	  clinical	  trials.	  	  
5.4.2	  Muscle	  strength	  was	  not	  affected	  by	  Arimoclomol	  treatment	  As	   the	   trial	   was	   not	   specifically	   powered	   to	   detect	   changes	   in	   secondary	  outcome	   measures,	   firm	   conclusions	   should	   not	   be	   drawn	   from	   the	  corresponding	  data.	  Nevertheless,	   certain	   trends	  were	  of	   interest	  and	  warrant	  further	   investigation	  in	  suitably	  powered	  studies.	  The	  data	  also	  provide	  useful	  indicators	  for	  which	  measures	  might	  be	  preferable	  when	  designing	  such	  studies.	  The	   lack	   of	   dramatic	  worsening	   of	   any	   clinical	   parameters,	   particularly	   those	  related	  to	  the	  IBM	  phenotype,	  is	  further	  evidence	  to	  support	  a	  lack	  of	  harm.	  It	  is	  notable	  that	  the	  decline	  manual	  muscle	  testing	  score	  (MMT)	  demonstrated	  a	   strong	   correlation	   with	   time,	   and	   to	   a	   far	   greater	   extent	   that	   MVICT.	   This	  implies	   that	   MMT	   could	   serve	   a	   useful	   outcome	   measure	   in	   future	   trials	   of	  efficacy	  in	  IBM.	  However,	   limitations	  remain.	  For	  example,	  the	  MRC	  scale	  is	  an	  ordinal	  scale	  rather	  than	  a	  numerical	   interval	  scale	  so	  the	  extrapolation	  of	   the	  magnitude	  of	  differences	  detected	  between	  time	  points	  or	  treatment	  groups	  to	  functional	   or	   symptomatic	   meaning	   is	   challenging.	   MVICT	   has	   the	   advantage	  here,	  through	  producing	  data	  distributed	  on	  an	  interval	  scale	  but	  large	  variance	  was	   demonstrated	   in	   the	   results	   described	   here,	   which	   would	   restrict	   its	  feasibility	  to	  detect	  realistic	  differences	   in	  future	  trials	  of	  drug	  efficacy	  in	  IBM.	  The	  issue	  of	  determining	  what	  is	  a	  clinically	  significant	  effect	  also	  remains.	  MMT	  and	   MVICT	   have	   demonstrated	   inter-­‐	   and	   intra-­‐observer	   reliability	   in	   other	  studies	   (Jain	   et	   al.	   2006;	   Lienhard	   et	   al.	   2013).	   The	   efforts	   to	   restrict	   MMT	  examinations	  to	  as	  few	  clinical	  examiners	  as	  possible	  may	  well	  have	  contributed	  to	  the	  relatively	  low	  variation	  demonstrated	  here.	  This	  should	  be	  an	  important	  consideration	  of	   future	   trial	  design	   if	  MMT	   is	   incorporated.	  The	  use	  of	  MVICT	  would	   need	   to	   be	   refined	   if	   it	  were	   pursued	   as	   an	   outcome	  measure	   and	   the	  results	   here	   would	   support	   restricting	   the	   measurement	   protocol	   to	   smaller	  number	  of	  muscles	  since	  no	  additional	  benefit	  was	  apparent	  through	  the	  testing	  of	   multiple	   muscles.	   Of	   these,	   handgrip	   is	   the	   most	   obvious	   candidate	   for	  inclusion;	  the	  relative	  ease	  of	  measurement	  due	  to	  simplicity	  of	  positioning	  the	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limb	   likely	   contributes	   to	   its	   smaller	   variation	   that	   was	   the	   case	   for	   other	  muscles	  or	  the	  sum	  score.	  Furthermore,	  it	  is	  an	  important	  function	  in	  IBM,	  both	  as	   a	   commonly	   affected	   movement	   and	   a	   source	   of	   considerable	   disability	  through	  reduced	  manual	  dexterity.	  It	   is	   interesting	   that	   the	   Arimoclomol	   group,	   versus	   placebo,	   demonstrated	   a	  reduced	  rate	  of	  decline	  over	  one	  year	  and	  a	  greater	  mean	  strength	  (by	  MMT)	  at	  each	  4-­‐month	  assessment	  interval.	  This	  difference	  was	  not	  significant,	  reflecting	  either	  the	  absence	  of	  a	  true	  treatment	  effect	  or	  the	  lack	  of	  power	  in	  this	  trial	  to	  detect	  a	  realistic	  treatment	  effect.	  	  	  
5.4.3	   IBM	   Functional	   Rating	   Scale	   (IBMFRS)	   was	   not	   affected	   by	   Arimoclomol	  
treatment	  As	   the	   only	   validated	   disability	   scale	   in	   IBM,	   it	   is	   highly	   likely	   that	   IBMFRS	  would	  serve	  as	  an	  outcome	  measure	   in	   future	  clinical	   trials.	   It	   is	   encouraging,	  therefore,	  that	  the	  change	  in	  patients’	  score	  in	  this	  study	  displayed	  very	  strong	  correlation	  with	  time,	  particularly	  in	  the	  placebo	  group.	  The	  mean	  decline	  of	  4	  points	   in	   the	   placebo	   group	   over	   the	   course	   of	   one	   year	   is	   likely	   to	   reflect	  meaningful	   symptomatic	   change	   for	   patients.	   If	   restricted	   to	   one	   measure,	   it	  would	  represent	  decline	  from	  normality	  to	  inability	  or	  full	  dependency.	  If,	  as	  is	  more	  likely	  (and	  was	  the	  case	  in	  this	  study)	  it	  reflects	  loss	  of	  individual	  points	  across	   a	   variety	   of	   domains,	   this	   still	   represents	   a	   decline	   from	   normality	   to	  difficulty	  with	   a	   given	   task	   or	   from	   difficulty	   to	   requiring	   assistance.	   Albeit	   a	  categorical	   scale,	   meaning	   that	   quantification	   of	   change	   cannot	   easily	   be	  extrapolated	  back	  onto	  the	  individual	  scale,	  Rasch	  analysis	  of	  IBMFRS	  has	  been	  promising	  (Rose	  2013).	  No	  significant	  difference	  was	  detected	  between	  treatment	  groups	  in	  this	  study,	  reflecting	  the	   lack	  of	  statistical	  power	  to	  do	  so.	  Nevertheless,	   it	   is	  notable	   that	  the	   8-­‐month	   time	   point	   approached	   statistical	   significance	   (p=0.055)	   in	   the	  context	   of	   the	  mean	   IBMFRS	   in	   the	   Arimoclomol	   group	   exceeding	   that	   of	   the	  placebo	  group	  at	  all	   intervals.	  Whether	  this	  reflects	   the	  evolution	  of	  a	  genuine	  treatment	  effect	  will	  require	  a	  larger	  study.	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5.4.4	  Lean	  Body	  Mass	  (DEXA)	  was	  not	  affected	  by	  Arimoclomol	  treatment	  It	  is	  unclear	  why	  the	  lean	  body	  mass	  (LBM)	  appeared	  to	  increase	  slightly	  in	  both	  groups	   between	   baseline	   assessment	   and	   the	   first	   4	   month	   interval,	   before	  subsequently	  declining	  to	  an	  overall	  reduction	  over	  one	  year.	  It	   is	  notable	  that	  the	  mean	   change	  over	  one	  year	   in	   the	  placebo	  group	  was	  only	   approximately	  1kg.	  This	  has	  implications	  for	  the	  use	  of	  this	  technique	  as	  an	  outcome	  measure	  in	   future	   trials	   of	   IBM.	   As	   here,	   populations	   of	   mixed	   sex	   display	   a	   the	   wide	  range	  of	   LBM,	   reflected	  by	   the	   fact	   that	   the	   standard	  deviation	   in	   the	  placebo	  group	  approached	  one	  third	  of	  the	  mean	  baseline	  value.	  Therefore,	  it	  is	  unlikely	  that	   a	   clinical	   trial	   of	   pragmatic	   length	   and	   size	   could	   be	   powered	   to	   detect	  attenuation	  of	  an	  annual	  decline	  of	  approximately	  2.5%	  of	  baseline	  value.	   It	   is	  likely	   that	  an	   investigational	  medicinal	  product	  would	  need	   to	  confer	  a	  rise	   in	  LBM	   to	   produce	   a	   statistically	   significant	   change,	   which,	   at	   least	   in	   IBM,	   is	  conceptually	   less	   likely	   than	  amelioration	  of	   the	  advancing	  underlying	  disease	  process.	  	  
5.4.5	  The	  effect	  of	  Arimoclomol	  on	  muscle	  histopathology	  This	   study	   demonstrated	   several	   limitations	   of	   interval	   muscle	   biopsy.	   The	  obligation	  to	  biopsy	  distinct	  sites,	  albeit	  within	  the	  same	  muscle	  group	  of	  either	  limb,	   in	   the	   context	   of	   a	   phenotypically	   asymmetrical	   disease,	   means	   the	  comparison	   of	   pre	   and	   post-­‐treatment	   tissue	   is	   masked	   by	   inter-­‐biopsy	  variability.	   Secondly,	   there	   was	   considerable	   variance	   in	   the	   extent	   to	   which	  individual	   patients’	   tissue	   demonstrated	   particular	   histopathological	   features,	  even	  within	  the	  confines	  of	  those	  relatively	  specific	  to	  IBM.	  This	  was	  reflected	  in	  high	   intra-­‐	   and	   inter-­‐patient	   variance.	   Third,	   even	   with	   experienced	  neurosurgeons	  performing	  the	  procedure,	  3	  of	  24	  biopsies	  transpired	  to	  contain	  predominantly	  adipose	  tissue	  and	  ‘end	  stage’	  myofibres	  that	  rendered	  detailed	  histological	  interpretation	  and,	  therefore,	  comparison	  impossible.	  Examining	  the	  mean	  values	  for	  inflammatory	  histological	  markers,	  it	  is	  notable	  that	   pre	   and	   post	   biopsies	   in	   either	   the	   placebo	   or	  Arimoclomol	   groups	  were	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very	   similar.	   Therefore,	   the	   large	   standard	   error,	   reflective	   of	   the	  aforementioned	   high	   variance,	   does	   not	   appear	   to	   have	   masked	   a	   significant	  change.	   	  Degenerative	  markers,	  however,	  displayed	  a	  wider	  range	  of	  means	  so	  determination	  of	  any	  underlying	  pattern	  related	  to	  treatment	  is	  more	  difficult	  to	  infer.	  The	  most	  consistently	  displayed	  degenerative	  feature	  was	  p62	  aggregate	  positivity	  but,	  again,	  the	  inter-­‐patient	  variance	  was	  high	  and	  the	  range	  exceeded	  the	  value	  of	  the	  population	  mean.	  These	  results	  imply	  that,	  if	  histological	  parameters	  are	  to	  be	  used	  to	  determine	  interval	   effects	   of	   a	   given	   intervention	   in	   IBM,	   it	   is	   likely	   that	   current	  immunohistochemical	  stains	  are	  unlikely	  to	  provide	  a	  useful	  outcome	  measure	  in	  a	  trial	  of	  pragmatic	  size.	  Alternative	  markers,	  perhaps	  related	  to	  unidentified	  upstream	  processes,	  may	  display	  lower	  inter-­‐	  and	  intra-­‐patient	  variance.	  More	  likely,	  tissue	  should	  be	  used	  to	  perform	  concentration	  based	  techniques	  such	  as	  western	   blotting	   or	   mass	   spectrometry	   which	   essentially	   reflect	   the	   mean	  concentration	  across	  the	  entire	  tissue	  sample	  taken,	  rather	  than	  relying	  on	  the	  pathological	  response	  of	  individual	  myofibres.	  	  
5.4.6	  HSP70	  concentration	  in	  IBM	  muscle	  is	  highly	  variable	  Analysis	   of	   muscle	   [HSP70]	   demonstrated	   an	   inconsistent	   baseline	  concentration	   and	   inconsistent	   change	   over	   time	   in	   the	   Arimoclomol	   and	  placebo	  groups.	  Therefore,	  the	  lack	  of	  detected	  treatment	  effect	  of	  Arimoclomol	  to	  augment	  [HSP70]	  in	  this	  context	  could	  reflect	  a	  number	  of	  factors.	  First,	   it	   is	   possible	   that	   a	   genuine	   treatment	   effect	   was	   obscured	   by	   a	   large	  underlying	   physiological	   variance.	   The	   wide	   range	   of	   the	   baseline	   [HSP70]	  among	  all	  24	  participants	  evidences	  a	  high	  inter-­‐subject	  variance.	  Additionally,	  the	   inconsistent	   pattern	   in	   change	   of	   [HSP70]	   between	   the	   two	   biopsies	   of	  subjects	   in	   the	   placebo	   group	   suggests	   either	   a	   high	   inter-­‐muscle	   variance	   or	  large	  physiological	  fluctuation	  of	  [HSP70]	  over	  time.	  In	  the	  overall	  comparison	  between	  Arimoclomol	  and	  placebo	  treatment	  groups,	  the	  standard	  deviations	  of	  [HSP70]	  approximated	  the	  value	  of	  the	  mean;	  therefore	  detection	  of	  a	  realistic	  treatment	  effect	  would	  have	  been	  masked.	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Secondly,	  it	  is	  possible	  no	  response	  to	  Arimoclomol	  occurred.	  This	  could	  reflect	  a	  number	  of	   factors	  relevant	   to	   the	  drug	  or	   the	  patients.	  The	  drug	  dosage	  and	  bioavailability	  was	   predetermined	   through	   a	   number	   of	   pre-­‐clinical	   and	   early	  phase	  clinical	  dosing	  studies	  so	  it	  is	  unlikely	  that	  an	  insufficient	  dose	  was	  used.	  Instead,	   it	   is	   more	   likely	   that	   any	   lack	   of	   action	   of	   Arimoclomol	   on	   skeletal	  muscle	  in	  vivo	  reflects	  properties	  of	  IBM	  tissue.	  The	  reliance	  of	  Arimoclomol	  on	  existing	  HSR	  activation	  in	  a	  target	  tissue	  should	  not	  preclude	  its	  action	  in	  IBM	  since	   the	  HSR	  does	  appear	   to	  be	  active	   in	   this	  context.	  Mass	  spectrometry	  has	  determined	   HSP70	   is	   upregulated	   (Parker	   et	   al.	   2009).	   Furthermore,	  immunohistochemical	  work	  implies	  upregulation	  of	  the	  small	  HSP	  αB-­‐crystallin	  (Banwell	   et	   al.	   2000).	   	   A	   genuine	   lack	   of	   response	   to	   Arimoclomol	   could,	  therefore,	  reflect	  dampening	  of	  HSR	  inducibility,	  which	  appears	  to	  occur	  in	  aged	  tissue	   (Sherman	   et	   al.	   2001).	   To	   determine	  whether	   this	   is,	   indeed,	   the	   case,	  would	   require	   a	   study	   including	   age-­‐matched	   and	   non-­‐age	   matched	   disease	  controls.	  It	  would	  be	  particularly	  interesting	  to	  note	  whether	  this	  phenomenon	  occurs	   in	   all	  muscles	   among	   IBM	  patients	   or	  whether	   it	   is	   restricted	   to	   those	  muscles	   that	   display	   particular	   histopathological	   features.	   Here,	   the	   two	  patients	   in	   the	  Arimoclomol	  group	   in	  whom	  the	   largest	   relative	   rise	   in	  HSP70	  was	  detected	  (to	  155%	  and	  181%	  of	  pre-­‐treatment	  concentration	  respectively)	  displayed	   relatively	   few	   degenerative	   features,	   but	   this	   is	   not	   a	   statistically	  distinct	  sub-­‐population.	  Third,	   it	   is	   possible	   that	   either	   the	   concentration	   of	   HSP70,	   or	   the	   effect	   of	  Arimoclomol	  thereon,	  had	  diminished	  by	  the	  time	  of	  the	  muscle	  biopsy.	  As	  the	  harvested	  tissue	  was	  frozen	  within	  minutes	  of	  retrieval,	  this	  is	  not	  likely	  to	  have	  occurred.	   Nevertheless,	   it	   is	   possible	   that	   the	   action	   of	   Arimoclomol	   on	   IBM	  muscle	  is	  brief	  and	  transient.	  Fourth,	   the	   measurement	   of	   HSP70	   may	   have	   been	   incorrect.	   The	   high	  sensitivity	   commercial	   ELISA	   employed	   is	   strongly	   validated	   and	   two	   distinct	  series	  of	  analysis,	  with	  and	  without	  contemporaneous	  measurement	  of	  myosin	  concentration,	  failed	  to	  determine	  a	  significant	  change	  in	  HSP70.	  Therefore,	  this	  possibility	  appears	  unlikely.	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Overall,	   it	   is	   most	   logical	   to	   conclude	   that,	   at	   least	   in	   IBM,	   skeletal	   muscle	  [HSP70]	  is	  likely	  to	  vary	  considerably	  between	  different	  muscles,	  whether	  from	  individual	  or	  multiple	  patients.	  In	  practical	  terms,	  this	  severely	  limits	  the	  use	  of	  muscle	  [HSP70]	  as	  a	  pathological	  outcome	  measure	  or	  biomarker.	  	  
5.4.7	  Summary	  The	   primary	   purpose	   of	   this	   study,	   to	   determine	   the	   safety	   and	   tolerability	  profile	  of	  Arimoclomol	  in	  IBM,	  was	  achieved	  and	  provides	  firm	  evidence	  that	  the	  drug	  does	  not	   cause	   significant	  worsening	  of	   symptoms	  or	  unanticipated	   side	  effects.	  The	  lack	  of	  biopsy	  related	  changes	  might	  reflect	  inherent	  limitations	  of	  this	   technique	   rather	   than	   an	   absence	   of	   effect	   and	   this	  means	   consideration	  would	  have	   to	  be	   given	   about	  whether	   the	   inclusion	  of	   this	   element	   to	   future	  trials	   can	   be	   justified,	   given	   the	   associated	   morbidity	   for	   participants.	  Alternative	   biomarker	   studies	   based	   on	   peripheral	   blood	  markers	   or	   imaging	  studies	  may	  be	  preferable	  outcome	  measures.	  The	  results	  of	  this	  clinical	  study	  advance	   Arimoclomol	   one	   step	   along	   the	   translational	   drug	   development	  pathway	   of	   IBM	   and	   support	   its	   further	   evaluation	   in	   humans.	   However,	   the	  absence	  of	  in	  vivo	  data	  on	  Arimoclomol’s	  effects	  means	  the	  decision	  whether	  to	  advance	   it	   to	   an	   efficacy	   study	  must	   still	   be	   carefully	   considered.	  The	   relative	  rarity	  of	  IBM	  places	  its	  small	  population	  is	  at	  risk	  of	  trial	  fatigue	  so	  only	  studies	  of	  the	  most	  promising	  therapeutic	  agents	  can	  be	  justified.	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Chapter	  6:	  General	  Discussion	  
6.1	  Introduction	  The	  experiments	  described	   in	   this	   thesis	   sought	   to	   address	   the	   following	   four	  specific	  aims:	  1.	   To	   establish	   a	   pre-­‐clinical	   disease	  model	   of	   salient	   pathological	  features	  of	  IBM	  2.	   To	   characterise	   these	   features	   in	   order	   to	   establish	   a	   panel	   of	  quantifiable	  IBM-­‐relevant	  pathological	  outcome	  measures	  3.	   To	   test	   the	   effectiveness	   of	   novel	   treatment	   strategies	   in	   this	  system,	  determined	  by	  consideration	  of	  the	  literature	  4.	  To	  determine	  how	  those	   treatments	  could	  be	  advanced	   towards	  clinical	  effectiveness	  in	  IBM	  IBM	  presents	  several	  particular	  challenges	  in	  this	  context,	  reflected	  by	  its	  lack	  of	  existing	   effective	   treatment.	   Perhaps	   the	   most	   fundamental	   of	   these	   is	   our	  limited	   understanding	   of	   its	   primary	   pathology.	   Although	   numerous	  downstream	   pathological	   features	   are	   consistently	   observed,	   the	   relative	  importance	  and	  position	  of	  these	  individually	  remain	  contested.	  	  The	  literature	  generally	   divides	   along	   the	   notion	   of	   whether	   IBM	   is,	   in	   essence,	   a	   primary	  inflammatory	  condition	  in	  which	  persistent	  cellular	  stress	  leads	  to	  a	  secondary	  degenerative	   phase	   or	  whether	   the	   inflammation	   observed	   is	   epiphenomenal,	  driven	   by	   an	   upstream	   degenerative	   event	   which	   leads	   to	   auto-­‐antigen	  exposure	   and	   breakdown	   of	   immune	   tolerance,	   perpetuated	   by	   MHC	  upregulation.	   Both	   hypotheses	   are	   plausible;	   the	   former	   is	   analogous	   to	   that	  proposed	   in	   multiple	   sclerosis,	   whereas	   secondary	   inflammation	   is	  demonstrated	   by	   several	   genetic	   conditions	   of	   muscle,	   most	   commonly	  mutations	   of	   dystrophin	   (Stadelmann	   et	   al.	   2011;	   De	   Paepe	   et	   al.	   2012).	  Regardless	  of	  which	  occurs	   first,	   there	  are	  several	  points	  of	   interaction	  where	  either	  group	  of	  processes	  might	  perpetuate	  the	  other.	  This	  debate	  on	  pathogenesis,	  combined	  with	   the	   lack	  of	  a	  genetic	   form	  of	   IBM	  which	  reproduces	  the	  clinical	  and	  pathological	  phenotype	  of	  the	  sporadic	  form	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sufficiently	  accurately,	  means	  there	  are	  no	  consistently	  used	  preclinical	  cellular	  or	   animal	   models	   of	   IBM.	   In	   turn,	   efforts	   to	   treat	   the	   disease	   have	   been	  restricted	   either	   to	   anecdotal	   evidence	   or	   clinical	   trials	   severely	   limited	   in	  patient	  numbers	  and	  duration.	  The	   tendency	  of	   IBM	  to	  manifest	   clinically	  at	  a	  relatively	  advanced	  pathological	  stage	  presents	  a	  further	  considerable	  challenge	  common	  to	  neurological	  conditions,	  such	  as	  in	  Parkinsonism,	  where	  over	  half	  of	  dopaminergic	   neurons	   are	   be	   lost	   before	   clinical	   signs	  manifest	   (Cheng	   et	   al.	  2010).	   Only	   serendipitous	   diagnosis	   or	   the	   development	   of	   highly	   sensitive	  biomarkers	  can	  circumvent	  this	  issue.	  Fortunately,	  it	  remains	  common	  for	  IBM	  to	   be	   diagnosed	   prior	   to	   the	   onset	   of	   significant	   disability,	   meaning	   that	  arresting	   rather	   than	   reversing	   the	   condition	   would	   still	   represent	   a	  considerable	  advance	   in	   current	   treatment.	  Reflecting	   the	  greater	   spectrum	  of	  available	  drugs	  that	  target	  the	  immune	  system,	  all	  previous	  approaches	  to	  IBM	  treatment	   have	   focused	   on	   the	   inflammatory	   component	   of	   the	   pathology.	  No	  individual	  trials	  have	  been	  of	  sufficient	  size	  or	  duration	  to	  prove	  the	  presence	  or	  absence	  of	  treatment	  effect.	  However,	  the	  combination	  of	  the	  negative	  findings	  of	   these	   trials	   with	   a	   large	   body	   of	   anecdotal	   evidence	   on	   the	   failure	   of	  immunosuppressive	   medication,	   suggests	   current	   immunotherapies	   are	  unlikely	  to	  produce	  significant	  effects	  in	  IBM	  when	  used	  in	  isolation.	  	  Therefore,	   an	   approach	   based	   on	   preclinical	   evaluation	   of	   novel	   therapeutic	  strategies	   appears	   justified.	   In	   establishing	   this,	   the	   starting	   position	   of	   this	  thesis	  was	  not	  to	  align	  the	  experiments	  strictly	  along	  either	  an	  inflammatory	  or	  degenerative	   hypothesis.	   Rather,	   they	   sought	   to	   recapitulate	   elements	   of	  downstream	  IBM	  pathology	  likely	  to	  be	  present	  at	  the	  current	  realistic	  point	  of	  diagnosis,	  and	  determine	  whether	  these	  were	  modifiable.	  Priority	  was	  given	  to	  those	  pathological	  elements	  that	  appear	  likely	  to	  represent	  points	  of	  interaction	  between	  inflammatory	  and	  degenerative	  mechanisms	  since	  these	  are	  the	  logical	  points	  of	  greatest	   therapeutic	  attraction.	  For	  example,	   the	  primary	  myositides,	  PM	   and	   DM,	   even	   in	   aggressive	   and	   necrotizing	   forms,	   are	   often	   successfully	  treated	   with	   immune	   therapies	   (Valiyil	   et	   al.	   2010).	   Therefore	   to	   inhibit	   the	  communication	   between	   inflammation	   and	   degeneration,	   in	   whichever	  direction	  this	  occurs,	  could	  improve	  the	  effectiveness	  of	  existing	  drugs	  through	  combination	  therapy.	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6.2	  Development	  of	  a	  preclinical	  model	  of	  IBM	  As	  no	   accepted	   animal	  model	   of	   IBM	  exists,	   it	  was	   felt	   that	   the	   advantages	   of	  higher	   throughput	   in	   cellular	   models	   made	   an	   in	   vitro	   approach	   more	  appropriate	   in	   this	   context.	   	   First,	   as	  described	   in	  Chapter	  3,	  primary	   satellite	  cell	  cultures	  were	  established	  from	  neonatal	  rat	  pups	  and	  the	  culture	  conditions	  then	   optimised	   to	   ensure	   a	   consistent	   proportion	   of	   readily	   identifiable	  myotubes	  could	  be	  maintained	  and	  demonstrated.	  This	  involved	  modification	  of	  the	   culture	   medium,	   plating	   density	   and	   a	   variety	   of	   myogenic	   purification	  techniques,	   including	   pre-­‐plating,	   differential	   centrifugation	   and	   fluorescence	  activated	   cell	   sorting.	   Rat	   satellite	   cells	   present	   several	   advantages	   over	   their	  human	  counterparts.	  They	  are	  readily	  available,	  with	  a	  high	  yield	  presented	  by	  neonatal	   pups	   meaning	   that	   a	   small	   number	   of	   animals	   can	   support	   a	   large	  number	  of	  cultures.	  The	  source	  can	  easily	  be	  standardised,	  with	  consistent	  age,	  genetic	   background	   and	   environmental	   conditions	   rather	   than	   the	   typically	  heterogeneous	  donor	  population	  represented	  by	  human	  cultures.	  Furthermore,	  each	  culture	  can	  be	  established	  afresh,	  without	  the	  need	  for	  multiple	  passages	  of	  subclones	  of	  the	  original	  cell	  population	  that	  is	  a	  necessity	  of	  human	  satellite	  cell	   work	   and,	   notably	   in	   the	   case	   of	   IBM,	   can	   reveal	   underlying	   biological	  changes	  of	  these	  precursors	  such	  as	  inherent	  tendency	  to	  amyloid	  accumulation	  (Morosetti	  et	  al.	  2010).	  	  Next,	   cultures	   cells	   were	   exposed	   to	   a	   variety	   of	   IBM-­‐relevant	   stressors,	  including	  the	  over-­‐expression	  of	  βAPP	  or	  exposure	  to	  cytokines	  IL1β,	  TNFα	  and	  IFNY.	   	   This	   panel	   represented	   a	   practical	   number	   of	   conditions	   for	   further	  testing,	   balancing	   degenerative	   and	   inflammatory	   stimuli.	   Furthermore,	  previous	   work	   on	   each	   stressor	   in	   vitro	   suggested	   associated	   with	   pathology	  that	  could	  feasibly	  be	  reproduced	  in	  this	  cellular	  model.	  The	  overexpression	  of	  βAPP	   in	  human	  myocytes	  has	  previously	  been	  shown	  to	   induce	  mitochondrial	  dysfunction,	   cytoplasmic	   inclusions	  and	  proteasomal	   inhibition	   (Askanas	  et	  al.	  1997;	  Fratta	  et	  al.	  2005).	  The	  exposure	  of	  human	  myocytes	  to	  cytokines	  appears	  to	  upregulate	  expression	  of	  βAPP	  (Schmidt	  et	  al.	  2008).	  Therefore,	   it	  was	   first	  confirmed	   that	   these	   techniques	   are	   applicable	   to	   primary	   rat	   satellite	   cell	  cultures.	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βAPP	   plasmid	   transfection	   with	   Lipofectamine™	   was	   optimised	   through	  comparison	   of	   a	   number	   of	   DNA:Lipofectamine™	   ratios,	   using	  immunocytochemistry	   and	   western	   blotting	   to	   examine	   the	   effect	   of	   each	   on	  culture	   myogenicity,	   differentiation	   and	   expression	   of	   βAPP	   and	   the	   amyloid	  oligomers	  Aβ40	  and	  Aβ42.	   It	  was	  determine	   that	  overexpression	  of	  βAPP	  and	  consequent	   upregulation	   of	   Aβ40	   and	   Aβ42	   with	   transfection	   could	   be	  successfully	   achieved	   without	   compromising	   the	   overall	   suitability	   of	   the	  cultures	  for	  further	  experimentation.	  βAPP	  overexpression	  was	  associated	  with	  the	   formation	   of	   cytoplasmic	   proteinaceous	   aggregates	   and	   ubiquinated	  inclusions.	  	  In	  keeping	  with	  previous	  work	  on	  human	  satellite	  cells,	  exposure	  to	  cytokines	   also	   increased	   β-­‐amyloid	   expression.	   These	   inflammatory	   stimuli,	  however,	  were	  not	  associated	  with	  consistent	  formation	  of	  aggregates,	  perhaps	  due	   to	   the	   relatively	   smaller	   effect	   on	   expression	   levels.	   This	   might	   reflect	   a	  threshold	   between	   the	   expression	   levels,	   or	   their	   rate	   of	   increase,	   observed	  after	   cytokine	   exposure	   and	   βAPP	   transfection	   beyond	  which	   normal	   cellular	  degradative	  machinery	   is	   overwhelmed.	   Surplus	   proteins	   would	   then	  misfold	  and	   aggregate.	   This	   is	   consistent	   with	   the	   inhibitory	   action	   of	   β-­‐amyloid	  proteins	  on	  proteasomal	  function	  (Fratta	  et	  al.	  2005).	  MHCI	   was	   not	   only	   upregulated	   by	   cytokines,	   but	   also	   by	   βAPP	   transfection,	  indicating	   that	   the	   environment	   of	   insufficient	   protein	   breakdown	   extends	   to	  additional	  proteins	  beyond	  β-­‐amyloid.	  This	  supports	  the	  hypothesis	  that	  MHCI	  expression	  might	  be	  a	  central	  interlinking	  feature	  of	  IBM	  pathogenesis,	  since	  it	  can	  be	  driven	  by	  both	  degenerative	  and	   inflammatory	  stimuli.	   Its	  downstream	  consequences	  include	  further	  inflammation	  and	  likely	  perpetuation	  of	  ER	  stress,	  thereby	  establishing	  a	  self-­‐perpetuating	  cycle	  (Dalakas	  2006).	  Notably,	  however,	  the	  MHCI	  upregulation	  demonstrated	  by	  PM	  and	  DM	  generally	  does	  not	  appear	  sufficient	   to	   induce	  downstream	  degenerative	   features	   in	   isolation.	   It	   remains	  unclear	   whether	   this	   distinction	   represents	   a	   fundamental	   disparity	   between	  IBM	   and	   these	   conditions,	   or	   whether	   the	   relatively	   aged	   cellular	   milieu	  characteristic	  of	  IBM	  confers	  particular	  susceptibility.	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6.3	  Evaluation	  of	  Arimoclomol	  on	  pathological	  outcome	  measures	  of	  IBM	  	  Having	  determined	  that	  several	  features	  of	  IBM	  could	  be	  recapitulated	  in	  this	  in	  
vitro	   model,	   the	   subsequent	   experiments	   described	   in	   Chapter	   4	   sought	   to	  characterise	   the	  model	   further,	  with	   the	   intention	   of	   developing	   IBM-­‐relevant	  pathological	  outcome	  measures	   for	   the	   testing	  of	  potential	  drugs.	  Here,	   it	  was	  hypothesised	   that	   Arimoclomol,	   a	   coinducer	   of	   the	   cytoprotective	   HSR,	   could	  inhibit	   some	   of	   the	   pathological	   processes	   observed	   in	   IBM.	   Previous	   work	  demonstrated	   that	   augmentation	   of	   the	   HSR,	   including	   when	   achieved	   with	  Arimoclomol,	   translated	   to	   pathological	   and	   functional	   improvement	   in	  preclinical	   models	   of	   other	   diseases	   characterised	   by	   protein	   misfolding	   and	  aggregation,	  such	  as	  ALS	  and	  spinobulbar	  muscular	  atrophy	  (Kieran	  et	  al.	  2004;	  Malik	  et	  al.	  2013).	  Theoretically,	   there	  was	  additional	  evidence	  to	  support	  this	  strategy,	  including	  HSP70’s	  inhibition	  of	  amyloidogenic	  aggregation	  (Evans	  et	  al.	  2006)	  and	  anti-­‐inflammatory	  effects,	  reflecting	  inhibition	  of	  NFκB	  (Feinstein	  et	  al.	  1997).	  It	   was	   first	   necessary	   to	   determine	   whether	   Arimoclomol	   affects	   overall	   cell	  viability	   in	  myogenic	   cultures	   exposed	   to	   IBM-­‐like	   pathology	   and	  whether	   its	  described	  pharmacological	  effect	   to	  augment	   the	  expression	  of	  key	  heat	  shock	  protein	  HSP70	   occurs	   here.	  MTT	   assays	   demonstrated	   that	   overexpression	   of	  βAPP	   is	   cytotoxic	   to	   myogenic	   cells,	   which	   progresses	   up	   to	   96	   hours	   after	  transfection.	   Similarly,	   exposure	   cytokines	   IL1β	   and	   TNFα	   produced	   a	   dose	  dependent	   cytotoxic	   effect.	   Arimoclomol	   treatment	   was	   associated	   with	  significant	  attenuation	  of	  the	  cytotoxic	  effects	  of	  these	  stimuli.	  By	  western	  blot,	  Arimoclomol	  increased	  the	  expression	  HSP70	  that	  followed	  either	  or	  exposure	  to	   cytokines	   or	   βAPP	   overexpression	   by	   between	   4	   and	   8	   fold,	   implying	   this	  improvement	  in	  cytotoxicity	  could	  reflect	  increased	  chaperone	  activity.	  Next,	   a	   panel	   of	   quantifiable	   measures	   was	   developed	   based	   on	   those	  pathological	   processes	   particularly	   distinctive	   of	   IBM,	   such	   as	   TDP-­‐43	  mislocalisation,	   or	   with	   potential	   interlinking	   roles	   between	   downstream	  degenerative	   and	   inflammatory	   processes,	   notably	   ER	   stress	   and	   NFκB	  activation.	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6.3.1	  TDP-­‐43	  TDP-­‐43	  histopathology,	  observed	  in	  a	  number	  of	  neurodegenerative	  conditions,	  is	   characterised	   by	   loss	   of	   normal	   nuclear	   staining	   and	   translocation	   to	   the	  cytoplasm,	  where	  it	  forms	  aggregates.	  This	  phenomenon	  appears	  to	  be	  the	  most	  common	   histopathological	   feature	   of	   IBM,	   affecting	   up	   to	   a	   quarter	   of	   fibres	  (Salajegheh	   et	   al.	   2009)	   and,	   notably,	   is	   absent	   from	   cases	   of	   PM.	   	   Here,	  myotubes	  cultured	  under	  control	  conditions	  also	  demonstrated	  nuclear	  TDP-­‐43	  staining.	  Marked	  redistribution	  occurred	  under	  the	  IBM-­‐relevant	  stressors	  of	  β-­‐amyloid	  overexpression	  and	  exposure	  to	  cytokines,	  where	  non-­‐nuclear	  TDP-­‐43	  was	   detected	   in	   the	   majority	   of	   cells.	   This	   was	   followed	   by	   loss	   of	   nuclear	  staining.	  There	  was	  significant	  contemporaneous	  increase	  in	  expression	  of	  TDP-­‐43	   which,	   although	   also	   a	   feature	   of	   IBM	   tissue,	   has	   not	   typically	   been	   a	  sufficient	   stimulus	   for	   TDP-­‐43	   aggregate	   formation	   when	   reproduced	   in	  isolation	  through	  over-­‐expression	  in	  previous	  in	  vitro	  studies	  (Ash	  et	  al.	  2010).	  Therefore,	   it	   appears	   more	   likely	   that	   the	   accumulation	   of	   TDP-­‐43	   in	   the	  cytoplasm	   is	   either	   its	   pathophysiological	   response	   to	   cellular	   stress	   or	  reflective	   of	   impaired	   protein	   degradative	   processes.	   Nevertheless,	   elevated	  TDP-­‐43	  does	  appear	  to	  be	  cytotoxic	  and	  sufficient	  to	  induce	  disease	  phenotypes,	  such	  as	  FTD	  (Tsai	  et	  al.	  2010).	  Although	  evidently	   indicative	  of	  pathology,	   the	  downstream	  consequences	  of	  TDP-­‐43	  mislocalisation	  and	  increased	  expression	  can	   only	   be	   speculated	   since	   the	   protein’s	   normal	   function	   is	   not	   fully	  understood.	   Here,	   its	   characteristic	   immunocytochemical	   changes	   lend	  themselves	   to	  being	  a	  quantitative	   indicator	  of	   IBM	  pathology.	  Therefore,	   it	   is	  notable	   that	   Arimoclomol	   treatment	   significantly	   attenuated	   TDP-­‐43	  mislocalisation	   and	   expression	   in	   primary	   myogenic	   cultures	   following	   over-­‐expression	   of	   βAPP	   or	   exposure	   to	   cytokines.	   This	   effect	   is	   consistent	   with	  Arimoclomol’s	  described	  anti-­‐aggregation	  actions	  on	  other	  proteins	  and	  might	  reflect	  increased	  chaperone	  activity	  of	  HSP70,	  which	  has	  previously	  been	  found	  to	  influence	  the	  nuclear	  processing	  of	  TDP-­‐43	  (Udan-­‐Johns	  et	  al.	  2014).	  Reduced	  expression	   may	   succeed	   attenuation	   of	   cytoplasmic	   aggregation	   through	  restoration	  of	  TDP-­‐43	   auto-­‐homeostatic	  mechanism	   (Lee	   et	   al.	   2012).	   Further	  alleviation	   of	   TDP-­‐43	   pathology	   may	   occur	   indirectly	   through	   Arimoclomol’s	  effect	  on	  ER	  stress,	  which	  were	  examined	  next.	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6.3.2	  Endoplasmic	  Reticulum	  Function	  The	   broad	   functions	   of	   the	   ER	   link	   it	   with	   several	   other	   components	   of	   IBM	  pathology,	   particularly	   via	   its	   role	   in	   intracellular	   calcium	   homeostasis	   and	  excitation-­‐contraction	  coupling	  by	  subspecialised	  SR	  of	  skeletal	  muscle.	  Indeed,	  ER	  dysfunction	   is	  widely	   implicated	   in	  neurodegenerative	  diseases	   in	  addition	  to	   IBM	   (Roussel	   et	   al.	   2013)	   (Vattemi	   et	   al.	   2004).	   Although	   several	  cytoprotective	  functions	  have	  evolved	  to	  constitute	  the	  initial	  phases	  of	  the	  ER	  stress	  response,	  post-­‐mitotic	  tissues	  remain	  inherently	  vulnerable	  to	  conditions	  that	  overwhelm	  these	  defences	  since	  they	  cannot	  dilute	  the	  insult	  itself	  through	  cell	   division.	   This	  may	   be	   exacerbated	   by	   the	   ‘ER	   handicap’	   of	   aged	   tissue,	   in	  which	   ER	   chaperone	   activity	   appears	   relatively	   reduced	   (Nuss	   et	   al.	   2008).	  Diseases	   of	   protein	   aggregation,	   such	   as	   IBM,	   represent	   a	   vicious	   pathogenic	  cycle	  in	  which	  the	  capacity	  of	  cellular	  degradative	  machinery	  has	  been	  exceeded,	  with	  the	  resulting	  additional	  ER	  stress	  further	  stimulating	  the	  accumulation	  of	  these	  misfolded	  proteins	  and	  so	  on.	  Regards	  the	  proteins	  of	  particular	  interest	  here,	   β-­‐amyloid	   and	   TDP-­‐43	   are	   well	   established	   as	   inducers	   of	   ER	   stress	  (LaFerla	   et	   al.	   2007;	  Walker	   et	   al.	   2013).	   In	   addition,	  MHCI	   upregulation	   has	  been	  proposed	  to	  exacerbate	  ER	  stress	  in	  myositis	  and	  IBM	  (Dalakas	  2006;	  Li	  et	  al.	  2009).	  The	  activation	  of	  NFκB	  by	  ER	  stress	  is	  perhaps	  the	  most	  direct	  link	  to	  explain	   how	   a	   secondary	   inflammatory	   response	   might	   be	   sustained	   by	   a	  primarily	  degenerative	  stimulus.	  Therefore,	   ER	   function	   was	   examined	   in	   this	   model.	   Two	   aspects	   were	  investigated;	   cytosolic	   and	   ER	   calcium	   concentration	   using	   live	   cell	   confocal	  imaging	  and	  expression	  of	  proteins	   involved	   in	  ER	  stress	  using	  western	  blots.	  Cytosolic	   calcium	   concentration,	   [Ca2+]Cyto,	   was	   found	   to	   be	   significantly	  elevated	  in	  myogenic	  cells	  of	  cultures	  transfected	  with	  βAPP	  or	  exposed	  to	  IL1β	  or	  TNFα.	  This	  finding	  is	  consistent	  with	  established	  features	  of	  cellular	  stress	  is	  likely	   to	   reflect	   ER	   Ca2+	   leak,	   with	   additional	   possibilities	   including	   store-­‐operated	  uptake	  via	  increased	  cell	  membrane	  permeability	  or	  channel	  opening	  (Altamirano	  et	  al.	  2012).	  It	  is	  in	  keeping	  with	  elevated	  [Ca2+]Cyto	  observed	  in	  the	  MCK-­‐BAPP	  transgenic	  mouse,	  where	  AB42	  is	  proposed	  to	  modulate	  ryanodine	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receptor	   opening,	   leading	   to	   impaired	   muscle	   force	   (Moussa	   et	   al.	   2006).	   In	  relation	  to	  wider	  IBM	  pathogenesis,	  the	  numerous	  deleterious	  consequences	  of	  perturbed	   intracellular	   [Ca2+]Cyto	   include	   activation	   of	   NFκB	   and,	   thereby	  increased	  expression	  of	  proinflammatory	  factors	  (Altamirano	  et	  al.	  2012).	  	  ER	   Stress	  was	   evidenced	  more	   directly	   through	   the	   observation	   that	   [Ca2+]ER,	  determined	   through	   the	   change	   in	   [Ca2+]Cyto	   in	   response	   to	   SERCA	   inhibition	  with	  thapsigargin,	  	  was	  significantly	  reduced	  following	  βAPP	  over-­‐expression	  or	  exposure	   to	   cytokines.	   This	   finding	   was	   supported	   by	   the	   observation	   of	  increased	  expression	  of	  ER	  stress	  markers	  BiP	  (following	  βAPP	  over-­‐expression	  or	   	  IL1β	  exposure)	  and	  CHOP	  (following	  βAPP	  over-­‐expression,	  or	  exposure	  to	  IL1β	   or	   TNFα).	   The	   demonstration	   of	   ER	   stress	   under	   these	   conditions	   is	  consistent	  with	  previous	  studies	  of	  βAPP	  and	  Aβ42,	  predominantly	  with	  respect	  to	  neurons	  in	  the	  context	  of	  Alzheimer’s	  disease	  (Ghribi	  et	  al.	  2001;	  Resende	  et	  al.	   2008;	   Lee	   do	   et	   al.	   2010).	   The	   mechanism	   through	   which	   cytokines	  perpetuate	  ER	  stress	  may	  differ,	  reflecting	  combined	  upregulation	  of	  βamyloid	  proteins	  and	  MHCI.	  	  	  	  Arimoclomol	   treatment	   significantly	   attenuated	   disturbances	   of	   cytosolic	   and	  ER	   calcium,	   implying	   it	   has	   a	   protective	   function	   against	   the	   development	   or	  perpetuation	   of	   ER	   stress.	   This	   was	   corroborated	   by	   the	   reduction	   of	   CHOP	  expression	  following	  Arimoclomol	  treatment	  of	  cultures	  over-­‐expressing	  βAPP	  or	  exposed	   to	   IL1β.	  The	  relative	   lack	  of	  effect	  of	  Arimoclomol	  on	  BiP	  and	  ATF	  expression	  in	  all	  culture	  conditions	  implies	  an	  action	  further	  downstream	  in	  the	  UPR	   pathway.	   The	   mechanism	   of	   this	   cytoprotective	   effect	   may	   reflect	   an	  increased	   chaperone	   effect	   associated	   with	   augmented	   HSP70	   expression,	  consistent	   with	   previous	   studies	   that	   observed	   stabilisation	   of	   SERCA	   and	  calcium	  homeostasis,	  and	  increased	  cytoplasmic	  refolding	  of	  misfolded	  proteins	  (Nanasi	  et	  al.	  2001;	  Liu	  et	  al.	  2008).	  	  	  
6.3.3	  NFκB	  activation	  Next	   to	   ER	   stress,	   the	   pro-­‐inflammatory	   transcription	   factor	  NFκB	   represents	  the	   most	   logical	   central	   pathogenic	   mechanism	   to	   link	   inflammation	   and	  degeneration	   in	   sporadic	   IBM,	   just	   as	   it	   appears	   fundamental	   to	   IBMPFD	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(Nogalska	   et	   al.	   2007;	   Custer	   et	   al.	   2010).	   This	  mechanism	  would	  mirror	   that	  established	   in	   the	   secondary	   inflammation	   of	   Duchenne	   muscular	   dystrophy	  (Messina	  et	  al.	  2011).	  An	  additional	  role	  in	  muscle	  atrophy	  further	  signifies	  its	  potential	  importance	  (Jackman	  et	  al.	  2004).	  	  In	   keeping	   with	   an	   established	   direct	   effect,	   cytokines	   activated	   NFκB,	  determined	   by	   translocation	   of	   the	   p65	   subunit	   to	   the	   cell	   nucleus	   by	  immunocytochemistry.	   Interestingly,	   βAPP	   overexpression	   also	   significantly	  increased	   NFκB	   activation.	   This	   mechanism	   could	   reflect	   the	   influence	   of	   ER	  stress	   and	  upregulated	  MHCI,	   evidenced	  under	   the	   same	   conditions	  here,	   and	  demonstrated	  by	  previous	  studies	   (Nagaraju	  et	  al.	  2005).	   	  The	  contribution	  of	  upregulated	   MHCI	   is	   likely	   to	   be	   small	   since	   Arimoclomol	   inhibited	   NFκB	  activation	  whilst	  not	  affecting	  MHCI	  expression.	  	  Indeed,	   Arimoclomol	   inhibited	   NFκB	   activation	   whether	   stimulated	   by	  cytokines	  or	  βAPP	  over-­‐expression.	  The	  mechanism	  of	  this	  effect	  is	  likely	  to	  be	  multifactorial,	  incorporating	  the	  consequences	  of	  attenuated	  ER	  stress,	  however	  since	   a	   direct	   stimulatory	   effect	   of	   cytokines	   on	   NFκB	   is	   also	   apparently	  inhibited,	   Arimoclomol	   or	   HSP70	  may	   also	   have	   a	   direct	   inhibitory	   action	   on	  NFκB.	   This	   would	   be	   consistent	   with	   previous	   work	   on	   astroglial	   cultures,	  where	  HSP70	  inhibits	  inflammatory	  signalling	  (Feinstein	  et	  al.	  1996).	  Next,	   it	   was	   determined	   whether	   Arimoclomol’s	   cytoprotective	   effects	   were	  mediated	   through	   alteration	   of	   βAPP	   or	  MHCI	   expression.	   Specifically,	   it	   was	  possible	   that	   Arimoclomol	   could	   reduce	   the	   βAPP	   expression	   associated	  with	  transfection.	  In	  turn,	  this	  would	  have	  been	  expected	  to	  attenuate	  its	  pathogenic	  effects.	   In	   fact,	   no	   such	   effect	   was	   observed	   and	   Arimoclomol	   did	   not	   effect	  βAPP	  expression	  after	  either	  transfection	  or	  exposure	  to	  cytokines.	  This	  implies	  its	   effects	   lie	   downstream.	   This	   is	   important	   since	   the	   importance	   of	   βAPP	  specifically	   in	   the	   pathogenesis	   of	   IBM	   is	   contested	   and	   other	   degenerative	  proteins	   might	   have	   equal	   or	   greater	   importance	   (Greenberg	   2009).	  Furthermore,	   it	   was	   not	   the	   central	   hypothesis	   of	   this	  work	   that	   βAPP	   is	   the	  primary	  upstream	  trigger	  of	  IBM.	  Rather,	  it	  was	  employed	  as	  a	  stimulus	  of	  other	  pathogenic	   elements.	   Arimoclomol	   did	   not	   affect	   MHCI	   expression	   either.	  Extrapolating	  the	  significance	  of	  this	  result	  to	  the	  in	  vivo	  pathogenesis	  requires	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caution	   since,	   there,	   MHCI	   is	   influenced	   by	   a	   systemic	   immune	   system	   and,	  whereas	   cultured	   myotubes	   do	   demonstrate	   some	   constitutive	   expression	   of	  MHCI	  under	  control	  conditions,	   this	  does	  not	  appear	   to	  be	   the	  case	   in	  skeletal	  muscle	   in	   vivo.	   Nevertheless,	   the	   lack	   of	   effect	   of	   Arimoclomol	   on	   MHCI	  expression	   here	   implies	   its	   effects	   instead	   lie	   further	   downstream,	   consistent	  with	  the	  lack	  of	  influence	  on	  βAPP.	  This	  could	  be	  inferred	  as	  a	  positive	  finding	  since	   the	   features	   of	  TDP-­‐43	   translocation,	   ER	   stress	   and	  NFκB	  activation	   are	  present	  on	  muscle	  biopsy	  by	  the	  time	  of	  clinical	  presentation	  in	  IBM	  (Salajegheh	  et	   al.	   2009).	   Therefore,	   it	   is	   unrealistic	   to	   prevent	   their	   onset.	   Rather,	   a	  reasonable	   therapeutic	   approach	   would	   be	   to	   inhibit	   them	   or	   limit	   their	  perpetuation.	   A	   pharmacological	   action	   that	   targets	   these	   processes	   more	  directly	   could	   be	   preferable	   to	   one	   that	   is	   dependent	   on	   a	   specific,	   as	   yet	  unidentified,	  upstream	  trigger.	  	  
6.4	  Translating	  the	  effects	  of	  Arimoclomol	  to	  clinical	  treatment	  To	  lay	  the	  required	  foundation	  to	  advance	  Arimoclomol	  along	  the	  translational	  research	  pathway	  of	  drug	  development,	  a	  small	  Phase	  IIa	  study	  was	  established	  in	   patients	   with	   IBM.	   The	   primary	   endpoint	   was	   safety	   and	   tolerability,	  determined	   by	   adverse	   events	   (AEs)	   and	   adherence	   to	   the	   medication.	   No	  significant	  difference	   in	  AEs	  between	  the	  Arimoclomol	  and	  placebo	  group	  was	  detected.	   No	   serious	   AEs	   deemed	   likely	   to	   be	   related	   to	   trial	   medication	  occurred	   in	   the	   Arimoclomol	   group.	   	   The	   trial	   subjects	   adhered	   tightly	   to	   the	  prescribed	  regimen,	  with	  a	  minimum	  of	  96.5%,	  indicating	  excellent	  tolerability	  over	  the	  four-­‐month	  treatment	  period.	  This	  is,	  in	  part,	  likely	  to	  reflect	  the	  lack	  of	  any	   significant	   detrimental	   impact	   on	   disease	   course	   suggested	   by	   the	  secondary	  outcome	  measures.	  These	  results	  were	  consistent	  with	   the	   findings	  of	   previous	   early	   phase	   human	   safety	   studies	   of	   Arimoclomol	   and	   the	   largest	  study	   of	   the	   drug	   to	   date,	   involving	   84	  patients	   (Cudkowicz	   et	   al.	   2008).	   This	  length	  of	  evaluation	  is	  longer	  than	  the	  equivalent	  Phase	  II	  study	  of	  many	  other	  subsequently	   licensed	  medications.	   Therefore,	   the	   safety	   and	   tolerability	   data	  for	   Arimoclomol	   in	   IBM	   appear	   suitable	   to	   support	   its	   further	   evaluation	   in	  larger	  trials.	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Additional	   challenges	   of	   such	   further	   studies	   were	   anticipated	   and	   this	   trial,	  therefore,	   took	   the	   opportunity	   to	   evaluate	   a	   number	   of	   secondary	   outcome	  measures	  to	  help	  inform	  a	  future	  trial’s	  framework.	  	  The	  measurement	   of	  muscle	   strength	   is	   an	   obvious	   candidate	   as	   an	   outcome	  measure	   in	   a	   study	   of	   myopathic	   disease.	   However,	   this	   trial	   evidenced	   the	  challenges	  presented	  by	  this.	  Even	  with	  consistency	  of	  evaluating	  personnel,	  the	  quantitative	   technique	   of	   maximal	   voluntary	   isometric	   contraction	   testing	  (MVICT)	   demonstrated	   high	   variability	   between	   subjects	   and	   did	   not	   change	  proportionately	  with	   time,	  meaning	   that	   the	  detection	  of	   a	   realistic	   treatment	  effect	   in	   a	   trial	   of	   realistic	   size	   and	   duration	   would	   be	   unlikely	   using	   this	  measure.	  However,	   improved	  correlation	  with	  time	  was	  observed	   in	  subgroup	  analysis	   of	   individual	   movements,	   notably	   handgrip,	   which	   is	   of	   particular	  relevance	   to	   IBM.	   Therefore,	   restricted	   MVICT	   testing	   might	   be	   reasonable.	  Manual	  muscle	  testing	  (MMT)	  sum	  score	  declined	  in	  close	  correlation	  with	  time	  in	  both	  treatment	  groups,	  meaning	  this	  technique	  could	  more	  effectively	  detect	  deviation	  from	  disease	  natural	  history	  through	  a	  treatment	  effect.	  However,	  as	  an	  ordinal	  scale,	  it	  is	  difficult	  to	  infer	  clinically	  meaningful	  effects	  from	  changes	  in	  MMT	  scores,	  even	  if	  numerically	  significant.	  Therefore,	  it	  is	  likely	  that	  patient	  reported	   outcome	   measures,	   such	   as	   functional	   rating	   scales,	   might	   form	   an	  important	   component	   of	   efficacy	   trials.	   Accordingly,	   it	   is	   reassuring	   that	   the	  validated	  IBM	  functional	  rating	  scale	  (IBMFRS)	  demonstrated	  a	  steady,	  closely	  correlated	  decline	  over	  the	  time	  course	  of	  this	  trial.	  Finally,	   evidence	   for	   Arimoclomol’s	   pharmacological	   actions	   to	   augment	   the	  expression	  of	  HSP70,	  inhibit	  inflammation	  and	  inhibit	  protein	  aggregation	  was	  sought	  using	  serial	  muscle	  biopsies.	  This	  approach	  was	  undermined	  by	  inherent	  limitations	   of	   the	   necessity	   to	   biopsy	   different	   anatomical	   sites	   in	   individual	  patients,	  combined	  with	  the	  apparent	  high	  variation	  in	  HSP70	  concentration,	  of	  over	  18	  fold,	  between	  patients.	  The	  same	  limitation	  applied	  to	  comparison	  of	  a	  panel	   of	   histopathological	  markers.	   In	   the	   context	   of	   a	   safety	   and	   tolerability	  study,	  it	  is,	  however,	  useful	  to	  observe	  a	  lack	  of	  large	  potentially	  harmful	  effect	  on	   the	   affected	   tissue,	   such	   as	   exacerbation	  of	   inflammation.	   For	   future	   trials,	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the	  evolution	  of	  MRI	  in	  neuromuscular	  diseases	  might	  provide	  a	  more	  practical	  outcome	  measure	  than	  direct	  muscle	  biopsy.	  	  
6.5	  Limitations	  and	  Conclusion	  Any	   preclinical	   cellular	   or	   animal	  model	   of	   sporadic	   disease	   is	   limited	   by	   the	  inherent	   complexity	   of	   aetiology	   that	   typically	   relies	   on	  multiple	   genetic	   and	  environmental	   factors.	   Recapitulating	   IBM	   is	   particularly	   difficult	   due	   to	   the	  opacity	   surrounding	   its	   fundamental	   cause,	   even	   to	   the	   extent	   that	   it	   remains	  unclear	   whether	   it	   is	   primarily	   an	   inflammatory	   or	   degenerative	   disease.	  Nevertheless,	  this	  does	  not	  preclude	  translational	  research	  on	  IBM.	  Indeed,	  even	  the	   identification	   of	   a	   disease	   trigger	   may	   not	   automatically	   yield	   a	   panacea.	  Instead,	   the	   logical	   approach	   is	   to	   identify,	   reproduce	   and	   seek	   to	  manipulate	  consistent	  and	  central	  pathogenic	  features.	  This	  is	  the	  underlying	  theme	  of	  this	  thesis	   and,	   therefore,	   it	   is	   important	   not	   to	   extrapolate	   the	   significance	   of	  certain	   results	   retrospectively	   as	   though	   they	   sought	   to	   characterise	   the	  mechanism	   of	   pathogenesis	   in	   vivo.	   For	   example,	   βAPP	   and	   inflammatory	  cytokines	   were	   de	   facto	   primary	   stimuli	   of	   IBM-­‐like	   features	   in	   these	  experiments	   but	   they	   may	   not	   assume	   the	   same	   upstream	   position	   in	   the	  context	  of	   the	  human	  disease.	   Instead,	   the	  most	  promising	  conclusion	  of	   these	  experiments	  is	  that	  recapitulation	  and	  manipulation	  of	  established	  components	  of	  IBM	  pathology	  can	  be	  achieved	  in	  vitro.	  This	   thesis	   demonstrates	   an	   alternative	   strategy	   in	   the	   development	   of	  treatment	  for	  IBM	  to	  that	  which	  has	  typically	  been	  used	  in	  the	  field.	  Rather	  than	  conduct	   sequential	   small	   clinical	   efficacy	   trials	   of	   drugs	   licensed	   for	   other	  conditions,	  this	  approach	  is	  based	  on	  a	  preclinical	  model	  that	  could	  be	  used	  to	  examine	   multiple	   new	   therapeutic	   strategies.	   Here,	   one	   such	   approach	   was	  investigated,	  using	  augmentation	  of	  the	  heat	  shock	  response	  with	  Arimoclomol.	  This	  was	  associated	  with	  significant	  effects	  on	  several	  aspects	  of	  IBM	  pathology	  and	   improved	  cell	  viability	   in	  a	  preclinical	  disease	  model,	  none	  of	  which	  were	  demonstrated	   by	   drugs	   previously	   studied	   on	   patients	   with	   the	   disease.	   To	  advance	   this	   in	  vitro	  work	  on	  Arimoclomol	   towards	  a	  study	  of	  clinical	  efficacy	  involves	   several	   more	   steps.	   The	   first	   of	   these,	   to	   demonstrate	   satisfactory	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safety	   and	   tolerability	   in	   patients	   with	   IBM,	   was	   successfully	   achieved.	  Therefore,	  careful	  consideration	  of	  a	  larger	  efficacy	  trial	  of	  Arimoclomol	  in	  IBM	  is	  justified.	  Evaluation	  of	  other	  new	  therapeutic	  strategies	  on	  preclinical	  models	  should	   occur	   simultaneously	   and	   thereby	  maintain	   the	   translational	   research	  process	   that	   will	   accelerate	   the	   discovery	   of	   an	   effective	   treatment	   for	   this	  disabling	  disease.	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Chapter	  7:	  Appendix	  
7.1	  Supplementary	  methods	  in	  clinical	  trial	  of	  Arimoclomol	  To	   standardise	   clinical	   assessment	   as	   far	   as	  possible,	   thereby	   to	   reduce	   inter-­‐observer	   variability,	   assessments	   were	   performed	   according	   to	   the	   following	  guidance	  provided	  to	  investigators.	  	  
7.1.1	  Clinical	  examination	  of	  power	  -­‐	  Explain	  or	  demonstrate	  the	  movement	  that	  is	  required	  of	  the	  patient.	  -­‐	   Ask	   the	   patient	   to	   perform	   the	   movement	   through	   the	   full	   range	   against	  gravity.	  -­‐	   If	   the	   patient	   does	   not	   perform	   or	   is	   unable	   to	   perform	   the	   complete	  movement,	  check	  for	  these	  limiting	  factors:	  i)	  Understanding	  of	  the	  required	  task	  ii)	   Availability	   of	   the	   appropriate	   range	   of	   motion	   (limitations	  may	   be	  due	  to	  soft	  tissue	  tightness)	  iii)	  Weakness	  	  -­‐	  Based	  on	  the	  limiting	  factor(s):	  -­‐	  Instruct	  and	  demonstrate	  again.	  -­‐	  Decide	  if	  joint	  restriction	  is	  affecting	  the	  performance.	  -­‐	  Repeat	  the	  test	  using	  the	  alternative	  gravity	  eliminated	  position.	  If	   the	   patient	   experiences	   pain	   during	   the	   testing,	   the	   clinical	   evaluator	  must	  determine	  whether	  the	  patient	  feels	  that	  he/she	  is	  able	  to	  give	  his	  best	  effort	  in	  spite	  of	   his	  discomfort.	   	   If	   yes,	   continue	   the	   testing	  but	  note	  under	   comments	  that	   the	   patient	   complained	   of	   pain.	   	   If	   the	   patient	   feels	   that	   discomfort	  prohibits	  him	  from	  giving	  a	  maximal	  effort,	  do	  not	  test	  that	  muscle.	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If	  the	  clinical	  evaluator	  is	  undecided	  between	  two	  muscle	  grades,	  he/she	  should	  always	  grade	  down.	   	  For	  example,	   if	   the	   left	  elbow	  flexors	  are	   to	  be	  graded	  as	  possibly	  a	  4+	  or	  a	  4,	  the	  evaluator	  should	  record	  a	  4.	  The	  precise	  order	  of	  testing,	  in	  terms	  of	  whether	  the	  evaluator	  should	  test	  R/L,	  R/L	   or	   complete	   one	   side	   in	   each	   position	   is	   left	   to	   the	   discretion	   of	   the	   CE.	  However,	   it	   is	   important	   that	   the	  evaluator	  always	  be	  on	   the	  same	  side	  as	   the	  muscle	   being	   tested	   (for	   example,	   if	   testing	   right	   knee	   flexion	   prone,	   the	  evaluator	  should	  be	  on	  the	  right	  side	  of	  the	  patient.	  	  To	  test	  left	  knee	  flexion,	  the	  evaluator	  would	  move	  to	  the	  opposite	  side	  of	  the	  exam	  table,	  and	  thus	  be	  on	  the	  patient’s	  left	  side).	  Because	  this	  is	  a	  research	  protocol,	   family	  members	  or	  support	  people	  are	  not	  allowed	  in	  the	  room	  during	  testing.	  	  If	  the	  clinical	  evaluator	  needs	  the	  assistance	  of	   a	   second	   person,	   his	   first	   choice	   should	   always	   be	   a	   staff	   person.	   	   If	   it	   is	  absolutely	   necessary	   to	   “borrow”	   a	   family	   member,	   that	   person	   should	   only	  remain	   in	   the	   testing	   area	   during	   the	   actual	   transfer	   and/or	   positioning.	   	   It	  should	   be	   explained	   to	   anxious	   patients	   or	   family	   that	   it	   is	   imperative	   to	  maintain	   consistent	   and	   exact	   testing	   conditions	   and	   that	   for	   this	   reason,	   no	  visitors	  are	  allowed.	  A	  firm	  testing	  surface	   is	  necessary	  to	  provide	  proper	  stability.	  An	  examination	  table	  is	  adequate,	  but	  a	  Hi-­‐Lo	  table	  is	  preferred	  to	  provide	  ease	  of	  transfer	  and	  adequate	  height	  for	  the	  evaluator	  during	  different	  tests.	  
MRC	  Grade	   Degree	  of	  Strength	  5	   Normal	  strength	  5-­‐	   Uncertain	  muscle	  weakness	  4+	   Ability	   to	   resist	   against	   all	   but	   maximal	   pressure	  throughout	  range	  of	  motion	  4	   Ability	   to	   resist	   against	   moderate	   pressure	   throughout	  range	  of	  motion	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4-­‐	   Ability	   to	   resist	   against	   minimal	   pressure	   throughout	  range	  of	  motion	  3+	   Ability	   to	   move	   through	   full	   range	   of	   motion	   against	  gravity	   and	   to	   resist	   against	   minimal	   pressure	   through	  partial	   range	   of	   motion,	   then	   the	   contraction	   breaks	  abruptly	  3	   Ability	   to	   move	   through	   full	   range	   of	   motion	   against	  gravity.	   	   If	   a	   patient	   has	   a	   contracture	   that	   limits	   joint	  movement,	   the	   mechanical	   range	   will	   be	   to	   the	   point	   at	  which	  the	  contracture	  causes	  joint	  restriction.	  3-­‐	   Ability	   to	   move	   through	   partial	   range	   of	   motion	   against	  gravity.	  2	   Ability	  to	  move	  through	  full	  or	  partial	  range	  of	  motion	  with	  gravity	  eliminated	  1	   	   	   A	  flicker	  of	  movement	  is	  seen	  or	  felt	  in	  the	  muscle	  0	   	   	   No	  contraction	  	  
	  
7.1.1.1	  Manual	  muscle	  testing	  Muscles	  are	  listed	  in	  the	  order	  and	  position	  of	  muscle	  testing.	  	  Certain	  muscles	  will	  be	  graded	  in	  one	  position	  only.	  	  For	  other	  muscles,	  the	  first	  testing	  position	  will	   indicate	  a	  grading	  ranged	  of	  5	   to	  3-­‐;	   if	   the	  muscle	  cannot	  be	  grade	   in	   this	  range,	  then	  it	  will	  be	  tested	  again	  in	  an	  alternate	  position.	  	  
A.	   POSITION	  I:	  	  SITTING	  The	  patient	  is	  sitting	  comfortably	  on	  the	  edge	  of	  the	  examination	  table	  with	  the	  legs	  dangling.	  The	  edges	  of	   the	  examination	  table	  should	  support	   the	  patient’s	  thigh	  to	  a	  level	  proximal	  to	  the	  knee	  joint.	  The	  patient’s	  shoes	  are	  off.	  	  The	  following	  are	  performed	  in	  this	  position:	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Shoulder	  Abduction	  The	  patient’s	  arm	   is	  by	  his/her	  side.	  He	   is	  asked	   to	  abduct	   the	  shoulder	   to	  90	  degrees	   with	   the	   elbow	   flexed	   and	   the	   forearm	   pronated.	   Stabilization	   is	  provided	   at	   the	   opposite	   shoulder	   to	   prevent	   the	   patient	   from	   leaning	   away	  from	  the	  abducted	  arm.	  The	  examiner	  places	  his/her	  hand	  just	  proximal	  to	  the	  patient’s	   elbow	  and	  pushes	   it	  downward.	  Enter	  grade	  5	   to	  3-­‐.	   If	   the	  patient	   is	  unable	  to	  raise	  the	  arm	  out	  from	  his	  side,	  no	  grade	  is	  entered.	  Retest	  the	  muscle	  when	  the	  patient	  is	  in	  the	  supine	  position.	  	  
Elbow	  Flexion	  The	  patient	  starts	  in	  slight	  shoulder	  flexion	  with	  the	  forearm	  supinated	  and	  the	  elbow	   extended.	   He	   is	   asked	   to	   bring	   the	   hand	   to	   the	   level	   of	   his	   shoulder,	  flexing	  proximal	  to	  the	  patient’s	  wrist	  and	  pressure	  is	  exerted	  to	  straighten	  the	  elbow.	  Resistance	  is	  given	  with	  the	  elbow	  flexed	  to	  90	  degrees.	  The	  examiner’s	  other	   hand	   stabilizes	   under	   the	   elbow	   at	   the	   distal	   humerus	   or	   against	   the	  anterior	   surface	  of	   the	  proximal	  humerus.	   If	   the	  patient	   is	  unable	   to	  bend	   the	  elbow	   against	   gravity,	   the	   examiner	   raises	   the	   patient’s	   upper	   arm	   so	   the	  motion	   becomes	   a	   horizontal	   movement	   of	   the	   forearm	   (i.e.,	   with	   gravity	  eliminated).	   The	   patient’s	   upper	   arm	   is	   supported	   passively	   during	   this	  maneuver.	  	  	  
Wrist	  Extension	  The	   patient’s	   forearm	   is	   pronated	   with	   the	   elbow	   at	   about	   30	   degrees	   from	  extension	  and	  the	  patient	  is	  asked	  to	  bring	  the	  wrist	  backwards.	  The	  examiner	  supports	   and	   stabilizes	   the	   forearm	   proximal	   to	   the	   wrist	   and	   presses	   the	  dorsum	  of	  the	  patient’s	  hand	  with	  the	  wrist	  in	  an	  extended	  position.	  The	  fingers	  may	   be	   fully	   flexed	   or	   relaxed.	   If	   the	   patient	   is	   not	   able	   to	   extend	   the	   wrist	  against	   gravity,	   the	   examiner	   raises	   the	   patient’s	   upper	   arm	   so	   the	   motion	  becomes	  a	  horizontal	  movement	  of	   the	   forearm	   (i.e.,	  with	  gravity	   eliminated).	  	  The	  patient’s	  upper	  arm	  is	  supported	  passively	  during	  this	  maneuver.	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Wrist	  Flexion	  The	   patient’s	   forearm	   is	   supinated	   with	   the	   elbow	   at	   about	   30	   degrees	   from	  extension	  and	  the	  patient	   is	  asked	  to	  bend	  the	  hand	  upward,	   flexing	  the	  wrist.	  The	  fingers	  may	  be	  fully	  flexed	  or	  relaxed.	  The	  examiner	  supports	  and	  stabilizes	  the	  forearm	  proximal	  to	  the	  wrist	  and	  exerts	  pressure	  on	  the	  patient’s	  palm	  to	  straighten	  out	  the	  wrist.	  If	  the	  patient	  cannot	  flex	  the	  wrist	  against	  gravity,	  the	  forearm	   is	   turned	   into	   a	   position	  midway	   between	   pronation	   and	   supination,	  and	  the	  patient	  attempts	  to	  flex	  the	  wrist	  in	  a	  horizontal	  plane.	  	  	  	  
Hip	  flexion	  The	  patient	  should	  be	  asked	  to	  sit	  up	  straight.	  The	  hands	  must	  grasp	  the	  edge	  of	  the	   examining	   table.	   During	   this	   test,	   the	   patient	   should	   be	   discouraged	   from	  leaning	  backwards	  or	  sideways,	  or	  from	  flexing	  his	  knee	  to	  support	  the	  limb	  by	  pressing	   the	   belly	   of	   the	   gastrocnemius	  muscle	   on	   the	   edge	   of	   the	   examining	  table.	   In	   addition,	   the	   thigh	   should	   remain	   in	   neutral	   position.	   Pressure	   is	  exerted	   on	   the	   anterior	   distal	   surface	   of	   the	   thigh	   in	   the	   direction	   of	   hip	  extension.	  Enter	  grade	  5	  to	  3-­‐.	  
NOTE:	  	  For	  this	  test,	  resistance	  can	  be	  graded	  if	  the	  hip	  can	  be	  actively	  flexed	  to	  at	  least	  30	  degrees	  from	  the	  plane	  of	  the	  table.	  Full	  active	  range	  is	  not	  required.	  To	  achieve	  a	  grade	  of	  3-­‐,	  the	  patient	  should	  be	  able	  to	  flex	  the	  hip	  enough	  that	  the	  examiner	  can	  slide	  his	  hand	  cleanly	  under	  the	  distal	  thigh.	  If	  the	  patient	  can	  lift	   the	   thigh,	   but	   cannot	  maintain	   neutral	   rotation,	   grade	   as	   3-­‐.	   If	   the	   patient	  cannot	  lift	  the	  leg,	  do	  not	  grade.	  Test	  again	  in	  the	  alternate	  testing	  positions	  (i.e.,	  side-­‐lying	  gravity	  eliminated).	  
	  
Knee	  Extension	  The	   examiner	  may	   put	   his	   hand	   or	   a	   rolled	   towel	   under	   the	   distal	   end	   of	   the	  thigh	  to	  cushion	  that	  part	  against	  pressure.	  The	  patient	  is	  then	  asked	  to	  extend	  the	   knee.	   Once	   full	   active	   range	   of	   motion	   has	   been	   observed,	   the	   patient	   is	  asked	   to	   bend	   his	   knee	   to	   about	   20	   degrees	   from	   0.	   The	   examiner	   places	   his	  other	  hand	  on	   the	   lower	   leg	   above	   the	   ankle,	   and	   exerts	   downward	  pressure.	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Enter	  grade	  5	   to	  3-­‐.	   If	   the	  patient	  cannot	  straighten	  his	   leg	  against	  gravity,	  do	  not	   grade	   in	   this	   position.	   Retest	   in	   the	   side-­‐lying	   position	   with	   gravity	  eliminated.	  
NOTE:	   	   For	   this	   test,	   resistance	   can	   be	   graded	   if	   the	   knee	   can	   be	   actively	  extended	  to	  within	  10	  degrees	  from	  0.	  	  
Ankle	  Dorsiflexion	  The	  examiner	  supports	  the	  leg	  just	  above	  the	  ankle	  joint.	  The	  patient	  is	  asked	  to	  bring	  the	  foot	  upwards.	  The	  examiner’s	  hand	  is	  placed	  on	  the	  dorsum	  of	  the	  foot,	  and	  downward	  pressure	  is	  exerted.	  Enter	  grade	  5	  to	  3-­‐.	  	  If	  the	  patient	  is	  unable	  to	   dorsiflex	   the	   foot,	   do	   not	   grade	   in	   this	   position.	   Retest	   in	   the	   side-­‐lying	  position	  with	  gravity	  eliminated.	  
NOTE:	   For	   this	   test,	   attempt	   to	   achieve	   dorsiflexion	  without	   inversion.	   If	   the	  patient	   can	   only	   dorsiflex	  with	   some	   inversion,	   it	  will	   be	   evaluator’s	   decision	  whether	  to	  allow	  the	  motion.	  	  
B.	  	  POSITION	  2:	  	  PRONE	  The	  examiner	  should	  remove	  any	  pillows	  on	  the	  exam	  table	  prior	  to	  testing.	  	  
Neck	  Extension	  The	  patient	   is	  asked	  to	  bring	  the	  head	  upward	  with	  his	  arms	  at	  his	  side	  while	  the	  examiner	  holds	  the	  shoulders	  stable.	  He	  should	  be	  able	  to	  do	  this	  so	  that	  his	  face	   is	   looking	   straight	   ahead	   for	   testing.	  One	  of	   the	   examiner’s	  hands	   is	   then	  placed	   over	   the	   occiput	   and	   pressure	   is	   exerted	   in	   the	   direction	   of	   the	   neck	  flexion.	   As	   a	   safety	   measure,	   the	   examiner	   keeps	   his	   other	   hand	   just	   off	   the	  patient’s	   chin.	   Enter	   grade	   5	   to	   3-­‐.	   If	   the	   patient	   cannot	   lift	   his	   eyes	   to	   the	  horizontal,	  the	  examiner	  must	  evaluate	  the	  passive	  range	  of	  motion	  available.	  If	  the	  patient	  cannot	  lift	  his	  head	  against	  gravity,	  retest	  in	  the	  side-­‐lying	  position.	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Hip	  Extension	  The	  patient	  is	  asked	  to	  hyperextend	  the	  hip	  with	  the	  knee	  flexed	  to	  90	  degrees	  or	  more.	   	  The	  examiner	  stabilizes	  at	   the	  pelvis,	  and	  gives	  pressure	  against	   the	  distal	   thigh	   in	   the	  direction	  of	  hip	   flexion.	  Enter	  grade	  5	   to	  3.	   If	   the	  patient	   is	  unable	   to	   lift	   the	   hip	   against	   gravity,	   or	   barely	   lifts	   it,	   retest	  with	   the	   patient	  leaning	  over	  the	  table	  so	  that	  his	  entire	  trunk	  is	  supported	  and	  his	  free	  leg	  is	  just	  touching	  the	  floor.	  The	  patient	  can	  stabilize	  by	  holding	  onto	  the	  table.	  Ask	  him	  to	  shift	  his	  weight	  onto	  one	  leg.	  The	  examiner	  then	  supports	  the	  opposite	  leg	  in	  90	  degrees	  of	  knee	   flexion,	   and	  asks	   the	  patient	   to	   lift	   that	   leg	  away	   from	   the	  table.	  Grade	  as	  3-­‐	  if	  the	  patient	  lifts	  the	  leg	  but	  not	  to	  the	  horizontal	  plane.	  If	  the	  patient	   cannot	   lift	   the	   thigh	   from	   the	   resting	   vertical	   position	   (with	   the	  examiner	  supporting	  the	  knee	  in	  flexion),	  do	  not	  grade.	  Retest	  in	  the	  side-­‐lying	  position	  with	  gravity	  eliminated.	  
NOTE:	   	   To	   avoid	   having	   the	   patient	   change	   position	   more	   than	   necessary,	  assessing	   for	   a	   grade	   3-­‐	   can	   be	   done	   as	   the	   first	   or	   last	  muscle	   tested,	   as	   the	  patient	  gets	  on	  or	  off	  from	  the	  exam	  table.	  	  
Knee	  Flexion	  The	  patient	  is	  asked	  to	  bend	  the	  knee	  90	  degrees.	  	  Once	  it	  has	  been	  shown	  that	  the	   patient	   has	   full	   range	   of	  motion,	   have	   him	   extend	   the	   knee	   to	   about	   120	  degrees	  so	  that	  the	  hamstring	  group	  is	  not	  too	  shortened.	  One	  of	  the	  examiner’s	  hands	  stabilizes	  just	  proximal	  to	  the	  Achilles	  tendon,	  and	  pressure	  is	  exerted	  to	  straighten	  the	  knee.	  	  Enter	  grade	  5	  to	  3-­‐.	  If	  the	  patient	  cannot	  flex	  the	  knee,	  do	  not	  grade.	  Instead,	  re-­‐test	  in	  the	  side-­‐lying	  position	  with	  gravity	  eliminated.	  	  
Ankle	  Plantar	  Flexion	  With	  the	  patient’	  knee	  flexed	  to	  90	  degrees,	  the	  patient	  is	  asked	  to	  plantar	  flex	  the	   ankle.	   	   The	   examiner	   grasps	   the	   calcaneus	   with	   one	   hand	   and	   pulls	   it	  upwards,	  towards	  the	  ceiling.	   	  At	  the	  same	  time,	  the	  other	  hand	  is	  placed	  over	  the	  ball	  of	  the	  foot	  and	  resistance	  is	  exerted	  in	  a	  downward	  fashion.	  Enter	  grade	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5	  to	  3-­‐.	  If	  the	  patient	  cannot	  plantar	  flex	  the	  ankle,	  do	  not	  grade.	  Re-­‐test	  in	  the	  side-­‐lying	  position	  with	  gravity	  eliminated.	  	  
C.	   POSITION	  3:	  	  SIDE-­‐LYING	  
Hip	  Abduction	  (emphasis	  on	  gluteus	  medius)	  The	  patient	  is	  lying	  comfortably	  on	  his	  side.	  His	  bottom	  leg	  is	  slightly	  flexed	  to	  help	  stabilize	  the	  pelvis.	   In	  addition,	  he	  is	  holding	  onto	  the	  table	  edge,	  and	  the	  examiner	   (standing	   behind	   the	   patient)	   steadies	   the	   pelvis	   with	   one	   hand	   to	  prevent	   it	   rolling	   backward.	  With	   the	   top	   knee	   extended	   and	  with	   the	   hip	   in	  
slight	  extension	  and	  external	  rotation	  the	  patient	  attempts	  to	  lift	  his	  leg	  towards	  the	   ceiling.	   Pressure	   is	   exerted	   downwards	   just	   proximal	   to	   the	   ankle	   in	   an	  angle	  of	  adduction	  and	  slight	  flexion.	  Enter	  grade	  5	  to	  3-­‐.	   	  If	  the	  patient	  cannot	  move	   the	   leg	  against	  gravity,	  do	  not	  grade.	   	  Re-­‐test	  with	  gravity	  eliminated	   in	  the	  supine	  position.	  Again,	  be	  sure	  to	  passively	  evaluate	  what	  range	  of	  motion	  is	  available.	  	  
ALTERNATE	  TESTING	  POSITIONS:	  
Neck	  Extension	  (Alternate	  Testing)	  With	  the	  examiner	  supporting	  the	  weight	  of	  the	  patient’s	  head	  if	  necessary,	  the	  patient’s	  neck	  is	  flexed	  and	  he	  is	  asked	  to	  extend	  it	  back.	  Enter	  grade	  2-­‐0.	  
NOTE:	   	  To	  avoid	  excessive	  positions	  changes,	  the	  clinical	  examiner	  may	  wish	  to	  test	   neck	   flexors	   in	   this	   position	   at	   this	   time.	   Also,	   if	   the	   evaluator	   has	   any	  uncertainty	  about	  a	  grade	  of	  2,	  the	  use	  of	  a	  powder	  board	  is	  recommended.	  	  
Hip	  Flexion	  (Alternate	  Testing)	  The	   leg,	   which	   is	   uppermost	   in	   this	   position,	   is	   supported	   by	   the	   examiner’s	  hands	  under	  the	  patient’s	  thigh	  and	  lower	  leg.	  The	  patient	  is	  then	  asked	  to	  flex	  the	  hip.	  Enter	  grade	  2-­‐0.	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Hip	  Extension	  (Alternate	  Testing)	  The	   leg	   that	   is	   uppermost	   in	   this	   position	   (side-­‐lying)	   is	   supported	   by	   the	  examiner’s	  hands/forearms	  under	  the	  patient’s	  thigh	  and	  lower	   leg.	  The	  hip	   is	  positioned	  in	  flexion,	  and	  the	  patient	  is	  asked	  to	  extend	  the	  hip.	  Enter	  grade	  2-­‐0.	  	  
Knee	  Flexion	  (Alternate	  Testing)	  The	  patient’s	  uppermost	   limb	  is	  supported	  by	  the	  examiner’s	  hands	  under	  the	  thigh	  and	  lower	  leg.	  The	  patient	  is	  then	  asked	  to	  bend	  the	  knee.	  Enter	  grade	  2-­‐0.	  	  
Knee	  Extension	  (Alternate	  Testing)	  The	  patient’s	  uppermost	   limb	  is	  supported	  by	  the	  examiner’s	  hands	  under	  the	  thigh	   and	   lower	   leg.	   The	   patient	   is	   then	   asked	   to	   straighten	   the	   knee.	   Enter	  grade	  2-­‐0.	  	  
Ankle	  Dorsiflexion	  (Alternate	  Testing)	  With	  the	  lower	  limb	  and	  foot	  supported	  by	  the	  examiner’s	  hands,	  the	  patient	  is	  asked	  to	  move	  the	  foot	  cranially.	  Enter	  grade	  2-­‐0.	  	  
Ankle	  Plantar	  Flexion	  (Alternate	  Testing)	  With	  the	  lower	  limb	  and	  foot	  supported	  by	  the	  examiner’s	  hands,	  the	  patient	  is	  asked	  to	  move	  the	  foot	  caudally.	  Enter	  grade	  2-­‐0.	  	  
D.	  POSITION	  4:	  	  SUPINE	  The	  examiner	  should	  remove	  any	  pillows	  on	  the	  exam	  table	  prior	  to	  testing.	  	  
Neck	  Flexion	  The	   patient	   is	   asked	   to	   flex	   the	   neck	   until	   the	   chin	   touches	   the	   chest,	   or	  whatever	  is	  full	  range	  for	  that	  patient.	  Pressure	  is	  exerted	  by	  the	  examiner	  with	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the	  hand	  on	  the	  patient’s	  forehead.	  For	  safety,	  the	  examiner’s	  other	  hand	  should	  be	  held	  just	  under	  the	  patient’s	  head.	  	  Enter	  grade	  5	  to	  3-­‐.	  If	  the	  patient	  cannot	  flex	  the	  cervical	  spine	  so	  that	  the	  chin	  moves	  toward	  the	  sternum,	  do	  not	  grade.	  	  Re-­‐test	   in	   the	   alternate	   position	   with	   gravity	   eliminated	   (NOTE:	   	   Raising	   the	  head	   from	   the	   table	   even	   against	   pressure,	   without	   cervical	   flexion,	   is	   not	  graded	  as	  neck	  flexion).	  	  
Elbow	  Extension	  The	   examiner	   supports	   the	   patient’s	   upper	   arm	   in	   90	   degrees	   of	   shoulder	  flexion	  so	  that	  the	  elbow	  is	  pointing	  towards	  the	  ceiling.	  The	  forearm	  is	   in	  the	  neutral	  position	  and	  lies	  across	  the	  patient’s	  chest.	  The	  patient	  is	  then	  asked	  to	  extend	  the	  elbow.	  Resistance	  is	  applied	  by	  the	  examiner’s	  hand	  just	  proximal	  to	  the	   patient’s	   wrist.	   The	   elbow	   must	   be	   flexed	   about	   20	   degrees	   from	   full	  extension	   when	   testing	   active	   strength.	   Enter	   grade	   5	   to	   3-­‐.	   If	   the	   patient	   is	  unable	   to	   move	   the	   forearm	   against	   gravity,	   do	   not	   grade.	   Re-­‐test	   in	   the	  alternate	  position	  with	  gravity	  eliminated.	  	  
Shoulder	  Abduction	  (Alternate	  Testing)	  The	  patient’s	  elbow	  is	  flexed	  to	  90	  degrees	  and	  the	  examiner	  holds	  the	  patient’s	  hand.	  In	  the	  way,	  the	  examiner	  can	  raise	  the	  elbow	  and	  upper	  arm	  just	  off	  the	  table	  (thus	  taking	  the	  weight	  off	  the	  patient’s	  arm).	  The	  patient	  is	  asked	  to	  move	  the	  upper	  arm	  into	  abduction.	  Enter	  grade	  2-­‐0.	  	  
Hip	  Abduction	  (Alternate	  Testing)	  The	  patient	   is	   asked	   to	   abduct	   his	   leg.	   The	  weight	   of	   the	   limb	   is	   taken	  by	   the	  examiner,	  usually	  under	  the	  knee	  and	  ankle.	  NOTE:	   	   Do	   not	   allow	   extreme	   external	   rotation,	   hip	   flexion,	   or	   knee	   flexion.	  	  Enter	  grade	  2-­‐0.	  
	  
E.	  	  POSITION	  5:	  	  REPEAT	  SIDE-­‐LYING	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Neck	  Flexion	  (Alternate	  Testing):	  With	  the	  examiner	  supporting	  the	  weight	  of	  the	  patient’s	  head	  if	  necessary,	  the	  patient	  is	  asked	  to	  flex	  his	  neck	  forward.	  	  Enter	  grade	  2-­‐0.	  	  
F.	  	  POSITION	  6:	  	  REPEAT	  SITTING	  	  
Elbow	  Extension	  (Alternate	  Testing)	  The	  patient’s	  shoulder	   is	   flexed	  to	  90	  degrees	  and	  the	  elbow	  is	   flexed	  towards	  his	  body	  in	  the	  horizontal	  plane.	  The	  forearm	  is	   in	  the	  neutral	  position.	  As	  the	  examiner	  supports	  the	  upper	  arm,	  the	  patient	  is	  asked	  to	  straighten	  his	  elbow.	  	  Enter	  grade	  2-­‐0.	  	  
7.1.1.2	  Myometry	  protocols	  The	  following	  protocols	  for	  quantitative	  myometry	  were	  followed:	  
	  
Elbow	  Extension:	  Subject	   is	   supine	   with	   arm	   resting	   on	   table,	   parallel	   with	   trunk	   (prop	   towel	  under	  elbow	  for	  maximum	  positioning)	  elbow	  at	  90-­‐degree	  angle.	   	  The	  trap	   is	  placed	   at	   distal	   end	   of	   forearm,	   two	   finger	  widths	   from	   the	  wrist,	  which	   is	   in	  neutral	  position	  with	  palm	  inward.	  The	  tester	  stabilises	  the	  arm	  by	  placing	  their	  hand	  over	  the	  biceps	  region	  so	  that	  the	  arm	  is	  unable	  to	  rise	  from	  the	  table	  and	  stabilises	   to	   avoid	   rotation	   of	   arm.	   The	   subject	   attempts	   maximal	   elbow	  extension	  in	  neutral	  forearm	  position.	  
Elbow	  Flexion:	  This	   employs	   the	   same	   position	   as	   elbow	   extension.	   The	   tester	   secures	   the	  elbow	   joint	   to	   prevent	   change	   of	   arm	   position	   and	   prevents	   shoulder	  protraction	   by	   placing	   hand	   on	   anterior	   aspect	   of	   shoulder.	   The	   subject	  attempts	  maximal	  elbow	  flexion	  in	  neutral	  forearm	  position.	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Ankle	  Dorsiflexion:	  The	  subject	  is	  supine	  with	  the	  feet	  hanging	  off	  of	  the	  bed,	  not	  touching	  the	  bed.	  A	  small	   towel	  may	  need	  to	  be	  placed	  under	  the	  ankle	  to	   lift	   the	  heel	  off	  of	   the	  bed.	   The	   strap	   is	   placed	   on	   the	   top	   of	   the	   foot	   and	   enough	   tension	   must	   be	  applied	   so	   that	  when	   the	   subject	  dorsiflexes	   their	   foot,	   their	   ankle	  must	  be	   at	  90-­‐degrees	  of	  dorsiflexion	  with	  the	  strap	  taut.	  	  
Knee	  Flexion:	  The	  subject	   sits	   at	   the	  end	  of	   the	  bed	  with	  a	   towel	   roll	  under	   the	   thigh	  at	   the	  knee.	   The	   strap	   is	   placed	   just	   above	   the	   ankle	   (no	  more	   than	   1	   finger	   width	  above	  the	  ankle).	  Enough	  tension	  must	  be	  applied,	  such	  that	  when	  the	  subject	  flexes	  the	  knee,	  they	  reach	  a	  90-­‐degree	  angle	  at	  the	  knee.	  
Knee	  Extension:	  The	  same	  position	  as	  knee	   flexion	   is	  use,	  with	   the	   strap	  placed	   just	  above	   the	  ankle	  (no	  more	  than	  1	   finger	  width	  above	  the	  ankle).	  Enough	  tension	  must	  be	  applied,	  so	  that	  when	  the	  subject	  extends	  the	  knee,	  they	  must	  reach	  a	  90-­‐degree	  angle	  at	  the	  knee.	  
Grip	  Strength:	  The	   subject	   sits	  with	   knees	   and	   hips	   at	   90	   degrees	   and	   feet	   flat	   on	   the	   floor.	  There	  is	  0	  degree	  of	  shoulder	  abduction,	  the	  arm	  is	  by	  the	  side	  and	  the	  elbow	  is	  flexed	   at	   90	   degrees.	   Subject	   holds	   the	   dynamometer	   in	   hand.	   Support	  dynamometer	  with	  a	  flat	  hand.	  The	  subject	  attempts	  maximal	  grip	  squeeze.	  	  	   	  
	   277	  
7.1.2	  Instructions	  to	  investigators	  on	  interpretation	  of	  IBMFRS	  All	  investigators	  were	  provided	  the	  following	  instructions	  on	  how	  to	  administer	  the	  IBM	  functional	  rating	  scale.	  Testing	  Procedures	  and	  Methods	  1)	   Advise	   the	   patient	   that	   he/she	   is	   to	   compare	   his/her	   current	   function	  with	  how	  he/she	  functioned	  prior	  to	  enquiring	  about	  any	  symptoms	  of	  IBM.	  2)	  	  	  	   State	   to	   the	   patient,	   “I’m	   going	   to	   ask	   you	   some	   questions	   about	   how	  you’re	  currently	  functioning	  at	  home”.	  The	  intention	  of	  this	  scale	  is	  to	  have	  the	  patient	   rate	   their	   own	   function.	   During	   the	   consultation,	   the	   caregiver	   should	  not	  offer	  any	  comments.	  	  3)	  	  	   Ask,	  “How	  are	  you	  doing	  with	  …	  ?”	  for	  each	  question	  in	  the	  IBMFRS.	  Even	  if	  you	  agree	  with	  the	  patient’s	  answer,	  be	  sure	  to	  clarify	  the	  patient’s	  choice	  by	  probing	  further.	  Ensure	  sure	  that	  the	  level	  below	  or	  above	  the	  number	  selected	  is	   not	   the	   more	   appropriate	   answer.	   If	   the	   patient	   is	   unable	   to	   volunteer	   a	  satisfactory	   response,	   or	   the	   response	   is	   clearly	   in	   conflict	   with	   observed	  function,	  the	  evaluator	  should	  prompt,	  using	  one	  of	  the	  available	  choices	  	  4)	   Record	   the	   patient’s	   response,	   to	   the	   closest	   available	   approximation	  from	  the	  5-­‐point	  list,	  on	  the	  case	  report	  form	  provided.	  5)	  	  	  	  	   The	  order	  of	  questioning	  should	  be	  followed	  as	  written	  6)	  	  	  	  	  	   It	  is	  important	  that	  the	  responses	  given	  by	  the	  patient	  reflect	  their	  actual	  abilities	   at	   the	   time	   of	   the	   visit	   not	  what	   the	   patient	   or	   caregiver	   thinks	   s/he	  “could”	  do.	  For	  example,	   if	   the	  caregiver	  normally	  dresses	   the	  patient,	  but	   the	  patient	  states	  that	  he	  could	  do	  it,	  given	  enough	  time,	  then	  the	  patient	  should	  be	  rated	  by	  his	  actual	  function	  which	  is	  “needs	  attendant	  for	  self	  care”.	  	  	  
1.	  	  Swallowing	  4	   Normal	  eating	  habits	  	   (No	  difficulty	  swallowing,	  can	  eat	  any	  foods	  of	  choice)	  3	   Early	  eating	  problems	  –	  occasional	  choking	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(Ask	   whether	   patient	   avoids	   any	   foods	   because	   they	   get	   “caught”	   in	   his/her	  throat.	   If	   yes,	   then	   rate	  3.	  This	   score	   indicates	   that	   the	  patient	   can	   still	   eat	   all	  foods	  of	  choice,	  but	  with	  occasional	  choking)	  2	   Dietary	  consistency	  changes	  1	   Frequent	  choking	  0	   Needs	  tube	  feeding	  	  
2.	  Handwriting	  (with	  dominant	  hand	  prior	  to	  IBM	  onset)	  (This	   item	   inquires	   about	   handwriting	   without	   any	   assistive	   devices,	   such	   as	  foam	  tubing	  &/or	  mechanical	  aids	  due	  to	  finger	  weakness)	  4	   Normal	  3	   Slow	  or	  sloppy:	  all	  words	  are	  legible	  2	  	  	  	  	  	  	  	  	  Not	  all	  words	  are	  legible	  	  1	   Able	  to	  grip	  pen	  but	  unable	  to	  write	  0	   Unable	  to	  grip	  pen	  	  
3.	  Cutting	  food	  and	  handling	  utensils	  	  4	   Normal	  (No	   difficulty	   cutting	   or	   handling	   utensils	   by	   methods	   used	   prior	   to	   disease	  onset)	  3	   Somewhat	  slow	  and	  clumsy,	  but	  no	  help	  needed	  (Some	  difficulty	  cutting	  or	  handling	  utensils	  by	  methods	  used	  prior	   to	  disease	  onset,	  but	  patient	  continues	  to	  do	  so	  independently)	  2	   Can	   cut	   most	   foods	   (>	   50%),	   although	   slow	   and	   clumsy;	   some	   help	  needed	  (Some	  difficulty	  cutting	  or	  handling	  utensils	  by	  methods	  used	  prior	   to	  disease	  onset;	  patient	  requires	  assistance,	  but	  still	  tries	  to	  cut	  some	  foods,	  and	  still	  does	  >50%	  of	  the	  task	  successfully.)	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1	   Food	  must	  be	  cut	  by	  someone,	  but	  can	  still	  feed	  slowly	  (Patient	  cannot	  cut	  foods	  by	  methods	  used	  prior	  to	  disease	  onset,	  but	  still	  tries	  to	  feed	  him/herself	  and	  succeeds	  at	  least	  occasionally)	  0	   Needs	  to	  be	  fed	  	  	  	  
4.	  Fine	  Motor	  Tasks	  (opening	  doors,	  using	  keys.	  Picking	  up	  small	  objects)	  	   4.	  	   Independent	  	   3.	  	   Slow	  or	  clumsy	  in	  completing	  task	  	  	   	  	  	  	  	   (Does	  not	  use	  any	  assistive	  device	  to	  perform)	  2.	   Independent	  but	  requires	  modified	  techniques	  or	  assistive	  devices	  	   1.	  	  	   Frequently	  requires	  assistance	  from	  caregiver	  	   0.	  	   Unable	  to	  perform	  	  
5.	  	  Dressing	  	   4.	  	   Normal	  	   3.	  	   Independent	  but	  with	  increased	  effort	  or	  decreased	  efficiency	  	   2.	  	   Independent	  but	  requires	  assistive	  devices	  or	  modified	  	  	   	   techniques	  	   	  	  	  	   (Velcro,	  shirts,	  without	  buttons,	  etc)	  	   1.	  	   Requires	  assistance	  from	  caregiver	  for	  some	  clothing	  items	  	   0.	  	   Total	  dependence	   	  	  
6.	  	  Hygiene	  (If	  the	  patient	  chooses	  not	  to	  bathe	  self	  for	  whatever	  reason,	  he/she	  is	  rated	  as	  not	  able)	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4	   Normal	  function	  Patient	   has	   no	   difficulty,	   and	   is	   still	   completely	   independent	   in	   dressing	   and	  hygiene	  by	  methods	  used	  prior	  to	  disease	  onset	  3	   Independent	  but	  with	  increased	  effort	  or	  decreased	  activity	  Patient	   still	   completely	   independent	   in	   dressing	   but	   requires	   more	   effort	   to	  dress.	  No	  substitute	  methods	  are	  used	  to	  dress.	  	  2	   Independent	  but	  requires	  use	  of	  assistive	  devices	  Patient	   requires	   occasional	   assistance	   or	   the	   use	   of	   assistive	   devices	   or	  substitute	  methods	  (e.g.,	  pull-­‐on	  clothes,	  velcro	  closures	  or	  shoes,	  pre-­‐buttoned	  shirt,	  lying	  down	  to	  don	  pants)	  in	  dressing	  and	  hygiene.	  Methods	  used	  are	  now	  different	  than	  those	  used	  prior	  to	  disease	  onset.	  1	   Requires	  occasional	  assistance	  from	  caregiver	  (Means	  patient	  needs	  daily	   caregiver	   assistance	  with	  dressing	  but	  patient	  has	  some	  level	  of	  function)	  0	   Completely	  dependent	  	  
7.	  	  Turning	  in	  bed	  and	  adjusting	  covers	  (If	   the	   patient	   chooses	   not	   to	   turn	   in	   bed	   or	   adjust	   bedclothes	   for	   whatever	  reason,	   he/she	   is	   rated	   as	   not	   able.	   This	   item	   refers	   to	   the	   ability	   to	   do	   both	  activities	   (turning	   and	   adjusting	  bedclothes)	   to	   be	  marked	  4	   or	   3.	   Performing	  one	  activity	  is	  2)	  4	   Normal	  	  3	   Somewhat	  slow	  and	  clumsy,	  but	  no	  help	  needed	  2	   Can	  turn	  alone,	  or	  adjust	  sheets,	  but	  with	  great	  difficulty	  (Patient	  can	  turn	  alone	  or	  adjust	  sheets,	  but	  completes	  task	  with	  great	  difficulty,	  no	  help	  needed.)	  1	   Can	  initiate,	  but	  not	  turn	  or	  adjust	  sheets	  alone	  0	   Unable	  or	  requires	  total	  assistance	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8.	  	  Sit	  to	  stand	  	   4.	   Independent	  (without	  use	  of	  the	  arms)	  	   3.	   Performs	  with	  substitute	  motions	  (leaning	  forward,	  rocking)	  	  	   	   but	  without	  use	  of	  arms	  	   2.	   Requires	  of	  use	  of	  arms	  	   1.	   Requires	  assistance	  from	  a	  device	  or	  person	  	   0.	   Unable	  to	  stand	  	   	  
9.	  	  Walking	  4	  	   Normal	   	  3	   Slow	  or	  mild	  unsteadiness	  	   (Patient	  notes	  some	  difficulty,	  but	  walks	  without	  assistance)	  2	   Intermittent	  use	  of	  an	  assistive	  device	  (includes	  AFO,	  cane,	  walker,	  or	  a	  caregiver)	  1	   Dependent	   on	   assistive	   device	   (includes	   AFO’s,	   cane,	   walker,	   or	   a	  caregiver)	  0	   Wheelchair	  dependent	  (includes	  scooters)	  	  
10.	   	   Climbing	   stairs	   (If	   the	   patient	   chooses	   not	   to	   climb	   stairs	   for	  whatever	  reason,	  he/she	  is	  rated	  as	  not	  able)	  4	   Normal	  3	   Slow	  with	  hesitation	  or	  increased	  effort;	  uses	  hand	  rail	  intermittently	  2	  	   Dependent	  on	  hand	  rail	  	  1	   Dependent	  on	  hand	  rail	  and	  additional	  support	  (cane	  or	  person)	  0	   Cannot	  climb	  stairs	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